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ABSTRACT 
Phenylpropanoids, consisting of the characteristic C6C3 subunits, are one of the most 
prevalent secondary metabolites in nature. While terrestrial plants produce a wide 
variety of these natural products, few examples from marine prokaryotes are known. In 
this thesis, we will discuss our investigations on the synthesis and biology of two 
marine natural product families. The maculalactones were isolated from the marine 
cyanobacterium Kyrtuthrix maculans. While maculalactone A was found to be a 
potential antifouling agent, maculalactone E exhibits interesting activities against 
human tumor cell lines. The structurally related ophiodilactones, isolated from 
Ophiocoma scolopendrina, showed comparable cytotoxicities against leukemia cells. 
All three literature known syntheses of maculalactone A possess yields below 10%. 
In our optimization, we investigated shortcuts of the known routes and a butenolide 
formation by metathesis. Finally, we obtained maculalactone A in an overall yield of 
45% utilizing a rare, intramolecular butenolide synthesis. 
In our concept for the antifouling protection of metal surfaces, we envisioned 
connecting maculalactone A through a linker to a catechol anchor. An appropriate 
derivative of the natural product for this purpose was identified in a small SAR study. 
We then labeled the active maculalactone A analogue with a rhodamine B fluorophore. 
In vivo experiments in Artemia salina demonstrated a selective accumulation of this 
molecular probe along the intestine.  
Unfortunately, our efforts towards the total synthesis of ophiodilactone A and B over 
two independent strategies were unsuccessful. In a linear strategy, a bisallylic precursor 
was desymmetrized via a Sharpless epoxidation. After Payne rearrangement and 
nucleophilic epoxide opening, we successfully elongated the linear chain. However, the 
steric repulsion of the benzyl- and protecting groups prevented further conversion. In an 
alternative, protecting group-free approach, maculalactone A was added to 
cinnamaldehyde in a diastereo- and enantioselective vinylogous Michael addition by 
phase transfer catalysis. Despite attempts with various reagents, the subsequent 
oxidation of the butenolide double bond was not achieved. In addition, different 
strategies to work around the insufficient reactivity of the olefin were investigated.  
In conclusion, we developed an efficient synthesis of maculalactone A and used this 
material for our biological investigations. Furthermore, we achieved the synthesis of the 
ophiodilactone A carbon skeleton in five steps. 
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ZUSAMMENFASSUNG 
Die Phenylpropanoide sind die wohl häufigsten sekundären Metaboliten in der 
Natur. Während diese Naturstoffe in grosser Variation in Pflanzen vorkommen, sind sie 
in im Meer lebenden Prokaryoten selten zu finden. In der hier vorliegenden Arbeit 
diskutieren wir unsere Erkenntnisse in der Synthese und Biologie zweier mariner 
Naturstofffamilien. Die Maculalactone wurden aus dem Cyanobakterium Kyrtuthrix 
maculans isoliert. Maculalacton A zeigt Potential als Antifouling Mittel und bei 
Maculalacton E wurden interessante Aktivitäten gegen menschliche Krebszellen 
nachgewiesen. Die strukturell ähnlichen Ophiodilactone wurden aus dem Seestern 
Ophiocoma scolopendrina isoliert und wirken cytotoxisch gegenüber Leukämiezellen. 
Die drei in der Literatur beschrieben Maculalacton A Synthesen erreichen Ausbeuten 
unter 10%. In unserer Optimierung untersuchten wir eine Synthese des Butenolids 
mittels Metathese und konnten Maculalacton A schlussendlich über eine seltene 
intramolekulare Zyklisierung in vier Schritten und einer Ausbeute von 45% herstellen. 
In unserem Konzept zum Biofoulingschutz von Metaloberflächen verbanden wir 
Maculalacton A über einen Linker mit einem unserer Catechol Anker. Ein geeignetes 
Derivat des Naturstoffes wurde in einer kleinen SAR Studie gefunden. Dieses 
Maculalacton A Analogon wurde ausserdem mit einem Rhodamin B Fluorophor 
markiert. In einem in vivo Experiment mit Artemia salina konnten wir eine 
Akkumulierung des Markers entlang des Darmes beobachten. 
Zwei verschiede Strategien zur Totalsynthese von Ophiodilacton A und B waren 
leider erfolglos. In einer linearen Route desymmetrisierten wir einen Bisallylalkohol 
mittels Sharpless Epoxidierung. Das Epoxid konnte nach einer Payne Umlagerung 
nukleophil geöffnet werden. Die Verlängerung der linearen Kette konnte ereichte 
werden, jedoch verhinderte die sterische Abschirmung der Schutz- und Benzylgruppen 
sämtliche Folgereaktionen. In einer alternativen, Schutzgruppen freien Strategie wurde 
Maculalacton A in einer enantio- und diastereoselektiven Reaktion mittels 
Phasentransferkatalysator an Zimtaldehyd addiert. Die folgende Oxidation der 
Doppelbindung des Butenolids konnte weder mit verschiedenen Reagenzien noch über 
reaktivere Intermediat erreichten werden. 
Zusammenfassend entwickelten wir eine effiziente Synthese von Maculalacton A 
und nutzen diese zur Untersuchung der biologischen Eigenschaften. Ausserdem konnten 
wir das Kohlenstoffgerüst von Ophiodilacton A in 5 Stufen aufbauen.  
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1.1 Phenylpropanoids 
Phenylpropanoids might be most prevalent secondary metabolites in nature and are 
most frequently found in terrestrial plants.1,2 In the colonization of landmass by plants 
500 million years ago, these pioneering organisms had to adapt to stresses such as UV 
radiation, desiccation and microbial attacks. Along with other evolutions, the 
emergence of the phenylpropanoid metabolic pathway was crucial (Section 1.2). In 
plants, low-molecular-weight phenylpropanoids play various roles such as antibiotics, 
UV protectants, insect repellents, flower pigments and signaling molecule in 
plant-microbe interactions.3 Furthermore, high-molecular-weight, polymeric 
phenylpropanoids are important components in surface and support structures. Due to 
these diverse biological functions, phenylpropanoids adopt various molecular structures, 
which consists of C6C3 subunits.4 In addition, other phenylpropanoid subunits such as 
C6C2 and C6C1 or acetate-derived C2 and aromatic C6 units and, in some cases, various 
primary and secondary metabolites can be present.  
 
Figure 1.1: Selected examples of phenylpropanoids from different plant sources.4,5 
Selected examples of well-known phenylpropanoids are depicted in figure 1.1.4,5 The 
least complex phenylpropanoid, cinnamaldehyde (1.01), consists of a single C6C3 unit 
and is known to cause the unique odor of cinnamon tree bark. Resveratrol (1.02) is 
present in grapes and red wine, and it’s suspected anti-aging effects are still debated. 
Resveratrol consists of one C6C3 phenylpropanoid subunit and an additional aromatic 
ring constructed from three acetate-derived C2 units. Therefore, it belongs to the family 
of stilbenes. Arylic hydroxyl groups are a typical feature of phenylpropanoids. The 
more complex, apigenin (1.03), belongs to the family of flavones and can be found in 
several herbs including parsley, thyme and peppermint.  
HO
cinnamaldehyde
(1.01)
HO
OH
OH
resveratrol
(1.02)
O
OH
HO
OH O
apigenin
(1.03)
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1.2 Biosynthesis of Phenylpropanoids 
Despite intensive studies on the biosynthesis of phenylpropanoids in the last decades, 
many details have yet to be revealed.1–4,6,7 The fundamental first steps of the biogenesis 
resulting in the different families of phenylpropanoids will be discussed (Scheme 1.1). 
Most of the described transformations are also known for the corresponding CoA-esters.  
 
Scheme 1.1: Parts of the phenylpropanoid metabolism in terrestrial plants. The enzymes are 
abbreviated as follows: phenylalanine ammonia lyase (PAL), cinnamate-4-hydroxylase (C4H), 
coumarate-3-hydroxylase (C3H) and aromatic amino acid decarboxylase (AADC). In some 
species, p-coumaric acid can be accessed from tyrosine. The required enzyme tyrosine ammonia 
lyase (TAL) is manly found in grasses.4 
In the first step, the proteogenic amino acid phenylalanine (1.04) is converted to the 
unsaturated cinnamic acid (1.05), representing the most elementary C6C3 subunit.4 
Subsequent oxidation by C4H results in the formation of p-coumaric acid (1.06) and 
further oxidation by C3H gives caffeic acid (1.07). As indicated in scheme 1.1, these 
three phenylpropanoids are the main building blocks of the many more complex 
NH2
OHO OHO
PAL
OHO OHO
C4H
OH OH
OH
caffeic acid
(1.07)
phenylalanine
(1.04)
cinnamic acid
(1.05)
C6C3
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(1.06)
AADC
NH2
phenethylamine
(1.09)
C6C2
O
(1.10)
?
OHO
benzoic acid
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structures such as lignans (Section 1.3). It is assumed that benzoic acid (1.08), a C1C6 
unit, is produced from cinnamic acid.7 However, this has not been proven thus far and 
benzoic acid can also be accessed from other metabolites. Recently, Tieman et al. 
discovered the first step of the biosynthesis of C2C6 subunits.8 The enzyme AADC is 
responsible for the one carbon deletion of 1.04, giving phenethylamine (1.09). Then, the 
amine group is assumed to be removed by oxidation to ketone 1.10. 
Crucial for the biosynthesis of phenylpropanoids is PAL, required to obtain the C6C3 
building block cinnamic acid (1.05). While this enzyme is found in all vascular plants, it 
is absent in animals and most algae. Therefore, this protein has been assumed to be a 
result of the evolutionary adoption of the plants during the colonization of the land 
(Section 1.1). However, the isolation of phenylpropanoid secondary metabolites from 
none plant organisms put this assumption in question. In 2007, Moffitt et al. 
characterized the first cyanobacterial PALs from Anabaena variabilis and Nostoc 
punctiforme.9 In combination with similar findings in other organisms, it is now debated 
if this enzyme has a prokaryotic origin and was transported to the vascular plants by a 
horizontal gene transfer.2 
1.3 Lignans 
Lignans are a family of phenylpropanoid natural products consisting of two C6C3 
units, linked by a C8-C8’ carbon bond.4,10 These secondary metabolites are widely 
distributed in the plant kingdom and are biosynthesized and deposited in significant 
amounts in the heartwood region of trees. Lignans show interesting biological 
properties and some members of this family are used in medicine and as nutritional 
supplements, such as podophyllotoxin-derivatives in cancer therapies and sesamin in 
health and nutrition. Additionally, the lignans are of special interest to us, as they are 
closely structurally related to the marine secondary metabolite families, the 
maculalactones and ophiodilactones.   
1.3.1 Classification and Biosynthesis 
Lignans are classified in eight subgroups, determined by the cyclization pattern and 
whether oxygen is present in the skeleton (Figure 1.2).10,11 Some of these subgroups are 
further divided to account for the oxidation state of the C9- and C9’-position, which is 
installed in the beginning of the biosynthesis. Furthermore, the members of each 
 INTRODUCTION 
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subgroup vary substantially in the oxidation levels of the alkyl chains and the aromatic 
rings. 
 
Figure 1.2: Subgroups of Lignans. The members without oxygen at the C9(C9’)-position were 
omitted for clarity.10 
Compared to the other lignans, the biosynthesis of the C9(C9’)-oxidized members is 
the most explored.7,11 In the initial steps of the biogenesis, p-caffeoyl-CoA (1.11) is 
converted to the dimerization precursor coniferyl alcohol (1.13) (Scheme 1.2). The 
regioselective methylation in the 3-position by COMT results in the formation of 
feruloyl-CoA (1.12). Subsequently, the CoA ester is reduced with NADPH in two steps 
to the corresponding alcohol 1.13. The formed coniferyl alcohol is a precursor of not 
only lignans, but also lignins. 
In the presence of DIR and an oxidase or a single electron oxidant, coniferyl 
alcohol (1.13) is dimerized to afford the C8(C8’) coupled pinoresinol (1.15).10 This 
reaction proceeds via a regioselective carbon-carbon bond formation of two resonance-
stabilized radicals. Lignans without oxygen at the C9(C9’)-position or two acid groups 
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originate from a similar reaction with isoeugenol (1.14) or caffeic acid (1.07), 
respectively.  In contrast to similar reactions in the biogenesis of lignins, these radical 
dimerizations are enantioselective. Lignans from natural sources are isolated either 
enantiopure or with an excess of one enantiomer. The absolute configuration of 
pinoresinol and all derived natural products can vary with plant species. 
 
Scheme 1.2: Biosynthesis of coniferyl alcohol and subsequent dimerization to 
(+)-pinoresinol.4,10 The enzymes are abbreviated as follows: caffeic acid methyltransferase 
(COMT), cinnamoyl-CoA reductase (CCR), cinnamyl alcohol dehydrogenase (CAD) and 
dirigent protein (DIR). 
The formed pinoresinol (1.15) is the central intermediate in the synthesis of all 
C9(C9’)-oxidized lignans and can be converted to the remaining seven subgroups 
(Figure 1.2). The biosynthetic pathway affording dibenzylbutyrolactones, which possess 
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a similar structure as maculalactone A (1.34) (Section 1.4), is well understood.4,10 In the 
beginning of this process, the benzylic ethers are cleaved by PLR in the presence of 
NADPH to afford lariciresoinol (1.17) first and secoisolariciresinol (1.18) second 
(Scheme 1.3). This is followed by a regioselective oxidation of one of the two primary 
alcohols, resulting in the formation of matairesinol (1.19). 
 
Scheme 1.3: Biosynthesis of (-)-matairesinol.4,10 The enzymes are abbreviated as follows: 
pinoresinol/lariciresinol reductase (PLR) and secoisolariciresinol dehydrogenase (SIRD). 
Secoisolariciresinol and matairesinol occur in numerous foodstuffs such as oilseeds, 
whole grains, vegetables and fruits.12 During the digestion of these foods, intestinal 
bacteria convert these lignans into enterodiol (1.20) and enterolactone (1.21), 
respectively (Scheme 1.4).4 These “mammalian” lignans are known to provide 
preventative effects including reduced risk of breast13 and lung14 cancer, as well as a 
reduction of vascular inflammations.15  
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Scheme 1.4: Transformation to enterodiol and enterolactone by intestinal bacteria.4 
1.3.2 Synthesis 
The promising biological properties and the interesting chemistry of the lignans has 
attracted much attention by synthetic groups.16–19 A modern synthetic route yielding 
four different furofuran lignans has been reported by Bruton an co-workers.20 Key steps 
of the synthesis include a Mn(III)-mediated intramolecular cyclopropanation and a 
carbene C-H insertion (Scheme 1.5). Enantiomerically enriched 1-phenylallyl 
alcohol (1.22) is converted to β-keto ester 1.23. A diastereoselective cyclopropanation 
affords intermediate 1.24, which is subsequently transformed to the ring-opened lactone 
1.25. A deacetylative diazo-transfer was followed by a rhodium catalyzed C-H insertion 
to provide 1.26. The furofuran core was established after reduction of the lactone in two 
further steps. The natural occurring lignans were accessed by the same strategy from the 
appropriately substituted analogues. 
secoisolariciresinol
(1.18)
matairesinol
(1.19)
HO
HO
OH
OH
O
O
HO
OH
enterodiol
(1.20)
enterolactone
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Scheme 1.5: Stereoselective synthesis of furofuran lignans as reported by Bruton and 
co-workers.20 
Other groups focused on more biomimetic approaches. While single electron 
oxidations of ethyl ferulate (1.27) have been known for years, selectivity issues 
resulting from the mesomeric delocalization of the radical could not be overcome. 
Instead of the desired C8(C8’) coupled bisester 1.29, the C8(C5’) linked product 1.28 
was observed as the major product (Scheme 1.6).21,22 Recently, Wang et al. reported a 
method to prevent the undesired formation of product 1.28. By blocking the arylic five 
position with a tert-butyl residue, the desired C8(C8’) linked product 1.30 was isolated 
in excellent yield and selectivity from the same reaction conditions. Olefin reduction 
gave the diastereomeric compounds 1.31 and 1.32. Subsequent removal of the tert-butyl 
groups by a retro Friedel-Crafts alkylation resulted in the formation of bisester 1.33. 
Reduction of the ester moieties afford rac-secoisolariciresinol (1.18). The 
diastereomeric compound 1.32 was transformed in the same manner. 
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Scheme 1.6: Biomimetic synthesis of lignans after blockage of the C5 position as reported by 
Wang et al.21 
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1.4 Maculalactones 
In 1996, the group of Brown published the isolation of a new secondary metabolite 
from the cyanobacteria Kyrtuthrix maculans.23 This organism forms colonies in high 
intertidal zones on rocky shores in Vietnam, Thailand, Australia, China, Japan, India, 
Hawaii and the Mediterranean. In Hong Kong, where the samples for isolation were 
collected, K. maculans dominates the moderately exposed shores and covers 
approximately about 50% of the rock surface. 
 
Figure 1.3: Butenolide secondary metabolites isolated from K. maculans.23–25 The relative 
stereochemistry of maculalactone L was established within this work (Chapter 6). 
Maculalactone A was later also isolated from Ophioplocus japonicus.26 
The isolated secondary metabolite was identified as an unsaturated γ-lactone 
substituted by three benzyl groups and was named maculalactone A (1.34) 
(Figure 1.3).23 The absolute configuration of the stereocenter was determined during the 
first total synthesis of 1.34 by the same group.27 Interestingly, isolated maculalactone A 
was found to be not optically pure. The probes from natural sources exhibit an 
enantiomeric excess of the (4S) enantiomer of 70 to 90%. A racemization during the 
isolation could be excluded. Neither racemic nor optically pure natural products are 
often observed in the family of the lignans (Section 1.3.1).  
In 1998, Brown and coworkers reported the structure of ten new compounds, isolated 
from the same cyanobacterium.24 Maculalactone B (1.35) and C (1.36) possess the same 
carbon skeleton as maculalactone A (1.34), but include an additional double bond in the 
γ-position. In contrast, maculalactone D (1.38), E (1.39), F (1.40), G (1.41), H (1.42), 
I (1.43), J (1.44) and K (1.45) are more complex and the structure is extended by 
another C6C3 unit, resulting in the tetrahydrobenzofuranone core of these new 
compounds (Figure 1.4). While the carbon skeletons of these maculalactones are 
identical, they can be differentiated by the oxidation patterns.  
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Figure 1.4: Tetrahydrobenzofuranone secondary metabolites isolated from K. maculans.24,28 
Maculalactone E was also isolated from O. japonicus and the absolute configuration was 
determined.26 All other absolute configurations are unknown, but were assumed to be the same.  
In the following years, two new members of this family were isolated from the same 
organism. Maculalactone L (1.37) possesses the carbon-skeleton of maculalactone A 
and is an oxidized analogue of this compound.25 Maculalactone M (1.46) is suspected to 
originate from an oxidative carbon bond cleavage, resulting in its ring open structure.28 
Recently, Wang et al. described the isolation of maculalactone A (1.34) and E (1.39) 
from the brittle star Ophioplocus japonicus.26 Furthermore, the absolute configuration 
of lactone 1.39 was determined by a modified Mosher method. It is here assumed that 
all other maculalactones with a tetrahydrobenzofuranone core exhibit the same absolute 
configuration. 
The biological properties of the maculalactones are not well investigated. Only the 
most abundant maculalactone A (1.34) was intensively studied by Brown and 
co-workers.29 Along with other experiments, the toxicity of maculalactone A against 
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potential grazers was determined. Furthermore, the use of maculalactone A as 
antifouling agent was investigated (Section 3.1.2).30 In their activity driven isolation 
from O. japonicus, Wang et al. examined the cytotoxicity of macualactone A (1.34) and 
E (1.39) against five human tumor cell lines (A549, SK-OV-3, SK-MEL-2, XF498, 
HTC15).26 While maculalactone A showed only modest activity, maculalactone E 
exhibited good IC50 values between 2.8 and 3.7 µg/ml. 
In accordance to the structure, oxidation pattern and the extent of aromatic moieties, 
the maculalactones are assumed to be a result of the phenylpropanoid metabolic 
pathway.24 Similarly saturated γ-lactones are known from lignans (Section 1.3). The 
biosynthesis is not yet understood, but the butenolide is assumed to be the result of a 
condensation of three C6C3 units. This would however require the loss of two carbons 
during this process. Alternatively, the core could be formed from two C6C3 and one 
C6C1 units. The tetrahydrobenzofuranone bicycle is assumed to originate from an 
additional C6C3 unit. 
1.5 Ophiodilactones 
In 2009, Ueoka et al. reported the isolation of similar compounds from Ophiocoma 
scolopendrina.31 This ophiuroid inhabits intertidal zones in the Indo-Pacific and is 
therefore a potential grazer of K. maculans. In contrast to the tetrahydrobenzofuranone 
bicycle of the maculalactones, the isolated compounds ophiodilactone A (1.47) and 
B (1.48) possess a second δ-lactone (Figure 1.5). It has been estimated that these 
dilactones are metabolites of the K. maculans nutrition.26  
 
Figure 1.5: Ophiodilactone A and B isolated from the ophiuroid Ophiocoma scolopendrina.31 
The absolute stereochemistry has been determined from CD data. 
To our knowledge, the γ,δ-dilactone core structure of ophiodilactone A (1.47) has 
been isolated for the first time from a biological sample. Only two examples of similar 
synthetic γ,δ-dilactones were found in literature, of which both exhibit minimal 
substitution. Even more fascinating is the additional connection between the aryl- and 
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the α-lactonic position in ophiodilactone B (1.48).32 Both compounds were found to 
exhibit cytotoxic activity against P388 murine leukemia cells with IC50 values of 5.0 
and 2.2 µg/ml for ophiodilactone A and B, respectively.31 
Recently, Matsubara et al. published their total synthesis of ophiodilactone A (1.47) 
and B (1.48).33,34 In their route, the assumed direct conversion of 1.47 to 1.48 by a 
radical mechanism was demonstrated.31  
1.6 Thesis Outlook 
This discussion will present our efforts to understand more about the chemistry and 
biology of the maculalactones and the ophiodilactones. Chapter 2 focuses on a new high 
yielding synthesis of maculalactone A (1.34). Our biological studies and investigations 
towards an antifouling application are discussed in chapter 3. Our efforts towards our 
main goal, the total synthesis of ophiodilactone A (1.47) and B (1.48), are described in 
chapters 4 and 5. Preliminary studies towards the synthesis of other maculalactones are 
presented in chapter 6. 
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2.1 Introduction 
2.1.1 Previous Approaches Reported in the Literature 
In literature, three different groups have completed the total synthesis of 
maculalactone A (1.34). The first synthesis was published in 2004 by Brown and 
co-workers (Scheme 2.1).1 Their route accessed racemic maculalactone A in five steps 
and in an overall yield of 7%. Additionally, maculalactone B (1.35), C (1.36) and 
enantiomerically enriched maculalactone A were synthesized. A main reason for the 
low yield of this route is the Stobbe condensation forming bisacid 2.02 in the first step. 
This intermediate is in principle commercially available, but starting from dimethyl 
succinate (2.01) is more economical. Despite the low yielding first step, this route offers 
considerably high yields. 
 
Scheme 2.1: Synthesis of racemic maculalactone A in five steps and 7% overall yield as 
published by Brown and co-workers.1 
One year later, the group of Argade published the second total synthesis of 
maculalactone A (1.34) in 10 steps and an overall yield of 10% (Scheme 2.2).2 This low 
yield is mainly a result of the high number of synthetic steps and an especially low 
yielding step of allylic substitution to afford anhydride 2.04. However, this synthesis 
shows similarities to the route of Brown et al., with anhydride 2.04 as common 
intermediate. 
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Scheme 2.2: Synthesis of racemic maculalactone A in 10 steps and 10% overall yield as 
published by Argade and co-workers.2,3  
In 2009, Romo and co-workers published the third total synthesis (Scheme 2.3).4 In 
the process of their investigations on the synthesis of tetronic acids, 
maculalactone A (1.34) was synthesized in five steps and in an overall yield of 6%. The 
sequence starts with the asymmetric synthesis for ketene dimer 2.08 from 2.07 
according to Calter et al.5 This olefin is then epoxidized to the spiro compound 2.09.  
 
Scheme 2.3: Synthesis of enantiomerically enriched maculalactone A in five steps and 6% 
overall yield as published by Romo and co-workers.4  
The required tetronic acid derivative 2.10 is formed after a base-induced 
rearrangement in a yield of 30% over the three steps. The following substitution of the 
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β-position by a benzyl group was found to be more problematic. The copper catalyzed 
coupling on lactone 2.11 affords (+)-maculalactone A in 30% yield, reducing the overall 
yield of the synthesis dramatically. 
2.1.2 Systematic Analysis of the Synthetic Problems 
In respect to the considerably high yield of Brown’s route, this route was chosen for 
the preparation of maculalactone A (1.34). Although the synthesis was successful, two 
problematic steps were identified. The hydrogenation and subsequent isomerization of 
diene 2.03 had selectivity issues. The following Grignard reaction was also found to be 
challenging, due to the tendency of benzyl Grignard reagents to dimerize and the 
difficult generation.  
These problematic steps encouraged us to compare the published syntheses in more 
detail. Despite the low number of steps, all routes possess low overall yields. These low 
yields of the syntheses revel a common problem. In a survey, the lowest yielding step in 
all three routes was found in the installation of a benzyl group on the finished 
butenolide core. Besides the Stobbe condensation in Brown’s synthesis, this step is 
typically performed with a nucleophilic benzyl species.1  
The second lowest yielding step in the synthesis of Brown et al. is the nucleophilic 
addition of a benzyl Grignard reagent to anhydride 2.04.1 The synthesis of Argade 
involves the same intermediate, but the last benzyl group is introduced in an 
electrophilic addition to 2.06, followed by a reduction of the formed double bond.2 A 
combination of these procedures would bypass the nucleophilic benzylation. However, 
the additionally required hydrogenation of 1.35 in moderate yield makes this 
combination not favorable. 
These considerations lead to two principles for an improved synthesis of 
maculalactone A. First, the benzyl groups should be introduced in a non-nucleophilic 
fashion and second, these groups should be introduced as early in the synthesis as 
possible. Ideally, the benzyl substituents would already be present in the starting 
materials, implying that the phenylic and benzylic bonds should not be formed in the 
synthesis. In principle, this is only possible if the butenolide is formed at the end of the 
synthesis. 
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2.2 Substitution by Electrophilic Addition 
Our first attempts focused on a combination of Brown’s synthesis and an 
electrophilic introduction of the last phenyl moiety.1 In contrast to the condensation in 
the synthesis of Argade, we proposed a substitution on an electrophilic halogen alkane.2 
This would not only remove one step in the route, but it also might allow for an 
enantioselective version of the reaction. 
Therefore, butenolide 2.06 was reacted with benzyl bromide in the presence of the 
cinchona alkaloid derived phase transfer catalyst 2.126 and a base (Scheme 2.4). Further 
information concerning these reaction conditions and a detailed optimization of the 
reaction conditions with a different substrate can be found in section 4.3.2. In contrast 
to the reaction with benzaldehyde, we observed a clear addition to the α-position giving 
lactone 2.13. This regioselectivity can be attributed to the nature of the electrophile. The 
same behavior was observed with other substrate described in section 6.2.3 and in 
literature.7 The addition to the α-position is kinetically favored. With benzaldehyde, this 
addition is reversible and the thermodynamically favored condensation product is 
formed. Since this selectivity cannot be overcome, no further investigations of this 
strategy were performed. 
 
Scheme 2.4: Synthesis of lactone 2.06 and addition of benzyl bromide under phase transfer 
catalysis (PTC).1,2 2.12 is a cinchona alkaloid derived PTC6 and was synthesized according to 
literature (Section 4.3.2).8 
2.3 Substitution by Radical Addition 
In 2008, the group of Messorosh published a new procedure for the addition of 
benzyl radicals to 2,3-dichloromaleic anhydride (2.14) (Scheme 2.5).9 The radical 
species are generated by the decomposition of di-tert-butyl peroxide in toluene. This 
method offers an alternative in the total synthesis of Brown and Argade, as it gives 
access to anhydride 2.04 in one step.1,2 However, the chlorinated compound 2.14 is 
expensive and cannot be prepared in the lab. We investigated the same system with the 
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brominated analogue 2.15, which was prepared from cheap starting material as 
described by Dubernet et al.10   
 
Scheme 2.5: Synthesis of anhydride 2.04 by radical substitution.1,2,9 
The yield of the radical substitution of the brominated maleic anhydride was found to 
be only 28%. Therefore, maculalactone A could theoretically be synthesized in five 
steps and an overall yield to 17%. Despite this first success, other synthetic strategies 
giving maculalactone A were investigated. 
2.4 Late Stage Ring-Closing Metathesis 
As described above, the optimization of the known total synthesis offered only little 
improvements. Therefore we decided to develop a completely new synthesis of 
maculalactone A (1.34). Due to the problematic formation of the phenylic or benzylic 
bonds, our strategy was to install these groups initially and form the lactone in a later 
stage of the synthesis. In literature, various procedures are known for the formation of 
butenolides.11–13 However, only some of these procedures are compatible with triple 
substituted lactones. An example is the ring closing metathesis, which has been 
successfully applied by various research groups.14–16 
Enone 2.16 was synthesized by a Mannich reaction, as described by Pihko and 
co-workers (Scheme 2.6).17 Consequently, the enone was converted to acid 2.17 by a 
Pinnick oxidation and to allylic alcohol 2.18 by a 1,2-addition. The latter proceeded 
nicely, despite the use of a nucleophilic benzyl Grignard reagent. The two fragments 
were then combined in a Steglich esterification to give diene 2.19. 
With this convergent approach, ester 2.19 was synthesized in four steps and in 42% 
and 38% overall yields, respectively. However, the following metathesis with Grubbs 
second generation catalyst18 resulted in no conversion. Some literature reports a 
beneficial effect with similar system by the addition of Lewis acids.16,19 In our case, the 
addition of titanium isopropoxide gave a maximal conversion of 11%. 
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Scheme 2.6: Synthesis of maculalactone A by a late-stage ring closing metathesis. The stated 
conversion in the metathesis is the maximally obtained value (1H-NMR). 
Eventually, the low conversion could be improve by an extensive catalyst screening 
or a relay strategy, how Hoye et al.20 introduced it, could overcome the problematic 
electronics and the steric hindrance. The latter would, however, complicate the 
synthesis of the precursor, as well as reduce the atom economy. Nevertheless, the 
synthesis of ester 2.19 in good yields acknowledged our efforts towards a convergent 
route with an early introduction of the benzyl moieties. 
2.5 Late Stage Ring Closure of an Activated Methylene 
2.5.1 Butenolide Synthesis by Knoevenagel Condensation 
The Knoevenagel condensation is a well known synthesis of α,β-unsaturated ester 
and various examples can be found in literature.21,22 Advantages include the mild 
conditions, high conversion and high tolerance of diverse functional groups. Not 
surprisingly, the Knoevenagel reaction has also been used for the synthesis of 
butenolides (Scheme 2.7). An advantage of this process is the spontaneous formation of 
the lactone under mild reaction conditions, as in the example of the total synthesis of 
camptothecin (2.20) by Peters et al.23 Disadvantages include the requirement of a strong 
electron acceptor in the α-position of the lactone. Although the decarboxylation of such 
substrates is well known, the late introduction of the required benzyl group would 
undermine our strategy.  
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Scheme 2.7: Butenolide formation in the synthesis of camptothecin.23 
Since the formation of the double bond by the elimination of water is the driving 
force and the final irreversible step of this reaction, very little work has been done on 
substituted malonic esters, which might inherently block this crucial elimination. We 
postulated that we could combine the elimination of carbon dioxide with the formation 
of the double bond. As literature examples show, β-lactones are known to eliminate 
carbon dioxide at higher temperatures.24–26 After the initial nucleophilic attack of the 
malonate, the formed alkoxide is in close proximity to the malonic ester. We suggested 
that an intramolecular attack on the carbonyl would occur by a transesterification to a 
β-lactone. Under higher temperatures, this could form the desired product via a 
[2+2] cycloelimination. 
 
Scheme 2.8: Condensation of α-hydroxy ketones with malonic esters and analogs.27,28  
Only one example by Avetisyan et al.27 in 1981 and a later application in an 
industrial setting28 of such a reaction with substituted malonic esters was found 
(Scheme 2.8). They investigated the condensation of α-hydroxy ketones with the 
substituted 1,3-electron acceptors 2.22 and 2.25. Using secondary alcohol 2.21, 
elimination of water occurred in the opposite direction giving β,γ-unsaturated 
lactone 2.23. Similar results were observed when β-keto esters were used. If the 
γ-position was blocked by an additional substituent as in tertiary alcohol 2.24, the 
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unexpected product 2.26 was formed. However, the required reaction conditions are 
rather harsh. 
2.5.2 Synthesis of Key Intermediate Ester 2.31 
An intermolecular reaction was assumed to be challenging, as the aromatic 
substituent on the ketone raises the acidity of the α-protons, promoting side reactions of 
the formed enolate. To increase not only the selectivity, but also to stabilize the 
quaternary intermediate after the nucleophilic attack and thereby accelerate the reaction 
rate, we focused on an intramolecular reaction. The properly substituted α-hydroxy 
ketone 2.30 was synthesized by an Umpolung reaction, as described by the group of 
Stetter (Scheme 2.9).29 The commercially available malonic ester 2.27 was transformed 
to potassium salt 2.28, as described by Goel et al.30 This salt was then reacted with 
pivaloyl chloride to the mixed anhydride. The activation of the acid by a mixed 
anhydride was found to be superior to other methods, as the mild conditions suppress 
the competitive decarboxylation. The mixed anhydride was then reacted with 
alcohol 2.30 to the required ester 2.31 as a mixture of diastereomers.  
 
Scheme 2.9: Synthesis of ester 2.31 in five steps as a mixture of diastereomers. Compounds 
2.3029 and 2.2830 were synthesized according to literature procedures. Compound 2.29 is 
Stetter’s catalyst (3-benzyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride). 
2.5.3 Optimization of the Late Stage Cyclization 
The cyclization was first tried with similar conditions as described by 
Avetisyan et al. (Table 1, entry 1).27 While the expected product maculalactone A was 
formed, the yield was considerably low. Variations of the reaction conditions, showed 
only little influence on the yield (entries 2 to 6). Different catalysts, solvents and 
additives were evaluated. While catalysts such as 2,6-lutidine, diisopropylamine, 
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Li2CO3, NaOAc, CsOAc, aq. NaOH and Na2SO4 showed no product formation, Cs2CO3 
was found to be superior compared to K2CO3 (results not shown). The addition of 
crown ethers accelerated the reaction with Cs2CO3 and K2CO3 as base. Other additives 
like Lewis acids such as FeCl3 and AlCl3 gave no improvement. Reactions with Cs2CO3 
were performed in THF, toluene, CH3CN and tBuOH, but THF showed the best results 
(results not shown). 
Entry Catalyst (eq.) Solvent Temp. 
[°C] 
Time Yield 
[%] 
1 K2CO3 (1.5) Diglyme 160 45 min 33 
2 K2CO3 (2.0) Diglyme 110 2.5 h 32 
3 K2CO3 (2.0) Diglyme 110 4 h 23 
4 K2CO3 (0.2) Diglyme 120 9.5 h 30 
5 K2CO3 (3.2) 
KHCO3 (0.9) 
Diglyme 110 3 h 33 
6 K2CO3 (2.0) Dioxane 100 4 h 35 
7 Cs2CO3 (2.0) THF rf 45 min 70 
8 Cs2CO3 (1.5) THF rf 55 min 70 
9 Cs2CO3 (0.2) THF rf 2.5 h 65 
10a Cs2CO3 (0.2) THF rf 3 h 76 
Table 2.1: Optimization of the cyclization. aThe refluxing THF was run over a bed of activated 
4 Å molecular sieves. 
Further optimizations of the conditions were carried out with cesium carbonate. No 
crown ethers were used, as the acceleration was no advantage in context of the 
purification of the reaction mixture. The amount of base could be reduced to 20 mol%, 
while the reaction time had to be extended (entry 7 to 9).  
However, 1H-NMR measurements of the crude product showed significant amounts 
of keto alcohol 2.30. Ethanol, formed in the course of the elimination, can attack 
ester 2.31 under the reaction conditions, affording diethyl malonate 2.27 and the 
observed keto alcohol 2.30. To circumvent this transesterification, the ethanol had to be 
removed from the reaction mixture. This was accomplished by a special reaction setup 
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as depicted in section 9.5.1. Thereby, the condensate of the refluxing reaction was run 
over a bed of activated 4 Å molecular sieves. While ethanol and carbon dioxide are 
small enough to get adsorbed by the molecular sieve, the solvent runs back into the 
reaction. With the removal of residual ethanol, the transesterification could be 
suppressed below 1H-NMR detection limits, increasing the yield to 76% 
(entry 9 and 10) (Scheme 2.10). The remaining lack in the mass balance can be 
explained by diffuse polymerization, as these yellow-colored side products are easily 
removed by filtration over silica gel. 
 
Scheme 2.10: Cyclization of ester 2.31 to afford maculalactone A. 
Finally, an intermolecular cyclization of keto alcohol 2.30 and malonate 2.27 under 
the optimized reaction conditions was tested. Within three hours, first traces of 
maculalactone A could be observed. However, neither a reaction time of two days, nor a 
higher concentration could bring the conversion over 15% as determined by 1H-NMR. 
Our newly developed method of a late stage cyclization, allowed the synthesis of 
maculalactone A (1.34) from inexpensive commercial starting material in three steps in 
the longest sequence and an overall yield of 45%. Additionally, only one short column 
chromatography is necessary, making this procedure easy to scale-up. This reaction 
sequence was performed up to a scale of 5 g of maculalactone A. The final product 
could be crystallized directly from the filtered reaction mixture in high purity.  
2.5.4 Proposed Mechanism of the Cyclization 
In their publication, Avetisyan et al.27 describe the β,γ-unsaturated lactone 2.23 as 
the condensation product of secondary keto alcohol substrates. Only for tertiary keto 
alcohols, the α,β-unsaturated lactone was observed (Scheme 2.8). In contrast, our 
intramolecular cyclization of the secondary ester 2.31 provides maculalactone A with 
the double bond in α,β-position. To explain this difference, we considered the 
mechanism. In a first step, the methylene group of ester 2.31 is deprotonated by cesium 
carbonate to form the anion A (Scheme 2.11).31 This is followed by a nucleophilic 
addition to the keto group to give alkoxide B. Both of these steps are reversible. In a 
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Knoevenagel condensation, this would than be followed by the protonation of the 
alcohol and an E1cb elimination of water. However, the activated methylene in 
intermediate B has no available protons.  
We then proposed three different mechanisms for conversion of intermediate B to the 
final product of our synthesis. In the first two, the alkoxide could be protonated, as in a 
classical Knoevenagel condensation, affording C. In pathway I, the ester moiety of this 
intermediate could then be hydrolyzed in solution, resulting in the formation of acid D. 
Such 3-carbonyl acids are prone to decomposition in basic solutions. Carbon dioxide 
would be liberated affording enol ester E. By an overall 1,4-elimination of water, this 
reactive intermediate E would be converted to the final product maculalactone A. 
 
Scheme 2.11: Proposed mechanisms for the cyclization to give maculalactone A. 
Alternatively, as in pathway II, alcohol C could eliminate water, forming relatively 
stable lactone F. While this was the major product in the reaction described by 
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Avetisyan et al.27, we did not find any evidence for its formation. However, as in the 
first mechanism, the decarboxylation would be introduced by a saponification to acid G. 
Following CO2 liberation, intermediate H could tautomerize to give the conjugated 
product, maculalactone A (1.34). 
The third mechanistic hypothesis (pathway III), would include the formation of a 
β-lactone as in dilactone I (Section 2.5.1). The formation of this second lactone would 
only be possible if the carbonyl group and the alkoxide were in a cis-relationship. Since 
the open form A and lactone B are in equilibrium, the trans-compound could be 
converted to the cis-form. Maculalactone A would be generated by the release of carbon 
dioxide from β-lactone I in a cyclo-elimination step. 
The investigation of the mechanism proved to be difficult. The intramolecular nature 
of the reaction, together with the potentially acid, base or thermal instability of the 
intermediate, tolerate only certain analytic methods such as NMR, IR or UV. In a first 
attempt, we wanted to determine the reaction order of the different starting materials. 
Therefore, two concentrations of ester 2.31 and two amounts of Cs2CO3 were reacted at 
80 °C for 3.5 hours. To run the reactions in parallel, a reduced reaction setup with 
sealed tubes was used. Surprisingly, the reactions with usual concentrations of ester 
2.31 showed no product formation and the three times diluted reactions showed only a 
minimal maculalactone A formation. Nevertheless, other unknown compounds were 
detected. However, to gain more information about the actual mechanism, further 
experiments are required. Tracking the reaction with IR in a setup, allowing refluxing, 
could give more information on the reaction speed, potential intermediates and the 
rate-limiting step. 
2.6 Conclusion 
To date, three groups have published total syntheses of maculalactone A, but all 
routes possess an overall yield below 10%.1,2,4 While we reproduced the synthesis of 
Brown et al., we identified the late nucleophilic introduction of benzyl groups as an 
obstacle in all reported syntheses.1 In a first attempt, we tried to work around such a 
nucleophilic substitution. While an electrophilic benzylation was unsuccessful, a radical 
reaction affording anhydride 2.04 in two-steps, was found to be more promising. This 
shortcut in the synthesis of Brown et al. enabled the synthesis of 
maculalactone A (1.34) in five steps and an overall yield of 17%. 
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In addition, an alternative route that prevented a late-stage benzylation was 
developed. This was accomplished by an early installation of all benzyl groups and a 
ring closure in the last step. In a first attempt, we planned to close the lactone by 
metathesis. While the synthesis of diene 2.19 was accomplished in sufficient yield, a 
maximal conversion of 11% in the metathesis could not be overcome. 
We then proposed a cyclization initiated by an intramolecular addition of an 
activated methylene, resulting in olefin formation by the elimination of ethanol and 
carbon dioxide. The synthesis of the cyclization precursor 2.31 was accomplished in 
three steps. In a first attempt, the desired maculalactone A (1.34) was isolated in 30% 
yield. As changes of the catalyst amount, temperature and reaction time had little 
influence on the yield, other catalysts, solvents and additives were screened. Cesium 
carbonate as catalyst doubled the yield, while optimization of the reaction set-up 
increased the yield to 76%. With our newly developed route, maculalactone A was 
synthesized from inexpensive commercially available starting materials in overall four 
steps and a yield of 45%. Additionally, only one short column chromatography is 
necessary, making the procedure easy to scale-up.  
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3.1 Introduction 
3.1.1 Biofouling, an Unsolved Problem 
The term biofouling describes the undesired accumulation of biological material on 
underwater structures such as platforms, jetties and ship hulls or inside water containing 
structures such as pipes, tanks and other technical equipment (Figure 3.1).1,2 The 
formation of such bio-films causes adverse effects such as faster corrosion, a reduced 
lifetime and changed surface properties.  
In marine trade, these biological settlements can cause additional problems such as 
dispersion of adhered species and a higher frictional resistance.1–5 Due to biofouling, 
fuel consumption of a ship can increase by up to 40%.2 In the marine environment, 
these problems were successfully prevented by the use of tributyltin compounds (TBT) 
as antifouling coatings. In the end of the last century, TBT was found to cause serious 
damage to the marine environment, forcing the international maritime organization to 
ban the use of TBT coatings.2,5,6 Since TBT coatings protected about 70% of the marine 
vessels, alternatives coatings are necessary.  
  
  
Figure 3.1: Left, heavily fouled ship hulls.2 Upper right, heat exchangers of a pump after six 
month of operation. Lower right, biofilm formation on a valve in a drinking water system.7 
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Fig. 1. Examples of heavily fouled hulls. Courtesy of Hempel’s Marine Paints A/S.
combating biofouling on ships. The widespread use of these
paints, estimated to cover 70% of the present world fleet in
[9,10], has led to important economic benefits [3,4]. Unfor-
tunately, the TBT-SPC systems affect adversely the environ-
ment. As an example, it has been shown that extremely low
concentrations of tributyltin moiety (TBT) cause defective
shell growth in the oyster Crassostrea gigas (20 ng/l) and
imposex, development of male characteristics in female gen-
italia, in the dog-whelk Nucella sp. (1 ng/l) [11,12]. Malfor-
mations have been observed in many other species and the
International Maritime Organization (IMO) also reports ac-
cumulation in mammals and debilitation of the immunolog-
ical defences in fishes. These facts forced the development
of national regulations in countries all over the world [3]:
• Restriction of the use of TBT-containing compounds on
vessels less than 25m in length.
• Restriction of the release rates of TBT-containing com-
pounds from the paints.
• Elimination of the use of free TBT-holding compounds
in paints.
Furthermore, after an International Convention held on 5
October 2001, parties to the convention are required to ban
the application of TBT-based antifouling (A/F) paints from 1
January 2003, and the presence of such paints on the surface
of the vessel from 1 January 2008 (effective dates) [10]. Al-
though the exact dates for the global application of the reso-
lutions of the convention are still uncertain, regional legisla-
tions have already been developed in the same direction (e.g.
Amendment to Marketing and Use Directive (76/769/EEC)).
Thus, the paint industry has been urged to develop TBT-free
products able to replace the TBT-based ones but yield the
same economic benefits and cause less harmful effects on the
environment. The major antifouling paint companies (e.g.
International Marine Coatings, Hempel’s Marine Paints, Jo-
tun, Ameron, Chugoku Marine Paints) have already decided
to comply with the regulation by removing all TBT-based
paints from their product assortment from 1 January 2003.
The other party concerned, the shipping companies, has also
started to react to the legislative changes by a fleet-wide con-
version to tin-free paints (e.g. A.P. Møller and Leif Höegh).
In contrast to previous reviews (e.g. [1,9,11,13–23]), this
paper seeks to combine all main topics related to antifoul-
ing (A/F) technology, and aims at a thorough picture of
the state of art in marine biofouling prevention systems.
Hence, it includes a description of sea water, an introduc-
tion to the biology of the fouling process, and a summary
of the historical development of A/F paints. The latter cov-
ers not only biocide-based systems, by far the most used,
but also alternative methods. This historical description
leads to a discussion of tributyltin (TBT)-based systems
and their tin-free biocide-based replacements, the analysis
of which constitutes the backbone of the paper. Tin-free
biocide-based products are described by an analysis of their
binder systems, pigments, and booster biocides used to
complement the biocidal action of copper. In addition, the
most promising options to dominate the A/F market in the
future are presented and described.
2. The marine environment
Little attention has been paid to the influence of the differ-
ent sea water parameters on the performance of chemically
active A/F paints. It has recently been shown that chemical
reactions and diffusion phenomena are key mechanisms in
the performance of biocide-based A/F paints, and that these
can be markedly affected by sea water conditions [24]. The
above-mentioned paints are based on the release of several
biocides, which are linked or, more often, embedded in a
film-forming organic matrix (see Fig. 2). Sea water has to
penetrate into the paint, dissolve such biocides and diffuse
out into the bulk phase again. To avoid the build-up of long
diffusion paths and consequently decreasing release rates,
the organic matrix is designed for slow reaction with sea wa-
ter (and sea water ions) within the paint pores. Once this re-
action has reached a certain conversion at the sea water–paint
interface, the binder phase is released, thus controlling the
thickness of the biocide-depleted layer (leached layer).
Many references to the influence of sea water parame-
ters on the performance of A/F paints can be found in the
open literature. For example, the salinity value influences
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diffusive heat transport. Thus, heat transfer by convec-
tive transport is inhibited. In addition, friction resistance
is increased, which increases energy consumption. This
aspect is considered to be an even more costly problem
in heat exchange (M
elo and Bott 1997). Similar to
membrane systems, heat exchangers in aqueous systems
operating in the temperature range 5–60°C always carry
biofilms which remain unnoticed, because their effects
stay below the threshold level of interference. Biofoul-
ing problems do not arise from micro-organisms which
have suddenly invaded the system, but are much more
likely to be caused by an increase in nutrient concentra-
tion or an absence of inhibiting factors. The additives
can represent nutrients. As an example, chromate has
been replaced by other corrosion inhibitors because of
its environmentally undesirable properties. A new or-
ganic inhibitor was introduced which had excellent
properties, including full biological degradability. The
system protected by this substance failed after 3months.
Biodegradation of the inhibitor had started during oper-
ation and coated the exchanger surfaces with a thick mi-
crobial layer (Fig.2). Thus, an environmentally reason-
able step has to be harmonised with all other effects in
the system.
If light has access, substantial algal growth can occur.
This is frequently the case in cooling towers. The instal-
lations can be overgrown so heavily that they physically
break down (Characklis 1990). In ocean thermal energy
conversion, biofouling is addressed as the most difficult
problem, seriously limiting the use of an otherwise
promising technology (Darby 1984).
Ship hulls
A classic case of surfaces prone to biofouling are ship
hulls. The speed of ships can be significantly reduced
even by thin biofilms. Prior to colonisation by higher or-
ganisms, such as mussels, a microbial biofilm develops.
D.C. W
hite (personal communication) has assessed that
the United States Navy has to spend more than U.S.
$
500 million for additional fuel, which is required to
overcome the additional friction resistance caused by
biofilms. A biofilm of only 100
µm thickness leads to a
5–15%
 increase in friction resistance (Characklis 1990).
The attempts at effective anti-fouling coatings go back to
the mediaeval ages when copper plating was introduced,
without long term effect. After a certain time, some or-
ganisms can tolerate the toxicity of copper, colonise it,
complex the ions and shield other organisms to which
copper would be poisonous. Successively colonising
species do not encounter the copper surface but the pri-
mary biofilm. The problem has been transiently solved
by modern anti-fouling paints containing tributyl tin
compounds (Fig.3). Unfortunately, they are so poison-
ous and recalcitrant to biological degradation (Cooney
and W
uertz 1989) that many countries have resorted to a
partial ban. Thus, the problem remains unresolved.
Drinking-water reservoirs anddistribution systems
The maintenance of the hygienic and aesthetic quality of
water during transport in the distribution systems still
challenges drinking-water technology (Percival et al.
Fig.2
Heat exchanger of a pump, protected by a biodegradable
corrosion inhibitor, after 6
months of operation. The corrosion in-
hibitor is completely degraded and causes massive biofouling
Fig.3
Structure of tributyl tin compounds which are used for anti-
fouling. RedSn, green(X) may be F, Cl, Br, O-( nBu)3 Sn, or others
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combating biofouling on ships. The widespread use of these
paints, estimated to cover 70% of the present world fleet in
[9,10], has led to important economic benefits [3,4]. Unfor-
tunately, the TBT-SPC systems affect adversely the environ-
ment. As an example, it has been shown that extremely low
concentrations of tributyltin moiety (TBT) cause defective
shell growth in the oyster Crassostrea gigas (20 ng/l) and
imposex, development of male characteristics in female gen-
italia, in the dog-whelk Nucella sp. (1 ng/l) [11,12]. Malfor-
mations have been observed in many other species and the
International Maritime Organization (IMO) also reports ac-
cumulation in mammals and debilitation of the immunolog-
ical defences in fishes. These facts forced the development
of national regulations in countries all over the world [3]:
• Restriction of the us of TBT-contai ing compounds on
vessels less than 25m in lengt .
• Restriction of the release rates of TBT-containing com-
pounds from the paints.
• Elimination of the use of free TBT-holding comp unds
in paints.
Furthermore, after an International Convention held on 5
October 2001, parties to the convention are required to ban
the application of TBT-based antifouling (A/F) paints from 1
January 2003, and the presence of such paints on the surface
of the vessel from 1 January 2008 (effective dates) [10]. Al-
though the exact dates for the global application of the reso-
lutions of the convention are still uncertain, regional legisla-
tions have already been developed in the same direction (e.g.
Amendment to Marketing and Use Directive (76/769/EEC)).
Thus, the paint industry has been urged to develop TBT-free
products able to replace the TBT-based ones but yield the
same economic benefits and cause less harmful effects on the
environment. The major antifouling paint companies (e.g.
International Marine Coatings, Hempel’s Marine Paints, Jo-
tun, Ameron, Chugoku Marine Paints) have already decided
to comply with the regulation by removing all TBT-based
paints from their product assortment from 1 January 2003.
The other party concerned, the shipping companies, has also
started to react to the legislative changes by a fleet-wide con-
version to tin-free paints (e.g. A.P. Møller and Leif Höegh).
In contrast to previous reviews (e.g. [1,9,11,13–23]), this
paper seeks to combine all main topics related to antifoul-
ing (A/F) technology, and aims at a thorough picture of
the state of art in marine biofouling prevention systems.
Hence, it includes a description of sea water, an introduc-
tion to the biology of the fouling process, and a summary
of the historical development of A/F paints. The latter cov-
ers not only biocide-based systems, by far the most used,
but also alternative methods. This historical description
leads to a discussion of tributyltin (TBT)-based systems
and their tin-free biocide-based replacements, the analysis
of which constitutes the backbone of the paper. Tin-free
biocide-based products are described by an analysis of their
binder systems, pigments, and booster biocides used to
complement the biocidal action of copper. In addition, the
most promising options to dominate the A/F market in the
future are presented and described.
2. The marine environment
Little attention has been paid to the influence of the differ-
ent sea water parameters on the performance of chemically
active A/F paints. It has recently been shown that chemical
reactions and diffusion phenomena are key mechanisms in
the performance of biocide-based A/F paints, and that these
can be markedly affected by sea water conditions [24]. The
above-mentioned paints are based on the release of several
biocides, which are linked or, more often, embedded in a
film-forming organic matrix (see Fig. 2). Sea water has to
penetrate into the paint, dissolve such biocides and diffuse
out into the bulk phase again. To avoid the build-up of long
diffusion paths and consequently decreasing release rates,
the organic matrix is designed for slow reaction with sea wa-
ter (and sea water ions) within the paint pores. Once this re-
action has reached a certain conversion at the sea water–paint
interface, the binder phase is released, thus controlling the
thickness of the biocide-depleted layer (leached layer).
Many references to the influence of sea water parame-
ters on the performance of A/F paints can be found in the
open literature. For example, the salinity value influences
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ed at the walls, with less than 5% in the water phase
(Flemming 1998). These biofilms contribute consider-
ably to the overall purification pr cess, because ey de-
grade diluted organic matter. There is no correlation be-
tween the cell concentration in th  water a d in the bio-
film, although most of the cells found in the water phase
originate from biofilms. However, ongoing large-scale
field research reveals that biofilms eveloping on certi-
fied materials seem not to represent a threat to drinking
water and in general do not harbour potentially patho-
genic organisms (Flemming et al., in preparation). The
situation is different when materials are involved which
support microbial growth. An exampl  is show  in
Fig. 5a: massive biofilm formation on synthetic elasto-
mers in drinking-water pipelines. Figure 5b shows a
scanning electron micrograph of the same biofilm. The
size of the cells indicates very good growth conditions,
in contrast to the starving microcolonies which are usu-
ally found on materials which do not leach nutrients.
This biofilm harboured coliform bacteria which were de-
tected in downstream drinking-water samples.
In medicine, mycobacteria have long been known as
trumpet bacteria, occurring in the mouthpieces of musi-
cal instruments of tuberculosic performers and, less ar-
tistically, in telephone handles (Müller 1946).
Countermeasures
In biofouling cases, it is reasonable to follow a three step
protocol: (1) identification of the cause and localisation of
the problem, (2) sanitation (cl aning is even more impor-
tant than killing the micro-organisms) and (3) prevention.
This has been described in detail earlier (Flemming
nd Schaule 1996). Usually, w en a problem arises in a
process, the diagnosis of biofouling will be made when
other causes do not explain the phenomenon. In order to
design the most effective countermeasures, it is impor-
Fig. 5a, b Biofilm develop-
ment. a Massive biofilm 
development on an elastomer
coating of a valve in a drink-
ing-water system. b Scanning
electron micrograph of a 
sectio  of the biofilm 
(Lange et al. 2002)
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In fresh water systems, biofilm formation is typically slower. Nevertheless, 
biofouling can cause problems such as drinking water contamination, changed surface 
properties such as a decreased thermal transmittance, reduced flow and pipes 
obstruction. In the past, these issues in fresh-water systems were addressed in a similar 
manner as in the marine environment.  
Heat exchangers in power stations or chemical plants, driven by fresh-water, are also 
strongly affected by biofouling.8–11 The build-up decreases not only the lifetime of the 
equipment, but also reduces also the heat transfer rate, which can lead to obstruction of 
parts or the entire apparatus. The methods to control the bio-film formation include 
filtration of the water supply, abrasive cleaning with sponge balls, or the use of highly 
toxic chemicals such as hypochlorite.  
3.1.2 Maculalactone A as an Antifouling Agent 
In contrast to man-made structures, marine organisms are usually less affected by 
biofouling. Nature developed different strategies to prevent the settlement of other 
species. One is the production of chemical compound such as secondary metabolites, 
often referred as natural products, to deter adhesion and grow.4,11,12 In recent years, 
butenolide systems moved into the focus of interest, as they show not only anti-fouling 
properties, but can also inhibit quorum sensing.13 Various antifouling butenolide 
structures from marine sources are described in literature,14–16 of which 
5-octylfuran-2[5H]-one is a great example.17–19 
 
Figure 3.2: K. maculans growing on a Hong Kong rocky shore.20 
The slow growing cyanobacterium Kyrtuthrix maculans forms pure colonies on 
moderately exposed shores (Figure 3.2). The low reproduction rate combined with the 
lack of other organisms in the colonies indicates an antifouling protection. Since the 
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colonies lack a kind of specialized surface, the cyanobacterium has been suggested to 
produce a chemical defense. In 1996, the group of Brown reported the isolation of 
(+)-maculalactone A (1.34) from K. maculans (Section 1.4).21 In addition to the 
isolation of other secondary metabolites from K. maculans and the first total syntheses 
of maculalactone A, B (1.35) and C (1.36), Brown and co-workers were also interested 
in the antifouling properties of maculalactone A. The capability of maculalactone A to 
act as a chemical defense was investigated in a toxicity study. The LC50 concentrations 
of the four potential herbivores Tetraclita japonica, Balanus amphitrite, Ibla cumingii 
and Artemina salina were found between 1.1 and 5.2 µg/ml.20 This moderate to high 
toxicity suggests maculalactone A to be a potential antifouling agent.  
 
Figure 3.3: Extent of fouling of painted PVC plates after exposure to seawater for 12 weeks.20 
In a further study, synthetic racemic maculalactone A (1.34) was incorporated in 
commercial “house-hold” paints with no anti-fouling activity.20 Both the natural and the 
ten-fold concentration of maculalactone A were used. Consequently, PVC plates were 
painted either with a copper containing antifouling paint, the unmodified household 
paint or the maculalactone A-containing paints. The plates were submerged for 12 
weeks in the Hong Kong Sea, before the surface coverage with marine organisms was 
determined (Figure 3.3). The addition of maculalactone A to the paint resulted in a 
reduction of settlement of bivalves. Although this reduction was partially compensated 
by increased algae growth, this test showed the potential of maculalactone A (1.34) as 
antifouling agent.  
3.1.3 Biomimetic Surface Modification 
In the recent years, our group developed a system for the chemical modification of 
metal oxide surfaces. In early systems, this technology based was on the observation 
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that the siderophore anachelin (3.01)22 strongly binds to metal oxides (Figure 3.4). The 
metal oxide binding side was identified as the catechol moiety (indicated in red). As 
metal surfaces are usually covered by a metal oxide layer, these catechols were thought 
to be the appropriate tool to modify such surfaces. In first studies, this anchor moiety 
was isolated and modified with a methylated PEG chain (3.02)23,24 and later connected 
to vancomycin, to afford antimicrobial surfaces.25,26  
 
Figure 3.4: Various catechol based anchors.23,27–29 
In parallel, an anchor inspired by the mussel adhesive protein (MAP) was developed 
by other groups.30–34 MAP consists of up to 27 mol% of 3,4-dihydroxyphenylalanine 
(DOPA, 3.03), facilitating the strong adhesive properties of this protein. Both anchors 
show distinct similarities and a combination of both was found to be superior.28 
Nitrodopamine (3.04) combines the easy accessibility of DOPA derivatives with the 
strong binding affinity of the electron sufficient catechols, as in the anachelin-derived 
systems. Such a nitrodopamine was, for example, used as anchor in the modulation of 
quorum sensing.35 Recently, the modified functional hybrid 3.05 was employed in a 
light induced surface release system.29 
Despite these various anchors and the multiple applications, there are still some 
issues with this system. The attachment of the cargo to the anchor is often realized by 
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ester or carbonate functions and little is known about the long-term stability of such 
compounds in water. Furthermore, the high affinity of these compounds to any metal 
oxide including silicon oxide makes the handling challenging. Often a protection of the 
catechol is necessary, causing further problems in the final deprotection step. 
3.2 Concept for the Antifouling Protection of Metal Surfaces 
with Maculalactone A 
The emerging biofouling issues after the ban of TBT and the promising biomimetic 
antifouling properties of maculalactone A (1.34) stimulated us to come up with a new 
concept for the protection of metal surfaces. In combination with our experience in 
surface modifications, we designed a functional hybrid combining the antifouling 
activity of maculalactone A with the surface stability of one of our anchors (Figure 3.5). 
The hybrid consists of three different, covalently linked parts. The anchor immobilizes 
the system on the metal surface and keeps the hybrid in place. A linker increases the 
flexibility of the hybrid and enhances the accessibility of the warhead. PEG linkers are 
often used for such applications, but also other chains are possible. The third part is the 
maculalactone A warhead, facilitating the antifouling protection. 
 
Figure 3.5: Concept for the antifouling protection of metal surfaces with a bifunctional hybrid. 
With this functional hybrid in hand, it could be immobilized on various metal 
surfaces through a dip and rinse procedure. Ideally, already a low density of the hybrid 
would be sufficient to protect the surface from biofouling, while a majority of the 
surface would remain free. Therefore the often-required properties of metal surfaces 
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would stay intact. This is of particular interest in heat exchangers and other technical 
equipment. However, such an application is only promising if the hybrid exhibits good 
long-term stability and if large quantities can be produced by a simple and inexpensive 
procedure. 
This concept and first results of the following studies were awarded with the first 
price of the Clariant CleanTech award 2012. 
3.3 Maculalactone A Analogues for Covalent Attachment and 
SAR Study 
3.3.1 Synthesis of Substituted Maculalactone A Analogues 
To enable a covalent linkage to the anchor, a modification site of maculalactone A 
needed to be devised. The para-position of one benzyl moiety was thought to have the 
least influence on the biological properties. The introduction of a methoxy group was 
found to offer the highest scope for later modifications and sufficient orthogonality for 
the synthesis. 
 
Scheme 3.1: Synthesis of modified maculalactone A precursors. PMB = p-methoxybenzyl. 
Synthesis of 3.07 as described in literature.36 Synthesis of 3.13 was conducted by a procedure 
from Pattenden et al. and 3.10 was synthesized in a similar fashion.37 
Consequently, the three methoxy-substituted precursors 3.08, 3.10 and 3.13 were 
synthesized (Scheme 3.1). Malonic ester 3.07 was accessed as described by Shiotani 
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et al.36 and converted to malonate 3.08 at reduced temperature in 81% yield. The 
asymmetrically substituted α-hydroxy ketones 3.10 and 3.13 were synthesized either by 
or similar to a procedure by Pattenden et al.37 Therefore, the aldehydes were converted 
to the TMS protected cyanohydrins 3.09 and 3.12. After the addition of the 
corresponding Grignard reagent, the resulting imines were hydrolyzed and the TMS 
protecting group was removed under acidic conditions. 
 
Scheme 3.2: Synthesis of modified maculalactone A analogues. 
Finally, the modified precursors were first converted to the corresponding esters 
3.14, 3.15 and 3.16 (Scheme 3.2). Subsequently, these were cyclized to the 
maculalactone A analogues 3.17, 3.18 and 3.19. This transformation was achieved 
under the same conditions as described earlier for the synthesis of maculalactone A 
(Section 2.5).  
3.3.2 SAR Study of Modified Maculalactone A Derivatives 
To identify a position that allows modifications, the biological properties of the three 
analogues have to be compared with the one of maculalactone A (1.34). Ideally, the 
antifouling capacity would be quantified. However, such assays are not standardized, 
vary widely and require incubation periods of several weeks. 
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In accordance with the work of Brown, an alternative was found in toxicity assays. 
Such standardized tests are commercially available, deliver reproducible results and can 
be accomplished in two to three days. Thamnocephalus platyurus together with Artemia 
franciscana were used as test organisms. The latter is a close relative of A. salina, 
which was employed in the studies of Brown.20 
The toxicity assays were obtained from MicrobioTest Inc. in Belgium and conducted 
by the standard method. Five concentrations of maculalactone A and analogues were 
analyzed in three repetitions. The mortality is the ratio between dead organisms and the 
total number in each repetition (Figure 3.6). 
 
Figure 3.6: SAR study of modified maculalactone A analogues. Grey: A. franciscana. Black: T. 
platyurus. Values are given as the mean of three independent experiments with ten animals, 
error bars denote the standard error of the mean (SEM). 
The assay shows a slightly lower toxicity of the synthetic maculalactone A (1.34), as 
compared to the findings of Brown et al.20 This is either caused by the racemic nature of 
the synthetic 1.34 or is a result of the differences in the conducted assays. 
Compared to maculalactone A, analogue 3.17 exhibited an increased toxicity in 
A. franciscana and similar values in T. platyurus. In contrast, the modified analogues 
3.18 and 3.19 showed a reduced or no effect on the test organisms. According to these 
findings, analogue 3.17 is the appropriate candidate for further investigations. 
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Beside the measured toxicity, the assays exposed a strong effect on the swimming 
ability of the organisms. While they show a normal movement in a 1 µM maculalactone 
A solution, they lose their ability to swim in a controlled manner at a concentration of 
10 µM. 
3.3.3 Validation of the Methoxy Platform 
Finally, the usage of the methoxy group as linkage point for further modifications 
was validated (Scheme 3.3). In a first step, the methyl group was removed in the 
presence of boron tribromide to give phenol 3.20 in quantitative yield. As the nature of 
the linker was not yet specified, two potential connections were investigated. 
 
Scheme 3.3: Deprotection of 3.16 and validation of the methoxy functionalization as linkage 
position for further modifications. EtO(CH2CH2O)3Ts (3.21) was prepared as described in 
literature.38,39  
To investigate the alkylation of phenol 3.20, it was first converted to the 
corresponding triflate by standard procedures. This intermediate was elongated through 
a Suzuki cross coupling with an aliphatic chain to give derivative 3.21 with a 
carbon-carbon type linkage.40 PEGylation was achieved by reacting phenol 3.20 with 
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the activated PEG chain 3.22 in the presence of a mild base. This Williamson 
etherification afforded compound 3.23 in modest yield.  
3.4 Studies Towards an Inexpensive PEGylated Anchor 
System 
3.4.1 Concept for the Desymmetrization of Longer PEG Chains 
Modifications of short PEG chain ends like the one used for the synthesis of 
maculalactone A analogue 3.23, have a big influence on the physical and chemical 
properties. In the preparation of the activated PEG 3.22 described by Baena et al.38 and 
Watanabe39, the unsubstituted symmetrical chain 3.24 is ethylated on one side 
(Scheme 3.4). This changes the properties of the compounds to allow for separation of 
the mono-alkylated 3.25 by distillation.  
 
Scheme 3.4: Preparation of the activated PEG chain 3.22, as described in literature.38,39  
Increasing the length of the PEG chain causes the separation of the single side 
modified species to become more challenging. Additionally, more expensive separation 
methods, such as column chromatography on silica gel, reversed phase columns 
chromatography or size exclusion chromatography have to be used. Thus, the longer 
single side modified PEG chains are much more expensive, and can, therefore, only be 
used for selected applications were the cost is not limiting (Section 3.6). In contrast to 
the usual modifications like protecting groups, the introduction of one of our anchors 
would offer an additional separation method. Since theses anchors are catechols, they 
can be deprotonated by strong bases. However, the miscibility of PEG with water and 
organic solvents prevents a separation from the coupling reaction by acid-base 
extraction. Alternatively, the acidic anchors could be isolated by solid phase extraction 
using a basic cationic ion exchange resin. 
In the here-described concept, a large excess of PEG would be used in the coupling 
reaction to the anchor. This would prevent double anchor attachment to the PEG chain. 
After the reaction, the modified PEG could be isolated from the non-modified PEG by 
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an appropriate work-up. Potential limitations in this plan include the unprotected 
catechol and a good base stability of the used functional groups. 
3.4.2 PEGylated Anchor Synthesis 
To obtain an inexpensive PEGylated anchor, the synthesis has to avoid expensive 
materials and the target has to be reached in a limited number of steps and high yield. 
Additionally, purification by crystallization or distillation would be ideal. Furthermore, 
the anchor should have good hydrolytic stability. For this reason, ester, amide and 
carbonate connections were avoided and the first heteroatom was planned to be at least 
three carbons away from the anchor to prevent cleavage by UV light.29 
In our first approach, the anchor was synthesized with a protected catechol moiety, 
which would be liberated readily after the PEG coupling. In this manner, veratrole 
(3.26) was reacted in a Friedel-Crafts acylation with succinic anhydride (3.27) in 
accordance to a procedure described by Ghosh et al. (Scheme 3.5).41 The formed acid 
3.28 was then nitrated under standard conditions to give nitrocatechol 3.29. The acid 
was then reduced in the presence of borane to alcohol 3.30. The remaining γ-carbonyl 
group was thought to decrease the aromatic electron density and, thereby, increasing the 
stability of the anchor attachment to metal surfaces. 
 
Scheme 3.5: Preparation of protected catechol 3.30. The deprotection was tried with boron 
tribromide in CH2Cl2 at -78 °C to room temperature and sodium ethanthiolate in THF and 
dioxane at temperatures up to 150 °C. 
To test the catechol deprotection without the PEG chain, alcohol 3.30 was subjected 
to standard conditions with boron tribromide or sodium ethanthiolate.42 In both cases, 
this led to complete decomposition. With boron tribromide and under certain 
conditions, the potential desired product was observed in the crude mixture, but 
decomposed during further workup. As such nitro catechols are usually stable, this has 
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to be a result of the additional carbonyl group. It is likely that, the negative mesomeric 
effect promotes the formation of the quinone methide, which can then undergo various 
side reactions. 
Consequently, we tried to remove the carbonyl group (Scheme 3.6). Such benzylic 
heteroatoms can be removed under reductive conditions. Therefore acid 3.28 was 
treated for two days with lithium aluminium hydride in refluxing THF. While all 
additional functionalities were reduced to give product 3.31, the oxygen remained in the 
benzylic position. Further reduction of diol 3.31 with palladium on activated carbon and 
hydrogen was unsuccessful. Other known methods would allow the conversion, but this 
would increase the reagent costs and the number of steps, which was undesirable for 
this work. 
 
Scheme 3.6: Removal of the carbonyl group under reductive conditions. The hydrogenation was 
tried with 10% palladium on activated coal in MeOH and EtOAc, with and without the addition 
of acetic acid at room temperature and at 50 °C. 
The addition ot the carbonyl group through the Friedel-Crafts acylation hinders the 
viability of the route. Furthermore, protection of the catechol moiety was not favorable 
due to deprotection issues. 
3.4.3 Protecting Group Free PEGylated Anchor Synthesis 
A new precursor with a three-carbon chain and an unprotected catechol was found in 
caffeic acid (1.07) (Scheme 3.7). This phenylpropanoid natural product is inexpensive 
and can be easily converted to alcohol 3.32 by catalytic hydrogenation and reduction 
with borane. Such free catechols are known to be extremely reactive in electrophilic 
aromatic substitutions. Therefore, a procedure with sodium nitrite in an acidic solution 
was used. A similar procedure was already applied in the synthesis of the nitrodopamine 
anchor (3.04).43,44 In the reaction with dopamine, the crystallization of the semi-sulfate 
product after the first substitution prevents the double nitration. In the synthesis of 
nitrocatechol 3.34, the over nitration was avoided by buffering the system to a pH of 4.4 
as it was described for similar substrates by de la Bretèche et al.45 With this route, the 
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nitrocatechol anchor 3.34 was synthesized in three step and 55% yield in sufficient 
purity without chromatography. 
 
Scheme 3.7: Synthesis of the caffeic acid derived nitrocatechol anchor 3.34. 
For the following etherification, we planned to activate the hydroxy function of 3.34 
and substitute it with PEG. However, free phenol groups are better nucleophiles and 
could potentially lead to polymerization of the anchor. For this reason, the catechol had 
to be inactivated for the next step. 
 
Scheme 3.8: Attempted PEGylation of anchor 3.34 over the dioxosulfinylbenzoid A and 
synthesis of the chlorinated intermediate 3.35.  
Reports by Frederick et al. and the group of Feller describe the surprisingly high 
stability of dioxosulfinylbenzoids, resulting from the treatment of catechols with thionyl 
chloride.46,47 With our anchor 3.34, this reaction leads not only to a deactivation of the 
catechol, but also to the activation of the hydroxy group by chlorination (Scheme 3.8). 
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It was at this point not clear if the bidentate nature of the dioxosulfinylbenzoid A was 
sufficient to prevent a nucleophilic substitution at the sulfur by PEG, liberating the 
phenols. After the chlorination of anchor 3.34, the excess thionyl chloride was removed 
by distillation and triethylene glycol was added as test substrate. Neither the addition of 
strongly basic sodium hydride nor the elevated temperatures were sufficient to show 
product formation by UPLC-MS. However, after quenching with water, chlorinated 
product 3.35 could be isolated. 
To overcome the low reactivity the chloride, an alternative activation of the hydroxy 
group by mesylation was tried. In this study, the more easily accessed catechol 3.33 was 
used. After treatment with methansulfonyl chloride, trisubstituted intermediate 3.36 was 
isolated (Scheme 3.9). However, under etherification conditions with triethylene glycol, 
none of the desired product was observed. An analysis of the reaction mixture by 
UPLC-MS showed mesylated triethylene glycol, resulting from a transesterification at 
the sulfur. The simultaneously liberated phenol is thought to lead to the observed 
polymerization of the anchor. 
 
Scheme 3.9: Tried PEGylation of anchor 3.33 over the triple mesylated intermediate 3.36. 
A second possibility to overcome the low reactivity of this substrate was to switch 
the role of the reaction partners. A tosylated PEG derivative, as it was used earlier, is a 
better electrophile due to the neighbor group effect of the adjacent oxygen 
(Section 3.3.3).48 To mask the catechol function, the synthesis was reordered. Acid 3.32 
was directly nitrated to give nitrocatechol 3.37 (Scheme 3.10). The degree of nitration 
was controlled by the pH of the reaction solution and the addition speed of the sodium 
nitrite solution. However, this reaction proved to be more difficult, as the nitration of 
alcohol 3.33 and the conditions had to be optimized after every scale-up step. The acid 
was then reduced with borane, affording intermediate boronic ester B with masked 
phenol groups only after the addition of stoichiometric amounts of water.49 However, 
the following substitution of the tosylated triethylene glycol was not successful.  
HO
HO
OH
3.33
MsO
MsO
OMs
3.36
MsCl
pyridine, rt
45%
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Scheme 3.10: Nitration of acid 3.32, reduction to the alcohol and masking of the catechol 
followed by a substitution. Alternative esterification of acid 3.37 with triethylene glycol. 
Alternatively, acid 3.37 formed ester 3.38 in the presence of ten equivalents of 
triethylene glycol under acidic catalysis in complete conversion. However, the ester is 
not base stable and isolation by solid phase extraction was not possible. Alternatively, 
neutral ion exchange resins are known to absorb phenols respectively catechols.50–52 A 
separation of ester 3.38 from remaining triethylene glycol by ion exchange 
chromatography showed initial positive results, but a method affording pure material 
was not achieved in the available time.  
In conclusion, these results show some interesting aspects of an inexpensive 
PEGylated anchor system, major issues still remain. One problem is the etherification of 
the anchor and the PEG chain. Further investigations are necessary to accomplish the 
goal of this project. If these issues could be overcome, the presented concept would give 
access to an affordable linker anchor couple. Furthermore, PEGylated anchors such as 
ester 3.38 have already been used to form protein resistant surfaces and prevent 
biofouling.23,24,53,54 
3.5 Synthesis of the Anchored Maculalactone A Hybrid 
In interest of time, a shorter and more straightforward hybrid was designed and 
synthesized. A shorter bifunctional fatty acid derived linker was chosen. Undecylenic 
acid (3.39) is isolated from castor oil by cracking under pressure and subsequent steam 
HO
HO
O
OH
3.32
i. BH3*THF
THF, rf
ii. H2O
HO
HO
O
OH
3.37
NaNO2
NaOAc/AcOH buffer 
rt
66%
NO2
HO
HO
O
NO2
3
OH
O
OH
NO2
O
B
O
HO
B
triethylene glycole
H2SO4 cat.
THF, rt
3.38
TsO(CH2CH2O)3Ts
KOH
THF
 FROM A NATURAL PRODUCT TO A FUNCTIONAL MOLECULE 
49 
distillation in good purity.55 As a result, this eleven-carbon fatty acid is the least 
expensive in the family of ω-unsaturated fatty acids. 
Acid 3.39 was converted to ω-hydroxy acid linker 3.40 by ozonolysis and subsequent 
reduction with NaBH4 as Diaper et al. described it (Scheme 3.11).56 The acid is then 
protected as ethyl ester 3.41 by a known procedure.57 Subsequently, the ω-hydroxy 
group is tosylated to obtain activated linker 3.42. The next steps are in the process of 
being optimized. Initial experiments of the Williamson etherification with 
tetrabutylammonium iodide as the catalyst show promise. The formed ester 3.43 will 
then be hydrolyzed before it is coupled to our dopamine anchor, as it was earlier 
demonstrated by Gomes et al.35 The dopamine anchor has been chosen due to the higher 
hydrolytic stability of the formed amide compared to an ester. The synthesized 
functional hybrids will then be coated on metal plates by a dip and rinse procedure. The 
surface properties of the plates will be measured and consequently, the antifouling 
activity will be examined by submerging the plates in our biofouling test facility.  
 
Scheme 3.11: Synthesis of anchored maculalactone A hybrid 3.44 with a ω-hydroxy fatty acid 
linker.  
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3.6 In Vivo Studies 
3.6.1 Synthesis of a Rhodamine B Labeled Maculalactone A Analogue 
While the toxicity of maculalactone A (1.34) is well described, nothing is known 
about the actual mode of action. A deeper understanding of this is certainly desirable 
and a first piece was found in our structure activity relationship study (Section 3.3.2).  
 
Scheme 3.12: Synthesis of the labeled maculalactone A analogue 3.47. Compound 3.46 is the 
N-methyl-N-propargyl amid of rhodamine B, synthesized as described by Yan et al.58 
The modified maculalactone A analogue 3.17, which was found as candidate for an 
antifouling coating, can also be used to collect some evidence about the molecular 
target (Scheme 3.12). Therefore, the corresponding phenol 3.20 was elongated with the 
activated PEG azide 3.45. By a Click reaction, the azide was connected to the 
rhodamine B derivative 3.46,58 giving fluorescently labeled maculalactone A analogue 
3.47. Additionally, the negative control 3.48 with a free hydroxyl group instead of the 
maculalactone A moiety was prepared. However, this compound was found to be 
predisposed for amide hydrolysis and could only be synthesized in very low quantity.  
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Figure 3.7: Toxicity assay of marker 3.47 and analogue 3.23 with A. franciscana. Values are 
given as the mean of three independent experiments with ten animals, error bars denote the 
standard error of the mean (SEM). 
Consequently, the validity of the synthesized marker 3.47 proved in a toxicity assay 
with A. franciscana (Figure 3.7). Additionally, the toxicity of analogue 3.23 with the 
short PEG chain was determined. In dissent to all earlier results, compound 3.23, 
bearing a short PEG residue, showed no toxicity at all. In contrast, the rhodamine B 
marker 3.47 exhibits a toxicity comparable to the one of maculalactone A. These 
partially positive results encouraged us to continue our investigations. 
3.6.2 Visualization of Maculalactone A Interactions in Artemia Salina 
Marker 3.47 needed to be validated through selective and specific staining in the 
in vivo experiments. In addition to the marker 3.47, the negative control 3.48 (without 
the maculalactone A moiety) was employed. Furthermore, pure rhodamine B and a 
blank control of DMSO were incorporated in this first experiment. 
For a microscope examination, the organisms should be fixed in a formalin solution. 
However, the media of A. franciscana was found to be incompatible with the fixation. 
Therefore, a more robust strain of A. salina was employed for the in vivo experiments. 
A concentration of 1 µM was found to be optimal, as no toxic side effects were expected 
and a sufficient fluorescence contrast was achieved. 
The two-days-old organisms were incubated for 24 hours in the staining solutions 
containing either 3.47, 3.48, rhodamine B or the blank control. This was followed by a 
washing procedure where the organisms were twice transferred to fresh media and 
incubated for three hours. Finally the larvae were fixed in a formalin solution in PBS 
buffer. 
The stained organisms were examined by fluorescent microscopy under identical 
lighting conditions (Section 8.3). While rhodamine B caused general staining of the 
entire body, the negative control 3.48 did not show any fluorescence at all. In contrast, 
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the maculalactone A marker 3.47 showed a selective staining of specific organs. Since 
the control experiments excluded a selective staining caused by the fluorophore or the 
linker, the stained regions show the specific areas that had accumulated maculalactone 
A. 
 
Figure 3.8: A combination of four microscope pictures of an A. salina nauplia stained with 
compound 3.47. Visual and fluorescence images, scale bar =100 µm. 
Initial images showed a highly stained, rod-shaped organ in the center of the body, 
which appears to be related to the intestine (Figure 3.8).59 At the tail of the animal, the 
stained tissue ends in a sharp line. Additionally, a cell like texture instead of a 
homogeneous staining was observed. The head area could not be completely focused 
and eventually a circular dyed shape was observed. 
Examination by bifocal microscopy gave more insight. Slices through the tail 
revealed a tube like structure, which is in agreement with a staining of the intestine wall 
and not it’s content (Figure 3.9). Consequently, it can be assumed that the labeled 
maculalactone A 3.47 was accumulated in the intestine wall or a related tissue.  
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Figure 3.9: Tail images of an A. salina nauplia stained with compound 3.47. Visual and 
fluorescence images, 10 µm slides in the z-axis, scale bar = 50 µm. 
Interesting to note are the sharp borders of dyed tissue towards the end of the 
organism, as well as along the structure (Figures 3.9 and 3.10). This excludes the 
possibility of an unspecific staining by diffusion from the gut into the body. 
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Figure 3.10: Magnification of the tail of an A. salina nauplia stained with compound 3.47. 
Left: fluorescence, right: visual image, scale bar = 20 µm. 
Images of the head revealed another dyed structure above the intestine, enclosed by a 
strongly stained ring. However, we have not yet been able to indentify this tissue. 
 
Figure 3.11: Head of an A. salina nauplia stained with compound 3.47. Visual and fluorescence 
images, 10 µm slides in the z-axis, scale bar = 20 µm. 
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Although A. salina is regularly employed in toxicity assays, little is known about the 
anatomy of its larvae stages. Therefore, a definitive assignment of the stained tissues 
would require further experiments with other organisms as well as with cell cultures. 
However, with these experiments we visualize the tissues targeted in A. salina and were 
able to get an initial look at the mode of action.  
3.7 Conclusion 
The accumulation of biological material, referred as biofouling, is a serious threat for 
many surfaces in contact with fluids.1,2,5,6,8–11 In contrast to man-made structures, 
biological organisms are usually less affected by biofouling.4,11,12 The slowly growing 
cyanobacterium K. maculans is suspected to produce maculalactone A (1.34) as a 
chemical defense against biofouling. 20 This compound showed promising activities 
against the settlement of bivalves.  
Together with our expertise in surface modifications, we developed a novel concept 
for the biofouling protection of metal surfaces. Thereby, we planned to form a covalent 
linkage between maculalactone A and one of our nitrocatechol anchors. With this 
functional hybrid, a metal surface could be coated in a dip and rinse procedure and 
would be protected from biofouling by the biological properties of maculalactone A. 
This concept and preliminary results were awarded in 2012 with the first prize of the 
Clariant CleanTech award. 
In a first phase of the project, three different maculalactone A derivatives for a 
covalent linkage were synthesized. The formed analogues were then compared in a 
SAR study and lactone 3.17 was found to be equally or more active as maculalactone A. 
Commercially viable surface coatings need to be made from inexpensive building 
blocks. Effort were made to build a system that would allow for the synthesis of 
inexpensive single side substituted PEG linkers. Towards this end, various new anchors 
were synthesized. Our idea was to connect one of these anchors to a PEG chain and use 
the acidic properties of the catechol to isolate the substituted linker from the reaction 
mixture. While significant progress was made toward the synthesis and purification of 
these anchors, further investigation are required. 
In the meantime, the biologically active lactone 3.47 was connected over a PEG 
linker with a rhodamine B fluorophore. Consequently, this marker was used to visualize 
the contribution of maculalactone A in A. salina. Interestingly, only defined tissues 
around the intestine and in the head of the organisms were stained. To disclose more 
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details about the mode of action of maculalactone A, further experiments with better 
known organisms or cells cultures are required. 
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4.1 Introduction 
4.1.1 Early Synthetic Examples of the γ,δ-Dilactone Core 
As described in section 1.5, the core structure of ophiodilactone A (1.47) and 
B (1.48) is unique among natural products. When we started our investigations, only 
two synthetic compounds were known bearing such a γ,δ-dilactone moiety 
(Scheme 4.1). In 1916, Borsche published his investigations on the structure of meconic 
acid (4.01).1 Following a catalytic reduction and treatment with acetic anhydride, he 
obtained the dilactone 4.02. About 90 years later, the group of Brückner described the 
dihydroxylation of trisubstituted β,γ-unsaturated ester derivative.2 After double 
dihydroxylation of the geranyl derivative 4.03, followed by an oxidative cleavage and 
oxidation, dilactone 4.04 was isolated.  
 
Scheme 4.1: The established synthetic examples of γ,δ-dilactone structures.1,2 
While both of these strategies would be unsuitable for the substitution pattern of the 
ophiodilactones, they provide interesting insights into this core. The intermediate after 
hydrogenation of 4.01 consists of two acids and four hydroxyl groups, allowing various 
structural isomers. However, the dehydration with acidic anhydride delivers selectively 
the required γ,δ-dilactone 4.02.  
4.1.2 Established Synthetic Efforts 
Early synthetic efforts in the Gademann group were conducted by Jean-Yves Wach 
and are discussed in section 5.1.3. The applied strategy focuses on a linear approach 
including a desymmetrization and is summarized, together with my work on this route, 
in chapter 5. 
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In 2012, Matsubara et al. published preliminary results towards the total synthesis of 
ophiodilactone A (1.47) and B (1.48).3 While the γ,δ-dilactone was synthesized 
successfully, they could not achieve the introduction of the last phenyl group by a 
nucleophilic 1,4-addition on 4.05 (Scheme 4.2).  
 
Scheme 4.2: Selected examples from the total synthesis of ophiodilactone A and B by 
Matsubara et al.3,4 
Very recently, the same group communicated their successful total synthesis of 
ophiodilactone A in 17 steps and a overall yield of 14%.4 Furthermore, Matsubara et al. 
presented the one step conversion of ophiodilactone A (1.47) to ophiodilactone B 
(1.48). Their employed strategy shows only little similarities to ours and interesting 
steps will be discussed at the appropriate position within this chapter. This includes 
especially the epoxidation and epoxide opening. 
4.2 Synthetic Strategy from Maculalactone A to 
Ophiodilactone A and B 
Ueoka et al. speculated in the isolation publication, that a radical reaction converts 
ophiodilactone A (1.47) to B (1.48).5 Therefore, we focused our efforts on the synthesis 
of ophiodilactone A, to later be converted to ophiodilactone B. 
As maculalactone A (1.34) possesses already most of the carbon skeleton of 
ophiodilactone A, our synthetic strategy was straightforward. The dilactone can be 
formed from the corresponding acid 4.06 by a nucleophilic epoxide opening 
(Scheme 4.3). The epoxide is generated from the double bond of the butenolide 4.07. 
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The elongation of maculalactone A (1.43) by another phenylpropanoid unit is the key 
step of the synthesis and can be achieved by a vinylogous Michael addition to 
cinnamaldehyde or an appropriate derivative. Due to the loss of chirality in the 
vinylogous addition, racemic maculalactone A can be used. However, this requires an 
enantioselective method for the phenylpropanoid elongation. 
 
Scheme 4.3: Synthetic strategy leading from maculalactone A (1.34) to ophiodilactone A (1.47). 
4.3 Elongation by a Phenylpropanoid Unit6 
4.3.1 Additions with γ-Lactones 
The proton in γ-position of butenolides is relatively acidic and can be removed by 
weak bases. The formed anion can then be used for nucleophilic substitutions and 
additions. Depending on the electrophile, either the α or the γ-position is modified. Such 
processes have been extensively used in the last few years. An example for a 
modification in γ-positions has already been described in the maculalactone A synthesis 
by Kar et al. (Scheme 2.2).7 Throughout our synthetic studies we observed a 
substitution in α-position, affording compound 2.13 (Scheme 2.4). 
Various methods have been studied for the addition of such nucleophilic butenolides 
to Michael acceptors. Most of these methods can be condensed to two principal systems 
(Scheme 4.4).8,9 In the direct approach, the butenolide is deprotonated in situ and 
directly reacted with the electrophile. More recently, enantioselective versions these 
O
Bn
O
ophiodilactone A
(1.47)
OBn
BnPh
OHO
O
Bn
O
BnPh
O
OH
O
Bn
4.06
O
Bn
O
BnPh O
Bn
4.07
O
Bn
O
Bn
Bn
maculalactone A
(1.34)
H
+
1.01
vinylogous
Michael 
addition
epoxidation
oxidation
ring closure and
epoxide opening
O
H
________________ 
The vinylolous Michael addition was developed by Michael Lüscher during his Master thesis.6 
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reactions can be facilitated by the addition of organocatalysts, such as proline 
derivatives10–12, amines13–17 and cinchona alkaloids18,19 or a combination of these. 
 
Scheme 4.4: Examples of direct10 and indirect20 vinylogous Michael additions with butenolides.  
In the indirect method, the butenolide is first converted to the silyloxy furan, 
followed by addition to the Michael acceptor in a Mukaiyama-type reaction. While 
racemic methods had been known, an enantioselective system was first developed by 
Kitajima et al.21 and eventually optimized by the group of Macmillan,20 where 
secondary amides are used as iminium catalysts. 
However, most of the established methods are applied on un- or little-substituted 
butenolides. The behavior of the densely substituted maculalactone A under these 
reaction conditions is hard to predict. This could include reduced reactivity due to steric 
hindrance and unknown changes in the acidity of the γ-proton. 
4.3.2 Implementation of the Vinylogous Michael Addition 
The direct reaction was more attractive. Therefore, our first experiments focused on 
the in situ generation of the nucleophile by weak bases (Table 4.1). In this early stage, 
manly achiral catalysts were tested. Under standard conditions with pyrrolidine, no 
reaction was observed (Entry 1). The addition of Lewis and Bronsted acids to 
pyrrolidine had no effect (Entries 2 and 3). The addition of equimolar amounts of 
pyrrolidine lead to decomposition of the starting material (Entry 4). The same was 
found with the more basic DBU (Entry 7). However, whit an excess of triethylamine, no 
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reaction was observed (Enties 5 and 6). Furthermore, no product was observed in the 
presence of primary diamines (Entries 8 and 9).  
Entry Enone 
[eq.] 
Catalyst (eq.) Additive (eq.) Temperature 
[°C] 
Solvent Yield 
[%] 
1 3.0 Pyrrolidine (0.2) - rt to 50 MeOH 0a 
2 3.0 Pyrrolidine (0.2) LiCl (0.2) rt to 50 MeOH 0a 
3 3.0 Pyrrolidine (0.2) AcOH (0.2) rt to 50 MeOH 0a 
4 3.0 Pyrrolidine (1.0) - rt MeOH 0b 
5 1.5 NEt3 (2.0) - rt to 40 MeOH 0a 
6 1.5 NEt3 (2.0) - rt to 40 CH2Cl2 0a 
7 1.0 DBU (1.0) - 0 to rt CH2Cl2 0b 
8 2.0 (±)-trans-Diamino-
cyclohexane (0.2) 
AcOH (0.4) rt to 40 MeOH 0c 
9 2.0 (±)-trans-Diamino-
cyclohexane (0.2) 
AchOH (0.4) rt to 40 CH2Cl2 0c 
Table 4.1: Direct vinylogous Michael addition of maculalactone A (1.34) to cinnamaldehyde 
(1.01) with weak bases. The reaction times vary between 24 and 72 hours. The following 
experiments were conducted according to literature procedures: 1-410, 8+913. aNo reaction. 
bMainly byproducts with traces of the desired product. cAlmost no reaction with traces of 
byproducts and no desired product. 
We then turned our attention to the indirect method, first employed by Macmillan.20 
The catalyst 4.09 was synthesized according to literature.22 Unfortunately, generation of 
the silyloxy furan species from maculalactone A was problematic. Literature examples 
are usually less substituted and, thus, can be isolated by distillation. However, this was 
not possible with our substrate. Additionally, the trimethylsilyloxy furan was found to 
be extremely instable and readily hydrolyzed. Different silylating agents including 
TESOTf, TBDMSOTf, TIPSOTf were tested. Finally, the triisopropylsilyloxy furan 
4.11 could be isolated by extraction at 0°C in 91% yield (Scheme 4.5). 
However, no conversion to product 4.07 was observed when the nucleophile 4.11 
was reacted with trans-cinnamaldehyde in the presence of catalyst 4.09. Most of the 
starting material hydrolyzed to maculalactone A (1.34). Also the addition of TFA 
instead of 2,4-dinitrobenzoic acid had no positive influence. TFA was used in the 
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literature to activate triisopropylsilyloxy furans.11 To reduce the steric repulsion of the 
formed iminium ion, the pyrrolidine TFA salt was used as catalyst. In our reaction, little 
conversion to the desired product was observed by 1H-NMR, most of the silyloxy furan 
hydrolyzed to maculalactone A. 
 
Scheme 4.5: Indirect vinylogous Michael addition utilizing Macmillan’s method.20 The second 
step was tried with 3.0 eq. trans-cinnamaldehyde, 2.0 eq. water in THF at 0 to 40 °C with either 
4.09*TFA or pyrrolidine*TFA as catalyst. 
To exclude a potential low reactivity of the triisopropylsilyloxy furan, we repeated 
the reaction described by Macmillan with the corresponding TIPS compound 4.12 
(Scheme 4.6). With an elongated reaction time, the expected conversion and a similar 
yield of 4.10 was observed, while the diastereoselectivity decreased to 75:25. Using 
TFA as an acidic additive, the reaction time was cut in half. These results reveal a 
problem with the steric hindrance, rather then with the reactivity, in our substrate.  
 
Scheme 4.6: Indirect vinylogous Michael addition with triisopropylsilyloxy furan 4.12. The 
second reaction was either promoted with 2,4-dinitrobenzoic acid or TFA. 
In the third approach, we studied reactions promoted by phase transfer catalysts 
(PTC). The advantages of these systems include the used strong bases, providing the 
necessary reactivity and no need for iminium ion formation. First experiments with 
achiral tetrabutylammonium salts as the PTC and methyl trans-cinnamate as 
electrophile showed promising results (Scheme 4.7). The isolation of ester 4.13 in 
moderate yield as a single diastereomer indicated strong substrate control. However, the 
employed PTCs were not stable under the reaction conditions and had to be added in 
portions over the reaction time to ensure full conversion of maculalactone A. 
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Scheme 4.7: Direct vinylogous Michael addition under PTC conditions. TBAH = 
tetrabutylammonium hydroxide in aqueous solution. TBAB = tetrabutylammonium bromide 
To improve the yield, the more reactive cinnamaldehyde was used as electrophile. 
Interestingly, the unexpected product 4.14 was isolated. This product is the result of a 
second deprotonation in the benzylic position, followed by a vinylogous Aldol reaction. 
Traces of the corresponding ring open intermediate 4.13 were observed in the reaction 
mixture by 1H-NMR. However, bicycle 4.14 seems to be an important intermediate in 
the synthesis of maculalactone D to K and M and is discussed in chapter 6. 
Additionally, compound 4.14 was crystallized and the relative configuration of the 
product was determined by X-ray diffraction analysis (Figure 4.1).   
O
Bn
O
BnPh O
Bn
4.13
O
Bn
O
Bn
Bn
maculalactone A
(1.34)
OMe
O
Bn
O
Bn
4.14
O
Bn
O
Bn
Bn
maculalactone A
(1.34)
methyl trans-cinnamate
TBAH and H2O or
TBAB and 50% aq. KOH
CH2Cl2, rt
25 or 35%
trans-cinnamaldehyde
TBAB, 1 M aq. NaOH
toluene, rt
53%
Ph
Ph
 SYNTHETIC STUDIES ON OPHIODILACTONE A AND B 
69 
  
Figure 4.1: X-ray crystal structure of bicycle 4.14. 
Various enantioselective phase transfer catalysts have been developed in the recent 
years.23 Asymmetric quaternary ammonium salts are the most promising for our 
purposes, of which the cinchona alkaloid derivatives are easily accessible (Figure 4.2).24 
Different third generation cinchona alkaloid PTCs introduced by Lygo (2.12)25 and by 
Corey (4.15, 4.16)26 were synthesized according to literature. 
 
Figure 4.2: Synthesized cinchona alkaloid derived PTCs. Synthesis of 2.1227, 4.1526 and 4.1628 
according to literature. 4.15 and 4.16 are pseudoenantiomers. 
Regrettably, the synthesized PTCs showed almost no reactivity towards methyl 
trans-cinnamate under the same conditions as in the racemic approach in scheme 4.7. 
Only Lygo’s catalyst (2.12) gave a low yield of 9%. To improve the conversion, the 
more reactive trans-cinnamaldehyde was used as electrophile (Scheme 4.8). As 
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expected, faster conversion to product was observed. But in contrast to earlier results 
with the tetrabutylammonium bromide catalyst, no second cyclization was observed and 
desired aldehyde 4.07 was obtained in sufficient yield. 
 
Scheme 4.8: Reaction of maculalactone A with cinnamaldehyde to key intermediate 4.07. 
The different outcome of the PTC reactions with cinnamaldehyde can be explained 
by different mechanisms. While the reaction with tetrabutylammonium bromide 
proceeds by an extraction mechanism, the cinchona alkaloids usually favor an 
interfacial mechanism. A detailed discussion of the mechanism is beyond the scope of 
this chapter, but can be found in literature.6,23 To confirm that the stereochemical 
outcome of the formed product are the same in both reactions, aldehyde 4.07 was 
converted with tetrabutylammonium bromide under phase transfer conditions to bicycle 
4.14 (Section 6.3).  
4.3.3 Optimization of the Vinylogous Michael Addition 
In a first optimization, the reaction conditions were adjusted to improve the yield and 
diastereoselectivity (Table 4.2). Different temperatures, catalysts and catalyst loadings 
were investigated. The reactions were run until complete conversion of the starting 
material was observed.  
As in the reactions with methyl trans-cinnamate, catalyst 2.12 showed the highest 
reactivity and selectivity (Entries 1 to 3). Lower temperatures elongate the reaction 
time, but were found to increase the diastereoselectivity (Entries 1, 4 to 6). The longer 
reaction time had a slight negative effect on the yields. Finally, different catalyst 
concentrations were tested (Entries 6 to 8). While higher loadings reduced the reaction 
time, no beneficial effect on the yield or the diastereoselectivity was observed. The 
optical rotations measured from the product indicated no further enantioenrichment. 
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Entry Catalyst (mol %) Temp. 
[°C] 
Time 
[h] 
d.r.a Yieldb 
[%] 
1 2.12 (5) 0 to 5 24 82:18 58 
2 4.15 (5) 0 to 5 48 77:23 43 
3 4.16 (5) 0 to 5 48 77:23 39 
4 2.12 (5) -20 120c 87:13 393 
5 2.12 (5) -10 to -5 36 84:16 55 
6 2.12 (5) -15 96 87:13 52d 
7 2.12 (10) -15 72 67:14 50 
8 2.12 (20) -15 60 88:12 47e 
Table 4.2: First round optimization of the vinylogous Michael addition as depicted in scheme 
4.8. Conditions: 5.0 eq. trans-cinnamaldehyde, 6.5 eq. 50% aq. KOH, toluene. aDiastereomeric 
ratio was determined by 1H-NMR. bYield of desired diastereomer 4.07. cIncomplete conversion. 
Optical rotations [α]D are d-70.5° (c = 0.43, CHCl3) and e-72.3° (c = 0.58, CHCl3). 
A determination of the enantiomeric excess was at this stage not possible, as 
aldehyde 4.07 decomposed under chiral HPLC or GC conditions. However, after a mild 
reduction, alcohol 4.17 could be separated on HPLC and the enantiomeric excess was 
measured (Scheme 4.9). A racemic sample of alcohol 4.17 was obtained by subsequent 
reduction of racemic ester 4.13 with DIBAL and NaBH4. 
In a second optimization round, we focused on improving the enantioselectivity 
(Table 4.3). As in the first round, catalyst 2.12 showed the highest selectivity, which is 
reflected in the high enantiomeric excess and the diastereomeric ratio (Entries 2 to 4). 
As expected, pseudoenantiomeric catalyst 4.16 gave a small excess of the opposite 
enantiomer (Entry 4). Additionally, we observed that the reaction temperature greatly 
influenced the enantioselectivity (Entry 5). 
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Entry Catalyst (mol%) Temp. 
[°C] 
d.r. ee 
[%] 
1a TBAB (1 eq.) rt <95 0a 
2 2.12 (5) 0 to 5 92:18 30 
3 4.15 (5) 0 to 5 77:23 5 
4 4.16 (5) 0 to 5 77:23 8b 
5 2.12 (5) -15 87:13 68 
Table 4.3: Second round optimization of the vinylogous Michael addition. Conditions: 5.0 eq. 
trans-cinnamaldehyde, 6.5 eq. 50% aq. KOH, toluene. The enantiomeric excess was determined 
after NaBH4 reduction by chiral HPLC (Appendix 9.3.1). aRacemic material was observed after 
reduction of 4.13, synthesized as depicted in scheme 4.7. bExcess of the opposite enantiomer. 
Due to the biphasic nature of the reaction system and the high influence of 
appropriate stirring, this reaction was found to be problematic during scale-up. While 
similar yields were obtained with more equivalents of base, reduced enantiomeric 
excess was observed. Upon optimization, we were able to conduct the synthetic key 
step of this strategy in a reasonable yield of 52% of the desired diastereomer and a high 
selectivity with a diastereomeric ratio of 87 to 13, and an enantiomeric excess of 68%. 
4.4 Oxidation of the Butenolide Double Bond 
4.4.1 Different Oxidation States 
As the aldehyde is a rather sensitive functionality and we knew that compound 4.07 
would easily cyclize, we converted this moiety into the corresponding alcohol 4.17 and 
acid 4.18 (Scheme 4.9). While the alcohol was easier to handle, we postulated that it 
could open the formed epoxide and give an undesired oxane ring. It was later 
demonstrated by Matsubara et al. that only harsh conditions could promote epoxide 
opening.4 Regardless, utilizing the acid 4.18 would give directly the correct product and 
thereby reducing the number of steps. 
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Scheme 4.9: Synthesis of acid 4.18 and alcohol 4.17 and X-ray crystal structure of the latter. 
Alcohol 4.17 was accessed by a mild reduction with NaBH4 in ethanol. The pure 
product could be crystallized and analyzed by X-ray diffraction to confirm the 
configuration. The corresponding acid 4.18 was synthesized by Pinnick oxidation.  
4.4.2 Reagent Screening 
Consequently, alcohol 4.17 and acid 4.18 were submitted to various epoxidation 
methods described in literature (Scheme 4.10). The conditions are summarized in table 
4.4 and, if available, a literature example with a similar substrate is mentioned.  
The electronic properties of this double bond are difficult to predict. Therefore, 
nucleophilic and electrophilic reagents were used. Furthermore, dihydroxylation 
reagents were also applied. Unfortunately, most reactions showed no conversion within 
several days and the reaction temperatures were stepwise increased until decomposition 
of the starting material was observed. With DMDO, interconversion of the alcohol to 
the acid was observed. However, none of the reactions showed even traces of the 
desired product.  
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Scheme 4.10: Unsuccessful epoxidation and halolactonisation of acid 4.18 and alcohol 4.17. 
Applied reaction conditions are listed in table 4.4. 
Alternatively, we attempted to form the second ring in an intramoleculat 
halolactonisation. These reaction conditions can be found in the table 4.4. As in the 
epoxidation, most reactions showed no conversion and were then pushed until 
decomposition of the starting material. 
 With acid 4.18 With alcohol 4.17 
Nucleophilic  
epoxidation 
H2O2, NaOH29,30; H2O2, KOH; 
NaOCl, pyridine31; H2O2, TBAH; 
H2O2, H2SO432; tBuOOH, 
triton B33; tBuOOH, DBU34 
tBuOOH, BuLi35; tBuOOH, 
DBU34; H2O2, KOH 
Electrophilic  
epoxidation 
MCPBA; O3; DMDO; 
peroxytrifluoroacetic acid; NaOCl, 
H+; KMnO4,  
cis-dicyclohexano-18-crown-636,37 
DMDO; OsO4, NaIO438 
Halolactonisation I2, NaHCO3, AgOTs; 
(SEt2)I2Cl7Sb39; NBS; TMSI, BBr3 
 
Table 4.4: Reagents used for epoxidation and halolactonisation of acid 4.18 and alcohol 4.17. 
No reaction showed traces of the desired product. The reaction temperatures were increased 
until decomposition of the starting material was observed. Analytics were conducted by TLC 
and UPLC-MS. If available, a literature example with a similar substrate is noted. The 
following reagents were synthesized or purified according to literature: MCPBA40, DMDO41, 
peroxytrifluoroacetic acid42, (SEt2)I2Cl7Sb39. 
At this point of our investigations, it was not clear whether the lack of reactivity was 
caused by the steric repulsion or the electronics of the double bond. As it is not possible 
to remove any of the substituents in this stage of the synthesis, we changed the 
electronics of the double bond.  
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4.4.3 Oxidation of a More Electron Rich Substrate 
One easy way to increase the electron density on the double bond is to reduce the 
adjacent carbonyl group. Cane et al. described this in an elegant way on a similar 
substrate.43 After reduction to the lactone, the intermediate hemiacetal was used to 
direct a vanadyl acetylacetonate catalyzed allylic epoxidation. The lactol epoxide was 
consequently oxidized to the lactone with the Jones reagent. 
The reduction of the aldehyde moiety was combined with the lactone reduction under 
Luche conditions (Scheme 4.11). While the first step worked well, the second step 
required more harsh conditions in refluxing THF to give lactol 4.19. However, the 
consequential epoxidation with vanadyl acetylacetonate could not be achieved. 
To test other epoxidation reagents, we attempted to isolate lactol 4.19. Thereby, it 
was found to be unstable and reacted spontaneously to the bicyclical acetal 4.20 by 
dehydration. Stirring 4.19 in the presence of molecular sieves accelerated this process. 
 
Scheme 4.11: Reduction of aldehyde 4.07 under Luche conditions. The formed lactol reacted 
spontaneously to acetal 4.20, a process accelerated under dehydrating conditions. 
Acetal 4.20 was then treated with the following reagents to achieve an epoxidation. 
If available, a literature reference with a similar substrate is given: MCPBA44; MCPBA, 
K2CO345,46; DMDO; MCPBA, NaHCO3, Cu(ACN)4PF647; peroxyacetic acid, Na2CO3; 
O3; FeCl3, NaIO4; RuCl3, NaIO448; RuCl3, NaIO4, 2,2’-dipyridin49; OsO4, NaIO4; OsO4, 
NMO50; peroxytrifluoroacetic acid, Na2HPO4; H2O2; H2O2, various acids and bases; 
H2O2, MgBr2. Most of the reactions showed no conversion. Therefore, the temperature 
was increased until the starting material decomposed. In case of reactions with MCPBA 
or H2O2 with MgBr2, alcohol 4.17 was formed. 
Matsubara et al. were able epoxidize the similar but less complex intermediate 4.21 
in a enantioselective reaction with a vanadyl complex at 0 °C in 6 days (Scheme 4.12).4 
In principle, a similar reaction might be possible, if the lactol 4.19 is further reduced to 
the expected ring open structure 4.23 with two allylic hydroxy groups.51,52 However, 
further reduction of lactol 4.19 was found to lead instead to dihydrofuran 4.24. 
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Scheme 4.12: Substrate 4.21 from the epoxidation in the total synthesis by Matubara et al.4 
Expected product 4.23 and found product 4.24 from a further reduction of 4.19. 
4.4.4 Oxidation of a Less Electron Rich Substrate 
As the epoxidation of the more electron rich double bond was not successful, a new 
strategy with a more electrophilic double bond was developed. To accomplish this, a 
carbonyl functionality was introduced in the benzylic position, as depicted in 
intermediate acid 4.25 (Scheme 4.13). Such benzylic ketones or the corresponding 
alcohols can be deleted in the presence of aliphatic alcohols. As such an additional 
carbonyl group increases the reactivity of the substrate, we decided to introduce it in the 
beginning, as it will also promote the γ-lactone formation (Section 2.5) and the 
vinylogous Michael addition (Section 4.3). 
With the additional electron acceptor, Maculalactone A derivative 4.27 could be 
synthesized by a standard Knoevenagel condensation (Section 2.5.1). Acid 4.26 was 
first synthesized as described by Cragg et al.53 Subsequently, the free acid was 
esterificated with alcohol 2.30, which was already used for our synthesis of 
maculalactone A (Section 2.5.2). While the ring-open ester was expected, the reaction 
conditions were surprisingly sufficient to form at least partially the Knoevenagel 
condensation product 4.27. Therefore, the yield of this transformation was relatively 
low. However, lactone 4.27 was crystallized and analyzed by X-ray diffraction. 
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Scheme 4.13: Synthesis of more electron deficient lactone 4.25. Synthesis of the corresponding 
maculalactone A derivative with X-ray crystal structure. Acid 4.26 was synthesized as described 
by Cragg et al.53 Compound 2.30, 3-oxo-3-phenylpropanoic acid, was already used in the 
synthesis of maculalactone A and was synthesized in accordance to a procedure by Stetter et 
al.54 (Scheme 2.9).  
Conducting the vinylogous Michael addition under the same conditions as for 
maculalactone A (1.34) (Section 4.3.3), yielded an unexpected product, with two 
aldehyde protons and the mass of double cinnamaldehyde addition. A reduction of the 
aldehyde excess to 1.2 equivalents prevented the double addition, affording a new 
product possessing the expected mass. The isolated product was analyzed and the 
structure was identified as aldehyde 4.28 (Scheme 4.14). This unexpected product 4.28 
is either the result of a vinylogous Michael addition on the extra circular position 
followed by a Aldol reaction or a Diels-Alder reaction between deprotonated 
intermediate A and trans-cinnamaldehyde. To test this, the reaction temperature was 
decreased to – 40 °C. While reactions with maculalactone A showed no turn over at this 
temperature (Section 4.3.3), good conversion was achieved without increasing the 
reaction time. Additionally, only one diastereomer was observed. Product 4.28 was 
crystallized and analyzed by X-ray diffraction analysis. The configuration was in 
agreement with the outcome of a regular-demand endo-selective Diels-Alder reaction. 
Despite the use of chiral catalyst 2.12, X-ray analysis and optical rotation revealed a 
racemic product. 
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Scheme 4.14: Transformation of maculalactone A analogue 4.27 with cinnamaldehyde to the 
unexpected product 4.28. The stereochemistry was determined by X-ray diffraction analysis. 
To overcome this predominant side reaction, other electrophiles as methyl 
trans-cinnamate and 3-phenyl-2-propenenitril were tested. As those showed no 
reactivity, singe phase systems with other bases were investigated. However, none of 
the expected products were observed. 
4.5 Stepwise Oxidation of the Butenolide 
In all previous strategies it was tried to oxidize the α- and the β-carbon of the 
butenolide simultaneously. Alternatively, this can be done in two separate steps, which 
was tried with the three following strategies. 
4.5.1 Nucleophilic oxa-Michael Addition 
In the first strategy, the β-carbon would be attacked in an oxa-Michael addition. The 
addition would be followed by a α-oxidation, for which different procedures by 
Rubottom and Davis are well known (Scheme 4.15).55,56 Due to the higher 
nucleophilicity of hydroxy groups opposed to the corresponding carboxylate, using 
alcohol 4.17 in the oxa-Michael addition, would be beneficial. However, this would 
require a final oxidation of the oxane to the lactone, which would be achieved by a 
procedure with ruthenium(III) chloride described by Ramon et al.57 
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Scheme 4.15: Investigated intramolecular oxa-Michael addition with acid 4.18 and alcohol 4.17. 
Applied reagents and conditions are discussed within the text.  
Oxa-Michael additions with acids are much less known in literature, as carboxylic 
acids are usually bad nucleophiles. A thermal method used by Jaroszewski et al. was 
attempted first.58 The neat acid 4.18 was warmed to 225 °C for 4.5 hours, but no 
reaction was observed. Also, heating with KOH in dioxane in the microwave to 200 °C 
showed only decomposition and none of the desired product. 
Oxa-Michael additions with hydroxy groups are better known. For example Blay 
et al. published an intramolecular addition to a butenolide.59 Alcohol 4.17 was treated 
with different bases and acids to promote this reaction. All experiments showed no 
reactivity and were, therefore, heated until decomposition of the starting material was 
observed. 
The driving force of these oxa-Michael additions was found to be too low to 
overcome the steric hindrance of the more rigid bicycle. In the accomplished total 
synthesis by Matsubara et al., the final nucleophilic attack of the acid on the more 
reactive epoxide in the same position required a temperature of 150 °C and gives a 
maximal yield of 55%.4 
4.5.2 Umpolung Michael Addition 
The low reactivity in the oxa-Michael addition due to the relative low nucleophilicity 
of the hydroxy group lead directly to a second indirect strategy. The idea was to use a 
more nucleophilic carbon nucleophile to attack the Michael acceptor (Scheme 4.16). 
This should deliver cyclopentanone 4.30, which could be converted to δ-lactone 4.29 
through a Baeyer-Villiger oxidation. However, this strategy requires Umpolung 
reactivity of the carbonyl group, resulting in a Stetter-type reaction.60  
Under standard conditions with Stetter’s thiazolium catalyst, aldehyde 4.07 was 
converted to maculalactone A (1.34) in a reversal of the vinylogous Michael addition. 
Other catalysts such as 1-butyl-3-methylimidazolium hexafluorophosphate led only to 
decomposition of the starting material.61 
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Scheme 4.16: Strategy for the synthesis of 4.31 by Umpolung and investigated Stetter reaction 
resulting in a retro vinylogous Michael addition giving maculalactone A (1.34). Compound 2.29 
is Stetter’s catalyst (3-benzyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride). 
As a negative charge on the aldehyde carbon was not tolerated, another Umpolung 
strategy was employed. The carbonyl group was thereby reduced by a single electron 
transfer, giving the corresponding acyl radical. The additions of such nucleophilic 
radicals to Michael acceptors are well known in literature and samarium(II) iodide is 
often the reductant of choice.62–64 Additional acyl radical generating reagents65,66 and 
light induced67–69 methods are known. 
The reaction of aldehyde 4.07 with samarium(II) iodide afforded the desired product 
4.31 in moderate yield (Table 4.5, Entry 1) (Scheme 4.17). The reaction conditions were 
further optimized. Reducing the reaction temperature and increasing the reaction time 
was found to be unfavorable (Entry 2). On the contrary, a shorter reaction time gave a 
higher yield (Entry 3). While the addition of HMPA led to a decrease in selectivity, 
ethanol as additive in small amounts showed a slightly positive effect (Entries 4 to 6). 
The samarium iodide solution was found to greatly influence the reaction. We 
attempted to titrate the reaction solution until the typical blue color persisted, but no 
improvement in yield was observed (Entry 7). 
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Entry SmI2 
[eq.] 
Additive (eq.) Temp. Time 
 
Yield 
[%] 
1 4 - rt 4 h 41 
2 4.9 - -78 °C to rt 12 h -a 
3 4 - rt 2 h 58 
4 4 HMPA (40) rt 1 h -b 
5 4 EtOH (1.2) rt 20 min 59 
6 4 EtOH (5) rt 20 min 31 
7 titr.c - 60 °C 10 min -b 
Table 4.5: Optimization of the samarium(II) iodide induced radical Michael addition of 4.07 to 
4.31. Samarium(II) iodide was synthesized as described by Procter.70 Reactions were conducted 
in dry THF. aNo reaction observed. bProduct formation observed, but in low purity and not 
isolated. cThe reaction was titrated with samarium(II) iodide until the blue color persisted for 
two minutes.  
As a next step, the α-position of lactone 4.31 was oxidized. While the reaction with 
the Davis reagent resulted in a mixture of products, another procedure with molecular 
oxygen, applied by Zhang et al. to solve a similar problem, gave diol 4.32 in good 
yield.71 Conducting the oxidation at -78°C resulted surprisingly in the undesired 
diastereomer. 
The intermediate product of the SmI2-induced addition before quenching is, in 
principle, the corresponding samarium enolate. A direct oxidation of the intermediate 
with oxygen was found to give directly diol 4.32, but lactone 4.31 was observed as the 
main product. A similar reaction with a different substrate has been published by Shi 
et al.72 
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Scheme 4.17: Synthesis of precursor 4.33 by radical Michael addition, α-oxidation and DMP 
oxidation. The final Baeyer-Villiger rearrangement showed no reaction in the most cases and in 
others decomposition to ketone 4.34. The applied conditions are listed in the text. The 
diastereomeric compounds of 4.31 and 4.32 were observed, but not completely characterized. 
To set the stage for the Baeyer-Villiger oxidation, diol 4.32 was converted to the 
corresponding ketone 4.33 by oxidation with DMP. With ketone 4.33 in hand, different 
procedures for the Baeyer-Villiger oxidation were tested. The following conditions 
were tried: MCPBA, TfOH73; MCPBA, K2CO374; MCPBA (s)75; peroxytrifluoroacetic 
acid; peroxytrifluoroacetic acid, KH2PO476; peroxyacetic acid; H2O2, KOH, but they 
were not sufficient to form ophiodilactone A (1.47). In some reactions, decomposition 
product 4.34 was observed.  
4.5.3 α-Oxidation 
A third strategy beginning with an oxidation in the α-position was investigated 
(Scheme 4.18). We expected to deprotonate acid 4.18 and perform the α-oxidation 
under the same conditions discussed in section 4.5.2. While acid 4.35 was observed by 
NMR and MS, we were unable to remove an unidentified impurity for a proper 
characterization of the product. This prevented us from being able to determine the 
relative configuration of the formed stereocenters. 
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Scheme 4.18: Oxidation of acid 4.18 to intermediate 4.35. The following addition to the double 
bond was not achieved. The applied reagents for the second step are listed in the text. 
Due to the issues encountered with isolating intermediate acid 4.35, we attempted to 
proceed with the cyclization. Different tactics were applied to facilitate the addition to 
the allylic double bond. However, none of the following conditions showed any 
conversion to the expected products: PTSA; TFA; H2SO4; I2, K2CO3; NBS; HgTFA277; 
(SEt2)I2Cl7Sb39; PhSeBr, AgBF478; BF3*Et2O; Au(I)PPh3Cl, AgOTf79; FeCl380; FeCl3, 
AgOTf80; Pd(II)OAc2; Rh(I)PPh3Cl.  
4.6 Conclusion 
The described synthetic strategy allowed us to synthesis the carbon skeleton of 
ophiodilactone A (1.47) in 5 steps from commercially available starting materials. This 
was achieved by the addition of cinnamaldehyde to maculalactone A (1.34) in a 
vinylogous Michael addition. Use of a chiral phase transfer catalyst in this step allowed 
us to obtain the product in an enantiomeric excess of 68%. Furthermore, a second 
vinylogous Aldol reaction, forming bicycle 4.14, was observed. This cyclization could 
be a key step in the synthesis of maculalactones D – K and M (Chapter 6). 
We attempted a variety of approaches and conditions to accomplish the required 
oxidation of the butenolide double bond. We initially tried to oxidize the double bond 
by an epoxidation or dihydroxylation method. As this was not successful, an alternative 
halo-lactonisation pathway was investigated. However, none of these methods were 
able to functionalize the double bond. 
In a different approach, we tried to alter the electronic properties of the double bond. 
First, the electron density on the olefin was increased by reduction to lactol 4.19, which 
dehydrated spontaneously to acetal 4.20. Despite the higher electron density, oxidation 
of the double bond could not been achieved. Consequently, we decreased the electron 
density by adding a conjugated carbonyl group to the substrate. In the synthesis of the 
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required ketone 4.25, the introduced group influenced the addition to cinnamaldehyde 
in a way to give unexpected bicycle 4.38.  
In the third attempt, we tried to oxidize the two carbons of the double bond 
individually. We first tried a oxa-Michael addition. As no conversion was achieved, a 
Stetter-type addition with a carbon nucleophile was attempted. Finally, the formation of 
bicycle 4.31 was achieved after single electron reduction with samarium(II) iodide. We 
then tried to convert cyclopentanone 4.33 to ophiodilactone A (1.47) by a 
Baeyer-Villiger oxidation. However, no conversion was observed. Finally, the α-carbon 
of the butenolide was oxidized, causing a migration of the double bond to an exocyclic 
benzylic position, forming 4.35. Unfortunately, all attempts to close the second lactone 
by addition to this double bond failed. 
While the carbon skeleton of ophiodilactone A was established in 5 steps, it was not 
possible to conduct the required oxidation in this late stage. Therefore, the required 
oxidations should be conducted in an earlier stage on less complex substrates, as 
Matsubara et al. did in their successful total synthesis.4  
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5.1 Introduction 
5.1.1 Enantioselective Synthesis by Desymmetrization 
Towards the end of the last century, the Schreiber research group developed a novel 
method for the synthesis of carbon chains with repeating elements.1 In contrast to the 
general strategy where a precursor is elongated in one direction, they proposed a 
bidirectional concept. Therefore, a central building block is simultaneously elongated in 
both directions, reducing the number of required steps by half. However, most of the 
synthetic targets have asymmetric chains or different chain ends. Therefore, the 
generated symmetrical carbon chain is desymmetrized by an appropriate and, mostly, 
enantioselective method. Advantageous is not only the reduced number of steps, but in 
some cases also the higher enantiomeric purity, as pointed out in section 5.1.2.  
 
Scheme 5.1: Desymmetrization in the total synthesis of 14,21-diepi-squamocin-K.2 
Recently, the group of Hou applied this strategy in their impressive total synthesis of 
14,21-diepi-squamocin-K (Scheme 5.1).2 The meso symmetric precursor 5.01 was 
synthesized in 13 steps by simultaneous elongation in both directions. The 
desymmetrization was accomplished by an enantioselective substitution with the chiral 
lactone 5.02. The total synthesis of 14,21-diepi-squamocin-K was finished within 
another four steps. In addition to linear chains like 5.01, this strategy was also applied in 
the synthesis of complex non-linear structures.3,4 
5.1.2 Desymmetrization by Sharpless Epoxidation 
Among the class of catalytic, enantioselective reactions, the Sharpless epoxidation is 
one of the most used.5 Advantages include the inexpensive commercially available 
pre-catalyst, ligand and oxidant, as well as the usually high substrate scope, yield and 
enantioselectivity. Consequently, Sharpless epoxidations are regularly employed in total 
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synthesis. Additionally, various groups have used and studied the desymmetrization of 
bisallylic alcohols.6–10  
Schreiber has made significant contributions to this field (Scheme 5.2).7 The studied 
epoxidation of bisallylic alcohol 5.03 can in principle result in four different products 
(5.04 to 5.07). These products result from whether the oxygen adds to the right (pro-R) 
or to the left (pro-S) double bond and it comes from the same side as the alcohol (syn) 
or the other side (anti). The anti and syn products are enantiomers of each other. 
 
Scheme 5.2: Desymmetrization of bisallyl alcohol 5.03 by Sharpless epoxidation through 
transition state A, substrate in blue.7,11 
The reaction rates of this enantio- and diastereoselective process toward each of the 
four products are different, which is reflected in the product distribution. These reaction 
rates are a result of the stability of transition state A. The chiral information of the 
tartaric ester differentiates between the pro-S and R sides. The steric repulsion between 
residue R and the isopropyl ester is reduced if the pro-S face is attacked. With this 
catalyst control, the formation of product 5.05 is faster than the one of enantiomeric 
5.07. In such bisallyl desymmetrizations, the enantiopurity is further increased if the 
reaction is run past completion of the first epoxidation. Since the second epoxidation of 
5.05 has to occur on the pro-R face, it is slow compared to the one of 5.07. Therefore, 
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the undesired enantiomer is more quickly converted to bisepoxide 5.08, which can be 
removed by chromatography. 
In contrast to the enantioselectivity, the diastereoselectivity relays on the orientation 
of the double bond to the substrates alcohol group in the transition state. Usually, both 
groups are on the same side as shown in A and the addition occurs from the backside in 
an anti fashion. As the syn/anti selectivity is controlled by the substrate, different 
substituents can influence the selectivity. In the upper example from Schreiber et al., 
none of the syn products 5.04 and 5.06 were observed. 
5.1.3 Asymmetric Routes Towards Triol 5.10  
Ophiodilactone A (1.47) can be traced back to the linear precursor 5.09 by cleavage 
of the lactone bonds (Scheme 5.3). The central section 5.10 of this linear precursor 
shows Cs-symmetry, making it achiral. Thus, we postulated to synthesize 
ophiodilactone A through a desymmetrization process, potentially using Sharpless 
epoxidation.5 
 
Scheme 5.3: Symmetric elements of ophiodilactone A. 
In a previous work by Jean-Yves Wach, we first attempted the synthesis of a 
desymmetrized analogue of 5.10.12 While two desymmetrization approaches over cyclic 
intermediates were unsuccessful, a linear precursor was found to be an appropriate 
candidate for the desymmetrization by epoxidation (Scheme 5.4). Vinyl bromide 5.11 
was synthesized by a procedure published by Breit et al.13 The bromide was then 
converted into both a Grignard reagent and an organo lithium reagent, and consequently 
added to methyl 2-phenylacetate. Unfortunately, none of product 5.12 was obtained. 
The acidic, benzylic protons of methyl 2-phenylacetate were suggested to protonate the 
organometallic reagent. Luckily, the less complex bisallyl alcohol 5.13 could be 
synthesized, as described in literature.13 
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Scheme 5.4: Synthesis of symmetric intermediate 5.13.12 
Subsequently, intermediate 5.13 was desymmetrized in a Sharpless epoxidation 
(Scheme 5.5).12 While first experiments with sub-stoichiometric amounts of catalyst 
were unsuccessful, the desired epoxide 5.14 was isolated with high diastereoselectivity 
and sufficient yield when 1.1 equivalents of titanium(IV) isopropoxide were used. 
Racemic epoxide 5.14 was synthesized by a diastereoselective epoxidation with vanadyl 
acetylacetonate. However, the analytical separation of the enantiomers by 
chromatography failed. Furthermore, all attempts to open the epoxide with a 
nucleophile were unsuccessful.  
 
Scheme 5.5: Desymmetrization of 5.13 by Sharpless epoxidation.12 
5.2 Synthetic Strategy by Desymmetrization 
Based on these early findings, a route towards ophiodilactone A (1.47) through linear 
precursor 5.09 was developed (Scheme 5.6). The bisacid would be formed by oxidation 
of the primary alcohols of 5.15. This compound would be accessible by oxidation of the 
secondary alcohol and subsequent benzylation of compound 5.16. In principle, the 
stereoselectivity of the secondary alcohol in 5.16 is not essential, but would be 
determined by the anti selectivity of the Sharpless epoxidation. The phenyl stereocenter 
would be established by a selective hydrogenation of alkene 5.17. This olefin itself 
would result from elongation of ketone 5.18 by an appropriate organometallic reagent. 
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The ketone can be formed by ozonolysis of 5.19, following the epoxide opening of the 
Sharpless epoxidation product 5.14. 
 
Scheme 5.6: Retro synthesis of Ophiodilactone A (1.47) and B (1.48). 
5.3 Improved Synthesis of Symmetric Alcohol 5.13 
5.3.1 Optimization of the Established Synthesis 
While literature describes the synthesis of symmetrical intermediate 5.13 in high 
yield, we had reproduction issues in our lab.12,13 The synthesis of vinyl bromide 5.11 
gave similar yields, but the double Grignard addition resulted in a significantly lower 
yield with varied reproducibility (Scheme 5.7). In our investigations, two major side 
products were identified. While the 1,4-addition product 5.20 was expected, albeit in 
smaller quantities, we were surprised by the formation of transesterification product 
5.21. Varying the reaction temperature and time gave no improvements, so we focused 
on the nature of the nucleophile. We postulated that solvent stabilization of the 
nucleophilic center was decreased by changing the solvent from THF to Et2O, and later 
to mixtures with toluene. While the resulting “harder” nucleophile should favor the 
1,2-addition, no improvement was made. Filtration of the Grignard reagent had no 
positive effect either. In a next step, additives like LiCl, LaCl and FeCl3 were employed 
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without any improvement of the yield. The use of tert-butyl formate showed no 
beneficial effect too. 
 
Scheme 5.7: Problematic double Grignard addition affording 5.13, and side products 5.20 and 
5.21. Different reaction times and temperatures, solvents (Et2O, THF, toluene), additives (LiCl, 
LaCl, FeCl3) and electrophiles (R = Et, tBu) were tested. 
Despite our unsuccessful attempts to improve the reaction, the identification of ester 
5.21 allowed us to transform this side product to the desired bisallyl alcohol through a 
quantitative reductive ester cleavage. 
5.3.2 Synthesis of Bisallyl Alcohol 5.13 
Our initial goal was to separate the two addition steps of the described Grignard 
reaction to better understand the chemistry and to potentially identify the synthetic 
problem (Scheme 5.8). Therefore, the vinyl Grignard reagent was added to DMF to give 
the desired unsaturated aldehyde 2.16. Since this addition failed, a procedure published 
by Pihko et al. through a Mannich reaction was applied, to afford aldehyde 2.16 in 
excellent yield.14  
 
Scheme 5.8: Synthesis of intermediate 2.16 by Mannich reaction.14 For the Grignard reaction, 
the same conditions as for the reaction with ethyl formate were applied. 
The facile Mannich reaction inspired us to change our synthetic route to bisallyl 
alcohol 5.13 (Scheme 5.9). Ketone 5.23 was synthesized from 
1,5-diphenylpenta-1,4-dien-3-one by hydrogenation.15 When we applied the conditions 
described by Pihko to this substrate, no conversion was observed (Table 5.1, Entry 1). 
This was likely due to the lower acidity of the ketone as compared to the aldehyde.  
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Scheme 5.9: Synthesis of bisallyl alcohol by double Mannich reaction and subsequent 
reduction. The attempted reaction conditions are listed in table 5.1. 
We considered other methods to transform the ketone. While the conditions 
described by Connell et al.16 gave no conversion (Entry 2), a reaction described by the 
group of Agosta17 showed the formation of the mono-methylenated product 5.24 
(Entry 3). Despite various modifications, none of the doubly reacted product 5.25 could 
be observed (Entries 4 and 5). 
Entry Catalyst Solvent Temperature 
[°C] 
Time 
[h] 
Product / Yield 
1a Pyrrolidine, 
propionic acid 
iPrOH 50 72 No conversion 
2b (iPr)2NH, TFA Toluene 100 72 No conversion 
3a Piperidine, HCl - 80 65 Traces 5.24 
4a Piperidine, HCl - 120 20 15% 5.24 
5a Piperidine, H2SO4 - 120 72 No conversion 
6a Morpholine AcOH 100 12 20% 5.24 and 
traces 5.25 
7a Morpholine AcOH 40 to 100 42 Slow conversion 
8b Morpholine AcOH 80 12 No conversion 
9a Morpholine AcOH 150 3 29% 5.25 
10a Morpholine AcOH 150c 1 Slow conversion 
Table 5.1: Optimization of the double Mannich reaction. Conditions: a37% aq. formaldehyde, 
bparaformaldehyde, cReaction performed in the microwave. 
Finally, a procedure described by Moran et al. using morpholine as catalyst and 
acetic acid as solvent promoted not only fast conversion to 5.24, but also traces of the 
desired product (Entries 6 to 8).18 We postulated that a fast elimination of the amine 
following the initial addition drives the reaction to promote double methylenation. This 
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elimination is accelerated either by higher temperatures or by a lower pH. By heating 
the reaction for three hours to 150 °C, the desired product was isolated in a yield of 31% 
(Entry 9). As the yield after several optimizations was still low, the synthesis of bisallyl 
alcohol 5.13 by Mannich reaction was found to be not feasible. However, we were 
successful in developing this rare double Mannich reaction, affording product 5.25 in 
31% yield. 
5.3.3 Asymmetric Synthesis of Bisallyl Alcohol 5.13 
As the synthesis of bisallyl alcohol 5.13 by a double Mannich reaction was 
inefficient, we continued our investigations of the double Grignard reaction described in 
section 5.3.1. We attempted the addition of vinyl bromide 5.11 to aldehyde 2.16 under a 
variety of conditions (Scheme 5.10). While conditions similar to the prior reaction with 
ethyl formate gave comparable yields, an experiment under Barbier conditions did not 
show any conversion. 
 
Scheme 5.10: Investigation on the second addition of the vinyl Grignard reagent. A: Mg, Et2O, 
0 °C to rt, 14%; B: Mg, DIBAL cat., THF, 0 to 60 °C, 12%; C: Zn, THF, NH4Cl, EtOAc, rt, no 
conversion. 
We then investigated the influence of the double bonds. The benzyl Grignard 
reaction with unsaturated aldehyde 2.16 proceeded in a good yield of 56%, but no 
expected allyl alcohol 5.26 was observed when the vinyl Grignard reagent was added to 
the simplified aldehyde 5.22. 
Bn
O
2.16
Bn
Br
5.11
Bn Bn
OH
5.13
A, B, C
Bn
O
2.16
BnBr
+
+
Bn
OH
2.18
Bn
Bn
O
Bn
Br
+
Bn
OH
Bn
5.22 5.11 5.26
i. Mg, 
DIBAL cat.
ii. 2.16
Et2O, 0 °C to rt
56%
i. Mg, 
DIBAL cat.
ii. 5.22
THF, 0 to 60 °C
H
H
H
CHAPTER 5 
98 
At this point, we identified the Grignard reagent as the problem. While it was known 
that the vinyl lithium reagent of 5.11 could not be added to ethyl formate,12 the reaction 
proceeded with the more electrophilic aldehyde 2.16 in 78% yield (Scheme 5.11).  
 
Scheme 5.11: High yielding synthesis of symmetrical bisallyl alcohol 5.13 from 2.16 prepared 
as described by Pihko et al.14 and 5.11 prepared as described by Breit et al.13 
5.4 Desymmetrization by Sharpless Epoxidation 
We wanted to investigate the influence of the tartaric ester on the enantioselectivity 
of the Sharpless epoxidation (Table 5.2). The enantioselectivity was improved by the 
use of diisopropyl tartrate as observed in literature.19 Using cumene hydroperoxide 
instead of tert-butyl hydroperoxide showed no improvements with our substrate.6  
Entry Additive Reaction time 
[h] 
Yield 
[%] 
ee 
[%] 
αD (c, solvent) 
1 DET 44 75 71  
2 DIPT 17 68 87  
3 DIPT 60 60 84 +21.5° (0.57, CHCl3) 
Table 5.2: Enantioselectivity of Sharpless epoxidation with diethyl tartrate (DET) and 
diisopropyl tartrate (DIPT). Conditions: 2.00 eq. tBuOOH, 1.10 eq. Ti(OiPr)4, 1.30 eq. 
DET/DIPT, pulverized molecular sieves, CH2Cl2, -20 °C. 
5.5 Nucleophilic Epoxide Opening 
As discussed in section 5.1.3, the ring opening of the epoxide 5.14 was unsuccessful 
in previous studies.12 Additionally, procedures utilizing TBAF20 and 
titanium(IV) isopropoxide10 failed to give conversion to the desired product. However, 
the protection of the hydroxy group to give ether 5.27 was facile (Scheme 5.12). 
Many literature examples describe a higher reactivity of the epoxide after a Payne 
rearrangement.5,19,21 While some groups found the Payne rearrangement to be a 
spontaneous process in the hydrolysis of the Sharpless reaction, our substrate required 
stronger conditions. Using sodium hydroxide as base in a mixture of water and 
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methanol at 50 °C, the reaction required 30 hours for completion. Other bases as sodium 
hydride and triethylamine did not show any conversion. Finally, sodium ethoxide in 
ethanol at room temperature was found to give the rearranged epoxide 5.28 in 3.5 hours 
at an acceptable yield of 75%. An alternative where the Sharpless reaction was 
quenched with aqueous sodium hydroxide and methanol to trigger a direct Payne 
rearrangement, required 50 °C and four days for complete conversion, giving only 37% 
of the rearranged product 5.28. 
 
Scheme 5.12: From bisallyl alcohol 5.13 to the pivaloyl protected triol 5.30. Intermediate A 
shows the activation in the epoxide opening.22 Transition state B is part of the 1,3 ester shift.24 
Ester 5.29 rearranged spontaneously at ambient conditions and could only be characterized after 
protection of the diol giving 5.45. 
In literature, titanium(IV) isopropoxide has been found to be superior in the opening 
of hydroxy epoxides.9,10,22 This is explained by a simultaneous coordination of titanium 
to the alcohol and the oxirane oxygen, thereby activating the leaving group as depicted 
in intermediate A. By this method, the epoxide could be opened with pivalic acid 
(Table 5.3, Entry 1). However, the product was not the expected ester 5.29, but isomer 
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5.30 with the ester on the terminal position. Such 1,3-shifts of esters are known in 
literature and may occur over the transition state B.23,24 
From a strategic point of view, this rearrangement is in our favor as it was part of the 
synthetic strategy to install a pivaloyl ester in the terminal position. Due to the Payne 
rearrangement, this transformation occurs with retention, changing the absolute 
configuration of the product. Therefore, parts of the studies were conducted with the 
undesired enantiomer. 
Entry PivOH 
[eq.] 
Catalyst (eq.) Solvent Temperature 
[°C] 
Yield 5.29, 5.30 
[%] 
1 1.3 Ti(OiPr)4 (1.5) Toluene rt -, 22 
2 1.3 TiCl(OiPr)3 (1.5) Benzene rt 0, 0a 
3 3.0 Ti(OiPr)4 (1.7) CH2Cl2 0 to rt 20, 52 
4 3.0 Ti(OiPr)4 (2.0) CH2Cl2 -18 to 0 27, 73 
Table 5.3: Opening of epoxide 5.28 by pivalic acid (PivOH). aAn unknown product was formed. 
Unfortunately, epoxide opening with the more reactive TiCl(OiPr)3 gave an 
unknown product (Entry 2). Consequently, the reaction conditions were optimized by 
changing the solvent to CH2Cl2 and lowering the temperature to obtain quantitative 
conversion (Entries 3 and 4). These optimized reaction conditions were tested for the 
opening of the not rearranged epoxide 5.14. Although the reaction required higher 
temperatures and a longer reaction time, 38% of the terminal pivaloyl ester 5.30 was 
isolated. However, the isolated product showed a similar optical rotation of 
αD = -18.3° (0.58, CHCl3) to the same product synthesized over the Payne 
rearrangement. Therefore, the direct reaction from the terminal epoxide 5.14 proceeds 
over the same intermediates, resulting in inversion. Furthermore, intermediate 5.28 
could be observed in the reaction mixture. 
 
Scheme 5.13: Isomerization of 5.29 to the thermodynamically favored 5.30 with PTSA in three 
days. 
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While the terminal pivalic ester 5.30 was isolated in high purity as a white solid, not 
rearranged 5.29 was unstable at ambient conditions. Locking the ester group by the 
protection of the remaining hydroxy functions enabled us to isolate and characterize 
compound 5.45. However, the terminal ester seems to be the thermodynamically 
favored product. Therefore, the isomerization of ester 5.29 to 5.30 seemed feasible 
(Scheme 5.13). While carboxylic acids were not strong enough to accelerate the 
rearrangement, TFA and PTSA showed from the beginning fast conversion. With 
PTSA, about three days were required for the isomerization to go to completion. The 
long reaction time caused degradation, decreasing the isolated yield of 5.30 to 73%. A 
similar reaction with titanium(IV) isopropoxide over three days resulted in 
decomposition. 
 
Scheme 5.14: Epoxide opening with various carboxylic acids. X-ray crystal structure of 5.34 for 
determination of absolute configuration. Compounds 5.31, 5.32 and 5.33 were unstable and 
could not be characterized. 
Additionally, the epoxide 5.28 was opened with other carboxylic acids 
(Scheme 5.14). While the equilibrium of the pivalic ester favored terminal product 5.30, 
this ratio varied with other carboxylic acids. Using 2,4,6-timethylbenzoic acid, products 
5.31 and 5.32 were isolated and quantified in an opposite ratio, but the spontaneous 
Bn Bn
5.28
O
HO
ROH, Ti(OiPr)4
CH2Cl2 Bn BnOH
HO
OR
Bn BnOH
RO
OH
R:
Piv-
2,4,6-Me3PhCO-
4-IPhCO-
5.29 27%
5.31 85%
5.33 28%
5.30 73%
5.32 15%
5.34 26%
(S)
(R) OHOHO
O
I
5.34
CHAPTER 5 
102 
isomerization was unavoidable and made the characterization impossible. When the 
epoxide was opened with p-iodobenzoic acid to give 5.33 and 5.34, the terminal ester 
could be isolated, crystallized, analyzed by X-ray diffraction, and the absolute 
configuration was determined as depicted in scheme 5.14. 
5.6 Evaluation of Nucleophiles for Chain Elongation 
5.6.1 Synthesis of the Precursor 
To yield the open bisacid 5.09, forming the desired dilactone core, the carbon chain 
has to be elongated by another two carbons. Additionally, a phenyl group has to be 
introduced at the vinylic position. Both can be done by shortening the chain by 
ozonolysis and adding a nucleophilic C6C3 subunit. 
 
Scheme 5.15: Synthesis of protected vinyl iodides 5.37 to 5.40, and selective reduction and 
iodination over intermediate A.26 Conditions for alcohol protection: 5.37: PivCl, DMAP cat., 
pyridine, CH2Cl2, rt; 5.38: TBDMSCl, NEt3, CH2Cl2, 0 °C to rt; 5.39: BnBr, (Bu)4NHSO4 cat., 
NaOH, toluene, 0 °C to rt; 5.40: TrtCl, pyridine, CH2Cl2, 0 °C to rt. Compound 5.40 could be 
crystallized and analyzed by X-ray diffraction (Section 8.4). 
The vinyl iodide 5.36 was chosen as appropriate precursor (Scheme 5.15). The 
Sonogashira coupling giving alkyne 5.35 proceeded nicely.25 The following reduction 
and selective iodination were performed in accordance to a procedure from Fürstner.26 
In this reaction, the hydroxy function coordinates to the aluminium and controls the 
addition to the triple bond, giving intermediate A.27–29 It was found that it was important 
to quench the remaining excess of Red-Al with ethyl acetate before treatment with 
iodine. Subsequently, the hydroxy function was protected. Benzyl protection was 
problematic, as elimination of hydroiodic acid and formation of the protected alkyne 
I
I
OH+
Pd(PPh3)4 cat.
CuI cat.
NEt3, 60 °C
95% OH
5.35
5.36
OH
A
Al- O
R
RNa
+
i. Red-Al
0 °C to rt
ii. EtOAc, 0 °C
iii. I2, -78 °C to rt
Et2O, 74%
H
I
OR
R:
Piv
TBDMS
Bn
Trt
5.37 74%
5.38 88%
5.39 85%
5.40 65%
 STUDIES ON A LINEAR APPROACH TOWARDS OPHIODILACTONE A AND B 
103 
was observed. Sodium hydride as base for this reaction led to quantitative elimination, 
while sodium hydroxide under phase transfer conditions gave minor amounts of the 
elimination product and the desired vinyl iodide in a yield of 85%. 
5.6.2 Nucleophilic Addition to a Model Substrate 
We sought an appropriate protecting group, a metal for the iodine exchange and the 
optimal reaction conditions without consuming the valuable intermediate 5.46. The 
pivalic ester 5.37 would give the same protecting group on both ends of the chain, 
circumventing one deprotection step. However, this protecting group was unstable to 
withstand the halogen metal exchange. The TBDMS-protection was found to be 
problematic as well. Lithiated intermediate A showed to be prone for a 1,4-Brook 
rearrangement, resulting in alcohol 5.42 (Scheme 5.16). This process has already been 
investigated by Kim et al.29 However, this rearrangement was not quantitative and a 
small yield of the addition product 5.41 was obtained. 
 
Scheme 5.16: Lithium iodine exchange to intermediate A and addition to test electrophile 
yielding 5.41 or Brook rearrangement to alcohol 5.42.29 Activation of iodide 5.39 with tBuLi 
and addition to the test substrate to give 5.43. Grignard formation of 5.39 was attempted with 
Mg, DIBAL cat., THF, 60 °C and iPrMgCl, THF, rt. 
Finally, the benzylated iodide 5.39 was lithiated with tBuLi and added to the test 
substrate to obtain alcohol 5.43 in moderate yield. Other halogen metal exchange 
methods with metallic magnesium or with iso-propyl magnesium chloride failed to give 
any product. A direct method utilizing the unprotected alcohol 5.36 over a 
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deprotonation with a Grignard reagent, followed by a halogen metal exchange with 
butyl lithium described by Knochel et al. showed to be ineffective in our case.30 
5.7 Chain Elongation 
5.7.1 Electrophile Synthesis 
The 1,2-diol of pivalic ester 5.30 was protected as an acetonide to give compound 
5.44 (Scheme 5.17). Subsequently, the double bond was treated with ozone to yield 
ketone 5.46. Over oxidation was prevented by the addition of Sudan III as an 
indicator.31  
 
Scheme 5.17: Synthesis of ketone 5.46 in two steps and oxidative cleavage of the product while 
storage. Instable ester 5.29 was converted to 5.45 under the same reaction conditions affording 
5.44. The protected 5.45 could be characterized. 
However, the product was found to be less stable than expected. Ketone 5.46 
degraded overtime to ester 5.47. Compound 5.47 is likely the result of an oxidative 
cleavage. A similar reaction was described by Carda et al., enabled by the addition of 
sodium periodate.32 
5.7.2 Stereoselectivity of Nucleophilic Additions 
The stereoselective outcome of nucleophilic additions to carbonyl compounds 
bearing a chiral center has been intensively studied in the last century. Models to predict 
the stereoselectivity were beside others introduced by Cram et al.33 and the group of 
Felkin34 and further developed by Anh and co-workers35 and Reetz et al.36 Each of this 
model accounts for another type of substrate. With a electron withdrawing and Lewis 
basic group in α- and β-position, ketone 5.46 comply with three of these models. Our 
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first task was to evaluate which model describes our substrate. These experiments were 
performed with the enantiomeric ketone ent-5.46.  
 
Scheme 5.18: Models A, B and C predicting the outcome of nucleophilic addition to ent-5.46. 
Addition of vinyl magnesium bromide and the formed product 5.48, with measured X-ray 
crystal structure. 
Three different models can be applied on our substrate (Scheme 5.18). In the 
Felkin-Anh model, intermediate A is the most reactive and gives D as the major 
product. The interaction between the π*-orbital of the carbonyl and the σ*-orbital of the 
electron withdrawing oxygen, causing a 90° angle between the two bonds, is essential 
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and the nucleophile then approaches from the Re face, giving product D. In his early 
descriptions, Cram excluded substrates with Lewis basic groups in α-position from his 
model, as they can build chelate complexes with certain metals. In these cases, the 
Cram-Chelate intermediate B has to be considered as most reactive intermediate. The 
two oxygens are both coordinated to the metal, forming an eclipsed five membered 
cyclic chelate. The nucleophile adds then from the Si face. Additionally, Reetz 
described a similar chelation with Lewis bases in the β-position. The six membered 
chelate C would result in a nucleophilic attack from the Re face. 
To test which model applies for our substrate, vinyl magnesium bromide was added 
to the carbonyl group. The major product 5.48 was isolated and the relative 
configuration was determined after crystallization and X-ray diffraction analysis. The 
Cram-Chelate model B was found to predict the observed product. As expected for 
magnesium with its potential for coordination, the Felkin-Ahn product was not 
observed. Furthermore, the chelation to the α-oxygen seems to dominate over the 
β-position. This finding is in accordance with reports of other groups with similar 
substitution patterns.37–40 
Unfortunately, the resulting stereocenter in 5.48 has the undesired orientation. With 
the addition over the Reetz intermediate C not being feasible, conditions favoring the 
Felkin-Ahn product had to be applied. Therefore, all further experiments were 
conducted with the less-coordinating lithium reagents. 
5.7.3 Addition of the Lithium Reagents 
 
Scheme 5.19: Addition of protected vinyl iodides to ketone 5.46.41–43 
In accordance with the findings in the vinyl Grignard reaction (Section 5.7.2), vinyl 
iodides were lithiated and added to ketone ent-5.46 (Scheme 5.19). While the TBDMS 
and trityl-protected compounds 5.38 and 5.40 gave no product, the benzylated 5.39 gave 
the chain-elongated tertiary alcohol 5.49 in a yield of 23%. The relative configuration of 
the new hydroxy group could not be determined.  
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However, the following deprotection of the diol under various conditions could not 
be accomplished. Our strategy intended the oxidation of the secondary hydroxy group, 
followed by benzylation. Therefore, other protecting groups and reaction orders were 
investigated. 
5.7.4 Further Attempts Towards Ophiodilactone A and B 
Consequently, other protecting groups for the diol moiety were evaluated 
(Scheme 5.20). In contrast to the former acetonide, we focused on single side protecting 
groups. Protection with MOM was only achieved for the secondary alcohol, forming 
5.50. In contrast, the TMS group could be introduced twice to give bissilyl ether 5.52 in 
98% yield. 
 
Scheme 5.20: Alternative protections of diol 5.30. Conditions giving 5.50: MOMCl, NaI, 
DIPEA, dioxane, 100 °C and 5.52: TMSCl, imidazole, CH2Cl2, rt. Eventually mono-TMS 
product 5.51 was observed. 
As allyl groups are not inert to ozonolysis conditions, the sequence was reversed and 
the double bond was first cleaved to ketone 5.53 (Scheme 5.21). However, the 
following allyl protection to afford 5.54 could not be accomplished. 
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Scheme 5.21: Addition of organolithium and cyanide nucleophiles to ketone 5.55. 
Three-dimensional model calculated with Spartan Student version 5.0.1 (Nov 14 2011), 
Equilibrium Geometry with “Molecular Mechanics” MMFF. 
TMS protected ketone 5.55 and unprotected ketone 5.53 were then subjected to the 
chain elongation conditions. In both cases, no desired product was isolated. Steric 
hindrance of the TMS and benzyl groups explains this result for TMS protected 
ketone 5.55. A structural model shows how the carbonyl group is shielded and, 
therefore, not accessible for the organolithium species (Scheme 5.21). An alternative 
nucleophilic addition whit trimethylsilyl cyanide also showed no conversion. This result 
demonstrates a general problem in the synthesis of the ophiodilactones. The benzyl 
moieties hinder the accessibility of the central chain, and protecting groups can make 
the access impossible. 
 
Scheme 5.22: Oxidation to ketone 5.56 and addition of the third benzyl group. The second step 
was attempted with BnMgBr, Et2O, rt and BnLi, toluene, rf. 
In a last attempt, the sequence of additions was changed. Instead of the chain 
elongation, we tried to introduce the remaining benzyl group (Scheme 5.22). Therefore, 
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the secondary hydroxy group of the allylic alcohol 5.30 was oxidized to ketone 5.56. 
For the organometallic nucleophile, Grignard reagents are known for a low 1,2- to 
1,4-selectivity, but benzyl lithium reagent is not well known and difficult to prepare. 
The latter was generated as described by Furber et al.44 However, neither of these 
nucleophiles gave the desired product.  
5.8 Conclusion 
The synthesis of ophiodilactone A (1.47) and B (1.48) over the linear bisacid 5.09, 
allows the application of a desymmetrization strategy. The advantage of this strategy is 
the bidirectional synthesis of a symmetric precursor, reducing the required amount of 
steps.1 First experiments on this route were conducted by Jean-Yves Wach and revealed 
problems in the synthesis of symmetrical intermediates with high complexity.12 
The relatively simple literature known bisallyl alcohol 5.13 was found to be a 
suitable intermediate.13 However, the high yields stated in literature could not be 
reproduced in our laboratory. Therefore, a new synthetic route over a Mannich reaction 
and an organolithium addition was developed. While this new procedure give the 
bisallyl alcohol in sufficient yield, it lacked the advantages of a bidirectional synthesis, 
increasing the number of steps from two to three. 
Consequently, bisallyl alcohol 5.13 was desymmetrized by a Sharpless epoxidation, 
giving epoxide 5.14 in an enantiomeric excess of 87%. The subsequent epoxide opening 
by pivalic acid was achieved, following a Payne rearrangement. Additionally, the ester 
moiety rearranged under the reaction conditions to the desired terminal hydroxy group. 
After protection of the diol as acetonide, the second double bond was cleaved by 
ozonolysis, giving ketone 5.46. 
Towards the nucleophilic three-carbon chain elongation, iodoalcohol 5.36 was 
protected by different groups, activated by lithium-halogen exchange and added to a test 
substrate. The benzyl protected vinyl iodide 5.39 was found to be superior and was 
added to ketone 5.46. However, all following attempts to conduct the required 
deprotection of the diol failed. 
Alternatively, the diol 5.30 was protected by two TMS groups. The following 
unsuccessful chain elongation was explained with the high steric demand of the two 
TMS protecting groups.  
Overall, a total synthesis over an asymmetric precursor offers several advantages, 
including a reduction in the number of steps. In the case of ophiodilactone A and B, the 
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high steric demand of the benzyl groups and the high complexity of the core requires 
the desymmetrization to be performed at an early stage. Furthermore, the 
desymmetrization strategy requires a linear synthesis over the open bisacid 5.09, 
necessitating the use of multiple protecting groups. However, these protecting groups 
were found to increase the steric bulk around the central carbon chain, shutting down 
the reactivity of the substrate. 
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6.1 Introduction 
To our knowledge, only maculalactone A, B and C have been synthesized so far 
(Chapters 1 and 2).1–5 These three structures and maculalactone L (1.37) possess a 
butenolide core (Figure 6.1).6 All other maculalactones, except maculalactone M, 
include a fourth phenylpropanoid resulting in a tetrahydrobenzofuranone skeleton.2,7  
 
Figure 6.1: Exemplary maculalactones formed from three and four phenylpropanoid subunits.  
While the biological properties of maculalactone A have been the objective of 
several studies (Chapters 1 and 3), little is known about the other members of this 
family.8 Recently, Wang et al. isolated maculalactone E (1.39) from the brittle star 
Ophioplocus japonicus and found promising cytotoxicities against five human tumor 
cell lines.9 To gain more insight into the chemistry and biology of these compounds, we 
investigated routes towards their total syntheses. 
These studies require the addition of an additional C6C3 phenylpropanoid unit, as it 
was done in the synthesis of ophiodilactone A (1.48) and B (1.48) (Section 4.3). 
However, the relative configuration of the phenyl and the neighboring benzyl group 
should be cis, instead of the earlier observed trans-product (Scheme 6.1). To obtain the 
correct stereochemistry as depicted in aldehyde 6.02, either the vinylogous Michael 
addition had to be changed in a way to afford the correct product, or the configuration 
of the phenylic stereocenter had to be inverted by the installation of a double bond and a 
subsequent stereoselective hydrogenation. Alternatively, the benzyl-substituted 
stereocenter could be inverted by a lactone opening followed by a re-closure causing 
inversion.  
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Scheme 6.1: Synthetic strategies toward common precursor 6.01. (In case of inversion of the 
lactone, the enantiomeric compound should be used) 
The required ring closure of the second ring, forming the dihydrobenzofuranone 6.01 
should be straightforward, as this reaction was already performed with the trans-isomer. 
The inversion of the lactone seems to be more feasible after the second ring closure, as 
the ring strain could favor the desired cis-product. Finally, common precursor 6.01 has 
to be oxidized in an appropriate way to give the different maculalactones. 
In our study, we focused on altering the stereochemical outcome of the vinylogous 
Michael addition over enone 6.03. 
6.2 Adjusting the Stereochemistry of Bicycle 4.1410 
6.2.1 Electrophiles in the Vinylogous Michael Addition 
In the phase transfer catalyzed vinylogous Michael addition in the synthesis towards 
ophiodilactone A and B, a strong prevalence toward the trans product was found 
(Section 4.3). This selectivity was observed in the tetrabutylammonium-catalyzed 
reactions with methyl cinnamate, as well as in the cinchona alkaloid-catalyzed systems 
with cinnamaldehyde. Since the stereoselectivity is thought to be a result of substrate 
O
Bn
O
Ph
BnPh
maculalactone 
D to K and M
oxidation
O
Bn
O
Ph
BnPh
lactone
inversion
cyclization
cyclization
O
Bn
O
BnPh
H
O
Bn
O
Bn
O
BnPh
H
O
Bn
O
Bn
Bn
O
Bn
maculalactone A
(1.34)
vinylogous
Michael
addition
O
Bn
O
BnPh
H
O
Bn vinylogousMichael
addition
6.01 6.02
4.14 4.07
6.03
_______________ 
Parts of the following study was conducted by Michael Lüscher during his Master thesis.10 
CHAPTER 6 
116 
control, alternative electrophiles were examined (Scheme 6.2).  
 
Scheme 6.2: Vinylogous Michael addition with different electrophiles. The reactions were 
usually catalyzed by Lygo’s PTC 2.12.11 Reaction temperatures were adapted to the 
electrophile. In some cases, further experiments with PTC 4.15 and/or CsOH*H2O as base were 
conducted.12 Reaction times were adjusted to the conversion. The electrophiles 6.0413 and 
6.0814,15 were prepared accordingly procedures in the stated literature. 
Despite multiple attempts, reactions with bromide 6.05 and nitrile 6.07 showed no 
conversion. Meldrum’s acid derivative 6.08 and cis-cinnamaldehyde 6.04 were not 
stable under the reaction conditions. The latter isomerized under the basic conditions to 
the thermodynamically favored trans-form. The usual trans-product was isolated and 
during the reaction, isomerization of 6.04 could be observed by TLC. Finally, malonate 
6.06 showed little conversion to an unidentified product.  
6.2.2 Hydrogenation of the Unsaturated Aldehyde 
As the usage of different electrophiles did not give the required cis-product 6.02, a 
second strategy over enone 6.03 and subsequent hydrogenation was investigated. We 
first attempted to synthesize the required unsaturated compound by dehydrogenation.  
The commonly used selenation, followed by oxidation and elimination, showed no 
conversion at lower temperatures and led to decomposition of the starting material at an 
elevated temperature of -40 °C. The same result was observed with IBX in DMSO, a 
method developed by Nicolaou et al.16 
A procedure published by Shvo et al. with allyl diethyl phosphate as the oxidant and 
palladium(II) acetate as the catalyst showed the formation of small amounts of an 
unknown product A (Table 5.1, Entry 1) (Scheme 6.3).17  
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Scheme 6.3: Dehydrogenation catalyzed with palladium. Decarboxylation product 6.10 was 
identified by NMR (1H, 13C, COSY, HMQC and HMBC) and ESI-MS. 
As only little conversion to the potential desired product A was observed, a stronger 
base was applied, leading to the unexpected decarbonylated products 6.09 and 6.10 
(Entry 2). While such palladium mediated decarbonylations are known in literature, 
they usually require more harsh conditions (T ≥ 150 °C).18 
Entry Reagents Ratio 
4.07 
Ratio 
A 
Ratio 
6.09 
Ratio 
6.10 
1 Pd(OAc)2 (0.3 eq.), allylOPO(OEt)2 
(2.0 eq.), NaHCO3 (1.5 eq) 
87 13 - - 
2 Pd(OAc)2 (0.3 eq.), allylOPO(OEt)2 
(2.0 eq.), Na2CO3 (1.5 eq) 
- 25 50 25 
3 Pd(OAc)2 (0.1 eq.), NaHCO3 (1.5 eq) - - 50 50 
4 Pd/C (10 eq.)a - - 50 50 
Table 6.1: Palladium mediated dehydrogenation. Conditions: THF, 80 °C. Ratios were 
calculated by 1H-NMR data. Product 6.10 was identified by NMR (1H, 13C, COSY, HMQC and 
HMBC) and ESI-MS. aReaction led to the formation of many side products. 
In the absence of allyl diethyl phosphate as oxidant, a one-to-one mixture of the 
decarbonylated products was observed (Entry 3). A similar result was found in the 
presence of palladium on charcoal, even though, many side products formed (Entry 4). 
6.2.3 Changing the Reaction Sequence 
We then attempted to change the reaction order to give access to the cis-product 
6.02. In this way, the vinylogous Michael addition should be performed with the 
γ-unsubstituted maculalactone A derivative 2.11, which would then be followed by 
benzyl group installation at this position (Scheme 6.4). The vinylogous Michael 
addition of the known intermediate 2.06 with cinnamaldehyde under standard 
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conditions afforded the desired product 6.11 as a diastereomeric mixture. Since the 
following step includes a deprotonation in γ-position, both products can be used. 
 
Scheme 6.4: Vinylogous Michael addition with maculalactone A precursor 2.06. The 
diastereomeric ratio was determined by 1H-NMR. Test reaction for the alkylation with 
maculalactone A. 
The following benzylation was first tested by the deprotonation and subsequent 
alkylation of maculalactone A (1.34). The addition to methyl iodide resulted in the 
formation of the α-disubstituted lactone 6.12. This is in accordance with earlier findings 
in the benzylation of lactone 2.06 and similar results were described in literature 
(Section 2.2).19 The predominate α-addition makes the inverted addition to the 
γ-position impossible. 
6.3 Synthesis of epi-Maculalactone F and M10 
Although the synthesis of key intermediate 6.01 was not yet achieved, first 
experiments were conducted over diastereomeric bicycle 4.14. This bicycle was formed 
in the tetrabutylammonium bromide catalyzed reaction of maculalactone A and 
cinnamaldehyde (Section 4.3.2) (Scheme 6.5). To obtain the enantiomerically enriched 
bicycle, aldehyde 4.07, formed in the asymmetric vinylogous Michael addition, was 
cyclized under the same conditions. 
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Scheme 6.5: Synthesis of enantiomerically enriched 4.14 from aldehyde 4.07. 
Epi-maculalactone M (6.14) was chosen as first target, as it should be accessible over 
an oxidative cleavage of bicycle 4.14. Such a cleavage was thought to be achieved in 
one step by treating this bicycle with ozone. To prevent oxidation of the second less 
electron dense double bond, Sudan III was added as indicator (Scheme 6.6).20 
Surprisingly, epoxide 6.13 was isolated as main product, along with minor amounts of 
the potential ring-opened aldehyde. 
 
Scheme 6.6: Ozonolysis of bicycle 4.14 giving epoxide 6.13. 
This unusual outcome of the ozonolysis step is not well known in literature. Bailey 
et al. explains the epoxide formation with the steric hindrance.21 In a common 
ozonolysis, all three oxygens of ozone take part in a [2+3]-cycloaddition, leading to the 
cleavage of the double bond. In sterically hindered systems, only one of the oxygens 
can approach the double bond, resulting in the observed epoxide formation. 
An alternative procedure to obtain epi-maculalactone M (6.14) involves the 
dihydroxylation of the double bond, followed by an in-situ oxidative cleavage 
(Scheme 6.7). Therefore, different dihydroxylation methods were tested, of which most 
did not show any conversion. Finally, a method introduced by the group of Sharpless 
with a ruthenium tetroxide catalyst was sufficient to give epi-maculalactone M.22 
Additionally, epoxide 6.13 and a ketone identified as epi-maculalactone F (6.15) were 
also isolated.  
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Scheme 6.7: Dihydroxylation and in-situ oxidative cleavage giving epi-maculalactone M (6.14), 
epoxide 6.13 and epi-maculalactone F (6.15). Including X-ray crystal structure of starting 
material 4.14. 
The diastereoselectivity of these oxygen additions is explained best with the X-ray 
crystal structure of bicycle 4.14. While the phenyl group blocks the bottom face of the 
double bond, the oxidizing agent can only approach from the top to afford the observed 
product. 
6.4 Synthesis of Maculalactone L Structures 
While maculalactone A, B and C have been synthesized, the synthesis of 
maculalactone L (1.37) has not yet been accomplished. Furthermore, it is the only 
maculalactone with an unknown relative configuration.  
In our studies towards ophiodilactone A and B, we performed several α-oxidations 
(Section 4.5.2 and 4.5.3). We postulated that maculalactone L is the result of 
α-oxidation of maculalactone A (1.34). Our initial experiment was conducted in 
accordance to the synthesis of 4.32 (Section 4.5.2). The oxygen addition was performed 
at -78 °C, but the reaction was warmed to 0 °C and stirred at this temperature for 
2 hours before quenching (Scheme 6.8). While mainly decomposition was observed, 
compound 6.16, possessing a similar structure as maculalactone L, was isolated.  
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Scheme 6.8: Oxidation of the α-position of maculalactone A to form two conformal isomers of 
maculalactone L. The relative configuration was determined by 2D-NMR experiments. 
In a next attempt, the reaction mixture was quenched at -78 °C. While slightly less 
decomposition was observed, two new products were isolated. One was identified as the 
γ-oxidation product 2.05, which is known from the synthesis of maculalactone A, B and 
C by Brown et al.3 The second product possessed the same structure as maculalactone L 
with the correct Z orientation of the double bond. However, the NMR spectra did not 
match to the isolated maculalactone L. Therefore, we surmised that the structure must 
be epi-maculalactone L (6.17). 
6.5 Conclusion 
While maculalactone A, B and C have already been synthesized years ago, little is 
known about the synthesis of the other members of this natural product family 
(Section 1.4). We proposed a route to access these natural products over the bicyclic 
key intermediate 6.01. While some transformations are known from our studies towards 
ophiodilactone A and B (Chapter 4), it is not clear how to obtain the required 
cis-orientation of the substituents in 6.02.  
In a first approach, we tried to change the outcome of the vinylogous Michael 
addition by varying the electrophile. However, all tested alternative Michael acceptors 
showed no reactivity or decomposition under the reaction conditions. Further studies 
were conducted on the possibility to convert aldehyde 4.07 to the corresponding 
enone 6.03 and to change the orientation of the β-substituent in a following 
stereoselective hydrogenation. While various methods were tested, the required enone 
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could not be observed. In a third attempt, we tried to vary the order of the steps. While 
the vinylogous Michael addition worked well, the following alkylation was found to 
result in a substitution at the α-position. 
Although key intermediate 6.01 could not be synthesized, the oxidations steps were 
tested with the diastereomeric bicycle 4.14. A dihydroxylation catalyzed by ruthenium 
tetroxide, followed by an in-situ oxidative cleavage afforded 
epi-maculalactone M (6.14) in a yield of 30%. Furthermore, a side product of the 
reaction was identified as epi-maculalactone F (6.15). 
In an attempt to synthesize maculalactone L (1.37), maculalactone A was 
deprotonated and oxidized with molecular oxygen. Thereby, different compounds 
having the same composition as maculalactone L were isolated. One compound was 
identified as epi-maculalactone L (6.17) and helped to define the unknown relative 
configuration of natural maculalactone L. 
 
 TOWARDS MACULALACTONE F, L AND M 
123 
6.6 References 
(1)  Tsui, W.-Y.; Williams, G. A.; Brown, G. D. Phytochemistry 1996, 43, 1083–1085. 
(2)  Lee, S.-C.; Brown, G. D. J. Nat. Prod. 1998, 61, 29–33. 
(3)  Brown, G. D.; Wong, H.-F. Tetrahedron 2004, 60, 5439–5451. 
(4)  Kar, A.; Gogoi, S.; Argade, N. P. Tetrahedron 2005, 61, 5297–5302. 
(5)  Duffy, R. J.; Morris, K. A.; Vallakati, R.; Zhang, W.; Romo, D. J. Org. Chem. 
2009, 74, 4772–4781. 
(6)  Lee, S.-C.; Williams, G. A.; Brown, G. D. Phytochemistry 1999, 52, 537–540. 
(7)  Wong, H.-F.; Williams, G. A.; Brown, G. D. Phytochemistry 2002, 60, 425–429. 
(8)  Brown, G. D.; Wong, H.-F.; Hutchinson, N.; Lee, S.-C.; Chan, B. K. K.; Williams, 
G. A. Phytochem. Rev. 2004, 3, 381–400. 
(9)  Weihong Wang; Jongki Hong; Chong-Ok Lee; Hee Young Cho; Sook Shin; Jee H. 
Jung. Nat. Prod. Sci. 2004, 10, 253–261. 
(10)  Lüscher, M. Synthetic Studies Towards the Total Synthesis of Maculalactone F & 
M, Ophiodilactone A & B. Master Thesis, University of Basel: Basel, 2012. 
(11)  Lygo, B.; Wainwright, P. G. Tetrahedron Lett. 1997, 38, 8595–8598. 
(12)  Corey, E. J.; Xu, F.; Noe, M. C. J. Am. Chem. Soc. 1997, 119, 12414–12415. 
(13)  Baas, P.; Cerfontain, H. Tetrahedron 1977, 33, 1509–1511. 
(14)  Trost, B. M.; Morris, P. J.; Sprague, S. J. J. Am. Chem. Soc. 2012, 134, 17823–
17831. 
(15)  Ayoubi, S. A.-E.; Texier-Boullet, F.; Hamelin, J. Synthesis 1994, 258–260. 
(16)  Nicolaou, K. C.; Montagnon, T.; Baran, P. S. Angew. Chem. Int. Ed. 2002, 41, 
993–996. 
(17)  Shvo, Y.; Arisha, A. H. I. J. Org. Chem. 1998, 63, 5640–5642. 
(18)  Tsuji, J.; Ohno, K. J. Am. Chem. Soc. 1968, 90, 94–98. 
(19)  Kraus, G. A.; Roth, B. Tetrahedron Lett. 1977, 18, 3129–3132. 
(20)  Veysoglu, T.; Mitscher, L. A.; Swayze, J. K. Synthesis 1980, 807–810. 
(21)  Bailey, P. S.; Hwang, H. H.; Chiang, C. Y. J. Org. Chem. 1985, 50, 231–234. 
(22)  Carlsen, P. H. J.; Katsuki, T.; Martin, V. S.; Sharpless, K. B. J. Org. Chem. 1981, 
46, 3936–3938. 
 
 
 
 CONCLUSION 
125 
7 - CONCLUSION 
In our studies on the synthesis and biology of marine, phenylpropanoid natural 
products, different approaches towards a more economical synthesis of maculalactone 
A (1.34) were investigated. A first attempt over a late stage ring-closing metathesis was 
partially successful, but the low conversion of the metathesis could not be overcome. 
Alternatively, a route via a late-stage intramolecular cyclization of malonic ester 2.31 
gave maculalactone A in modest yield. This final key step includes a nucleophilic 
addition to a carbonyl moiety and subsequent loss of ethanol and carbon dioxide to 
establish the butenolide double bond. After careful optimization, this cyclization was 
achieved in 76% yield, allowing the synthesis of maculalactone A in total of four steps 
and 45% yield. 
The same methodology was used for the synthesis of the three maculalactone A 
analogues 3.17, 3.18 and 3.19, each bearing a methoxy group on one of the benzyl 
moieties. The biological properties of these analogues were compared in a small SAR 
study with Artemia franciscana and Thamnocephalus platyurus. Subsequently, 
analogue 3.17 was used in our investigations on the antifouling protection of metal 
surfaces. Therefore, we utilized the methoxy group to connect the analogue to one of 
our surface anchors. In a similar manner, we synthesized the rhodamine B labeled 
analogue 3.47. In an in vivo staining experiment with Artemia salina, we observed 
specific accumulation of maculalactone A in two tissues. 
Two different strategies towards the synthesis of ophiodilactone A (1.47) and B 
(1.48) were investigated. In an initial linear route, we first developed a new synthesis of 
bisallyl precursor 5.13, which was subsequently desymmetrized via a Sharpless 
epoxidation. Eventually, the epoxide was opened after a Payne rearrangement, followed 
by an ozonolysis, affording ketone 5.46. While the following carbon chain elongation 
was successful, it was not possible to remove the protecting groups. In a second, 
protecting group-free strategy, maculalactone A was the starting material. By a 
vinylogous Michael addition, we could add the required C6C3 unit in 52% yield and 
68% ee. Various efforts to achieve the required oxidation of the butenolide double bond 
failed. Furthermore, different approaches to alter the reactivity of the olefin or to 
convert it into a more reactive intermediate were unsuccessful. However, by this second 
strategy, we obtained the carbon skeleton of ophiodilactone A (1.47) in five steps and 
an overall yield of 23%. 
 
8 - EXPERIMENTAL 
PART 
 
 
CHAPTER 8 
128 
8.1 General Information 
Reagents and Solvents: All chemicals and solvents were purchased from Acros, 
Alfa Aesar, Fluka, Fluorochem, Apollo, TCI or Sigma-Aldrich and used without any 
prior purification if not otherwise reported. Dry solvents were purchased from 
Sigma-Aldrich. Technical grade solvents for extractions and chromatography were 
distilled before usage. NMR solvents were obtained from Cambridge Isotope 
Laboratories, Inc. (Andover, MA, USA).  
Reactions: Yields refer to purified, dried and spectroscopically pure compounds. Air 
or moisture sensitive reactions were set up in dry glassware under nitrogen atmosphere. 
Chromatography: Column chromatography was carried out on silica gel 60 with a 
particle size of 0.04 – 0.063 mm (230 – 400 mesh) from Merck or Silicycle. Preparative 
TLC was performed on the same plates, usually in a size of 20 to 20 cm. The developed 
plates were examined under UV light at 254 nm, the sections of interest were removed 
with a knife and extracted with CH2Cl2 or EtOAc. Preparative HPLC chromatography 
was performed using Varian Prep Star pumps and a Dionex UltiMate 3000 RS detector 
ore a Dionex P680 pump and a Dionex PDA-100 detector. 
Distillation: Concentration was performed by rotary evaporation under reduced 
pressure at 40 to 50 °C. Kugelrohr distillation was done using a Büchi GKR-51 
apparatus. 
Retention Factor (Rf): Analytical thin layer chromatography (TLC) was performed 
either on Merck Silica gel 60 F254 Plates with a thickness of 0.25 mm on glass support 
or on Merck Silica gel 60 RP-18 F254 Plates with a thickness of 0.2 mm on aluminum 
support. The developed plates were examined under UV light at 254 nm and stained 
with an aqueous KMnO4/Na2CO3 solution or an aqueous 
(NH4)6Mo7O24/Ce(SO4)2/H2SO4 solution. 
1H-, 13C- and 19F-Nuclear Magnetic Resonance (NMR): All spectra were recorded 
either using a Bruker BZH-NMR (250 MHz), a Bruker DPX-NMR (400/101/376 MHz), 
a Bruker Avance DRX (500/126 MHz) or a Bruker Avance III (600/151 MHz) 
spectrometer at room temperature if not otherwise reported. Two-dimensional spectra 
were recorded on a Bruker Avance DRX. Chemical shifts (δ) are reported in parts per 
million (ppm) relative to residual solvent peaks or tetramethylsilane (TMS), coupling 
constants (J) are reported in Hertz (Hz). The multiplicities are given as: s=singlet, 
d=doublet, t=triplet, m=multiplet and their combination, as dd=doublet of a doublet and 
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so on. For multiplets the range of the chemical shift (ppm) is reported. Solvents are 
abbreviated as follows: chloroform-d (CDCl3), water-d2 (D2O), methanol-d4 (MeOD), 
dimethylsulfoxide-d6 (DMSO-d6), benzene-d6 (C6D6). 
Infrared Spectroscopy (IR): The spectra were recorded on a Varian 800 FT-IR 
ATR Spectrometer. The absorptions are reported in cm-1. 
Mass Spectrometry (MS): Mass spectra with electronic ionization (EI-MS) were 
recorded on a Finnigan MAT 95Q instrument. Fast atom bombardment mass 
spectrometry (FAB-MS) was measured on a Finnigan MAR 312 instrument. Mass 
spectra with electron spray ionization (ESI-MS) were measured on a Bruker esquire 
3000 plus instrument. EI-MS and FAB-MS were performed by Dr. H. Nadig, University 
of Basel.  
High Resolution Mass Spectroscopy (HR-MS): Mass spectra were measured by 
the Mass spectrometric service of the University of Bern on a Sciex QSTAR Pulsar 
mass spectrometer or by Dr. H. Nadig on a Bruker maXis 4G using electrospray 
ionization in both cases. 
Elementary Analysis (EA): The elementary analysis was measured on a 
Perkin-Elmer Analysator 240 performed by Hr. W. Kirsch, University of Basel 
Gas Chromatography with Mass Spectrometry (GC-MS): For GC-MS analysis, 
either a Hewlett Packard 5890 Series II gas chromatography system with a 
Macherey-Nagel OPTIMA 1 Me2Si column (25 m x 0.2 mm x 0.35 µm), at 1 ml/min 
He-flowrate with a Hewlett Packard 5971 Series mass selective detector (EI 70 eV) or a 
Thermo Trace 1300 gas chromatography system with an Agilent Ultra 1 column (25 m 
x 0.2 mm x 0.33 µm) at 1 ml/min He-flowrate with a Thermo ISQ mass detector 
(EI 70 eV) was used. 
Ultra Pressure Liquid Chromatography with Mass Sectrometry (UPLC-MS): 
For UPLC-MS analysis a Agilent 1290 Infinity instrument with an Agilent Eclipse Plus 
C18 column, a CH3CN/water gradient (acidified with TFA or formic acid) and an 
Agilent 6130 ESI-MS detector was used. 
High Performance Liquid Chomatography (HPLC): Analytic HPLC was 
performed on a Dionex system using a P680 pump and a PDA-100 detector. 
Chiral HPLC: Chiral HPLC was performed on a Shimadzu LC-20A prominence 
system with a LC-20AD pump and a SPD-M20A diode array detector. 
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Optical Rotations ([α]D): Optical rotations were measured at the sodium D line 
using a 1 ml cell with a 1 dm path length on a Jasco P-2000 digital polarimeter and the 
concentration (c) is given in g/100 ml. 
Melting point (Mp): A Büchi B545 apparatus was used. The measured temperatures 
are not corrected. 
Absorptions spectra (UV/VIS): Spectra were recorded on a Shimadzu UV-1650 PC 
instrument. 
Emission spectra (EM): The fluorescent emission was recorded on a Shimadzu 
RF-5301 PC instrument. 
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8.2 An Improved Synthesis of Maculalactone A 
2,3-Dibenzylmaleic anhydride (2.04) 
 
A solution of 2,3-dibromomaleic anhydride (2.15, 1.00 eq., 0.758 mmol, 194 mg) in 
toluene (1.6 ml) was heated to reflux. Subsequently, di-tert-butyl peroxide (0.500 eq., 
0.379 mmol, 69.3 µl) was added in five portions over ten hours and the mixture was 
refluxed for another four hours. The reaction mixture was then cooled to room 
temperature and filtrated over basic aluminium oxide. The solid was washed with Et2O. 
The filtrate was concentrated and purified by column chromatography (SiO2, 
pentane/EtOAc (10:1)) to give the title compound 2.04 (61 mg, 0.21 mmol, 28%) as 
pale yellow oil. 
Rf (SiO2, pentane/EtOAc (11:1)): 0.40. 
1H-NMR (400 MHz, CDCl3): 7.34 – 7.27 (m, 6 H), 7.17 – 7.10 (m, 4 H), 3.80 
(s, 4 H). 
13C-NMR (101 MHz, CDCl3): 165.9, 143.1, 135.1, 129.2, 129.0, 127.6, 30.4. 
The analytical data of product 2.04 correspond to those reported in the literature.1–3 
3,3,4-Tribenzylfuran-2(3H)-one (2.13) 
 
To a solution of 3,4-dibenzylfuran-2(5H)-one (2.06, 1.0 eq., 0.11 mmol, 29 mg) in 
toluene (5.4 ml) were added benzyl bromide (3.0 eq., 0.323 mmol, 38.7 µl) and the 
cinchona alkaloid catalyst (2.12, 0.05 eq., 5 mmol, 3 mg) in one portion. The mixture 
was cooled to 0 °C and stirred for 10 minutes before a 50% aq. KOH solution (6.5 eq., 
0.701 mmol, 52.5 µl) was added within five minutes. After vigorous stirring for 
30 minutes at 0 °C, the mixture was heated to room temperature and stirred for 
72 hours. The resulting suspension was filtrated through a SiO2 pad and the filtrate was 
O
O
O
O
O
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concentrated. The crude mixture was purified by column chromatography (SiO2, 
pentane/EtOAc (20:1)) to give the title compound 2.13 (21 mg, 0.059 mmol, 51%) as 
pale yellow solid. 
Rf (SiO2, pentane/EtOAc (5:1)): 0.43. 
1H-NMR (400 MHz, CDCl3): 7.41 (dd, J = 10.2, 4.6 Hz, 2 H), 7.35 – 7.19 (m,11 H), 
7.07 (d, J = 7.3 Hz, 2 H), 6.60 (t, J = 2.5 Hz, 1 H), 4.18 (d, J = 2.6 Hz, 2 H), 3.50 (d, 
J = 13.1 Hz, 2 H), 3.11 (d, J = 13.2 Hz, 2 H). 
13C-NMR (101 MHz, CDCl3): 179.4, 137.0, 136.0, 135.7, 130.4, 129.0, 128.6, 
128.5, 128.3, 128.3, 128.2, 128.1, 127.7, 127.2, 125.7, 70.2, 56.4, 45.6. 
IR (neat): 3028, 2927, 1764, 1725, 1493, 1454, 1141, 1025, 698. 
HR-MS: Calculated for C25H23O2 [M+H]+: 355.1693, found: 355.1696. 
Mp: 102 – 103 °C. 
2-Benzylacrylic acid (2.17) 
 
To a solution of 2-benzylacrylaldehyde (2.16, 1.00 eq., 3.42 mmol, 500 mg) in 
tert-butanol (4 ml) was added 2-methyl-2-butene (3.00 eq., 10.3 mmol, 1.09 ml). The 
reaction was cooled to 15 – 20 °C in a ice bath before a mixture of sodium chlorite 
(2.30 eq., 7.87 mmol, 889 mg) and monobasic sodium phosphate (2.00 eq., 6.84 mmol, 
821 mg) in water (2.5 ml) was added dropwise within 30 minutes, maintaining the 
temperature below 20 °C. The reaction mixture was allowed to reach room temperature 
over two days. Subsequently, the mixture was concentrated, diluted with water and 
acidified to pH 3 with phosphoric acid. A white solid precipitated, which was collected 
by filtration to give the title compound 2.17 (197 mg, 1.2 mmol, 36%) as white solid. 
The filtrate was extracted three times with CH2Cl2. The org. layers were washed with 
brine, combined, dried with Na2SO4 and concentrated to give the title compound 2.17 
(358 mg, 2.2 mmol, 65%) as white solid. 
1H-NMR (400 MHz, CDCl3): 7.30 (t, J = 7.3 Hz, 2 H), 7.22 (dd, J = 9.8, 7.8 Hz, 
3 H), 6.38 (s, 1 H), 5.58 (d, J = 1.3 Hz, 1 H), 3.63 (s, 2 H). 
The analytical data of product 2.17 correspond to those reported in the literature.4 
OH
O
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3-Benzyl-1-phenylbut-3-en-2-ol (2.18) 
 
Pre-dried magnesium turnings (1.40 eq., 4.79 mmol, 116 mg) were mixed with dry 
Et2O (2 ml) and cooled to 0 °C. Then diisobutylaluminium hydride (1 M solution in 
hexane, 0.015 eq., 0.05 mmol, 0.05 ml) was added and the mixture was stirred for 
10 minutes. Subsequently, benzyl bromide (1.25 eq., 4.28 mmol, 508 µl) in dry Et2O 
(1 ml) was added dropwise. The resulting solution was stirred for two hours at 0 °C. To 
the resulting yellow suspension, a solution of 2-benzylacrylaldehyde (2.16, 1.00 eq., 
3.42 mmol, 500 mg) in dry Et2O (1 ml) was added dropwise. The mixture was stirred 
for three hours at room temperature before it was quenched with a sat. aq. NH4Cl 
solution, stirred for another 30 minutes and filtrated over Celite. The layers were 
separated and the aq. layer was extracted three times with TBME. The org. layers were 
subsequently washed with water and brine, combined, dried with Na2SO4 and 
concentrated. The crude product was purified by column chromatography (SiO2, 
pentane/EtOAc (9:1)) to give the title compound 2.18 (460 mg, 1.9 mmol, 56%) as 
colorless oil. 
Rf (SiO2, pentane/EtOAc (9:1)): 0.29. 
1H-NMR (400 MHz, CDCl3): 7.33 – 7.27 (m, 4 H), 7.25 – 7.17 (m, 6 H), 5.17 (s, 
1 H), 4.82 (d, J = 1.1 Hz, 1 H), 4.33 – 4.25 (m, 1 H), 3.52 (d, J = 15.5 Hz, 1 H), 3.39 (d, 
J = 15.5 Hz, 1 H), 2.95 (dd, J = 13.7, 4.1 Hz, 1 H), 2.76 (dd, J = 13.7, 8.9 Hz, 1 H), 1.58 
(d, J = 3.5 Hz, 1 H). 
13C-NMR (101 MHz, CDCl3): 150.7, 139.2, 138.3, 129.4, 129.2, 128.5, 128.4, 
126.6, 126.3, 112.3, 75.0, 42.8, 39.4. 
IR (neat): 3558, 3421, 3062, 3027, 2919, 1647, 1602, 1494, 1453, 1049, 1030, 906, 
743, 697. 
HR-MS: Calculated for C17H18NaO [M+Na]+: 261.1250, found: 261.1254. 
EI-MS (70 eV) m/z (%): 238 (3, [M]+), 147 (63), 146 (78), 145 (15), 130 (10), 129 
(100), 117 (25), 116 (24), 115 (13), 92 (61), 91 (88), 65 (12). 
The analytical data of product 2.18 correspond to those reported in the literature.5 
OH
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3-Benzyl-1-phenylbut-3-en-2-yl 2-benzylacrylate (2.19) 
 
To a solution of 3-benzyl-1-phenylbut-3-en-2-ol (2.18, 1.0 eq., 0.093 mmol, 22 mg) 
and 2-benzylacrylic acid (2.17, 1.3 eq., 0.12 mmol, 20 mg) in dry CH2Cl2 (2 ml) was 
added 4-dimethylaminopyridine (1.1 eq., 0.10 mmol, 13 mg). Five minutes later, 
N,N’-dicyclohexylcarbodiimide (1.5 eq., 0.14 mmol, 29 mg) was added and the mixture 
was heated to reflux. After five hours at reflux, the reaction was cooled to room 
temperature and the precipitate was filtered off. After concentrating the filtrate, the 
crude product was purified by preparative TLC (SiO2, pentane/EtOAc (15:1)) to give 
the title compound 2.19 (27 mg, 0.071 mmol, 76%) as pale yellow oil.  
Rf (SiO2, pentane/EtOAc (15:1)): 0.73. 
1H-NMR (500 MHz, CDCl3): 7.30 – 7.24 (m, 5 H), 7.24 – 7.18 (m, 4 H), 7.13 (dd, 
J = 6.9, 5.2 Hz, 4 H), 7.10 – 7.06 (m, 2 H), 6.16 (s, 1 H), 5.43 (dd, J = 7.9, 5.6 Hz, 1 H), 
5.39 (d, J = 1.4 Hz, 1 H), 4.96 (s, 1 H), 4.71 (d, J = 1.0 Hz, 1 H), 3.54 (s, 2 H), 3.36 (d, 
J = 15.8 Hz, 1 H), 3.30 (d, J = 15.8 Hz, 1 H), 2.92 (dd, J = 13.9, 8.0 Hz, 1 H), 2.86 (dd, 
J = 14.0, 5.5 Hz, 1 H). 
13C-NMR (126 MHz, CDCl3): 166.0, 146.8, 140.1, 138.8, 138.7, 137.4, 129.5, 
129.5, 129.1, 128.6, 128.5, 128.4, 126.6, 126.5, 126.4, 114.4, 77.7, 40.4, 39.5, 38.1. 
IR (neat): 3062, 3028, 2922, 1716, 1632, 1603, 1494, 1453, 1297, 1191, 1129, 1000, 
908, 737, 697. 
HR-MS: Calculated for C27H26NaO2 [M+Na]+: 405.1825, found: 405.1825. 
Potassium 2-benzyl-3-ethoxy-3-oxopropanoate (2.28) 
 
A published procedure6 was modified as follows: To a solution of diethyl 
benzylmalonate (2.27, 1.00 eq., 20.0 mmol, 5.11 g) in EtOH (20 ml) was added a 
freshly filtrated solution of potassium hydroxide (1.05 eq., 21.0 mmol, 1.39 g) in EtOH 
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(20 ml) at room temperature. The reaction was stirred for six hours at room temperature. 
The precipitate was filtered off and the filtrate was concentrated to a yellowish foam. 
The residue was suspended twice in Et2O and again concentrated. After drying at high 
vacuum, the foam was triturated overnight in Et2O (50 ml). The precipitate was filtered 
off, washed twice with Et2O and dried in vacuum to give the title compound 2.28 
(4.44 g, 17 mmol, 85%) as white solid. 
1H-NMR (400 MHz, D2O): 7.30 – 7.22 (m, 2 H), 7.22 – 7.15 (m, 3 H), 4.06 – 3.96 
(m, 2 H), 3.51 (dd, J = 8.8, 7.4 Hz, 1 H), 3.05 – 3.00 (m, 2 H), 1.07 (t, J = 7.1 Hz, 3 H). 
13C-NMR (101 MHz, D2O): 176.0, 173.3, 139.1, 128.7, 128.6, 126.6, 62.0, 57.3, 
35.0, 13.2. 
IR (neat): 3396, 2980, 1710, 1598, 1496, 1454, 1359, 1321, 1234, 1150, 1095, 1061, 
1028, 950, 914, 858, 830, 745, 698. 
HR-MS: Calculated for C12H13O4 [M-K]- 221.0819, found: 221.0822. 
Mp: 120 °C decomposition.  
The analytical data of product 2.28 correspond to those reported in the literature.6 
3-Hydroxy-1,4-diphenylbutan-2-one (2.30) 
 
A published procedure7 was modified as follows: To a solution of sodium acetate 
(0.200 eq., 4.00 mmol, 328 mg) and freshly distilled phenyl acetaldehyde (1.10, 
2.00 eq., 40.0 mmol, 4.77 ml) in EtOH (20 ml) was added 
3-benzyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride (2.29, 0.100 eq., 2.00 mmol, 
540 mg). The mixture was heated to reflux for three hours, cooled down and mixed with 
ice water (20 ml). After stirring for another hour, the mixture was saturated with NaCl 
and extracted three times with EtOAc. The org. layers were washed with brine, 
combined, dried with Na2SO4 and concentrated. The crude product was purified by 
column chromatography (SiO2, pentane/EtOAc (7:1 to 5:1)) to give the title compound 
2.30 (2.9 g, 12 mmol, 61%) as yellow liquid, which crystallized after several days. 
1H-NMR (500 MHz, CDCl3): 7.39 – 7.26 (m, 6 H), 7.25 – 7.12 (m, 4 H), 4.51 (ddd, 
J = 7.4, 5.5, 4.9 Hz, 1 H), 3.81 (d, J = 15.9 Hz, 1 H), 3.75 (d, J = 15.9 Hz, 1 H), 3.22 (d, 
J = 5.6 Hz, 1 H), 3.15 (dd, J = 14.1, 4.7 Hz, 1 H), 2.90 (dd, J = 14.1, 7.4 Hz, 1 H). 
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13C-NMR (126 MHz, CDCl3): 209.2, 136.5, 133.1, 129.6, 129.5, 128.9, 128.8, 
127.5, 127.2, 76.8, 45.9, 40.3. 
The analytical data of product 2.30 correspond to those reported in the literature.7,8 
1-Ethyl 3-(3-oxo-1,4-diphenylbutan-2-yl) 2-benzylmalonate (2.31) as a mixture of 
diastereomers 
 
To a suspension of potassium 2-benzyl-3-ethoxy-3-oxopropanoate (2.28, 1.40 eq., 
72.8 mmol, 19.0 g) in dry THF (250 ml) at 0 °C was added DMF (0.050 eq., 5.20 mmol, 
201 µl) followed by the dropwise addition of pivaloyl chloride (1.70 eq., 88.4 mmol, 
11.0 ml) over five minutes. During the addition of pivaloyl chloride, the reaction 
mixture turned to a solution and after another 10 minutes to a jelly. This was then kept 
for one hour at 0 °C and for 2.5 hours at room temperature. During that time, the jelly 
dissolved and the reaction mixture could be stirred again. The resulting solution was 
concentrated, dried in high vacuum, again dissolved in dry CH2Cl2 (250 ml), 
concentrated and dried again in high vacuum without exceeding a temperature of 25 °C. 
The residue was dissolved in dry CH2Cl2 (250 ml) and cooled to 0 °C. The addition of 
4-dimethylaminopyridine (0.100 eq., 5.20 mmol, 635 mg) to the reaction mixture was 
followed by the addition of a solution of 3-hydroxy-1,4-diphenylbutan-2-one (2.30, 
1.00 eq., 52.0 mmol, 12.5 g) in dry CH2Cl2 (50 ml) over 10 minutes. The reaction was 
allowed to reach room temperature overnight before it was quenched at 0 °C with a 
mixture of water and a sat. aq. NaHCO3 solution (1:1 v/v). The layers were separated 
and the aq. layer was extracted three times with CH2Cl2. The org. layers were washed 
with a sat. aq. NH4Cl solution, combined, dried with Na2SO4 and concentrated. The 
crude product was purified by column chromatography (SiO2, pentane/EtOAc (6:1)) to 
give the title compound 2.31 (23.1 g, 52 mmol, quantitative) as yellowish liquid. 
Rf (SiO2, pentane/Et2O (2:1)): 0.7. 
1H-NMR (500 MHz, CDCl3): 7.32 – 7.20 (m, 8 H), 7.20 – 7.15 (m, 2 H), 7.14 – 7.09 
(m, 2 H), 7.06 – 6.99 (m, 3 H), 5.35 – 5.25 (m, 1 H), 4.21 – 4.04 (m, 2 H), 3.76 – 3.69 
(m, 1 H), 3.58 (s, 1 H), 3.50 (d, J = 16.9 Hz, 0.5 H), 3.38 (d, J = 16.9 Hz, 0.5 H), 3.26 – 
3.11 (m, 2 H), 3.06 – 2.93 (m, 2 H), 1.19 – 1.11 (m, 3 H). 
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13C-NMR (126 MHz, CDCl3): 204.4, 204.3, 168.5, 168.4, 168.4, 168.3, 137.7, 
137.6, 135.7, 135.5, 132.9, 132.9, 129.9, 129.9, 129.6, 129.6, 129.0, 129.0, 128.7, 
128.7, 128.7, 127.3, 127.3, 127.2, 127.1, 127.1, 79.6, 79.4, 61.9, 61.9, 53.8, 53.7, 46.5, 
46.4, 37.1, 34.7, 34.7, 14.1, 14.1. 
IR (neat): 3031, 2982, 2936, 1732, 1497, 1454, 1369, 1276, 1229, 1149, 701, 633. 
HR-MS: Calculated for C28H32NO5 [M+NH4]+: 462.2275, found: 462.2274. 
EI-MS (70 eV) m/z (%): 444(3, [M]+), 353 (9), 205 (43), 160 (10), 159 (100), 131 
(68), 91 (94). 
Maculalactone A (1.34) 
 
A two neck round bottom flask was equipped with a condenser and a device to run 
the condensed solvent over a bed of 4 Å molecular sieves (Section 9.5.1). In the flask, a 
mixture of cesium carbonate (0.200 eq., 3.78 mmol, 1.23 g) and THF (400 ml) was 
heated until the suspension was strongly refluxing. After refluxing for 30 minutes, a 
solution of 1-ethyl 3-(3-oxo-1,4-diphenylbutan-2-yl) 2-benzylmalonate (2.31, 1.00 eq., 
18.9 mmol, 8.40 g) in THF (20 ml) was added over 25 minutes. The reaction was 
further stirred under strong reflux. After 3.5 hours, the finished reaction was cooled to 
room temperature. The mixture was filtrated over a bed of SiO2 and the solids were 
washed with TBME. The filtrate was concentrated. The crude product was dissolved in 
a hot mixture of MeOH/water (3:1, 300 ml) before activated carbon (90 mg) was added. 
After boiling for 10 minutes, the mixture was filtrated and the solids were washed with 
a hot mixture of MeOH/water (3:1, 20 ml). The filtrate was again heated to reflux and 
MeOH (22 ml) were added to get a solution. The solution was cooled down overnight 
and after addition of some crystals, the product started to crystallize. The resulting 
suspension was cooled to 0 °C before precipitate was filtered off and washed twice with 
a cold mixture of MeOH/water (2:1, 25 ml). The crystals were dried in high vacuum to 
give the title compound 1.34 (5.1 g, 14 mmol, 76%) as brownish crystals. The filtrate 
was concentrated and purified by column chromatography (SiO2, 
O
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pentane/EtOAc (12:1)) to give the title compound 1.34 (290 mg, 0.82 mmol, 4%) as 
yellow oil. 
1H-NMR (400 MHz, CDCl3): 7.34 – 7.23 (m, 6 H), 7.22 – 7.10 (m, 5 H), 7.03 (d, 
J = 6.5 Hz, 2 H), 6.92 – 6.85 (m, 2 H), 4.99 – 4.89 (m, 1 H), 3.92 (d, J = 15.6 Hz, 1 H), 
3.63 (d, J = 15.3 Hz, 1 H), 3.57 (d, J = 15.3 Hz, 1 H), 3.48 (d, J = 15.6 Hz, 1 H), 3.23 
(dd, J = 14.5, 3.9 Hz, 1 H), 2.82 (dd, J = 14.6, 6.1 Hz, 1 H). 
13C-NMR (101 MHz, CDCl3): 173.7, 161.8, 137.8, 136.1, 135.0, 129.6, 129.2, 
128.8, 128.7, 128.3, 127.5, 127.3, 126.5, 81.7, 77.4, 38.1, 33.4, 29.5. 
The analytical data of product 1.34 correspond to those reported in the literature.1 
Methyl (2-oxo-2-phenylethyl) malonate 
 
To a suspension of potassium 3-methoxy-3-oxopropanoate (1.10 eq., 1.10 mmol, 
172 mg) in CH2Cl2 (2 ml) at 0 °C was added freshly distilled oxayl chloride (1.30 eq., 
1.30 mmol, 112 µl) over five minutes. This was followed by the addition of some drops 
of dry DMF. The reaction was stirred for 30 minutes at 0 °C and for one hour at room 
temperature. The resulting mixture was concentrated, again dissolved in CH2Cl2 (4 ml), 
concentrated, dried in high vacuum and finally dissolved in CH2Cl2 (2 ml) and cooled to 
0 °C. A mixture of 2-hydroxy-1-phenylethanone (1.00 eq., 1.00 mmol, 136 mg) and 
pyridine (2.00 eq., 2.00 mmol, 161 µl) in CH2Cl2 (2 ml) was slowly added. The 
resulting mixture was stirred overnight at room temperature. The reaction was cooled to 
0 °C and quenched with water. Then a sat. aq. NH4Cl solution was added and the pH 
was adjusted to 4 – 5 with a 1 M aq. HCl solution. The layers were separated and the aq. 
layer was extracted with CH2Cl2 and twice with EtOAc. The org. layers were washed 
with a mixture of water and a sat. aq. NaHCO3 solution (1:1 v/v), combined, dried with 
Na2SO4 and concentrated. The crude product was purified by column chromatography 
(SiO2, pentane/Et2O (2:1)) to give the title compound (90 mg, 0.38 mmol, 90%) as pale 
yellow oil. 
Rf (SiO2, pentane/Et2O (2:1)): 0.19. 
1H-NMR (500 MHz, CDCl3): 7.93 – 7.89 (m, 2 H), 7.64 – 7.59 (m, 1 H), 7.52 – 7.47 
(m, 2 H), 5.41 (s, 2 H), 3.78 (s, 3 H), 3.59 (s, 2 H). 
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13C-NMR (126 MHz, CDCl3): 191.4, 166.8, 166.1, 134.2, 134.1, 129.1, 127.9, 66.9, 
52.8, 41.1. 
IR (neat): 3001, 2954, 1737, 1702, 1449, 1341, 1225, 1148, 1015, 973, 756, 692, 
661, 609. 
HR-MS: Calculated for C12H13O5 [M+H]+: 237.0757, found: 237.0759. 
FAB-MS (8 kV, Xe) m/z (%): 238 (15), 237 (100, [M+H]+), 137 (57), 136 (15), 119 
(10), 105 (18), 101 (10), 91 (10). 
The analytical data of product correspond to those reported in the literature.9 
Methyl 2-oxo-4-phenyl-2,5-dihydrofuran-3-carboxylate 
 
To a solution of methyl (2-oxo-2-phenylethyl) malonate (1.0 eq., 0.22 mmol, 52 mg) 
in THF (2.5 ml) at 0 °C was added sodium hydride (1.3 eq., 0.29 mmol, 11 mg) in one 
portion. The reaction was stirred for 15 minutes at 0 °C and for two hours at room 
temperature. The resulting suspension was quenched at 0 °C with a sat. aq. NH4Cl 
solution. The layers were separated and the aq. layer was extracted six times with 
TBME. The org. layers were combined, washed with brine, dried with Na2SO4 and 
concentrated. The crude product was purified by column chromatography (SiO2, 
pentane/Et2O (1:1)) to give the title compound (44 mg, 0.20 mmol, 92%) as yellowish 
solid. 
Rf (SiO2, pentane/Et2O (1:1)): 0.21. 
1H-NMR (400 MHz, CDCl3): 7.57 – 7.45 (m, 5 H), 5.18 (s, 2 H), 3.90 (s, 3 H). 
13C-NMR (101 MHz, CDCl3): 169.6, 165.3, 162.9, 132.4, 129.3, 128.0, 119.4, 70.7, 
52.9. 
IR (neat): 2956, 1744, 1721, 1634 ,1440, 1341, 1239, 1208, 1196, 1070, 1038, 767, 
744, 694. 
HR-MS: Calculated for C12H10NaO4 [M+Na]+: 241.0471, found: 241.0474. 
EI-MS (70 eV) m/z (%): 219 (13), 218 (100, [M]+), 203 (26), 188 (20), 187 (56), 
160 (27), 129 (46), 121 (32), 119 (28), 105 (26), 91 (56). 
Mp: 134 – 135 °C. 
The analytical data of product correspond to those reported in the literature.9 
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8.3 From a Natural Product to a Functional Molecule 
Potassium 3-ethoxy-2-(4-methoxybenzyl)-3-oxopropanoate (3.08) 
 
A solution of diethyl 2-(4-methoxybenzyl)malonate (3.07, 1.00 eq., 1.80 mmol, 
505 mg) in dry EtOH (2 ml) was cooled to -15 °C. A freshly filtrated solution of KOH 
(1.05 eq., 1.89 mmol, 125 mg) in dry EtOH (2 ml) was added at -15 °C over 15 minutes. 
The resulting mixture was stirred for 17 hours at -15 °C before it was concentrated to 
give a white honey with some solid parts. This was suspended twice in Et2O and again 
concentrated. The residue was triturated in Et2O overnight. The precipitate was filtered 
off, washed twice with Et2O and dried in high vacuum to give the title compound 3.08 
(421 mg, 1.5 mmol, 81%) as white solid. 
1H-NMR (400 MHz, D2O): 7.22 (d, J = 8.7 Hz, 2 H), 6.97 – 6.90 (m, 2 H), 4.09 (q, 
J = 7.1 Hz, 2 H), 3.80 (s, 3 H), 3.56 (dd, J = 8.9, 7.3 Hz, 1 H), 3.07 (s, 1 H), 3.05 (d, 
J = 2.9 Hz, 1 H), 1.15 (t, J = 7.1 Hz, 3 H). 
13C-NMR (101 MHz, D2O): 176.0, 173.4, 157.4, 131.7, 129.9, 114.1, 62.0, 57.5, 
55.4, 34.2, 13.2. 
IR (neat): 3383, 1714, 1597, 1512, 1361, 1247, 1150, 1034, 818, 687. 
FAB-MS (8 kV Xe) m/z (%): 291 (100, [M+K]+), 281 (18), 253 (15), 252 (18), 242 
(16), 121 (39), 39 (75). 
HR-MS: Calculated for C13H16NaO5 [M+Na]+: 275.0890, found: 275.0890. 
Mp: 129 – 130 °C. 
3-Hydroxy-1-(4-methoxyphenyl)-4-phenylbutan-2-one (3.10) 
 
For the formation of the cyanohydrin, a published procedure8 was modified as 
follows: To neat trimethylsilyl cyanide (1.00 eq., 20.0 mmol, 2.67 ml) was added a 
crystal of ZnI2 and the mixture was cooled to 0 °C. Then freshly distilled 
phenylacetaldehyde (1.10, 1.00 eq., 20.0 mmol, 2.38 ml) was added over five minutes. 
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The reaction was stirred and allowed to reach room temperature over three hours. The 
TMS protected cyanohydrin was isolated by Kugelrohr distillation at 80 to 110 °C and 
0.5 mbar to give the intermediate 3.09 (2.85 g, 13 mmol, 65%) as colorless liquid.  
1H-NMR (400 MHz, CDCl3): 7.27 – 7.13 (m, 5 H), 4.41 (dd, J = 7.3, 6.4 Hz, 1 H), 
2.98 (d, J = 6.4 Hz, 1 H), 2.97 (d, J = 7.3 Hz, 1 H), 0.00 (s, 9 H). 
13C-NMR (101 MHz, CDCl3): 199.6, 135.0, 129.8, 128.7, 127.6, 63.0, 42.9, -0.5. 
The analytical data of the intermediate cyanohydrin correspond to those reported in 
the literature.8 
A solution of the TMS protected cyanohydrin (1.00 eq., 13.0 mmol) in dry Et2O 
(20 ml) was added dropwise to a solution of (4-methoxybenzyl)magnesium chloride 
(1.50 eq., 19.5 mmol) in dry Et2O (60 ml) at reflux (preparation can be found after the 
analytical data). The mixture was stirred for five hours at reflux. A GC-MS analysis 
showed about 50% conversion. Therefore another portion of 
(4-methoxybenzyl)magnesium chloride (1.50 eq., 19.5 mmol) in dry Et2O (70 ml) was 
added to the refluxing reaction. After another four hours at reflux, the GC-MS analysis 
showed complete conversion. The reaction was cooled down and poured on a mixture 
of 35% aq. HCl (60 ml) and ice (100 ml). The resulting mixture was allowed to reach 
room temperature overnight. The layers were separated and the aq. layer was extracted 
twice with TBME. The org. layers were washed with a sat. aq. Na2CO3 solution, 
combined, dried with Na2SO4 and concentrated. The crude product was purified by 
column chromatography (SiO2, pentane/EtOAc (5:1)) to give the title compound 3.10 
(1.89 g, 7.0 mmol, 54%) as yellowish solid. Over both steps, a yield of 35% was 
achieved. 
Rf (SiO2, pentane/EtOAc (4:1)): 0.31. 
1H-NMR (400 MHz, CDCl3): 7.35 – 7.20 (m, 5 H), 7.09 – 7.04 (m, 2 H), 6.89 – 6.84 
(m, 2 H), 4.55 – 4.47 (m, 1 H), 3.80 (s, 3 H), 3.75 (d, J = 16.0 Hz, 1 H), 3.69 (d, 
J = 16.0 Hz, 1 H), 3.22 (d, J = 5.6 Hz, 1 H), 3.15 (dd, J = 14.1, 4.7 Hz, 1 H), 2.89 (dd, 
J = 14.1, 7.4 Hz, 1 H). 
13C-NMR (101 MHz, CDCl3): 209.5, 159.0, 136.6, 130.7 129.5, 128.8, 127.1, 125.0, 
114.4, 76.7, 55.4, 45.0, 40.4. 
IR (neat): 3391, 2837, 1694, 1614, 1513, 1467, 1301, 1245, 1177, 1090, 1033, 798, 
741. 
HR-MS: Calculated for C17H22NO3 [M+NH4]+: 288.1594, found: 288.1592. 
Mp: < 50 °C. 
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Crucial is the generation of the Grignard reagent as benzyl magnesium compounds 
are prone for reductive homo couplings. A efficient method was found to be as follows. 
Pre-dried magnesium turnings (1.60 eq., 20.8 mmol, 506 mg) were mixed with dry Et2O 
(50 ml) and cooled to -20 °C. Then diisobutylaluminium hydride (1 M solution in 
hexane, 0.010 eq., 0.13 mmol, 0.13 ml) was added and the solution was stirred for 
10 minutes. This was followed by the addition of a solution of 
1-(chloromethyl)-4-methoxybenzene (1.50 eq., 19.5 mmol, 2.66 ml) in dry Et2O (20 ml) 
over two hours at -20 °C. The reaction was stirred for 17 hours at -20 °C. According to 
GC-MS the resulting solution consists of starting material, Grignard reagent and 
dimerization product in a ration of 1 to 3 to 1. 
1-Ethyl 3-(3-oxo-1,4-diphenylbutan-2-yl) 2-(4-methoxybenzyl)malonate (3.14) as 
mixture of diastereomers 
 
To a suspension of potassium 3-ethoxy-2-(4-methoxybenzyl)-3-oxopropanoate (3.08, 
1.40 eq., 1.33 mmol, 386 mg) in dry THF (6 ml) at 0 °C was added DMF (0.05 eq., 
0.05 mmol, 4 µl) followed by the dropwise addition of pivaloyl chloride (1.70 eq., 
1.61 mmol, 201 µl) over five minutes. The reaction was then stirred for two hours at 
0 °C and for 3.5 hours at room temperature. The resulting solution was concentrated and 
dried in high vacuum. Then, the residue was twice dissolved in dry CH2Cl2 (60 ml), 
concentrated and dried in high vacuum without exceeding a temperature of 25 °C. The 
residue was dissolved in dry CH2Cl2 (50 ml) and cooled to 0 °C. The addition of 
4-dimethylaminopyridine (0.10 eq., 0.10 mmol, 12 mg) was followed by the addition of 
a solution of 3-hydroxy-1,4-diphenylbutan-2-one (2.30, 1.00 eq., 0.95 mmol, 228 mg) 
in dry CH2Cl2 (2 ml) over five minutes. The reaction was allowed to reach room 
temperature overnight before it was quenched with a mixture of water and a sat. aq. 
NaHCO3 solution (1:1 v/v). The layers were separated and the aq. layer was extracted 
three times with CH2Cl2. The org. layers were washed with a sat. aq. NH4Cl solution, 
combined, dried with Na2SO4 and concentrated. The crude was purified by column 
chromatography (SiO2, pentane/EtOAc (6:1)) to give the title compound 3.14 (408 mg, 
0.86 mmol, 91%) as yellowish oil. 
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Rf (SiO2, pentane/EtOAc (8:1)): 0.42. 
1H-NMR (400 MHz, CDCl3): 7.33 – 7.22 (m, 6 H), 7.16 – 7.07 (m, 2 H), 7.07 – 6.98 
(m, 4 H), 6.83 – 6.73 (m, 2 H), 5.35 – 5.26 (m, 1 H), 4.17 – 4.05 (m, 2 H), 3.76 (s, 
1.3 H), 3.71 – 3.64 (m, 2.6 H), 3.58 (s, 0.9 H), 3.47 (d, J = 17.1 Hz, 0.6 H), 3.34 (d, 
J = 17.1 Hz, 0.6 H), 3.22 – 3.07 (m, 2 H), 3.06 – 2.93 (m, 2 H), 1.20 – 1.13 (m, 3 H). 
13C-NMR (101 MHz, CDCl3): 204.4, 204.4, 168.6, 168.5, 168.4, 168.3, 158.6, 
135.7, 135.6, 132.9, 132.9, 130.0, 130.0, 129.9, 129.9, 129.6, 129.6, 129.6, 129.5, 
128.7, 128.7, 128.7, 127.2, 127.2, 127.2, 114.1, 79.6, 79.4, 61.8, 61.8, 55.3, 55.2, 54.1, 
54.0, 46.4, 46.3, 37.1, 33.9, 33.9, 14.2, 14.1. 
IR (neat): 3063, 3031, 2935, 1729, 1612, 1514, 1455, 1248, 1178, 1148, 1032, 700. 
HR-MS: Calculated for C29H30NaO6 [M+Na]+: 497.1935, found: 497.1938. 
1-Ethyl 3-(4-(4-methoxyphenyl)-3-oxo-1-phenylbutan-2-yl) 2-benzylmalonate 
(3.15) as a mixture of diastereomers 
 
To a suspension of potassium 2-benzyl-3-ethoxy-3-oxopropanoate (2.28, 1.40 eq., 
9.10 mmol, 2.37 g) in dry THF (40 ml) at 0 °C was added DMF (0.050 eq., 0.32 mmol, 
25 µl) followed by the dropwise addition of pivaloyl chloride (1.70 eq., 11.1 mmol, 
1.37 ml) over five minutes. The reaction was then kept for 1.5 hour at 0 °C and for 
2.5 hours at room temperature. The resulting solution was concentrated, dried in high 
vacuum and then twice dissolved in dry CH2Cl2 (40 ml), concentrated and dried in high 
vacuum without exceeding a temperature of 27 °C. The residue was dissolved in dry 
CH2Cl2 (40 ml) and cooled to 0 °C. The addition of 4-dimethylaminopyridine (0.10 eq., 
0.65 mmol, 79 mg) to the reaction mixture was followed by the addition of a solution of 
3-hydroxy-1-(4-methoxyphenyl)-4-phenylbutan-2-one (3.10, 1.00 eq., 6.50 mmol, 
1.76 g) in dry CH2Cl2 (10 ml) over five minutes. The reaction was allowed to reach 
room temperature overnight before it was quenched with a mixture of water and a sat. 
aq. NaHCO3 solution (1:1 v/v). The layers were separated and the aq. layer was 
extracted three times with CH2Cl2. The org. layers were washed with a sat. aq. NH4Cl 
solution, combined, dried with Na2SO4 and concentrated to give the title compound 
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3.15 (3.33 g, 6.5 mmol, quantitative) as a yellow liquid, which started to crystallize 
upon long standing. 
Rf (SiO2, pentane/EtOAc (4:1)): 0.59. 
1H-NMR (400 MHz, CDCl3): 7.30 – 7.20 (m, 6 H), 7.20 – 7.15 (m, 2 H), 7.14 – 7.10 
(m, 2 H), 7.04 – 7.00 (m, 1 H), 6.98 – 6.90 (m, 2 H), 6.86 – 6.81 (m, 2 H), 5.34 – 5.25 
(m, 1 H), 4.17 – 4.05 (m, 2 H), 3.79 (s, 1.5 H), 3.79 (s, 1.5 H), 3.75 – 3.69 (m, 1 H), 
3.52 (s, 1 H), 3.44 (d, J = 17.0 Hz, 0.5 H), 3.33 (d, J = 17.0 Hz, 0.5 H), 3.27 – 3.11 (m, 
2 H), 3.06 – 2.91 (m, 2 H), 1.19 – 1.11 (m, 3 H). 
13C-NMR (101 MHz, CDCl3): 204.7, 204.7, 168.5, 168.4, 168.4, 168.3, 158.9, 
137.7, 137.6, 135.7, 135.6, 130.9, 130.9, 129.6, 129.6, 129.0, 129.0, 128.7, 128.7, 
128.7, 127.2, 127.2, 127.1, 124.8, 124.8, 114.2, 79.6, 79.4, 62.0, 61.8, 55.4, 53.8, 53.7, 
45.6, 45.6, 37.1, 34.7, 34.7, 14.1, 14.1. 
IR (neat): 3982, 2936, 1728, 1612, 1513, 1247, 1177, 1147, 1030, 737, 699. 
HR-MS: Calculated for C29H30NaO6 [M+Na]+: 497.1935, found: 497.1934. 
Mp: < 50 °C. 
1-Ethyl 3-(1-(4-methoxyphenyl)-3-oxo-4-phenylbutan-2-yl) 2-benzylmalonate 
(3.16) as a mixture of diastereomers 
 
To a suspension of potassium 2-benzyl-3-ethoxy-3-oxopropanoate (2.28, 1.40 eq., 
3.75 mmol, 977 mg) in dry THF (20 ml) at 0 °C was added pivaloyl chloride (1.70 eq., 
4.56 mmol, 566 µl) dropwise over five minutes followed by the addition of DMF 
(0.050 eq., 0.13 mmol, 10 µl). The reaction was then kept for 1.5 hour at 0 °C and for 
three hours at room temperature. The resulting solution is concentrated, dried in high 
vacuum and then twice dissolved in dry CH2Cl2 (20 ml), concentrated and dried in high 
vacuum without exceeding a temperature of 27 °C. The residue was dissolved in dry 
CH2Cl2 (20 ml) and cooled to 0 °C. The addition of 4-dimethylaminopyridine (0.10 eq., 
0.27 mmol, 33 mg) to the reaction mixture was followed by the addition of a solution of 
3-hydroxy-4-(4-methoxyphenyl)-1-phenylbutan-2-one (3.13, 1.00 eq., 2.68 mmol, 
724 mg) in dry CH2Cl2 (10 ml) over five minutes. The reaction was allowed to reach 
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room temperature overnight before it was quenched with a mixture of water and a sat. 
aq. NaHCO3 solution (1:1 v/v). The layers were separated and the aq. layer was 
extracted three times with CH2Cl2. The org. layers were washed with a sat. aq. NH4Cl 
solution, combined, dried with Na2SO4 and concentrated. The crude product was 
purified by column chromatography (SiO2, pentane/EtOAc (6:1)) to give the title 
compound 3.16 (733 mg, 1.5 mmol, 58%) as yellowish liquid. 
Rf (SiO2, pentane/EtOAc (6:1)): 0.35. 
1H-NMR (400 MHz, CDCl3): 7.33 – 7.21 (m, 6 H), 7.20 – 7.16 (m, 1 H), 7.15 – 7.10 
(m, 1 H), 7.07 – 6.98 (m, 3 H), 6.94 – 6.90 (m, 1 H), 6.84 – 6.75 (m, 2 H), 5.30 – 5.22 
(m, 1 H), 4.16 – 4.08 (m, 2 H), 3.78 (s, 1.5 H), 3.78 (s, 1.5 H), 3.74 – 3.70 (m, 1 H), 
3.58 (s, 1 H), 3.49 (d, J = 16.9 Hz, 0.5 H), 3.37 (d, J = 16.9 Hz, 0.5 H), 3.28 – 3.11 (m, 
2 H), 3.00 – 2.89 (m, 2 H), 1.19 – 1.13 (m, 3 H). 
13C-NMR (101 MHz, CDCl3): 204.4, 204.3, 168.4, 168.1, 168.2, 168.2, 158.7, 
158.7, 137.5, 137.5, 132.8, 132.8, 130.5, 130.5, 129.8, 129.7, 128.8, 128.8, 128.6, 
128.6, 127.4, 127.3, 127.1, 126.9, 126.9, 114.0, 113.9, 79.7, 79.5, 61.8, 61.7, 55.3, 53.7, 
53.6, 46.4, 46.3, 36.1, 34.6, 34.6, 14.0, 14.0. 
IR (neat): 1727, 1612, 1514, 1455, 1246, 1177, 1146, 1030, 832, 752, 698. 
HR-MS: Calculated for C29H30NaO6 [M+Na]+: 497.1935, found: 497.1943. 
4,5-Dibenzyl-3-(4-methoxybenzyl)furan-2(5H)-one (3.17) 
 
A two neck round bottom flask was equipped with a condenser and a device to run 
the condensed solvent over a bed of 4 Å molecular sieves (Section 9.5.1). In the flask, a 
mixture of cesium carbonate (0.20 eq., 0.17 mmol, 56 mg) and THF (60 ml) was heated 
until the suspension was strongly refluxing. After refluxing for 30 minutes, a solution of 
1-ethyl 3-(3-oxo-1,4-diphenylbutan-2-yl) 2-(4-methoxybenzyl)malonate (3.14, 1.00 eq., 
0.860 mmol, 408 mg) in THF (8 ml) was added over five minutes. The reaction was 
further stirred under strong reflux. After four hours, a TLC showed only little 
conversion and additional cesium carbonate (0.20 eq., 0.17 mmol, 56 mg) was added. 
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After another four hours, the mixture was cooled down and filtrated over a bed of SiO2. 
The solids were washed with TBME and the filtrate was concentrated. The crude 
product was purified by column chromatography (SiO2, pentane/EtOAc (6:1)) to give 
the title compound 3.17 (252 mg, 0.66 mmol, 76%) as pale yellow oil. 
Rf (SiO2, pentane/EtOAc (6:1)): 0.36. 
1H-NMR (500 MHz, C6D6): 7.06 – 7.01 (m, 6 H), 6.98 – 6.95 (m, 2 H), 6.87 – 6.83 
(m, 2 H), 6.73 – 6.67 (m, 4 H), 4.56 – 4.52 (m, 1 H), 3.47 (dd, J = 15.2, 3.8 Hz, 2 H), 
3.32 (s, 3 H), 2.97 (d, J = 15.7 Hz, 1 H), 2.77 (dd, J = 14.5, 3.9 Hz, 1 H), 2.33 (dd, 
J = 14.5, 6.4 Hz, 1 H). 
13C-NMR (126 MHz, C6D6): 172.9, 160.1, 158.8, 136.7, 135.6, 130.5, 129.8, 129.7, 
129.7, 129.1, 128.9, 128.7, 128.4, 128.2, 128.0, 127.2, 127.2, 114.4, 81.2, 54.8, 38.2, 
33.0, 28.9. 
IR (neat): 3028, 2910, 2836, 1729, 1510, 1246, 1049, 1032, 702. 
HR-MS: Calculated for C26H24NaO3 [M+Na]+: 407.1618, found: 407.1618. 
3,5-Dibenzyl-4-(4-methoxybenzyl)furan-2(5H)-one (3.18) 
 
A two neck round bottom flask was equipped with a condenser and a device to run 
the condensed solvent over a bed of 4 Å molecular sieves (Section 9.5.1). In the flask, a 
mixture of cesium carbonate (0.20 eq., 0.21 mmol, 69 mg) and THF (75 ml) was heated 
until the suspension was strongly refluxing. After refluxing for 30 minutes, a solution of 
1-ethyl 3-(4-(4-methoxyphenyl)-3-oxo-1-phenylbutan-2-yl) 2-benzylmalonate (3.15, 
1.00 eq., 1.05 mmol, 498 mg) in THF (25 ml) was added over five minutes. The 
reaction was further stirred under strong reflux. After 3.5 hours, the finished reaction 
was cooled to room temperature. The mixture was filtrated over a bed of SiO2 and the 
solids were washed with TBME. The filtrate was concentrated. The crude product was 
purified by column chromatography (SiO2, pentane/EtOAc (6:1)) to give the title 
compound 3.18 (241 mg, 0.63 mmol, 60%) as yellowish solid. 
Rf (SiO2, pentane/EtOAc (5:1)): 0.31. 
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1H-NMR (400 MHz, CDCl3): 7.27 – 7.23 (m, 3 H), 7.21 – 7.13 (m, 5 H), 6.95 – 6.86 
(m, 4 H), 6.84 – 6.80 (m, 2 H), 4.97 – 4.90 (m, 1 H), 3.86 (d, J = 15.6 Hz, 1 H), 3.79 (s, 
3 H), 3.62 (d, J = 15.3 Hz, 1 H), 3.56 (d, J = 15.3 Hz, 1 H), 3.42 (d, J = 15.7 Hz, 1 H), 
3.22 (dd, J = 14.6, 4.0 Hz, 1 H), 2.81 (dd, J = 14.6, 6.2 Hz, 1 H). 
13C-NMR (101 MHz, CDCl3): 173.7, 162.3, 158.9, 137.9, 135.0, 129.8, 129.6, 
128.8, 128.7, 128.6, 128.3, 127.9, 127.3, 126.5, 114.6, 81.7, 55.5, 38.1, 32.5, 29.4. 
IR (neat): 3029, 2838, 1747, 1511, 1249, 1177, 1024, 836, 725, 698, 655. 
HR-MS: Calculated for C26H25O3 [M+H]+: 385.1798, found: 385.1797. 
Mp: 62 – 63 °C. 
3,4-Dibenzyl-5-(4-methoxybenzyl)furan-2(5H)-one (3.19) 
 
A two neck round bottom flask was equipped with a condenser and a device to run 
the condensed solvent over a bed of 4 Å molecular sieves (Section 9.5.1). In the flask, a 
mixture of cesium carbonate (0.20 eq., 0.17 mmol, 55 mg) and THF (60 ml) was heated 
until the suspension was strongly refluxing. After refluxing for 30 minutes, a solution of 
1-ethyl 3-(1-(4-methoxyphenyl)-3-oxo-4-phenylbutan-2-yl) 2-benzylmalonate (3.16, 
1.00 eq., 0.850 mmol, 403 mg) in THF (20 ml) was added over five minutes. The 
reaction was further stirred under strong reflux. After 7.5 hours, the finished reaction 
was cooled to room temperature. The mixture was filtrated over a bed of SiO2 and the 
solids were washed with TBME. The filtrate was concentrated. The crude product was 
purified by column chromatography (SiO2, pentane/EtOAc (6:1)) to give the title 
compound 3.19 (230 mg, 0.60 mmol, 70%) as yellowish solid. 
Rf (SiO2, pentane/EtOAc (6:1)): 0.25. 
1H-NMR (400 MHz, CDCl3): 7.34 – 7.24 (m, 4 H), 7.19 – 7.15 (m, 3 H), 7.09 – 7.03 
(m, 4 H), 6.87 – 6.83 (m, 2 H), 6.80 – 6.75 (m, 2 H), 4.92 (t, J = 4.7 Hz, 1 H), 3.92 (d, 
J = 15.6 Hz, 1 H), 3.79 (s, 3 H), 3.63 (d, J = 15.4 Hz, 1 H), 3.56 (d, J = 15.3 Hz, 1 H), 
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3.46 (d, J = 15.6 Hz, 1 H), 3.20 (dd, J = 14.7, 4.0 Hz, 1 H), 2.80 (dd, J = 14.7, 5.6 Hz, 
1 H). 
13C-NMR (101 MHz, CDCl3): 173.7, 161.8, 158.9, 137.8, 136.1, 130.7, 129.2, 
128.8, 128.8, 128.6, 128.3, 127.4, 126.7, 126.5, 114.1, 81.8, 55.3, 37.0, 33.4, 29.5. 
IR (neat): 2932, 1735, 1676, 1612, 1454, 1332, 1244, 1178, 1132, 1099, 1033, 1006, 
836, 706, 658. 
HR-MS: Calculated for C26H24NaO3 [M+Na]+: 407.1618, found: 407.1618. 
Mp: 101 – 102 °C. 
4,5-Dibenzyl-3-(4-hydroxybenzyl)furan-2(5H)-one (3.20) 
 
To a solution of 4,5-dibenzyl-3-(4-methoxybenzyl)furan-2(5H)-one (3.17, 1.00 eq., 
0.655 mmol 252 mg) in dry CH2Cl2 (15 ml) at -78 °C was added BBr3 (1 M solution in 
CH2Cl2, 5.0 eq., 3.3 mmol, 3.3 ml) over 15 minutes. The reaction was allowed to reach 
room temperature overnight. Subsequently, the reaction mixture was cooled to 0 °C and 
poured on ice. The layers were separated and the aq. layer was extracted two times with 
CH2Cl2. The org. layers were washed with brine, combined, dried with Na2SO4 and 
concentrated to give the title compound 3.20 (258 mg, 0.66 mmol, quantitative) as 
brownish foam. 
Rf (SiO2, pentane/EtOAc (3:1)): 0.31. 
1H-NMR (500 MHz, C6D6): 7.07 – 6.99 (m, 6 H), 6.95 (dd, J = 7.4, 1.8 Hz, 2 H), 
6.74 – 6.66 (m, 4 H), 6.55 – 6.49 (m, 2 H), 4.78 (s, 1 H), 4.57 – 4.47 (m, 1 H), 3.48 – 
3.36 (m, 2 H), 3.28 (d, J = 15.0 Hz, 1 H), 2.95 (d, J = 15.7 Hz, 1 H), 2.75 (dd, J = 14.5, 
3.9 Hz, 1 H), 2.31 (dd, J = 14.5, 6.2 Hz, 1 H). 
13C-NMR (101 MHz, C6D6): 173.4, 160.5, 155.3, 136.6, 135.5, 129.8, 129.8, 129.8, 
129.7, 129.1, 128.9, 128.8, 128.2, 127.9, 127.2, 115.8, 81.5, 38.1, 33.0, 28.8. 
IR (neat): 3357, 3029, 2922, 1723, 1512, 1452, 1341, 1225, 1051, 831, 748, 699. 
HR-MS: Calculated for C25H22NaO3 [M+Na]+: 393.1461, found: 393.1460. 
EI-MS (70 eV) m/z (%): 280 (7), 279 (35, [M]+), 276 (18), 107 (45), 91 (100). 
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4,5-Dibenzyl-3-(4-octylbenzyl)furan-2(5H)-one (3.21) 
 
A solution of 4,5-dibenzyl-3-(4-hydroxybenzyl)furan-2(5H)-one (3.20, 1.0 eq., 
0.14 mmol, 50 mg) in a mixture of dry CH2Cl2 (3 ml) and dry pyridine (1 ml) was 
cooled to 0 °C. To the cooled solution was added trifluoromethansulfonic anhydride 
(1.2 eq., 0.16 mmol, 28 µl) over five minutes. The reaction mixture was stirred for 
30 minutes at 0 °C and 30 minutes at room temperature. Since a TLC shows only little 
conversion, additional trifluoromethansulfonic anhydride (1.2 eq., 0.16 mmol, 28 µl) 
was added at 0 °C. After stirring for 15 minutes at 0 °C and 45 minutes at room 
temperature a TLC confirmed complete conversion. The reaction was cooled to 0 °C 
and quenched with a 1 M aq. HCl solution. The layers were separated and the aq. layer 
was extracted twice with CH2Cl2. The org. layers were subsequently washed with a 1 M 
aq. HCl solution and a sat. aq. NaHCO3 solution, combined, dried with Na2SO4 and 
concentrated to give the activated intermediate (59 mg, 0.12 mmol, 87%) as colorless 
oil. 
1H-NMR (400 MHz, CDCl3): 7.39 – 7.23 (m, 6 H), 7.19 – 7.12 (m, 2 H), 7.08 – 7.01 
(m, 4 H), 6.82 (d, J = 8.6 Hz, 2 H), 5.02 (t, J = 4.6 Hz, 1 H), 3.89 (d, J = 15.7 Hz, 1 H), 
3.67 – 3.47 (m, 3 H), 3.30 (dd, J = 14.6, 4.1 Hz, 1 H), 2.88 (dd, J = 14.6, 5.4 Hz, 1 H). 
19F-NMR (376 MHz, CDCl3, no 19F reference): -72.86 (s). 
A solution of 9-borabicyclo[3.3.1]nonane (0.5 M solution in THF, 1.4 eq., 
0.16 mmol, 320 µl) was cooled to 0 °C before 1-octene (1.4 eq., 0.16 mmol, 26 µl) was 
added. The mixture was stirred for 30 minutes at 0 °C, giving the solution A. To a 
second solution of the triflate intermediate (1.0 eq., 0.12 mmol, 58 mg) and 
1,1’-bis(diphenylphosphino)ferrocene-paladium(II) dichloride*CH2Cl2 (0.05 eq., 
6 µmol, 5 mg) in dry THF (1 ml) was added a 3 M aq. NaOH solution (0.12 ml). This 
was followed by the addition of solution A. The reaction mixture was stirred at reflux 
overnight and concentrated forming a black residue. The residue was mixed with water 
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and extracted three times with TBME. The org layers were combined, dried with 
Na2SO4 and concentrated. The crude product was purified by column chromatography 
(SiO2, pentane/EtOAc (10:1)) and subsequently by preparative TLC (SiO2, 
pentane/EtOAc (9:1)) to give the title compound 3.21 (14 mg, 0.030 mmol, 26%) as 
pale yellow oil. Over both steps, a yield of 23% was achieved. 
Rf (SiO2, pentane/EtOAc (9:1)): 0.45. 
1H-NMR (500 MHz, CDCl3): 7.32 – 7.23 (m, 6 H), 7.17 – 7.12 (m, 2 H), 7.04 – 6.97 
(m, 4 H), 6.82 (d, J = 7.9 Hz, 2 H), 4.96 – 4.88 (m, 1 H), 3.94 (d, J = 15.5 Hz, 1 H), 
3.58 (d, J = 5.3 Hz, 2 H), 3.47 (d, J = 15.5 Hz, 1 H), 3.22 (dd, J = 14.5, 4.0 Hz, 1 H), 
2.81 (dd, J = 14.6, 6.3 Hz, 1 H), 2.59 – 2.50 (m, 2 H), 1.60 – 1.55 (m, 3 H), 1.33 – 1.24 
(m, 10 H), 0.88 (t, J = 6.9 Hz, 3 H). 
13C-NMR (126 MHz, CDCl3): 173.7, 161.6, 141.1, 136.2, 135.1, 135.0, 129.6, 
129.2, 128.9, 128.8, 128.8, 128.7, 128.2, 127.4, 127.2, 81.7, 38.2, 35.7, 33.3, 32.1, 31.7, 
29.7, 29.5, 29.4, 29.1, 22.8, 14.3. 
IR (neat): 2925, 2854, 1752, 1512, 1495, 1454, 1337, 1078, 1049, 1008, 750, 700. 
HR-MS: Calculated for C33H38NaO2 [M+Na]+: 489.2760, found: 489.2763. 
4,5-Dibenzyl-3-(4-(2-(2-(2-ethoxyethoxy)ethoxy)ethoxy)benzyl)furan-2(5H)-one 
(3.23) 
 
To a solution of 4,5-dibenzyl-3-(4-hydroxybenzyl)furan-2(5H)-one (3.22, 1.0 eq., 
0.14 mmol, 50 mg) and potassium carbonate (2.0 eq., 0.27 mmol, 37 mg) in acetone 
(1 ml) was added triethylene glycol monoethyl ether p-tosylate10,11 (3.22, 1.1 eq., 
0.15 mmol, 54 mg). The reaction mixture was stirred for 50 hours at reflux before it was 
concentrated. The crude product was first purified by column chromatography (SiO2, 
pentane/EtOAc (3:2)) and then by preparative HPLC chromatography (Gemini-NX 10u 
C18 250x21.2 mm, CH3CN/water (95:5 to 0:100)) to give the title compound 3.23 
(31 mg, 0.058 mmol, 43%) as pale yellow oil. 
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Rf (SiO2, pentane/EtOAc (1:1)): 0.47. 
1H-NMR (400 MHz, CDCl3): 7.34 – 7.23 (m, 6 H), 7.17 – 7.12 (m, 2 H), 7.07 – 7.02 
(m, 2 H), 6.81 – 6.76 (m, 2 H), 6.76 – 6.70 (m, 2 H), 4.97 – 4.89 (m, 1 H), 4.14 – 4.06 
(m, 2 H), 3.91 (d, J = 15.6 Hz, 1 H), 3.87 – 3.82 (m, 2 H), 3.77 – 3.72 (m, 2 H), 3.72 – 
3.64 (m, 4 H), 3.60 (dt, J = 4.4, 1.6 Hz, 2 H), 3.57 – 3.49 (m, 4 H), 3.46 (d, J = 15.4 Hz, 
1 H), 3.22 (dd, J = 14.5, 4.0 Hz, 1 H), 2.81 (dd, J = 14.5, 6.2 Hz, 1 H), 1.21 (t, J = 7.0 
Hz, 3 H). 
13C-NMR (101 MHz, CDCl3): 173.7, 161.5, 157.5, 136.1, 135.0, 130.1, 129.6, 
129.3, 129.2, 129.0, 128.8, 128.7, 127.4, 127.3, 114.9, 81.7, 71.0, 70.9, 70.8, 70.0, 69.9, 
67.6, 66.8, 38.1, 33.3, 28.7, 15.3. 
IR (neat): 2870, 1750, 1609, 1510, 1454, 1245, 1107, 1049, 830, 749, 702. 
HR-MS: Calculated for C33H42NO6 [M+NH4]+: 548.3007, found: 548.3003. 
4-(3,4-Dimethoxyphenyl)-4-oxobutanoic acid (3.28) 
 
A published procedure12 was modified as follows: To a solution of veratrole (3.26, 
1.00 eq., 50.0 mmol, 6.55 ml) in nitrobenzene (30 ml) at 0 °C was added carefully 
aluminium chloride (2.40 eq., 120 mmol, 16.0 g) keeping the temperature below 5 °C. 
This was followed by the dropwise addition of succinic anhydride (3.27, 1.20 eq., 
60.0 mmol, 6.00 g) in nitrobenzene (80 ml), keeping the temperature below 5 °C. After 
stirring for 10 minutes at 0 °C, the mixture was allowed to reach room temperature and 
stirred for one hour. Subsequently, the reaction mixture was stirred at 60 °C for three 
hours. The finished reaction was cooled down and poured on a mixture of ice, water and 
a 37% aq. HCl solution. The resulting mixture was steam distilled to remove remaining 
veratrole and the nitrobenzene solvent. The residue was stirred for two days before the 
precipitate was filtered off and washed twice with water and once with Et2O. The solid 
was again suspended in water and a sat. aq. Na2CO3 solution was added until clear 
solution was formed. Activated coal was added and the mixture was boiled for 
15 minutes before it was filtrated. The filtrate was cooled down to 0 °C and a 37% aq. 
HCl solution was added until it gets cloudy. After stirring for another 30 minutes, the 
pH was set to 1 by the addition of further 37% aq. HCl. The suspension was stirred for 
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three hours, before the precipitate was filtered off, washed twice with water and dried to 
give the title compound 3.28 (6.2 g, 26 mmol, 52%) as grey solid. 
1H-NMR (500 MHz, MeOD): 7.69 (dd, J = 8.4, 2.1 Hz, 1 H), 7.54 (d, J = 2.0 Hz, 
1 H), 7.03 (d, J = 8.5 Hz, 1 H), 3.90 (s, 3 H), 3.87 (s, 3 H), 3.30 – 3.26 (m, 2 H), 2.71 – 
2.66 (m, 2 H). 
13C-NMR (126 MHz, MeOD): 199.2, 176.7, 155.1, 150.4, 131.1, 124.1, 111.7, 
111.5, 56.5, 56.4, 33.9, 29.0. 
IR (neat): 3351, 1737, 1661, 1588, 1514, 1413, 1334, 1266, 1139, 1020, 876, 758. 
HR-MS: Calculated for C12H14NaO5 [M+Na]+: 261.0733, found: 261.0737. 
Mp: 160 °C (decomposition). 
The analytical data of product 3.28 correspond to those reported in the literature.13 
4-(4,5-Dimethoxy-2-nitrophenyl)-4-oxobutanoic acid (3.29) 
 
To a 70% aq. HNO3 solution (10 ml), acetic anhydride (2 ml) was added at 0 °C. To 
this solution, a suspension of 4-(3,4-dimethoxyphenyl)-4-oxobutanoic acid (3.28, 
1.00 eq., 2.10 mmol, 500 mg) in acetic anhydride (3 ml) was added, keeping the 
temperature below 5 °C. The mixture was stirred for four hours at 0 °C before it was 
poured on a ice/water mixture. The precipitate was filtered off, washed three times with 
water and dried in vacuum. The solid was stirred in boiling toluene for 15 minutes. 
After cooling down, cyclohexane was added and the precipitate was isolated by 
filtration to give the title compound 3.29 (397 mg, 1.4 mmol, 67%) as yellow solid. 
1H-NMR (400 MHz, DMSO-d6): 12.26 (s, 1 H), 7.64 (s, 1 H), 7.22 (s, 1 H), 3.92 (s, 
3 H), 3.90 (s, 3 H), 3.10 (t, J = 6.8 Hz, 2 H), 2.58 (t, J = 6.8 Hz, 2 H). 
13C-NMR (101 MHz, DMSO-d6): 200.5, 173.5, 153.1, 149.4, 138.5, 130.6, 109.7, 
107.2, 56.6, 56.4, 37.1, 28.3. 
IR (neat): 2634, 1685, 1507, 1443, 1320, 1277, 1332, 1094, 1012, 877, 791, 666. 
HR-MS: Calculated for C12H12NO7 [M-H]-: 282.0619, found: 282.0621. 
Mp: 212 – 214 °C. 
Compound 3.29 has earlier been reported.14 
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1-(4,5-Dimethoxy-2-nitrophenyl)-4-hydroxybutan-1-one (3.30) 
 
To a refluxing solution of 4-(4,5-dimethoxy-2-nitrophenyl)-4-oxobutanoic acid 
(3.29, 1.0 eq., 0.35 mmol, 99 mg) in dry THF (5 ml) was added borane (1 M solution in 
THF, 1.5 eq., 0.525 mmol, 525 µl) within five minutes. The reaction was stirred for 
70 minutes at reflux, before it was cooled to 0 °C and quenched with 1 M aq. HCl. The 
resulting mixture was extracted three times with EtOAc. The org. layers were washed 
with a sat. aq. Na2CO3 solution, combined, dried with Na2SO4 and concentrated. The 
crude solid was purified by recrystallization with water to give the title compound 3.30 
(45 mg, 0.17 mmol, 48%) as brown solid.  
1H-NMR (400 MHz, CDCl3): 7.64 (s, 1 H), 6.74 (s, 1 H), 3.99 (s, 3 H), 3.98 (s, 3 H), 
3.78 (t, J = 6.1 Hz, 2 H), 2.86 (t, J = 6.9 Hz, 2 H), 2.05 (t, J = 6.4 Hz, 2 H). 
13C-NMR (101 MHz, CDCl3): 203.0, 154.3, 150.0, 149.7, 133.1, 108.7, 107.0, 62.0, 
56.9, 56.7, 40.1, 27.0. 
IR (neat): 2943, 2360, 1704, 1577, 1522, 1336, 1281, 1225, 1069, 1013, 870, 791. 
HR-MS: Calculated for C12H15NNaO6 [M+Na]+: 292.0792, found: 292.0793. 
Mp: 121 – 123 °C. 
1-(3,4-Dimethoxyphenyl)butane-1,4-diol (3.31) 
 
The initial goal of this procedure was to synthesize 
4-(3,4-dimethoxyphenyl)butan-1-ol. To a solution of lithium aluminium hydride 
(1.0 eq., 0.42 mmol, 16 mg) in dry THF (5 ml) at 0 °C was added a solution of 
4-(3,4-dimethoxyphenyl)-4-oxobutanoic acid (3.28, 1.00 eq., 0.420 mmol, 100 mg) in 
dry THF (5 ml) over 10 minutes. The resulting mixture was stirred for another 
30 minutes at 0 °C and then heated to reflux. After stirring for two days, the reaction 
mixture was quenched with a 1 M aq. HCl solution (pH = 1) and again heated to reflux 
for another three hours. Then, the mixture was cooled down and extracted three times 
with EtOAc. The org. layers were combined, dried with Na2SO4 and concentrated to 
give the title compound 3.31 (82 mg, 0.36 mmol, 86%) as colorless oil. 
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Rf (SiO2, pentane/EtOAc (1:3)): 0.78. 
1H-NMR (400 MHz, CDCl3): 6.91 – 6.80 (m, 3 H), 4.86 – 4.79 (m, 1 H), 4.13 – 4.05 
(m, 1 H), 3.96 – 3.84 (m, 7 H), 2.35 – 2.23 (m, 1 H), 2.08 – 1.95 (m, 2 H), 1.86 – 1.74 
(m, 1 H). 
13C-NMR (101 MHz, CDCl3): 149.1, 148.3, 136.0, 118.0, 111.1, 109.1, 80.7, 68.6, 
56.1, 56.0, 34.6, 26.1. 
IR (neat): 2945, 2871, 1593, 1515, 1464, 1263, 1235, 1139, 1028, 810, 762. 
HR-MS: Calculated for C12H16NaO3 [M+Na]+: 231.0992, found: 231.0994. 
3-(3,4-Dihydroxyphenyl)propanoic acid (3.32) 
 
To a solution of caffeic acid (1.07, 1.00 eq., 5.00 mmol, 901 mg) in EtOH (25 ml), 
palladium (10% palladium on activated coal, 45 mg) was added. Subsequently, in a 
steal autoclave, a hydrogen pressure of 10 bar was applied on the reaction mixture. 
After stirring for three hours under this atmosphere, the pressure was released and the 
mixture was filtrated over Celite. The filtrate was concentrated to give the title 
compound 3.32 (902 mg, 5.0 mmol, quantitative) as brownish crystals. 
1H-NMR (400 MHz, MeOD): 6.69 – 6.66 (m, 1 H), 6.65 (d, J = 2.1 Hz, 1 H), 6.55 – 
6.49 (m, 1 H), 2.75 (t, J = 7.7 Hz, 2 H), 2.56 – 2.48 (m, 2 H). 
13C-NMR (101 MHz, MeOD): 177.0, 146.1, 144.5, 133.8, 120.5, 116.4, 116.3, 37.1, 
31.4. 
The analytical data of product 3.32 correspond to those reported in the literature.15 
4-(3-Hydroxypropyl)benzene-1,2-diol (3.33) 
 
A solution of 3-(3,4-dihydroxyphenyl)propanoic acid (3.32, 1.00 eq., 5.00 mmol, 
902 mg) in dry THF (25 ml) was heated to reflux. Subsequently, borane (1 M solution in 
THF, 5.00 eq., 25.0 mmol, 25.0 ml) was slowly added and the resulting mixture was 
refluxed overnight. Then, the reaction was cooled to room temperature and quenched 
with a 1 M aq. HCl solution and stirred for another 45 minutes. The THF was removed 
by vacuum distillation and the aqueous residue was extracted three times with EtOAc. 
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The org. layers were washed with a mixture of brine and a 0.5 M aq. Na2S2O4 solution 
(1:1 v/v), combined, dried with Na2SO4 and concentrated. The residue was dissolved in 
MeOH, brought to reflux for some minutes and concentrated to give the title compound 
3.33 (874 mg, 5.0 mmol, quantitative) as colorless liquid. 
1H-NMR (400 MHz, MeOD): 6.66 (d, J = 8.0 Hz, 1 H), 6.62 (d, J = 2.0 Hz, 1 H), 
6.50 (dd, J = 8.0, 2.1 Hz, 1 H), 3.54 (t, J = 6.6 Hz, 2 H), 2.56 – 2.46 (m, 2 H), 1.77 (ddt, 
J = 13.1, 9.1, 6.5 Hz, 2 H). 
13C-NMR (101 MHz, MeOD): 146.1, 144.2, 135.0, 120.6, 116.5, 116.3, 62.3, 35.7, 
32.4. 
The analytical data of product 3.33 correspond to those reported in the literature.16 
4-(3-Hydroxypropyl)-5-nitrobenzene-1,2-diol (3.34) 
 
To a stirred solution of 4-(3-hydroxypropyl)-1,2-diol (3.33, 1.00eq., 0.600 mmol, 
101 mg) in a 0.2 M aq. sodium acetate/ acetic acid buffer (pH 4.4, 4 ml) was added 
every hour one of four identical portions of a solution of sodium nitrite (5.00 eq., 
3.00 mmol, 207 mg) in water (1 ml). After totally four hours, a 0.5 M aq. Na2S2O4 
solution was added and the mixture was stirred for 15 minutes. This solution was 
saturated with sodium chloride and extracted three times with EtOAc. The org. layers 
were washed with brine, combined, dried with Na2SO4 and concentrated. The formed 
solid was triturated in toluene first at 80 °C and then at room temperature overnight. 
After decanting the solvent, the solids were twice washed with toluene. Finally the 
remaining solid was dissolved in MeOH and again concentrated to give the title 
compound 3.34 (78 mg, 0.33 mmol, 55%) as brown solid. 
1H-NMR (500 MHz, MeOD): 7.50 (s, 1 H), 6.73 (s, 1 H), 3.60 (t, J = 6.5 Hz, 2 H), 
2.92 – 2.84 (m, 2 H), 1.86 – 1.77 (m, 2 H). 
13C-NMR (101 MHz, MeOD): 152.3, 144.9, 141.5, 132.5, 118.6, 113.3, 62.5, 34.6, 
30.8. 
IR (neat): 3481, 2942, 2582, 1597, 1531, 1496, 1439, 1323, 1277, 1195, 1154, 1052, 
997, 878, 808, 757. 
HR-MS: Calculated for C9H10NNa2O5 [M-H+2Na]+: 258.0349, found: 258.0349. 
The analytical data of product 3.34 correspond to those reported in the literature.17 
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4-(3-Chloropropyl)-5-nitrobenzene-1,2-diol (3.35) 
 
To pure 4-(3-hydroxypropyl)-5-nitrobenzene-1,2-diol (3.34, 1.0 eq., 0.12 mmol, 
25 mg) at 0 °C was added thionyl chloride (1 ml). This mixture was stirred for 
10 minutes at 0 °C and then heated to 60 °C. After 16 hours, only little conversion was 
observed and pyridine (10 µl) was added. After four hours, UPLC-MS showed complete 
conversion and the reaction mixture was cooled to 0 °C and quenched with water. The 
resulting mixture was extracted three times with EtOAc. The org. layers were 
combined, dried with Na2SO4 and concentrated to give the title compound 3.35 (17 mg, 
0.073 mmol, 63%) as yellowish oil. 
1H-NMR (400 MHz, MeOD): 7.52 (s, 1 H), 6.74 (s, 1 H), 3.58 (t, J = 6.4 Hz, 2 H), 
3.02 – 2.91 (m, 2 H), 2.13 – 2.00 (m, 2 H). 
13C-NMR (101 MHz, MeOD): 152.3, 145.2, 141.5, 131.2, 118.7, 113.4, 45.2, 34.5, 
31.6. 
IR (neat): 3341, 2968, 1599, 1532, 1330, 1286, 1195, 1047, 887, 809, 758, 547. 
HR-MS: Calculated for C9H9ClNO4 [M-H]-: 230.0226, found: 230.0228. 
4-(3-((Methylsulfonyl)oxy)propyl)-1,2-phenylene dimethanesulfonate (3.36) 
 
To a solution of 4-(3-hydroxypropyl)-1,2-diol (3.33, 1.0 eq., 0.13 mmol, 22 mg) in 
CH2Cl2 (1 ml) at 0 °C was first added pyridine (15 eq., 2.0 mmol, 160 µl) followed by 
methanesulfonyl chloride (6.0 eq., 0.80 mmol, 62 µl). The reaction was allowed to reach 
room temperature overnight before additional methanesulfonyl chloride (3.0 eq., 
0.40 mmol, 31 µl) was added. After stirring for another 24 hours, the reaction was 
poured on a mixture of ice and a 37% aq. HCl solution (1 ml). The resulting mixture 
was extracted three times with EtOAc. The org. layers were combined, dried with 
Na2SO4 and concentrated to give the title compound 3.36 (25 mg, 0.060 mmol, 45%) as 
pale yellow oil. 
1H-NMR (400 MHz, CDCl3): 7.41 – 7.37 (m, 1 H), 7.30 (d, J = 2.1 Hz, 1 H), 7.19 
(dd, J = 8.4, 2.1 Hz, 1 H), 4.23 (t, J = 6.1 Hz, 2 H), 3.24 (s, 3 H), 3.23 (s, 3 H), 3.00 (s, 
3 H), 2.83 – 2.75 (m, 2 H), 2.12 – 2.03 (m, 2 H). 
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13C-NMR (101 MHz, CDCl3) δ 141.7, 141.0, 139.4, 128.5, 124.4, 124.4, 68.6, 38.7, 
38.6, 37.5, 31.1, 30.3. 
IR (neat): 3032, 2939, 2854, 1501, 1348, 1253, 1168, 1097, 952, 927, 853, 807, 730, 
510. 
HR-MS: Calculated for C12H22NO9O3 [M+NH4]+: 420.0451, found: 420.0453. 
3-(4,5-Dihydroxy-2-nitrophenyl)propanoic acid (3.37) 
 
To a stirred solution of 3-(4,5-dihydroxyphenyl)propanoic acid (3.32, 1.0 eq., 
0.060 mmol, 11 mg) in a mixture of a 0.2 M aq. sodium acetate solution (344 µl) and a 
0.2 M aq. acetic acid solution (56 µl) was added a solution of sodium nitrite (5.0 eq., 
0.30 mmol, 21 mg) in water (0.1 ml). After stirring at room temperature for four hours, 
a 0.5 M aq. Na2S2O4 solution was added and the mixture was stirred for 15 minutes. 
This solution was acidified with a 1 M aq. HCl solution and extracted four times with 
EtOAc. The org. layers were combined, dried with Na2SO4 and concentrated to give the 
title compound 3.37 (9 mg, 0.040 mmol, 66%) as brown solid.  
1H-NMR (400 MHz, MeOD): 7.53 (s, 1 H), 6.77 (s, 1 H), 3.11 (td, J = 7.7, 3.9 Hz, 
2 H), 2.68 – 2.58 (m, 2 H). 
13C-NMR (101 MHz, MeOD): 176.4, 152.4, 145.3, 141.5, 131.0, 118.7, 113.4, 35.7, 
29.8. 
IR (neat): 3226, 1707, 1595, 1527, 1329, 1286, 1197, 1085, 1055, 885, 809, 761. 
HR-MS: Calculated for C9H8NO6 [M-H]-: 226.0357, found: 226.0357. 
Ethyl 10-hydroxydecanoate (3.41) 
 
A published procedure18 was modified as follows: To a solution of undecylenic acid 
(3.39, 1.00 eq., 27.0 mmol, 4.98 g) in EtOH (15 ml) at 0 °C was added Sudan III 
(traces). Subsequently, ozone was passed through the solution until the red color 
disappeared. Then, the reaction was flushed with oxygen for some minutes, before the 
mixture was added carefully to a solution of NaOH (1.50 eq., 40.5 mmol, 1.62 g) and 
NaBH4 (2.00 eq., 54.0 mmol, 2.08 g) in water (25 ml) and EtOH (25 ml) at 0 °C. The 
mixture was allowed to reach room temperature over night. The ethanol was removed in 
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by vacuum distillation before the mixture was carefully acidified at 0 °C with a 35% aq. 
HCl solution. The precipitate was filtered off and washed with ice-cold water to give 
10-hydroxydecanoic acid (3.40) (5.09 g) as white solid. 
1H-NMR (400 MHz, CDCl3): 7.11 (s, 2 H), 3.93 – 3.50 (m, 2 H), 2.33 (t, J = 7.5 Hz, 
2 H), 1.70 – 1.45 (m, 4 H), 1.42 – 1.21 (m, 10 H). 
13C-NMR (101 MHz, CDCl3): 179.8, 63.2, 34.2, 32.8, 29.5, 29.4, 29.3, 29.1, 25.8, 
24.8. 
IR (neat): 3243, 2912, 2849, 1690, 1469, 1414, 1302, 1047, 1020, 976, 719. 
HR-MS: Calculated for C10H19O3 [M-H]-: 187.1340, found: 187.1341. 
The analytical data of product 3.40 correspond to those reported in the literature.18 
A published procedure19 was modified as follows: To a solution of the previously 
formed 10-hydroxydecanoic acid in EtOH (65 ml) were added traces of sulfuric acid 
and the mixture was refluxed for 22 hours. Subsequently, the reaction mixture was 
cooled down and concentrated. The residue was mixed with a sat. aq. Na2CO3 solution 
and then extracted three times with TBME. The org. layers were washed with a sat. aq. 
Na2CO3 solution, combined, dried with Na2SO4 and concentrated to give the title 
compound 3.41 (5.3 g, 25 mmol, 91% over two steps) as a clear liquid. 
1H-NMR (400 MHz, CDCl3): 4.09 (q, J = 7.1 Hz, 2 H), 3.59 (t, J = 6.7 Hz, 2 H), 
2.25 (t, J = 7.5 Hz, 2 H), 1.75 (s, 1 H), 1.65 – 1.48 (m, 4 H), 1.37 – 1.17 (m, 13 H). 
13C-NMR (101 MHz, CDCl3): 174.0, 63.0, 60.3, 34.4, 32.8, 29.5, 29.4, 29.2, 29.2, 
25.8, 25.0, 14.3. 
IR (neat): 3451, 2927, 2855, 1735, 1465, 1372, 1236, 1180, 1098, 1031. 
HR-MS: Calculated for C12H24NaO3 [M+Na]+: 239.1618, found: 239.1617. 
The analytical data of product 3.41 correspond to those reported in the literature.19 
Ethyl 10-(tosyloxy)decanoate (3.42) 
 
To a solution of ethyl 10-hydroxydecanoate (3.41, 1.00 eq., 2.00 mmol, 433 mg) in 
triethyl amine (6 ml) and dry THF (6 ml) at 0 °C was added p-toluenesulfonyl chloride 
(5.00 eq., 10.0 mmol, 1.91 g). The mixture was allowed to reach room temperature 
overnight. The reaction mixture was poured on a mixture of ice and a 32% aq. HCl 
solution (5 ml). This mixture was extracted three times with TBME. The org. layers 
were washed with brine, combined, dried with Na2SO4 and concentrated. The crude 
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product was purified by column chromatography (SiO2, pentane/EtOAc (12:1)) to give 
the title compound 3.42 (650 mg, 1.8 mmol, 88%) as clear liquid. 
Rf (SiO2, pentane/EtOAc (12:1)): 0.15. 
1H-NMR (400 MHz, CDCl3): 7.82 – 7.75 (m, 2 H), 7.34 (dd, J = 8.5, 0.6 Hz, 2 H), 
4.12 (q, J = 7.1 Hz, 2 H), 4.01 (t, J = 6.5 Hz, 2 H), 2.44 (s, 3 H), 2.27 (t, J = 7.5 Hz, 
2 H), 1.67 – 1.54 (m, 4 H), 1.31 – 1.19 (m, 13 H). 
13C-NMR (101 MHz, CDCl3): 174.0, 144.8, 133.4, 129.9, 128.0, 70.8, 60.3, 34.5, 
29.3, 29.2, 29.2, 29.0, 28.9, 25.4, 25.1, 21.8, 14.4. 
IR (neat): 2929, 2857, 1733, 1361, 1177, 1098, 952, 816, 664, 555. 
HR-MS: Calculated for C19H31O5S [M+H]+: 371.1887, found: 371.1890. 
O-(2-Azidoethyl)-O’-tosylnonadecaethylene glycol (3.45) 
 
To a solution of O-(2-azidoethyl)nonadecaethylene (1.0 eq., 0.020 mmol, 19 mg) in 
dry THF (0.5 ml) and NEt3 (0.2 ml) at 0 °C was added p-toluenesulfonyl chloride 
(3.0 eq., 0.060 mmol, 11 mg). The reaction was allowed to reach room temperature 
overnight. An ESI-MS measurement showed still starting material in the reaction 
mixture. Additional p-toluenesulfonyl chloride (4.1 eq., 0.082 mmol, 15 mg) was added 
and the reaction was stirred overnight. The finished reaction was poured on a mixture of 
ice and a 37% aq. HCl solution. The resulting mixture was once extracted with Et2O. 
The aq. layer was saturated with NaCl and extracted four times with EtOAc. The org. 
layers were washed with a sat. aq. NaHCO3 solution, combined, dried with Na2SO4 and 
concentrated to give the title compound 3.45 (19 mg, 0.018 mmol, 88%) as clear oil. 
1H-NMR (400 MHz, CDCl3): 7.81 – 7.76 (m, 2 H), 7.33 (d, J = 8.0 Hz, 2 H), 4.14 
(dd, J = 5.4, 4.3 Hz, 2 H), 3.69 – 3.59 (m, 72 H), 3.57 (s, 4 H), 3.41 – 3.34 (m, 2 H), 
2.43 (s, 3 H). 
13C-NMR (101 MHz, CDCl3): 144.9, 133.1, 129.9, 128.1, 70.9, 70.8, 70.8, 70.7, 
70.7, 70.6, 70.1, 69.4, 68.8, 50.8, 21.8. 
IR (neat): 2921, 2858, 2108, 1457, 1351, 1293, 1248, 1177, 1095, 1037, 923, 849, 
818, 778, 664, 555. 
HR-MS: Calculated for C47H87N3Na2O22S [M+2Na]2+ 561.7645, found: 561.7643. 
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3-(O-(2-Azidoethyl)nonadecaethylene glycol)-4,5-dibenzylfuran-2(5H)-one (3.47a) 
 
To a solution of O-(2-Azidoethyl)-O’-tosylnonadecaethylene glycol (3.45, 1.0 eq., 
0.065 mmol, 76 mg) in acetone (2 ml) was first added 
4,5-dibenzyl-3-(4-hydroxybenzyl)furan-2(5H)-one (3.20, 2.0 eq., 0.13 mmol, 48 mg) 
followed by potassium carbonate (2.2 eq., 0.14 mmol, 20 mg). The mixture was heated 
to reflux for 24 hours. The reaction was filtrated and concentrated to 220 mg crude 
product. However, the reaction reached only 50% conversion, however the product was 
used for the next step without further purification. 
Rhodamine B maculalactone A hybrid (3.47) 
 
To a solution of 3-(O-(2-Azidoethyl)nonadecaethylene glycol)-4,5-dibenzylfuran-
2(5H)-one (3.47a, 1.0 eq., 0.065 mmol, 83 mg) and N-(6-(diethylamino)-9-(2-
(methyl(prop-2-yn-1-yl)carbamoyl)phenyl)-3H-xanthen-3-ylidene)-N-
ethylethanaminium chloride (3.46, 1.0 eq., 0.065 mmol, 35 mg) in CH2Cl2 (5 ml) and 
water (5 ml) was added copper(II) sulfate (0.2 eq., 0.01 mmol, 2 mg) and L-ascorbic 
acid (0.2 eq., 0.01 mmol, 3 mg). The mixture was vigorously stirred at room 
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temperature. After four days, tBuOH (5 ml) and after seven days, additional L-ascorbic 
acid (0.2 eq., 0.01 mmol, 3 mg) was added. After 10 days, the reaction was concentrated 
and separated by preparative HPLC (Phenomenex Gemini C18, CH3CN/water (1:4 to 
3:2)) and (Phenomenex Gemini C18, CH3CN/water + 0.1% HCO2H (2:3 to 3:2)) to give 
the title compound 3.47 (26 mg, 0.014 mmol, 22%) as purple oil. 
1H-NMR (500 MHz, MeOD): 7.95 (d, J = 14.0 Hz, 0.4 H), 7.75 (t, J = 5.7 Hz, 2 H), 
7.69 (d, J = 7.0 Hz, 0.6 H), 7.53 – 7.42 (m, 2 H), 7.33 – 7.13 (m, 12 H), 7.06 (d, J = 8.8 
Hz, 0.4 H), 7.02 – 6.92 (m, 3.6 H), 6.73 (s, 4 H), 5.01 (t, J = 4.5 Hz, 1 H), 4.59 – 4.52 
(m, 0.6 H), 4.48 – 4.39 (m, 3 H), 4.10 – 4.04 (m, 2 H), 3.96 (d, J = 15.5 Hz, 1 H), 3.88 
(s, 0.4 H), 3.85 – 3.77 (m, 4 H), 3.73 – 3.48 (m, 81.4 H), 3.46 (s, 2 H), 3.28 (dd, J = 
14.7, 3.9 Hz, 1 H), 2.99 (s, 2 H), 2.90 (dd, J = 14.6, 5.7 Hz, 1 H), 2.67 (s, 0.6 H), 1.32 
(t, J = 6.3 Hz, 12 H). 
13C-NMR (126 MHz, MeOD): 175.8, 170.2, 164.3, 159.3, 159.1, 158.7, 157.2, 
157.1, 156.8, 137.8, 137.0, 136.4, 133.1, 132.1, 131.7, 131.4, 131.3, 131.1, 130.8, 
130.3, 130.1, 129.5, 129.5, 128.6, 128.2, 128.1, 125.4, 115.7, 115.4, 115.2, 114.8, 97.3, 
83.6, 71.7, 71.6, 71.5, 71.4, 70.9, 70.3, 68.6, 51.5, 46.9, 42.8, 38.5, 38.5, 33.9, 29.1, 
13.0. 
IR (neat): 3398, 2907, 2871, 2359, 2332, 1750, 1634, 1589, 1470, 1414, 1346, 1276, 
1249, 1182, 1133, 1105, 684. 
HR-MS: Calculated for C97H137N6Na2O24 [M+2Na]3+ 605.3154, found: 605.3163. 
HPLC (Phenomenex Gemini C18, CH3CN/water (5 min 2:3, in 25 min to 3:2), 
1 ml/min, 540 nm): single peak at 14.5 minutes retention time. 
UV/VIS: λmax (H2O) = 568 nm (Section 9.5.2). 
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Rhodamine B with linker (3.48) 
 
To a solution of O-(2-Azidoethyl)nonadecaethylene (1.0 eq., 0.055 mmol, 54 mg) 
and N-(6-(diethylamino)-9-(2-(methyl(prop-2-yn-1-yl)carbamoyl)phenyl)-3H-xanthen-
3-ylidene)-N-ethylethanaminium chloride (3.46, 1.0 eq., 0.055 mmol, 29 mg) in tBuOH 
(4 ml) and water (4 ml) was added copper(II) sulfate (0.5 eq., 0.03 mmol, 4 mg) and 
L-ascorbic acid (1.0 eq., 0.055 mmol, 11 mg). The mixture was vigorously stirred at 
room temperature. After five and again after six days, additional L-ascorbic acid 
(1.0 eq., 0.055 mmol, 11 mg) was added. After 13 days, the reaction was concentrated 
and separated by preparative HPLC (Phenomenex Gemini C18, CH3CN/water 
+ 0.1% HCO2H (1:17 to 9:11)) and (Phenomenex Synergi Hydro-RP, CH3CN/water 
+ 0.1% HCO2H (1:19 to 4:1)) giving 19 mg of still impure product. The amid was found 
to be instable under HPLC conditions. Therefore, the mixture was purified by 
preparative TLC (SiO2, CH2Cl2/MeOH (4:1)) giving 10 mg still impure product. This 
was again separated by semi-preparative HPLC (Phenomenex Synergi Hydro-RP, 
CH3CN/water + 0.1% HCO2H (2 min 1:19, in 3 min to 3:7, in 25 min to 4:1)) to give 
the title compound 3.48 (2 mg, 1.2 µmol, 3%) as purple oil. 
1H-NMR (400 MHz, MeOD): 8.55 (s, 1 H), 8.10 (s, 0.4 H), 7.80 – 7.67 (m, 1.6 H), 
7.51 – 7.42 (m, 0.6 H), 7.35 – 7.29 (m, 0.4 H), 7.27 – 7.18 (m, 2 H), 7.04 – 6.93 (m, 
2 H), 6.42 – 6.33 (m, 2 H), 4.64 – 4.51 (m, 2 H), 4.49 – 4.39 (m, 2 H), 3.80 (t, J = 5.0 
Hz, 1 H), 3.75 – 3.47 (m, 83 H), 3.42 – 3.33 (m, 4 H), 3.05 (s, 1 H), 3.00 (s, 1 H), 1.33 
(t, J = 7.1 Hz, 6 H), 1.19 – 1.10 (m, 6 H). 
IR (neat): 3485, 2871, 1618, 1590, 1512, 1468, 1414, 1349, 1276, 1249, 1181 ,1112, 
949, 824, 779, 646, 609. 
HR-MS: Calculated for C72H119N6O22 [M+2H]3+ 473.2787, found: 473.2793. 
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HPLC (Phenomenex Synergi Hydro-RP, CH3CN/water + 0.1% HCO2H (2 min 1:19, 
in 3 min to 3:7, in 25 min to 4:1), 1 ml/min, 540 nm): single peak at 14.8 minutes 
retention time. 
UV/VIS: λmax (H2O) = 563 nm (Section 9.5.2). 
Assay with Thamnocephalus platyurus 
The assay “Thamnotoxkit FTM” was purchased from MicrobioTest Inc., Kleimoer 15, 
9030 Mariakerke (Gent), Belgium. The assay was conducted as described in the 
standard operating procedure.  
The standard freshwater (SFW) was prepared as described and oxygenated prior use 
by bubbling air for 30 minutes through it. Diluted standard freshwater (DFW) was 
prepared by mixing SFW (2.5 ml) with deionized water (17.5 ml). The T. platyurus 
cysts were hydrated in DFW (0.2 ml) for 30 minutes before they were added to DFW 
(10 ml) and incubated in a Petri dish for 24 hours at 25 °C under continuous light (8 W 
fluorescent tube lamp). 
Dilutions of the test substances with concentrations of 50, 12.5, 5 and 0.5 mM in 
methanol were prepared. In a 24 well plate, four repetitions of each concentration were 
prepared by mixing 2 µl of the substance solution with 998 µl SFW giving aqueous 
solutions with concentrations of 100, 25, 10 and 1 µM. A blank from 2 µl methanol and 
998 µl SFW was prepared. About 40 larvae were added to the first vial of each dilution 
by a pipette. From there, 10 larvae were transported to each of the remaining three vials 
of each concentration. Only these three vials were counted. The plate was covered with 
parafilm and incubated for 24 hours at 25 °C in the dark. 
The mortality was determined by counting the dead larvae. Dead was defined as no 
movement within 10 seconds. The remaining larvae were killed by adding CO2 
containing water (dry ice in water) and the total amount of individuals in each vial was 
determined. 
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Test Substance 0 µM 
Dead/ 
Total 
1 µM 
Dead/ 
Total 
10 µM 
Dead/ 
Total 
25 µM 
Dead/ 
Total 
100 µM 
Dead/ 
Total 
1.34 1/10 
0/10 
0/10 
1/10 
0/10 
0/10 
3/10 
2/11 
5/9 
2/10 
4/10 
3/10 
5/10 
5/11 
7/10 
3.17 0/10 
0/10 
0/8 
0/10 
0/9 
0/8 
2/8 
3/10 
6/10 
8/14 
1/10 
3/9 
7/10 
3/10 
5/10 
3.18 0/9 
0/11 
0/11 
0/10 
0/10 
0/11 
5/12 
1/10 
2/9 
2/10 
1/10 
1/10 
3/10 
2/10 
3.19 0/10 
0/10 
0/10 
0/10 
0/10 
0/10 
0/10 
2/10 
1/10 
0/11 
0/10 
0/11 
0/10 
2/10 
4/10 
Table 8.1: Raw Data of Assay with Thamnocephalus platyurus. Cysts Lot: TP070512, SFW 
Lot: EPA200912. 
Assay with Artemia franciscana 
The assay “Artoxkit MTM” was purchased from MicrobioTest Inc., Kleimoer 15, 
9030 Mariakerke (Gent), Belgium. The assay was conducted as described in the 
standard operating procedure.  
The standard seawater (SSW) was prepared as described and oxygenated prior use by 
bubbling air for 30 minutes trough it. The A. franciscana cysts were added to SSW 
(10 ml) and incubated in a Petri dish for 30 to 32 hours at 25 °C under continuous light 
(8 W fluorescent tube lamp). 
Dilutions of the test substances with concentrations of 50, 12.5, 5 and 0.5 mM in 
methanol were prepared. In a 24 well plate, four repetitions of each concentration were 
prepared by mixing 2 µl of the substance solution with 998 µl SSW giving aqueous 
solutions with concentrations of 100, 25, 10 and 1 µM. A blank from 2 µl methanol and 
998 µl SSW was prepared. About 40 larvae were added to the first vial of each dilution 
by a pipette. From there, 10 larvae were transported to each of the remaining three vials 
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of each concentration. Only these three vials were counted. The plate was covered with 
parafilm and incubated for 33 hours at 25 °C in the dark. 
The mortality was determined by counting the dead larvae. Dead was defined as no 
movement within 10 seconds. The remaining larvae were killed by adding CO2 
containing water (dry ice in water) and the total amount of individuals in each vial was 
determined. 
Test Substance 0 µM 
Dead/ 
Total 
1 µM 
Dead/ 
Total 
10 µM 
Dead/ 
Total 
25 µM 
Dead/ 
Total 
100 µM 
Dead/ 
Total 
1.34 0/9 
1/10 
0/10 
0/11 
0/11 
0/10 
1/9 
0/11 
0/10 
2/10 
1/11 
1/10 
5/10 
0/10 
4/9 
3.17 1/11 
0/10 
0/9 
0/9 
0/10 
0/10 
0/10 
1/10 
0/9 
3/9 
7/10 
7/11 
10/11 
9/10 
9/12 
3.18 0/10 
0/9 
1/10 
0/10 
0/10 
1/9 
0/11 
0/10 
0/9 
0/10 
0/11 
0/10 
0/11 
1/10 
0/10 
3.19 1/10 
0/10 
0/10 
0/9 
0/8 
1/12 
0/10 
0/11 
0/10 
0/10 
0/11 
0/10 
2/10 
3/10 
2/10 
3.23 0/10 
0/9 
0/8 
0/10 
0/7 
0/8 
0/11 
0/11 
0/10 
0/9 
0/10 
1/10 
0/10 
0/9 
0/10 
3.47 0/10 
0/11 
0/11 
1/10 
1/8 
1/10 
0/10 
0/12 
0/10 
1/10 
0/11 
0/10 
4/9 
4/11 
4/10 
Table 8.2: Raw Data of Assay with Artemia franciscana. Cysts Lot: AF/F2006, SFW Lot: 
ASPM060712. 
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Staining experiments with Artemia salina 
The A. salina cysts were purchased from OOO Biotrade, Peschanaya Str. 96V of 29, 
Barnaul, 656049, Russia. The standard seawater (SSW) was prepared by dissolving 
1.4 g “Artemia Salz” (Artemia-sal. JBL GmBH & co. KG, D-67141 Neuhofen) in tab 
water. The SSW was oxygenated prior use by bubbling air for 30 minutes through it. 
20 mg A. salina cysts were added to SSW (20 ml) in a Petri and illuminated for 
30 minutes trough a 3 mm layer of water (20 W energy-saver lamp). The cysts were 
then incubated for 48 hours at 25 °C under continuous light (8 W fluorescent tube 
lamp). 
Solutions with a concentration of 0.5 mM of rhodamine B, 3.47 and 3.48 in DMSO 
were prepared. In a 24 well plate, 2 µl of this solutions were diluted with 998 µl SSW 
giving a concentration of 1 µM. A blank from 2 µl DMSO and 998 µl SSW was 
prepared. With a pipette, about 25 larvae were added to each solution. The plate was 
covered with parafilm and incubated for 25 hours at 25 °C in the dark. 
After incubation, some individuals were investigated under the fluorescence 
microscope (Figure 8.1). 
 
Fig 8.1: Pictures taken before washing. 3.47 results in a specific staining while 3.48 is inactive 
and rhodamine B colors the complete organism. 
 The remaining nauplia were transferred in a mixture of 2 µl DMSO and 998 µl SSW 
and incubated for three hours at 25 °C in the dark. The transfer was repeated and they 
were again incubated for three hours under the same conditions. 
The larvae were transported in a mixture of formalin 10% and a standard PBS puffer 
(1:1 v/v). The larvae were fixed at 4 °C in the dark. 
 Blank Rhodamine B 3.48 3.47 
Visual 
    
Fluorescence 
    
Combination 
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Fig 8.2: Pictures series taken after washing. While the blank and 3.48 shows no fluorescence, 
rhodamine B marks the complete organism and 3.47 stains only specific parts. 
 
 
#  Blank Rhodamine B 3.48 3.47 
Visual 
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Fluorescence 
    
Visual 
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Fluorescence 
    
Visual 
    3 
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8.4 Synthetic Studies on Ophiodilactone A and B 
3-Phenyl-3-(2,3,4-tribenzyl-5-oxo-2,5-dihydrofuran-2-yl)propanal (4.07) 
 
Method A: To a solution of maculalactone A (1.34, 1.0 eq., 0.13 mmol, 50 mg) in 
toluene (3 ml) was added trans-cinnamaldehyde (5.0 eq., 0.67 mmol, 85 µl). The 
solution was cooled to -15 °C. The mixture was stirred for five minutes at this 
temperature, followed by the addition of the cinchona alkaloid catalyst (2.12, 0.05 eq., 
0.01 mmol, 4 mg). Subsequently, a 50% aq. KOH solution (6.5 eq., 0.87 mmol, 65 µl) 
was added over two minutes. The resulting mixture was vigorously stirred at -15 °C for 
three days, before it was filtrated over SiO2. The filter cake was extensively washed 
with EtOAc. The filtrate was concentrated and the residue was purified by column 
chromatography (SiO2, pentane/EtOAc (6:1)) to give the title compound 4.07 (34 mg, 
0.069 mmol, 52%) as a white solid. Additionally, the potential diastereomer 6.02 
(12 mg, 0.025 mmol, 11%) was isolated in a purity of about 80%. 
Method B: This method was used to yield the racemic product. To a solution of 
methyl 3-phenyl-3-(2,3,4-tribenzyl-5-oxo-2,5-dihydrofuran-2-yl)propanoate (4.13, 
1.0 eq., 0.10 mmol, 50 mg) in toluene (1.1 ml) at -78 °C, diisobutylaluminium hydride 
(1.2 M solution in toluene, 1.2 eq., 0.12 mmol, 99 µl) was added dropwise. The reaction 
was stirred for five hours at -78 °C. As the reaction was not finished, additional portions 
of diisobutylaluminium hydride (1.2 M solution in toluene, 0.55 eq., 0.050 mmol, 45 µl) 
were added. The finished reaction was quenched at -78 °C with a sat. aq. NH4Cl 
solution. The layers were separated and the aq. layer was extracted three times with 
EtOAc. The org. layers were washed with brine, dried with Na2SO4 and concentrated. 
The crude product was purified by column chromatography (SiO2, pentane/EtOAc 
(8:1)) to give the racemic title compound 4.07 (20 mg, 0.041 mmol, 41%) as white 
solid. 
Rf (SiO2, pentane/EtOAc (6:1)): 0.31. 
O
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1H-NMR (500 MHz, CDCl3): 8.92 (d, J = 1.5 Hz, 1 H), 7.41 (s, 2 H), 7.34 (t, J = 7.6 
Hz, 2 H), 7.31 – 7.24 (m, 4 H), 7.24 – 7.14 (m, 3 H), 7.14 – 7.04 (m, 5 H), 7.02 – 6.98 
(m, 2 H), 6.52 – 6.46 (m, 2 H), 3.86 (d, J = 15.4 Hz, 1 H), 3.58 – 3.42 (m, 3 H), 3.35 
(dd, J = 11.1, 2.5 Hz, 1 H), 2.87 (d, J = 14.6 Hz, 1 H), 2.79 – 2.69 (m, 2 H), 2.11 (dd, 
J = 17.6, 2.0 Hz, 1 H). 
13C-NMR (126 MHz, CDCl3): 199.2, 172.9, 161.5, 138.7, 137.1, 134.9, 134.4, 
131.5, 129.9, 129.4, 129.4, 129.3, 128.7, 128.7, 128.7, 128.1, 128.0, 127.8, 127.4, 
126.3, 92.4, 45.5, 44.7, 41.5, 33.7, 29.8. 
IR (neat): 3031, 2923, 2827, 2725, 1746, 1724, 1495, 1454 ,699. 
HR-MS: Calculated for C34H31O3 [M+H]+: 487.2268, found: 487.2272. 
 [α]D (c = 0.34, CHCl3, 36% ee): -88.9°. 
Mp: 75 – 76 °C. 
Side product 6.02 was rationalized to be the diastereomer of the desired product 4.07. 
Pure 6.02 could not be isolated. Therefore, a complete characterization was not 
possible. 
 
1H-NMR (500 MHz, CDCl3) δ 9.70 (t, J = 0.9 Hz, 1 H), 7.27 – 7.19 (m, 8 H), 7.14 – 
7.08 (m, 4 H), 7.02 (t, J = 7.6 Hz, 2 H), 6.86 (t, J = 7.6 Hz, 2 H), 6.47 (dd, J = 7.9, 0.8 
Hz, 2 H), 5.94 (dd, J = 7.9, 0.8 Hz, 2 H), 3.90 (dd, J = 8.6, 4.2 Hz, 1 H), 3.61 (d, 
J = 17.6 Hz, 1 H), 3.56 (d, J = 17.4 Hz, 1 H), 3.51 (d, J = 14.4 Hz, 1 H), 3.39 (dd, 
J = 18.4, 4.2 Hz, 1 H), 3.23 (ddd, J = 18.4, 8.6, 1.2 Hz, 1 H), 3.01 (d, J = 14.4 Hz, 1 H), 
2.75 (d, J = 15.8 Hz, 1 H), 2.66 (d, J = 15.9 Hz, 1 H). 
13C-NMR (126 MHz, CDCl3): 200.1, 173.3, 161.7, 139.0, 137.2, 134.5, 134.1, 
130.5, 130.2, 129.5, 129.2, 128.9, 128.8, 128.6, 128.1, 128.0, 127.8, 127.6, 127.1, 
125.6, 91.3, 47.2, 45.0, 41.5, 34.3, 29.1. 
O
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Triisopropyl((3,4,5-tribenzylfuran-2-yl)oxy)silane (4.11) 
 
To a solution of maculalactone A (1.34, 1.0 eq., 0.14 mmol, 50 mg) in dry CH2Cl2 
(2 ml), diisopropylamine (6.0 eq., 0.840 mmol, 119 µl) was slowly added. This was 
followed by the addition of triisopropylsilyl-trifluoromethanesulfonate (5.0 eq., 
0.700 mmol, 194 µl). The resulting mixture was stirred for three hours at room 
temperature. The reaction mixture was cooled to 0 °C and diluted with CH2Cl2. This 
mixture was extracted at 0 °C consecutively with a sat. aq. NaHCO3 solution, a 1 M aq. 
CuSO4 solution and brine. The aq. layers were extracted with CH2Cl2. The org. layers 
were combined, dried with Na2SO4, concentrated and extensively dried in high vacuum 
to give the title compound 4.11 (65 mg, 0.13 mmol, 91%) as clear oil in sufficient 
purity. The formed product is highly reactive and cannot be further purified and 
completely characterized. 
1H-NMR (500 MHz, CDCl3): 7.26 – 7.10 (m, 11 H), 7.08 – 7.04 (m, 2 H), 7.01 – 
6.98 (m, 2 H), 3.77 (s, 2 H), 3.53 (s, 2 H), 3.37 (s, 2 H), 1.01 (s, 18 H), 0.99 (s, 6 H). 
13C-NMR (101 MHz, CDCl3): 152.6, 141.4, 140.5, 139.5, 138.9, 128.7, 128.5, 
128.3, 128.2, 126.1, 125.9, 125.7, 119.3, 95.5, 32.4, 30.1, 28.7, 17.7, 12.4. 
rac-Methyl 3-phenyl-3-(2,3,4-tribenzyl-5-oxo-2,5-dihydrofuran-2-yl)propanoate 
(4.13) 
 
To a solution of maculalactone A (1.34, 1.00 eq., 0.509 mmol, 181 mg) in CH2Cl2 
(5.5 ml) were added methyl trans-cinnamate (5.00 eq., 2.55 mmol, 413 mg) and 
tetrabutylammonium bromide (1.00 eq., 0.509 mmol, 168 mg). After stirring for five 
O
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minutes, a 50% aq. KOH solution (6.50 eq., 3.31 mmol, 246 µl) was added over five 
minutes. The reaction was vigorously stirred for three days at room temperature and 
filtrated over SiO2. The solid was washed with CH2Cl2 and the filtrate was 
concentrated. The crude product was purified by column chromatography (SiO2, 
pentane/EtOAc (7:1)) to give the title compound 4.13 (90 mg, 0.18 mmol, 35%) as 
colorless solid. 
Rf (SiO2, pentane/EtOAc (5:1)): 0.26. 
1H-NMR (400 MHz, CDCl3): 7.45 (s, 2 H), 7.34 (t, J = 7.5 Hz, 2 H), 7.31 – 6.95 (m, 
14 H), 6.44 – 6.37 (m, 2 H), 3.80 (d, J = 15.7 Hz, 1 H), 3.62 (d, J = 15.7 Hz, 1 H), 3.48 
(d, J = 15.7 Hz, 1 H), 3.40 (dd, J = 11.4, 2.7 Hz, 1 H), 3.37 – 3.31 (m, 4 H), 2.86 (d, 
J = 14.6 Hz, 1 H), 2.73 (d, J = 14.6 Hz, 1 H), 2.62 (dd, J = 16.4, 11.3 Hz, 1 H), 2.19 
(dd, J = 16.4, 2.7 Hz, 1 H). 
13C-NMR (101 MHz, CDCl3) δ 173.0, 171.4, 161.8, 138.7, 137.1, 134.9, 134.5, 
131.2, 130.0, 129.4, 129.2, 128.7, 128.7, 128.6, 128.5, 128.0, 127.8, 127.5, 127.3, 
126.1, 92.4, 51.6, 47.5, 41.6, 35.5, 33.8, 29.7. 
IR (neat): 3063, 3030, 2950, 1743, 1495, 1247, 1166, 910, 731, 702, 632. 
HR-MS: Calculated for C35H33O4 [M+H]+: 517.2373, found: 517.2381. 
Mp: < 50 °C. 
3,4,5-Tribenzyl-5-(3-hydroxy-1-phenylpropyl)furan-2(5H)-one (4.17) 
 
A solution of 3-phenyl-3-(2,3,4-tribenzyl-5-oxo-2,5-dihydrofuran-2-yl)propanal 
(4.07, 1.00 eq., 0.310 mmol, 151 mg) in anhydrous EtOH (10 ml) was cooled to -16 °C. 
This was followed by the addition of a solution of NaBH4 (1.3 eq., 0.40 mmol, 16 mg) 
in anhydrous EtOH (2 ml) over five minutes. The mixture was stirred for 50 minutes at 
-18 °C and for 30 minutes at 0 °C. The reaction was quenched with water (3 ml). The 
resulting mixture was diluted with brine and EtOAc. The formed layers were separated 
and the aq. layer was extracted three times with EtOAc. The org. layers were 
subsequently washed with brine, combined, dried with Na2SO4 and concentrated. The 
O
O OH
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crude product was purified by column chromatography (SiO2, pentane/EtOAc (2:1)) to 
give the title compound 4.17 (113 mg, 0.23 mmol, 75%) as white solid. An X-ray 
diffraction analysis was performed after recrystallization. 
Rf (SiO2, pentane/EtOAc (3:1)): 0.27. 
1H-NMR (400 MHz, CDCl3): 7.40 – 7.27 (m, 7 H), 7.23 – 7.13 (m, 6 H), 7.12 – 6.98 
(m, 5 H), 6.45 (dd, J = 7.9, 1.4 Hz, 2 H), 3.84 (d, J = 15.5 Hz, 1 H), 3.61 – 3.50 (m, 
2 H), 3.43 (d, J = 15.7 Hz, 1 H), 3.13 (ddd, J = 10.6, 6.8, 3.7 Hz, 1 H), 2.94 (dd, 
J = 12.0, 2.6 Hz, 1 H), 2.88 (d, J = 14.6 Hz, 1 H), 2.76 – 2.64 (m, 2 H), 1.81 – 1.69 (m, 
1 H), 1.38 (dddd, J = 13.6, 9.4, 6.8, 2.7 Hz, 1 H), 0.26 (s, 1 H). 
13C-NMR (101 MHz, CDCl3) δ 173.3, 162.0, 139.2, 137.3, 135.5, 134.8, 130.8, 
130.0, 129.8, 129.1, 128.6, 128.5, 128.1, 127.6, 127.2, 126.1, 93.0, 60.0, 48.0, 42.0, 
33.8, 32.8, 29.8. 
IR (neat): 3432, 3028, 2954, 1716, 1493, 1157, 754, 701. 
HR-MS: Calculated for C34H33O3 [M+H]+: 489.2424, found: 489.2425. 
[α]D (c = 0.44, CHCl3): -87.0°. 
Chiral HPLC (Chiralpak IC column from Daicel, heptan/iPrOH (80:20), 
0.5 ml/min, 25 °C, 210 nm) Rt: 18.6 and 23.5 minutes. 
Mp: 169 – 170 °C. 
3-Phenyl-3-(2,3,4-tribenzyl-5-oxo-2,5-dihydrofuran-2-yl)propanoic acid (4.18) 
 
A solution of 3-phenyl-3-(2,3,4-tribenzyl-5-oxo-2,5-dihydrofuran-2-yl)propanal 
(4.07, 1.0 eq., 0.19 mmol, 93 mg) in tert-butanol (12 ml) and water (0.8 ml) was cooled 
to 15 – 20 °C. First 2-methyl-2-butene (3.0 eq., 0.57 mmol, 61 µl) was added followed 
by the addition of a solution of sodium chlorite (2.3 eq., 0.44 mmol, 40 mg) and 
NaH2PO4*H2O (2.0 eq., 0.38 mmol, 53 mg) in water (1.2 ml) within 15 minutes, 
remaining the temperature below 20 °C. The mixture was vigorously stirred for seven 
hours at room temperature. The tert-butanol was removed in vacuum from the finished 
reaction mixture, before additional water and CH2Cl2 were added. The mixture was 
O
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acidified to pH 1 by the addition of phosphoric acid. The layers were separated and the 
aq. layer was extracted three times with CH2Cl2. The org. layers were subsequently 
washed with a mixture of brine and a small amount of phosphoric acid. The combined 
org. layers were dried with Na2SO4 and concentrated to give the title compound 4.18 
(103 mg, 0.19 mmol, quantitative) as white solid. 
Rf (RP-18, CH3CN/H2O/TFA (10:4:0.002)): 0.34. 
1H-NMR (500 MHz, CDCl3): 10.33 (s, 1 H), 7.44 (s, 2 H), 7.36 (dd, J = 13.6, 
7.1 Hz, 2 H), 7.32 – 7.27 (m, 1 H), 7.23 – 7.11 (m, 5 H), 7.11 – 6.99 (m, 6 H), 6.99 – 
6.96 (m, 2 H), 6.44 – 6.39 (m, 2 H), 3.81 (d, J = 15.5 Hz, 1 H), 3.59 – 3.48 (m, 2 H), 
3.40 (d, J = 15.7 Hz, 1 H), 3.28 (ddd, J = 10.9, 8.5, 2.4 Hz, 1 H), 2.82 (d, J = 14.6 Hz, 
1 H), 2.72 (d, J = 14.6 Hz, 1 H), 2.61 (ddd, J = 17.1, 11.4, 1.6 Hz, 1 H), 2.16 (ddd, 
J = 17.1, 8.3, 2.4 Hz, 1 H). 
13C-NMR (126 MHz, CDCl3): 176.0, 172.9, 161.7, 138.5, 137.0, 134.7, 134.4, 
131.4, 129.9, 129.3, 129.2, 129.1, 128.7, 128.6, 128.0, 127.9, 127.7, 127.6, 127.4, 
126.2, 92.4, 47.0, 41.6, 35.2, 33.7, 29.8. 
IR (neat): 2923, 2852, 1738, 1715, 1495, 1454, 1252, 1080, 1002, 915, 757, 699. 
HR-MS: Calculated for C34H30NaO4 [M+Na]+: 525.2036, found: 525.2032. 
 [α]D (c = 0.27, CHCl3): -68.9°. 
Mp: 82 – 83 °C. 
6,7,8-Tribenzyl-5-phenyl-2,9-dioxabicyclo[4.2.1]non-7-ene (4.20) 
 
To a solution of 3-phenyl-3-(2,3,4-tribenzyl-5-oxo-2,5-dihydrofuran-2-yl)propanal 
(4.07, 1.0 eq., 0.10 mmol, 49 mg) in dry THF (4 ml) at 0 °C was added dry cerium(III) 
chloride (2.1 eq., 0.21 mmol, 52 mg). This was followed by the addition of LiAlH4 
(4.0 eq., 0.40 mmol, 15 mg) at once. The reaction was stirred for one hours at 0 °C and 
overnight at room temperature. To complete the conversion, the mixture was heated to 
reflux for 1.5 hours before it was cooled to 0 °C and quenched with water. After letting 
the reaction come to room temperature, it was filtrated over Celite. The solid was 
washed with TBME and water. The filtrate was diluted with brine before the layers 
OO
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were separated. The aq. layer was extracted twice with TBME. The org. layers were 
combined, dried with Na2SO4 and concentrated. The intermediately formed lactol 4.19 
reacts spontaneously to the desired product 4.20. This process was accelerated by 
dissolving the lactol in TBME (5 ml). To this solution was added 4Å mole sieve (1 g) 
and the mixture was stirred at room temperature for 24 hours. The finished reaction 
mixture was filtrated over Celite and the filtrate was concentrated. The crude product 
was purified by column chromatography (SiO2, pentane/EtOAc (20:1)) to give the title 
compound 4.20 (28 mg, 0.60 mmol, 60%) as pale colorless oil. 
Rf (SiO2, pentane/EtOAc (13:1)): 0.47. 
1H-NMR (500 MHz, C6D6): 7.27 (dd, J = 6.7, 2.7 Hz, 2 H), 7.19 – 7.11 (m, 9 H), 
7.10 – 7.04 (m, 7 H), 6.53 (dd, J = 6.6, 2.5 Hz, 2 H), 5.85 (s, 1 H), 3.80 (ddd, J = 12.4, 
6.3, 2.1 Hz, 1 H), 3.77 – 3.70 (m, 1 H), 3.45 (d, J = 15.4 Hz, 1 H), 3.34 (d, J = 15.6 Hz, 
1 H), 3.22 (d, J = 15.4 Hz, 1 H), 3.04 (dd, J = 15.2, 10.4 Hz, 2 H), 2.84 (dd, J = 9.6, 5.6 
Hz, 1 H), 2.36 (d, J = 14.9 Hz, 1 H), 2.25 (dtd, J = 14.9, 10.0, 2.1 Hz, 1 H), 1.61 (ddd, 
J = 11.8, 11.0, 5.5 Hz, 1 H). 
13C-NMR (126 MHz, C6D6): 143.8, 142.0, 139.3, 138.1, 133.3, 130.9, 129.8, 128.9, 
128.8, 128.7, 128.6, 128.4, 128.2, 128.1, 128.0, 127.0, 126.9, 126.3, 106.2, 96.0, 62.1, 
53.1, 42.4, 39.0, 32.8, 30.8. 
IR (neat): 3026, 2950, 1601, 1493, 1453, 1084, 997, 952, 874, 417. 
HR-MS: Calculated for C34H32O2 [M+H]+: 473.2475, found: 473.2473. 
 [α]D (c = 0.30, CHCl3, 68% ee): -55.5°. 
The intermediate lactol 3,4,5-tribenzyl-5-(3-hydroxy-1-phenylpropyl)-2,5-
dihydrofuran-2-ol (4.19) could not be characterized, as it spontaneously reacted to 
acetal 4.20. Nevertheless, the intermediate lactol could be observed as crude by NMR. 
 
Rf (SiO2, pentane/EtOAc (2:1)): 0.22. 
1H-NMR (500 MHz, C6D6): 7.29 – 7.01 (m, 18 H), 6.39 – 6.33 (m, 2 H), 5.35 (s, 
1 H), 3.47 (d, J = 15.3 Hz, 1 H), 3.43 (d, J = 15.7 Hz, 1 H), 3.26 (d, J = 15.6 Hz, 1 H), 
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3.14 (d, J = 15.3 Hz, 1 H), 3.11 – 3.05 (m, 1 H), 2.83 (d, J = 14.0 Hz, 1 H), 2.74 – 2.65 
(m, 2 H), 2.51 (d, J = 14.0 Hz, 1 H), 2.34 (s, 1 H), 2.06 – 1.95 (m, 1 H), 1.69 – 1.60 (m, 
1 H). 
13C-NMR (126 MHz, C6D6): 142.3, 138.6, 138.4, 138.4, 138.0, 136.7, 130.6, 129.8, 
128.8, 128.8, 128.6, 128.4, 128.2, 128.0, 127.0, 127.0, 126.4, 126.1, 102.5, 98.2, 60.7, 
48.5, 44.0, 35.8, 32.6, 31.5. 
Under more harsh conditions like refluxing overnight, the further reduced product 
3-phenyl-3-(2,3,4-tribenzyl-2,5-dihydrofuran-2-yl)propan-1-ol (4.24) was formed as 
side product. 
 
Rf (SiO2, pentane/EtOAc (5:1)): 0.32. 
1H-NMR (500 MHz, C6D6): 7.50 (s, 1 H), 7.23 (s, 2 H), 7.18 – 7.02 (m, 15 H), 6.39 
(dd, J = 6.4, 2.9 Hz, 2 H), 4.37 (d, J = 12.0 Hz, 1 H), 4.19 (d, J = 11.9 Hz, 1 H), 3.50 (d, 
J = 15.3 Hz, 1 H), 3.35 (d, J = 15.7 Hz, 1 H), 3.16 (d, J = 15.3 Hz, 1 H), 3.08 (ddd, 
J = 10.4, 7.7, 4.0 Hz, 1 H), 2.87 – 2.80 (m, 2 H), 2.74 (ddd, J = 10.3, 8.5, 6.8 Hz, 1 H), 
2.67 (dd, J = 11.8, 2.6 Hz, 1 H), 2.53 (d, J = 14.1 Hz, 1 H), 1.92 (tdd, J = 15.9, 6.8, 
4.1 Hz, 1 H), 1.82 – 1.72 (m, 1 H), 1.36 (s, 1 H). 
13C-NMR (126 MHz, C6D6) δ 142.7, 139.5, 139.0, 135.6, 135.6, 133.9, 130.7, 129.7, 
128.8, 128.7, 128.5, 128.4, 128.2, 128.0, 126.9, 126.8, 126.2, 126.2, 99.5, 77.5, 60.8, 
50.8, 44.4, 34.6, 32.6, 32.1. 
IR (neat): 3027, 2923, 2358, 1749, 1601, 1494, 1454, 1029, 910, 701. 
HR-MS: Calculated for C34H32NaO2 [M+Na]+: 497.2451, found: 497.2449. 
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3-Benzoyl-4,5-dibenzylfuran-2(5H)-one (4.27) 
 
To a solution of 3-oxo-3-phenylpropanoic acid (4.26, 1.10 eq., 3.48 mmol, 571 mg) 
and 3-hydroxy-1,4-diphenylbutan-2-one (2.30, 1.00 eq., 3.16 mmol, 759 mg) in CH2Cl2 
(40 ml) were added 4-dimethylaminopyridine (0.12 eq., 0.38 mmol, 46 mg) and 
pentafluorophenol (1.10 eq., 3.48 mmol, 640 mg). Subsequently, a solution of 
N,N’-dicyclohexylcarbodiimide (1.30 eq., 4.11 mmol, 848 mg) in CH2Cl2 (5 ml) was 
added in one minute. After stirring for 20 hours at room temperature, the finished 
reaction was quenched with water and filtrated. The filter cake was washed with 
CH2Cl2. The filtrate was mixed with a sat. aq. NaHCO3 solution before the layers were 
separated. The aq. layer was extracted twice with CH2Cl2. The org. layers were washed 
with a sat. aq. NH4Cl solution, combined, dried with Na2SO4 and concentrated. The 
crude product was purified by column chromatography (SiO2, pentane/EtOAc (1:6)) to 
give the already cyclized product 4.27 as a brownish solid. The solid was recrystallized 
from MeOH and water to give the title compound 4.27 (304 mg, 0.83 mmol, 26%) as 
grey solid. An X-ray diffraction analysis was performed after recrystallization. 
Rf (SiO2, pentane/EtOAc (6:1)): 0.36. 
1H-NMR (500 MHz, CDCl3): 7.54 (tt, J = 7.6, 1.3 Hz, 1 H), 7.41 – 7.37 (m, 3 H), 
7.35 – 7.22 (m, 11 H), 5.14 (t, J = 4.5 Hz, 1 H), 4.06 (d, J = 15.0 Hz, 1 H), 3.54 (d, 
J = 15.0 Hz, 1 H), 3.45 (dd, J = 14.5, 4.5 Hz, 1 H), 3.08 (dd, J = 14.5, 4.6 Hz, 1 H). 
13C-NMR (126 MHz, CDCl3): 190.0, 170.2, 169.4, 136.0, 135.2, 134.2, 133.9, 
130.1, 129.8, 129.5, 129.4, 129.2, 129.1, 128.7, 127.8, 127.7, 81.5, 37.5, 34.2. 
IR (neat): 2930, 1761, 1662, 1599, 1493, 1451, 1322, 1262, 1040, 998, 895, 766, 
699. 
EI-MS (70 eV) m/z (%): 369 (12), 368 (44, [M]+), 277 (24), 259 (14), 105 (100), 91 
(53), 77 (24). 
HR-MS: Calculated for C25H20NaO3 [M+Na]+: 391.1305, found: 391.1301. 
Mp: 109 – 111 °C. 
O
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1-Benzyl-4-hydroxy-3-oxo-4,6,7-triphenyl-1,3,4,5,6,7-hexahydroisobenzofuran-5-
carbaldehyde (4.28) 
 
A solution of 3-benzoyl-4,5-dibenzylfuran-2(5H)-one (4.27, 1.0 eq., 0.070 mmol, 
26 mg), trans-cinnamaldehyde (1.2 eq., 0.0840 mmol, 10.7 µl) and cinchona alkaloid 
catalyst (2.12, 0.05 eq., 4 µmol, 2 mg) in CH2Cl2 (2 ml) was cooled to -40 °C. 
Subsequently, a 50% aq. KOH solution (20 eq., 1.40 mmol, 104 µl) was added over five 
minutes. The reaction was vigorously stirred for four days at -40 °C before some SiO2 
was added. After stirring for another 30 minutes, the reaction was filtrated over SiO2. 
The filter cake was washed with EtOAc and TBME. The filtrate was concentrated and 
the crude product was purified by preparative TLC (SiO2, pentane/EtOAc (2:1)) to give 
the title compound 4.28 (11 mg, 0.022 mmol, 31%) as colorless solids. An X-ray 
diffraction analysis was performed after recrystallization. 
Rf (SiO2, pentane/EtOAc (2:1)): 0.57. 
1H-NMR (400 MHz, CDCl3): 9.33 (d, J = 3.8 Hz, 1 H), 7.50 – 7.41 (m, 3 H), 7.33 – 
7.07 (m, 13 H), 6.92 – 6.86 (m, 2 H), 6.53 – 6.48 (m, 2 H), 5.05 (t, J = 4.0 Hz, 1 H), 
3.85 – 3.78 (m, 2 H), 3.25 (dd, J = 14.6, 4.4 Hz, 2 H), 2.93 – 2.83 (m, 1 H), 2.68 (dd, 
J = 14.6, 3.7 Hz, 1 H). 
13C-NMR (101 MHz, CDCl3) δ 201.4, 169.7, 166.1, 141.8, 138.1, 137.5, 133.9, 
132.4, 130.1, 129.3, 129.1, 128.9, 128.7, 128.3, 128.2, 127.9, 127.7, 127.7, 124.7, 80.4, 
73.1, 63.3, 50.9, 47.6, 36.7. 
IR (neat): 3029, 2929, 2849, 1749, 1494, 1454, 1336, 1069, 1008, 910, 756, 732, 
699, 637. 
HR-MS: Calculated for C34H28NaO4 [M+Na]+: 523.1880, found: 523.1879. 
Mp: polymerization. 
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3,3a,6a-Tribenzyl-4-hydroxy-6-phenylhexahydro-2H-cyclopenta[b]furan-2-one 
(4.31) 
 
To a solution of 3-phenyl-3-(2,3,4-tribenzyl-5-oxo-2,5-dihydrofuran-2-yl)propanal 
(4.07, 1.0 eq., 0.062 mmol, 30mg) in dry THF (distilled from sodium, 6 ml) was added 
anhydrous EtOH (1.2 eq., 0.074 mmol, 4.4 µl). This was followed by the addition of 
samarium iodine (0.1 M solution in THF, 4.0 eq., 0.025 mmol, 2.5 ml) over 15 minutes 
at room temperature. The samarium iodine solution was prepared as described in 
literature.20 After stirring the reaction mixture for 20 minutes, it was quenched with a 
half saturated aq. NH4Cl solution. The resulting mixture was extracted three times with 
EtOAc. The org. layers were washed with brine, combined, dried with Na2SO4 and 
concentrated. The crude product was purified by column chromatography (SiO2, 
pentane/EtOAc (6:1)) to give the title compound 4.31 (18 mg, 0.037 mmol, 59%) as 
colorless oil. 
Rf (SiO2, pentane/EtOAc (3:1)): 0.50. 
1H-NMR (500 MHz, CDCl3): 7.38 (dt, J = 5.1, 3.0 Hz, 2 H), 7.30 – 7.18 (m, 15 H), 
7.17 – 7.09 (m, 3 H), 6.83 – 6.78 (m, 2 H), 4.51 (dt, J = 6.2, 3.3 Hz, 1 H), 3.47 – 3.38 
(m, 2 H), 3.20 (d, J = 15.0 Hz, 1 H), 3.10 (d, J = 15.0 Hz, 1 H), 3.06 (d, J = 13.4 Hz, 
1 H), 2.64 (dd, J = 14.2, 9.2 Hz, 1 H), 2.51 (dd, J = 9.2, 3.7 Hz, 1 H), 2.30 (ddd, 
J = 13.9, 11.7, 6.0 Hz, 1 H), 2.24 (dd, J = 14.2, 3.6 Hz, 1 H), 2.07 (ddd, J = 14.0, 7.8, 
3.2 Hz, 1 H), 1.75 (d, J = 3.5 Hz, 1 H). 
13C-NMR (126 MHz, CDCl3): 177.3, 139.2, 137.9, 137.9, 136.4, 135.7, 131.1, 
131.1, 131.0, 130.2, 129.0, 128.7, 128.5, 128.2, 128.1, 127.2, 127.1, 126.3, 95.5, 73.5, 
60.7, 52.2, 50.2, 40.5, 40.1, 36.2. 
HR-MS: Calculated for C34H32NaO3 [M+Na]+: 511.2244, found: 511.2242. 
O
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3,3a,6a-Tribenzyl-3,4-dihydroxy-6-phenylhexahydro-2H-cyclopenta[b]furan-2-one 
(4.32) 
 
To a solution of 3,3a,6a-tribenzyl-4-hydroxy-6-phenylhexahydro-2H-
cyclopenta[b]furan-2-one (4.31, 1.00 eq., 0.050 mmol, 24 mg) in dry THF (5 ml) at 
-78 °C was added NaHMDS (0.6 M solution in toluene, 3.00 eq., 0.150 mmol, 250 µl) in 
ten minutes. The slightly yellowish mixture was stirred for one hour at -78 °C and then 
heated to 0 °C. First, triethyl phosphite (distilled from sodium, 1.2 eq., 0.060 mmol, 
10.7 µl) was added followed by the introduction of oxygen (dried over solid KOH) in 
the reaction atmosphere. The reaction was stirred under oxygen atmosphere at 0 °C for 
three hours. The yellowish reaction solution was quenched at 0 °C with a 1 M aq. HCl 
solution. The resulting mixture was extracted three times with EtOAc. The org. layers 
were washed with a mixture of brine and a 1 M aq. HCl solution (1:1 v/v), combined, 
dried with Na2SO4 and concentrated. The crude product was purified by preparative 
TLC (SiO2, pentane/EtOAc (4:1)) to give the title compound 4.32 (16 mg, 0.032 mmol, 
63%) as colorless oil. 
Rf (SiO2, pentane/EtOAc (4:1)): 0.56. 
1H-NMR (400 MHz, CDCl3): 7.77 (d, J = 7.1 Hz, 2 H), 7.42 – 7.27 (m, 8 H), 7.07 – 
6.96 (m, 8 H), 6.86 (dd, J = 6.4, 3.2 Hz, 2 H), 4.62 (dd, J = 9.3, 5.6 Hz, 1 H), 3.63 (d, 
J = 14.6 Hz, 1 H), 3.53 (d, J = 13.8 Hz, 1 H), 3.31 (dd, J = 21.0, 11.5 Hz, 2 H), 3.21 (d, 
J = 14.6 Hz, 1 H), 3.16 (d, J = 14.0 Hz, 1 H), 3.06 (d, J = 14.0 Hz, 1 H), 2.16 (dd, 
J = 7.9, 5.5 Hz, 2 H), 1.94 (d, J = 4.4 Hz, 1 H). 
13C-NMR (126 MHz, CDCl3, as measured by HMBC and HMQC, no aromatic 
carbons): 176.0, 96.3, 77.9, 74.0, 63.6, 50.4, 41.8, 41.6, 38.3, 30.8. 
IR (neat): 3526, 2927, 2361, 2343, 1742, 1496, 1455, 1198, 955, 751. 
HR-MS: Calculated for C34H32NaO4 [M+Na]+: 527.2193, found: 527.2191. 
 [α]D (c = 0.06, CHCl3, 25% ee): -12.1°. 
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3,3a,6a-Tribenzyl-3-hydroxy-6-phenyltetrahydro-2H-cyclopenta[b]furan-2,4(5H)-
dione (4.33) 
 
To a solution of 3,3a,6a-tribenzyl-3,4-dihydroxy-6-phenylhexahydro-2H-
cyclopenta[b]furan-2-one (4.32, 1.0 eq., 0.030 mmol, 15 mg) in dry CH2Cl2 (1.5 ml) 
was added Dess-Martin periodinane (2.0 eq., 0.060 mmol, 25 mg). After stirring for 1.5 
hours at room temperature, the reaction was quenched with a 1 M aq. NaOH solution. 
The resulting mixture was extracted three times with TBME. The org. layers were 
washed with brine, combined, dried with Na2SO4 and concentrated. The crude product 
was filtrated over SiO2 using pentane/EtOAc (1:1). The filtrate was concentrated to give 
the title compound 4.33 (15 mg, 0.030 mmol, quantitative) as colorless oil. 
Rf (SiO2, pentane/EtOAc (6:1)): 0.65. 
1H-NMR (400 MHz, CDCl3): 7.60 – 7.55 (m, 2 H), 7.43 – 7.31 (m, 8 H), 7.09 – 7.02 
(m, 3 H), 6.98 – 6.86 (m, 5 H), 6.73 (dd, J = 8.1, 1.3 Hz, 2 H), 3.87 (d, J = 14.3 Hz, 
1 H), 3.45 (d, J = 14.6 Hz, 1 H), 3.40 (d, J = 14.1 Hz, 1 H), 3.32 (d, J = 14.1 Hz, 1 H), 
3.20 (d, J = 14.3 Hz, 1 H), 3.08 (d, J = 14.6 Hz, 1 H), 2.64 (dd, J = 16.9, 12.2 Hz, 1 H), 
2.57 – 2.49 (m, 1 H), 2.49 – 2.40 (m, 1 H), 2.31 (s, 1 H). 
13C-NMR (101 MHz, CDCl3): 215.5, 174.9, 136.7, 135.6, 134.7, 133.3, 132.4, 
131.1, 130.9, 129.8, 128.9, 128.8, 128.2, 127.9, 127.8, 127.7, 127.4, 126.4, 94.3, 75.7, 
68.5, 49.1, 46.2, 40.2, 38.5, 33.3. 
IR (neat): 3520, 3031, 2924, 2854, 1778, 1741, 1497, 1455, 1246, 1171, 1081, 991, 
699. 
HR-MS: Calculated for C34H29Na2O4 [M-H+2Na]+: 547.1856, found: 547.1865. 
 [α]D (c = 0.09, CHCl3, 25% ee): +11.2°. 
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2,3-Dibenzyl-4-phenylcyclopent-2-enone (4.34) 
 
Under various reaction conditions with 3,3a,6a-tribenzyl-3-hydroxy-6-
phenyltetrahydro-2H-cyclopenta[b]furan-2,4(5H)-dione (4.33) as starting material or 
product, 2,3-dibenzyl-4-phenylcyclopent-2-enone (4.34) was observed as side product. 
Rf (SiO2, pentane/EtOAc (4:1)): 0.75. 
1H-NMR (500 MHz, CDCl3): 7.33 – 7.19 (m, 11 H), 6.99 – 6.94 (m, 2 H), 6.82 (dd, 
J = 6.6, 2.8 Hz, 2 H), 3.96 (d, J = 14.6 Hz, 1 H), 3.81 – 3.71 (m, 3 H), 3.11 (d, J = 14.6 
Hz, 1 H), 2.87 (dd, J = 18.9, 7.2 Hz, 1 H), 2.38 (dd, J = 19.1, 2.1 Hz, 1 H). 
13C-NMR (101 MHz, CDCl3): 208.8, 174.3, 140.8, 129.2, 129.1, 129.1, 128.8, 
128.8, 128.7, 127.8, 127.3, 126.9, 126.9, 126.4, 126.4, 46.3, 44.8, 35.4, 29.9. 
IR (neat): 3028, 2924, 2853, 1703, 1639, 1495, 1455, 1352, 1241, 1078, 759, 700. 
HR-MS: Calculated for C25H22NaO [M+Na]+: 361.1563, found: 361.1565. 
3-(2,4-Dibenzyl-3-benzylidene-4-hydroxy-5-oxotetrahydrofuran-2-yl)-3-
phenylpropanoic acid (4.35) 
 
To a solution of 3-phenyl-3-(2,3,4-tribenzyl-5-oxo-2,5-dihydrofuran-2-yl)propanoic 
acid (4.18, 1.0 eq., 0.030 mmol, 15 mg) in dry THF (5 ml) at -78 °C was added 
NaHMDS (0.6 M solution in toluene, 4.00 eq., 0.120 mmol, 200 µl) over five minutes. 
The slightly yellowish solution was stirred for one hour. This was followed by the 
addition of triethyl phosphite (distilled from sodium, 1.5 eq., 0.045 mmol, 7.9 µl) and 
the gas phase was flushed with oxygen (dried over solid KOH) at -78 °C. After stirring 
for another three hours at -78 °C, the reaction was quenched with a 1 M aq. HCl solution 
O
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and subsequently heated to room temperature. The resulting mixture was extracted three 
times with EtOAc. The org. layers were combined, dried with Na2SO4 and concentrated. 
The crude product was purified twice by preparative TLC (SiO2, pentane/EtOAc (1:2) 
and pentane/EtOAc (2:3)) to obtain the title compound 4.35 (6 mg) as clear oil, 
containing still small amounts of impurities. 
Rf (SiO2, pentane/EtOAc (2:3)): 0.72. 
1H-NMR (400 MHz, CDCl3): 9.22 (s, 1 H), 7.85 (d, J = 7.4 Hz, 2 H), 7.51 – 7.41 (m, 
4 H), 7.41 – 7.28 (m, 4 H), 7.25 – 7.06 (m, 8 H), 6.93 (s, 1 H), 6.79 (dd, J = 6.4, 3.0 Hz, 
2 H), 3.54 (dd, J = 11.2, 3.1 Hz, 1 H), 3.15 (dd, J = 16.2, 2.8 Hz, 1 H), 2.91 – 2.78 (m, 
2 H), 2.74 (d, J = 14.1 Hz, 1 H), 2.53 (s, 1 H), 2.45 (d, J = 14.3 Hz, 1 H). 
HR-MS: Calculated for C34H34NO5 [M+NH4]+: 536.2434, found: 536.2431. 
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8.5 Studies on a Linear Approach Towards Ophiodilactone A 
and B 
2,4-Dibenzylpenta-1,4-dien-3-ol (5.13) 
 
Method A: To a solution of (2-bromoallyl)benzene (5.11, 1.00 eq., 1.00 mmol, 
197 mg) in dry THF (4 ml) at -78 °C was added tBuLi (1.6 M solution in hexanes, 
2.00 eq., 2.00 mmol, 1.25 ml). This mixture was stirred at that temperature for 
30 minutes while the reaction turned dark yellow. Then, a solution of 
2-benzylacrylaldehyde (2.16, 1.00 eq., 1.00 mmol, 146 mg) in THF (2 ml) was added 
dropwise. In doing so, the reaction turned colorless. Subsequently, the reaction mixture 
was stirred for one hour at -78 °C and was then allowed to warm to room temperature. 
The resulting colorless solution was quenched with water and stirred for 20 minutes. 
The mixture was extracted three times with EtOAc. The org. layers were washed with 
water and brine, combined, dried with Na2SO4 and concentrated. The colorless oil was 
purified by column chromatography (SiO2, pentane/EtOAc (19:1)) to give the title 
compound 5.13 (205 mg, 0.78 mmol, 78%) as colorless oil. 
Method B: A published procedure21 was modified as follows: Pre-dried magnesium 
turnings (4.40 eq., 5.06 mmol, 132 mg) were mixed with dry THF (5 ml). Then 
diisobutylaluminium hydride (1 M solution in hexane, 0.002 eq., 2 µmol, 2 µl) was 
added and the solution was stirred for 10 minutes. This was followed by the addition of 
(2-bromoally)benzene (5.11, 2.22 eq., 2.53 mmol, 499 mg) at once. The mixture was 
stirred for 10 minutes at room temperature and heated for two hours to reflux. Then, the 
reaction mixture was cooled to 0 °C while it became turbid. The precipitate was filtered 
off and washed with dry THF (1 ml) using Schlock technique. To the clear brownish 
solution at 0 °C, freshly distilled ethyl formate (1.00 eq., 1.14 mmol, 92.1 µl) was 
added, while the Grignard solution losses its color immediately. After 10 minutes, the 
mixture was allowed to warm to room temperature and was stirred for one hour. The 
reaction was quenched with a sat. aq. NH4Cl solution and stirred for another 
40 minutes. The mixture was filtrated over Celite and the solids were washed 
OH
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alternating with TBME and water. The layers of the filtrate were separated and the aq. 
layer was extracted twice with TBME. The org. layers were washed with brine, 
combined, dried with Na2SO4 and concentrated to 259 mg. The crude product was 
purified by column chromatography (SiO2, pentane/EtOAc (20:1)) to give the title 
compound 5.13 (81 mg, 0.31 mmol, 27%) as colorless oil and a 58:42 mixture 
(1H-NMR) of the two side products 5.21 (52 mg, 0.10 mmol, 9%) and 5.20 (52 mg, 
0.083 mmol, 7%). Side product 5.21 was isolated as colorless oil by column 
chromatography (SiO2, pentane/EtOAc (20:1) and characterized. The 1H-NMR of 
compound 5.21 reveals the depicted structure. 
Method C: The side product 5.21 (1.00 eq., 3.36 mmol, 982 mg) was dissolved in 
dry toluene (20 ml) and cooled to -78 °C. Diisopropylaluminium hydride (1 M solution 
in hexane, 1.1 eq., 3.7 mmol, 3.7 ml) was slowly added and the reaction was stirred for 
three hours at -78 °C. Then the reaction was quenched with water and the mixture was 
heated to room temperature. Some Celite was added and the mixture was stirred for 
15 minutes before the solids were filtered off. The filtrate was extracted three times 
with TBME. The org. layers were washed with brine, combined, dried with Na2SO4 and 
concentrated to give the title compound 5.13 (885 mg, 3.4 mmol, quantitative) as 
colorless oil. 
1H-NMR (400 MHz, CDCl3): 7.32 – 7.24 (m, 4 H), 7.24 – 7.17 (m, 2 H), 7.14 (d, 
J = 7.3 Hz, 4 H), 5.24 (s, 2 H), 4.89 (s, 2 H), 4.54 (d, J = 3.1 Hz, 1 H), 3.39 (d, J = 15.6 
Hz, 2 H), 3.23 (d, J = 15.6 Hz, 2 H), 1.62 (d, J = 3.9 Hz, 1 H). 
13C-NMR (101 MHz, CDCl3): 148.8, 139.4, 129.5, 128.5, 126.3, 113.8, 77.3, 38.6. 
The analytical data of product 5.13 correspond to those reported in the literature.21 
Side product 5.21 was identified as 2,4-dibenzylpenta-1,4-dien-3-yl formate. 
 
Rf (SiO2, pentane/EtOAc (10:1)): 0.87. 
1H-NMR (500 MHz, CDCl3): 8.02 (d, J = 0.9 Hz, 1 H), 7.31 – 7.24 (m, 4 H), 7.24 – 
7.19 (m, 2 H), 7.12 (d, J = 7.0 Hz, 4 H), 5.71 (s, 1 H), 5.25 (s, 2 H), 4.92 (d, J = 1.0 Hz, 
2 H), 3.35 (d, J = 15.9 Hz, 2 H), 3.28 (d, J = 15.9 Hz, 2 H). 
OH
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13C-NMR (126 MHz, CDCl3): 159.8, 144.5, 138.5, 129.5, 128.5, 126.5, 115.8, 78.0, 
38.6. 
IR (neat): 3028, 2917, 2331, 1729, 1646, 1495, 1454, 1163, 915, 701. 
HR-MS: Calculated for C20H20NaO2 [M+Na]+: 247.1480, found: 247.1481. 
Side product 5.20 was rationalized as the 1,4-addition product 2,4-dibenzylpent-4-
enal. 
 
1H-NMR (500 MHz, CDCl3): 9.59 (d, J = 2.5 Hz, 1 H), 7.26 (t, J = 7.5 Hz, 4 H), 
7.20 (t, J = 7.2 Hz, 2 H), 7.11 (q, J = 6.8 Hz, 4 H), 4.88 (d, J = 5.7 Hz, 2 H), 3.34 (d, 
J = 15.0 Hz, 1 H), 3.29 (d, J = 15.0 Hz, 1 H), 2.91 (dd, J = 13.5, 7.5 Hz, 1 H), 2.87 – 
2.75 (m, 1 H), 2.69 (dd, J = 13.6, 6.3 Hz, 1 H), 2.35 (dd, J = 15.1, 8.2 Hz, 1 H), 2.10 
(dd, J = 15.1, 6.0 Hz, 1 H). 
(R)-2-Benzyl-1-((S)-2-benzyloxiran-2-yl)prop-2-en-1-ol (5.14) 
 
Method A (giving a high enantiomeric excess): A published procedure22 was 
modified as follows: A mixture of pulverized 4 Å molecular sieve (25 mg) in dry 
CH2Cl2 (4 ml) was cooled to -20 °C. Titanium(IV) isopropoxide (1.10 eq., 0.627 mmol, 
193 µl) and (+)-diisopropyl L-tartrate (1.30 eq., 0.741 mmol, 156 µl) were added at 
-20 °C. This mixture was stirred for 20 minutes. Subsequently, a solution of 
2,4-dibenzylpenta-1,4-dien-3-ol (5.13, 1.00 eq., 0.570 mmol, 151 mg) in dry CH2Cl2 
(1 ml) was added, followed by the addition of tert-butyl hydroperoxide (5.5 M solution 
in decane, 2.00 eq., 1.14 mmol, 207 µl). The reaction was stirred for 22 hours at -20 °C. 
Water, CH2Cl2 and Celite were added to the mixture and it was stirred for further 
1.5 hours at -20 °C. The reaction mixture was brought to room temperature and filtrated 
over SiO2. The solid were washed with CH2Cl2. The layers of the filtrate were separated 
and the aq. layer was extracted four times with CH2Cl2. The org. layers were washed 
with half concentrated brine, combined, dried with Na2SO4 and concentrated. The crude 
product was purified by column chromatography (SiO2, pentane/EtOAc (5:1)) to give 
O
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the title compound 5.14 (108 mg, 0.39 mmol, 68%) as clear oil with an enantiomeric 
excess of 87%. 
Method B (giving a high yield): A mixture of pulverized 4 Å molecular sieve 
(25 mg) in dry CH2Cl2 (4 ml) was cooled to -20 °C. Titanium(IV) isopropoxide 
(1.10 eq., 0.627 mmol, 193 µl) and (+)-diethyl L-tartrate (1.30 eq., 0.741 mmol, 127 µl) 
were added at -20 °C. This mixture was stirred for 20 minutes. Subsequently, a solution 
of 2,4-dibenzylpenta-1,4-dien-3-ol (5.13, 1.00 eq., 0.570 mmol, 151 mg) in dry CH2Cl2 
(1 ml) was added, followed by the addition of tert-butyl hydroperoxide (5.5 M solution 
in decane, 2.00 eq., 1.14 mmol, 0.207 ml). The reaction was stirred for 44 hours at 
-20 °C. To the cold mixture was added a sat. aq. Na2SO4 solution and the reaction was 
allowed to reach room temperature in three hours. After the addition of CH2Cl2 and 
Celite, the mixture was stirred for another 30 minutes, before the solids were filtered off 
and washed with CH2Cl2. The layers of the filtrate were separated and the aq. layer was 
extracted four times with CH2Cl2. The org. layers were subsequently washed with half 
sat. brine, combined, dried with Na2SO4 and concentrated. The crude product was 
purified by column chromatography (SiO2, pentane/EtOAc (19:1)) to give the title 
compound 5.14 (119 mg, 0.42 mmol, 75%) as clear oil with an enantiomeric excess of 
71%. 
Method C: This method was used to yield the racemic product. A published 
procedure22 was modified as follows: To a mixture of pulverized 4 Å molecular sieve 
(100 mg) and vanadyl(IV) acetylacetonate (0.06 eq., 0.02mmol, 5mg) in dry CH2Cl2 
(2 ml) at 0 °C was added a solution of 2,4-dibenzylpenta-1,4-dien-3-ol (5.13, 1.0 eq., 
0.33 mmol, 87 mg) in dry CH2Cl2 (1.8 ml). By the addition, the color of the solution 
turned from blue to brown. After stirring for 10 minutes, tert-butyl hydroperoxide 
(5.5 M solution in decane, 1.0 eq., 0.33 mmol, 60 µl) was added dropwise. The reaction 
was stirred for one hour at 0 °C and anther 28 hours at room temperature. The reaction 
was quenched with a sat. aq. NH4Cl solution. The layers were separated and the aq. 
layer was extracted three times with CH2Cl2. The org. layers were washed with brine, 
combined, dried with Na2SO4 and concentrated. The crude product was purified by 
column chromatography (SiO2, pentane/EtOAc (10:1)) to give the racemic title 
compound 5.14 (34 mg, 0.121 mmol, 37%) as clear oil. 
Rf (SiO2, pentane/EtOAc (5:1)): 0.38. 
1H-NMR (400 MHz, CDCl3): 7.34 – 7.18 (m, 8 H), 7.12 – 7.07 (m, 2 H), 5.24 (s, 
1 H), 4.96 (dd, J = 2.7, 1.4 Hz, 1 H), 4.24 (d, J = 1.6 Hz, 1 H), 3.51 (d, J = 15.7 Hz, 
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1 H), 3.35 (d, J = 15.7 Hz, 1 H), 3.00 – 2.82 (m, 3 H), 2.38 (d, J = 4.7 Hz, 1 H), 2.16 (d, 
J = 2.0 Hz, 1 H). 
1H-NMR (400 MHz, DMSO-d6): 7.32 – 7.15 (m, 8 H), 7.13 – 7.08 (m, 2 H), 5.26 (d, 
J = 4.3 Hz, 1 H), 5.16 (d, J = 0.7 Hz, 1 H), 4.78 (d, J = 1.3 Hz, 1 H), 3.82 (d, J = 3.3 Hz, 
1 H), 3.43 (d, J = 15.4 Hz, 1 H), 3.30 (d, J = 15.4 Hz, 1 H), 2.95 (d, J = 14.4 Hz, 1 H), 
2.80 (d, J = 14.5 Hz, 1 H), 2.60 (d, J = 5.2 Hz, 1 H), 2.17 (d, J = 5.1 Hz, 1 H). 
13C-NMR (101 MHz, CDCl3): 147.1, 139.0, 135.7, 130.2, 129.5, 128.6, 128.4, 
126.9, 126.4, 116.9, 73.8, 60.6, 48.7, 38.4, 37.1. 
IR (neat): 3463, 3029, 2914, 1495, 1454, 1058, 910, 702, 632. 
EI-MS (70 eV) m/z (%): 280 (0.59, [M]+), 249 (13), 189 (18), 171 (34), 145 (17), 
143 (15), 129 (37), 128 (10), 117 (25), 116 (30), 115 (23), 105 (17), 92 (18), 91 (100), 
65 (11). 
EA: Calculated for C19H20O2: C 81.40% H 7.19% , found: C 80.70% H 7.02%. 
[α]D (c = 0.57, CHCl3, 84% ee): +21.5°. 
Chiral HPLC (Chiralpak IC column from Daicel, heptan/iPrOH (95:5 or 97:3), 
0.5 ml/min, 20 °C, 258 nm) Rt: 17.7 and 19.0 or 23.7 and 25.6 minutes.  
The analytical data of product 5.14 correspond to those reported in the literature.22 
A observed side product is (S)-((R)-2-benzyloxiran-2-yl)((S)-2-benzyloxiran-2-
yl)methanol originating from the double epoxidation. 
 
1H-NMR (400 MHz, CDCl3): 7.33 – 7.19 (m, 10 H), 3.48 (s, 1 H), 3.13 (d, 
J = 14.7 Hz, 2 H), 3.06 (d, J = 14.6 Hz, 2 H), 2.81 (d, J = 4.7 Hz, 2 H), 2.43 (d, 
J = 4.7 Hz, 2 H), 2.26 (s, 1 H). 
13C-NMR (101 MHz, CDCl3): 135.6, 130.5, 128.3, 126.9, 73.4, 59.3, 49.6, 36.0. 
The analytical data of the product correspond to those reported in the literature.22 
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2,4-Dibenzylpenta-1,4-dien-3-one (5.25) 
 
To a solution of 1,5-diphenylpentan-3-one (5.23, 1.00 eq., 1.05 mmol, 250 mg) in 
acetic acid (3 ml) was added formaldehyde (37% solution in water, 3.00 eq., 3.15 mmol, 
234 µl) and morpholine (1.0 eq., 1.1 mmol, 91 µl). The mixture was heated in a 
microwave to 150 °C for one hour. Then additional morpholine (2.00 eq., 2.10 mmol, 
181 µl) was added and the mixture was heated another hour to 150 °C. The reaction 
mixture was cooled down and neutralized with a 1 M aq. NaOH solution. This mixture 
was extracted three times with EtOAc. The org. layers were subsequently washed with a 
sat. aq. NaHCO3 solution and brine, dried with Na2SO4 and concentrated. The crude 
product was purified by column chromatography (SiO2, pentane/EtOAc (19:1)) to give 
the title compound 5.25 (80 mg, 0.30 mmol, 29%) as colorless oil. 
Rf (SiO2, pentane/EtOAc (20:1)): 0.61. 
1H-NMR (400 MHz, CDCl3): 7.30 – 7.24 (m, 4 H), 7.22 – 7.13 (m, 6 H), 5.67 (d, 
J = 0.9 Hz, 2 H), 5.54 (dd, J = 2.5, 1.4 Hz, 2 H), 3.65 (s, 4 H). 
13C-NMR (101 MHz, CDCl3): 198.6, 147.7, 138.8, 129.3, 128.6, 126.5, 125.7, 38.3. 
IR (neat): 3030, 2920, 2854, 1712, 1602, 1496, 1454, 1076, 1029, 802, 739, 699. 
HR-MS: Calculated for C19H18NaO [M+Na]+: 285.1250, found: 285.1250. 
(S)-2-Benzyl-2-((R)-2-benzyl-1-(benzyloxy)allyl)oxirane (5.27) 
 
To a solution of (R)-2-benzyl-1-((S)-2-benzyloxiran-2-yl)prop-2-en-1-ol (5.14, 
1.0 eq., 0.071 mmol, 20 mg), benzyl bromide (1.2 eq., 0.085mmol, 10 µl) and 
tetrabutylammonium iodide (0.1 eq., 7 µmol, 3 mg) in dry THF (0.5 ml) at -20 °C was 
added half a micro spatula of sodium hydride (60%). The mixture was stirred for two 
hours at -20 °C and for 20 hours at room temperature. After complete consumption of 
the starting material, the reaction was quenched with a sat. aq. NH4Cl solution and 
TBME was added. The layers were separated and the aq. layer was extracted twice with 
O
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TBME. The org. layers were washed with brine, combined, dried with Na2SO4 and 
concentrated. The crude product was purified by prep. TLC (SiO2, pentane/EtOAc 
(9:1)) to give the title compound 5.27 (10 mg, 0.027 mmol, 38%) as pale yellow oil. 
Rf (SiO2, pentane/EtOAc (9:1)): 0.67. 
1H-NMR (400 MHz, CDCl3): 7.33 – 7.20 (m, 9 H), 7.16 (dd, J = 7.4, 1.9 Hz, 2 H), 
7.13 – 7.09 (m, 2 H), 7.07 – 7.02 (m, 2 H), 5.21 (s, 1 H), 5.01 (d, J = 1.4 Hz, 1 H), 4.50 
(d, J = 11.9 Hz, 1 H), 4.21 (d, J = 11.9 Hz, 1 H), 3.76 (s, 1 H), 3.45 (d, J = 15.5 Hz, 
1 H), 3.30 (d, J = 15.4 Hz, 1 H), 3.06 (d, J = 14.5 Hz, 1 H), 2.87 (d, J = 14.5 Hz, 1 H), 
2.68 (d, J = 5.1 Hz, 1 H), 2.39 (d, J = 5.1 Hz, 1 H). 
13C-NMR (126 MHz, CDCl3): 145.4, 139.1, 138.3, 136.4, 130.2, 129.7, 128.5, 
128.4, 128.3, 128.1, 127.7, 126.6, 126.3, 116.0, 80.7, 71.0, 59.8, 49.5, 39.4, 37.0. 
IR (neat): 3029, 2923, 2853, 1725, 1496, 1454, 1269, 1072, 1029, 913, 740, 699. 
HR-MS: Calculated for C26H30NO2 [M+NH4]+: 388.2271, found: 388.2271. 
[α]D (c = 0.41, CHCl3): -2.3°. 
((2R,3R)-2-Benzyl-3-(3-phenylprop-1-en-2-yl)oxiran-2-yl)methanol (5.28) 
 
To a solution of (R)-2-benzyl-1-((S)-2-benzyloxiran-2-yl)prop-2-en-1-ol (5.14, 
1.00 eq., 4.80 mmol, 1.35 g) in EtOH (40 ml) at 0 °C was added sodium ethoxide 
(1.50 eq., 7.20 mmol, 490 mg). The color of the solution turns immediately to orange 
and later to red. The reaction mixture is heated to room temperature and stirred for 
8.5 hours, cooled to 0 °C and quenched with ice. The EtOH is removed from the 
mixture under vacuum before water and CH2Cl2 is added. The layers were separated 
and the aq. layer was extracted twice with CH2Cl2. The org. layers were washed with 
brine, combined, dried with Na2SO4 and concentrated. The crude mixture was purified 
by column chromatography (SiO2, pentane/EtOAc (10:1)) to give the title compound 
5.28 (1.01 g, 3.6 mmol, 75%) as colorless oil. 
Rf (SiO2, pentane/EtOAc (8:1)): 0.16. 
1H-NMR (500 MHz, CDCl3): 7.34 – 7.29 (m, 2 H), 7.28 – 7.18 (m, 6 H), 7.12 (d, 
J = 7.0 Hz, 2 H), 5.20 (s, 1 H), 5.17 (d, J = 1.2 Hz, 1 H), 3.59 (s, 1 H), 3.53 – 3.41 (m, 
4 H), 2.64 (d, J = 14.6 Hz, 1 H), 2.22 (d, J = 14.6 Hz, 1 H), 1.46 (s, 1 H). 
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1H-NMR (500 MHz, C6D6): 7.18 – 7.02 (m, 8 H), 7.01 – 6.97 (m, 2 H), 5.31 (dd, 
J = 1.2, 0.7 Hz, 1 H), 5.00 – 4.98 (m, 1 H), 3.50 (s, 1 H), 3.37 – 3.27 (m, 2 H), 3.20 (d, 
J = 14.6 Hz, 1 H), 3.15 (d, J = 14.6 Hz, 1 H), 2.62 (d, J = 14.5 Hz, 1 H), 2.17 (d, 
J = 14.5 Hz, 1 H), 0.93 (dd, J = 8.9, 4.2 Hz, 1 H). 
13C-NMR (101 MHz, CDCl3): 142.4, 138.4, 137.1, 129.7, 129.2, 128.7, 128.5, 
126.8, 126.7, 113.3, 65.8, 62.2, 60.8, 41.5, 33.1. 
IR (neat): 3452, 3028, 2921, 1650, 1603, 1494, 1453, 1076, 908, 829, 750, 632. 
EI-MS (70 eV) m/z (%): 280 (1.5, [M]+), 189 (15), 159 (14), 129 (22), 128 (12), 115 
(16), 92 (21), 91 (100), 81 (16). 
EA: Calculated for C19H20O2: C 81.40% H 7.19%, found: C 80.92% H 7.08%. 
 [α]D (c = 0.76, CHCl3, 84% ee): +119.9°. 
(2R,3S)-2,4-Dibenzyl-2,3-dihydroxypent-4-en-1-yl pivalate (5.30) 
 
Method A: A solution of (S)-2-benzyl-2-((R)-2-benzyl-1-(benzyloxy)allyl)oxirane 
(5.28, 1.00 eq., 0.360 mmol, 101 mg) in dry CH2Cl2 (1.5 ml) was cooled to -18 °C 
before pivalic acid (3.00 eq., 1.08 mmol, 110 mg) followed by titanium(IV) 
isopropoxide (2.00 eq., 0.720 mmol, 222 µl) were added. By the addition of 
titanium(IV) isopropoxide, the reaction turned dark red. The mixture was stirred for 
three hours at -15 °C and one hour at 0 °C before it was quenched with a 10% aq. tartric 
acid solution at 0 °C and stirred for another two hours. The precipitate was filtered off 
and washed with water and TBME. The layers of the filtrate were separated and the aq. 
layer was extracted twice with TBME. The org. layers were combined, dried with 
Na2SO4 and concentrated. The crude product was purified by column chromatography 
(SiO2, pentane/EtOAc (8:1)) to give the title compound 5.30 (101 mg, 0.26 mmol, 73%) 
as white powder and the not rearranged (3S,4R)-2,4-dibenzyl-4,5-dihydroxypent-1-en-
3-yl pivalate (5.29, 48 mg, 0.10 mmol, 27%) as clear oil. 
Method B: This method was used to rearrange the undesired product 5.29 to the 
desired 5.30. To a solution of (3S,4R)-2,4-dibenzyl-4,5-dihydroxypent-1-en-3-yl 
pivalate (5.29, 1.00 eq., 1.04mmol, 497 mg) in dry CH2Cl2 (5 ml) was first added 
pivalic acid (1.00 eq., 1.04 mmol, 106 mg) followed by the addition of 
PivO OH
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p-toluenesulfonic acid monohydrate (0.10 eq., 0.10 mmol, 20 mg ). The reaction turns 
immediately yellowish. After stirring for three days at room temperature, the reaction 
was quenched at 0 °C with a sat. aq. NaHCO3 solution. The layers were separated and 
the aq. layer was extracted twice with CH2Cl2. The org. layers were washed with brine, 
combined, dried with Na2SO4 and concentrated. The crude product was purified by 
column chromatography (SiO2, pentane/EtOAc (10:1)) to give the title compound 5.30 
(292 mg, 0.76 mmol, 73%) as a white powder. 
Rf (SiO2, pentane/EtOAc (5:1)): 0.51. 
1H-NMR (500 MHz, CDCl3): 7.34 – 7.18 (m, 10 H), 5.16 (s, 1 H), 4.91 (dd, J = 1.4, 
1.4 Hz, 1 H), 4.15 – 4.09 (m, 2 H), 3.77 (d, J = 11.6 Hz, 1 H), 3.61 (d, J = 15.8 Hz, 
1 H), 3.52 (d, J = 15.8 Hz, 1 H), 3.07 (d, J = 13.7 Hz, 1 H), 2.98 (d, J = 13.7 Hz, 1 H), 
2.39 (s, 1 H), 2.31 (d, J = 5.8 Hz, 1 H), 1.21 (s, 9 H). 
13C-NMR (126 MHz, CDCl3): 178.8, 148.3, 139.6, 136.2, 130.6, 129.5, 128.7, 
128.6, 127.0, 126.4, 116.3, 76.0, 75.6, 66.3, 40.2, 39.9, 39.0, 27.4. 
IR (neat): 3453, 3401, 1723, 1464, 1283, 1158, 1032, 920, 700. 
EI-MS (70 eV) m/z (%): 235 (55), 151 (15), 133 (22), 91 (40), 85 (53), 57 (100). 
EA: Calculated for C24H30O4: C 75.36% H 7.91%, found: C 75.24% H 7.81%. 
[α]D (c = 0.47, CHCl3, 84% ee): -21.5°. 
Mp: 124 – 125 °C. 
  
Product 5.29 could not be completely characterized, due to the low stability and the 
tendency to rearrange to compound 5.30. If the remaining hydroxyl groups are 
protected, the compound is stable for analysis, see synthesis of 
(S)-2-benzyl-1-((R)-4-benzyl-2,2-dimethyl-1,3-dioxolan-4-yl)allyl pivalate (5.45). 
However, the following spectra’s of 5.29 could be recorded. 
1H-NMR (500 MHz, CDCl3): 7.34 – 7.17 (m, 10 H), 5.31 (s, 1 H), 5.25 (s, 1 H), 4.89 
(s, 1 H), 3.63 (s, 2 H), 3.38 (dd, J = 11.8, 4.3 Hz, 1 H), 3.26 (dd, J = 11.7, 7.2 Hz, 1 H), 
3.08 (d, J = 13.9 Hz, 1 H), 2.75 (d, J = 13.9 Hz, 1 H), 2.51 (s, 1 H), 2.09 (t, J = 6.3 Hz, 
1 H), 1.25 (s, 9 H). 
13C-NMR (126 MHz, CDCl3): 177.7, 145.6, 139.1, 136.3, 130.6, 129.7, 128.5, 
128.5, 126.9, 126.4, 116.1, 76.1, 76.0, 64.8, 41.2, 39.2, 39.1, 27.3. 
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(2R,3S)-2,4-Dibenzyl-2,3-dihydroxypent-4-en-1-yl 4-iodobenzoate (5.34) 
 
To a solution of (S)-2-benzyl-2-((R)-2-benzyl-1-(benzyloxy)allyl)oxirane (5.28, 
1.0 eq., 0.18 mmol, 50 mg) in dry toluene (6 ml) was added titanium(IV) isopropoxide 
(1.5 eq., 0.27 mmol, 82 µl) at room temperature. Ten minutes later, 4-iodobenzoic acid 
(1.5 eq., 0.27 mmol, 68 mg) was added and the mixture was stirred for 44 hours at room 
temperature. The finished reaction was poured on a mixture of TBME and a 5% aq. 
H2SO4 solution. After stirring for two hours, the mixture was first made basic with a sat. 
aq. NaHCO3 solution and then filtrated over Celite. The layers of the filtrate were 
separated and the aq. layer was extracted twice with TBME. The org. layers were 
washed with brine, combined, dried with Na2SO4 and concentrated. The crude product 
was purified by column chromatography (SiO2, pentane/EtOAc (1:10)) to give the title 
compound 5.34 (24 mg, 0.045 mmol, 26%) as white crystals. For X-ray analysis, the 
solid was twice recrystallized from EtOH/water (2:1).  
Rf (SiO2, pentane/EtOAc (5:1)): 0.36. 
1H-NMR (400 MHz, CDCl3): 7.83 – 7.78 (m, 2 H), 7.66 – 7.60 (m, 2 H), 7.34 – 7.14 
(m, 10 H), 5.18 (s, 1 H), 4.94 (d, J = 1.2 Hz, 1 H), 4.31 (d, J = 11.5 Hz, 1 H), 4.26 (d, 
J = 5.2 Hz, 1 H), 4.07 (d, J = 11.6 Hz, 1 H), 3.63 (d, J = 15.7 Hz, 1 H), 3.52 (d, J = 15.7 
Hz, 1 H), 3.14 (d, J = 13.7 Hz, 1 H), 3.07 (d, J = 13.7 Hz, 1 H), 2.45 (s, 1 H), 2.16 (d, 
J = 5.3 Hz, 1 H). 
13C-NMR (101 MHz, CDCl3): 166.1, 148.4, 139.5, 138.0, 136.2, 131.2, 130.6, 
129.4, 129.3, 128.8, 128.7, 128.7, 127.1, 126.4, 116.5, 101.3, 75.8, 67.1, 40.6, 40.3. 
IR (neat): 3378, 3028, 2922, 2853, 1717, 1586, 1361, 1275, 1106, 1038, 925, 842, 
743, 700. 
EI-MS (70 eV) m/z (%): 381 (30), 231 (100), 91 (17). 
HR-MS: Calculated for C26H26IO4 [M+H]+: 529.0870, found: 529.0867. 
[α]D (c = 0.10, CHCl3): -1.9°. 
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3-Phenylprop-2-yn-1-ol (5.35) 
 
To a stirred solution of copper(I) iodide (0.015 eq., 0.15 mmol, 29 mg) and tetra 
is(triphenylphosphine)palladium(0) (0.010 eq., 0.100 mmol, 116 mg) in freshly distilled 
triethylamine (18 ml) at room temperature was added iodobenzene (1.00 eq., 10.0 
mmol, 1.13 ml). After stirring for 30 minutes, propargyl alcohol (1.10 eq., 11.0 mmol, 
650 µl) was added. The mixture was stirred for 20 hours at 60 °C. The finished reaction 
mixture was cooled down, diluted with Et2O, filtered over Celite and concentrated. The 
crude product was purified by a filtration over SiO2 using pentane/EtOAc (5:1) as 
solvent. The filtrate was concentrated and extensively dried in high vacuum to receive 
the title compound 5.35 (1.26 g, 9.5 mmol, 95%) as brownish liquid. 
1H-NMR (400 MHz, CDCl3): 7.44 (dd, J = 6.6, 3.1 Hz, 2 H), 7.35 – 7.27 (m, 3 H), 
4.50 (d, J = 6.0 Hz, 2 H), 1.71 (t, J = 6.1 Hz, 1 H). 
13C-NMR (101 MHz, CDCl3): 131.8, 128.6, 128.5, 122.7, 87.3, 85.9, 51.8. 
The analytical data of product 5.35 correspond to those reported in the literature.23 
(Z)-3-Iodo-3-phenylprop-2-en-1-ol (5.36) 
 
A published procedure24 was modified as follows: To a solution of sodium 
bis(2-methoxyethoxy)aluminiumhydride (70% solution in toluene, 2.00 eq., 2.00 mmol, 
558 µl) in dry Et2O (5 ml) at 0 °C was slowly added a solution of 
3-phenylprop-2-yn-1-ol (5.35, 1.00 eq., 1.00 mmol, 132 mg) in dry Et2O (3 ml). The 
mixture was stirred for 10 minutes at 0 °C and for four hours at room temperature. 
Subsequently, the mixture was again cooled to 0 °C and dry EtOAc (1.0 eq., 1.0 mmol, 
98 µl) was added to quench the excess of sodium 
bis(2-methoxyethoxy)aluminiumhydride. After stirring for 15 minutes, the reaction was 
cooled to -78 °C and a solution of iodine (1.50 eq., 1.50 mmol, 381 mg) in dry Et2O 
(3 ml) was added in one portion. The mixture was allowed to warm to room temperature 
overnight. The finished reaction was quenched with a sat. aq. Na2S2O3 solution and 
diluted with TBME and water. The layers were separated and the aq. layer was 
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extracted three times with TBME. The org. layers were washed with brine, combined, 
dried with Na2SO4 and concentrated. The crude product was purified by column 
chromatography (SiO2, pentane/Et2O (17:3)) to give the title compound 5.36 (193 mg, 
0.74 mmol, 74%) as pale brownish oil. 
1H-NMR (400 MHz, CDCl3): 7.51 – 7.43 (m, 2 H), 7.35 – 7.26 (m, 3 H), 6.26 (t, 
J = 5.7 Hz, 1 H), 4.40 (t, J = 5.8 Hz, 2 H), 1.73 (t, J = 5.9 Hz, 1 H). 
13C-NMR (101 MHz, CDCl3): 142.3, 137.1, 128.9, 128.6, 128.5, 105.3, 68.4. 
The analytical data of product 5.36 correspond to those reported in the literature.24 
(Z)-3-Iodo-3-phenylallyl pivalate (5.37) 
 
To a solution of (Z)-3-iodo-3-phenylprop-2-en-1-ol (5.36, 1.00 eq., 0.940 mmol, 
244 mg), 4-dimethylaminopyridine (0.10 eq., 0.094 mmol, 12 mg) and pyridine 
(3.00 eq., 2.82 mmol, 227 µl) in CH2Cl2 (10 ml) was added pivaloyl chloride (1.20 eq., 
1.13 mmol, 140 µl) at room temperature. After stirring for five hours, a TLC showed 
incomplete conversion. Therefore, additional pivaloyl chloride (0.50 eq., 0.47 mmol, 
58 µl) was added. After stirring for another 18 hours, the reaction was quenched with a 
sat. aq. NaHCO3 solution. The layers were separated and the aq. layer was washed with 
CH2Cl2. The org. layers were combined and subsequently washed with a 1 M aq. HCl 
solution, a 10% aq. NaOH solution and brine. The org. layer was dried with Na2SO4, 
concentrated and extensively dried in high vacuum to give the title compound 5.37 
(240 mg, 0.70 mmol, 74%) as brown liquid. 
1H-NMR (400 MHz, CDCl3): 7.53 – 7.45 (m, 2 H), 7.34 – 7.28 (m, 3 H), 6.18 (t, 
J = 5.7 Hz, 1 H), 4.78 (d, J = 5.7 Hz, 2 H), 1.23 (s, 9 H). 
13C-NMR (101 MHz, CDCl3): 178.4, 142.3, 133.0, 129.0, 128.6, 128.5, 106.7, 69.5, 
39.0, 27.4. 
IR (neat): 2971, 1728, 1479, 1443, 1280, 1141, 1033, 985, 750, 692. 
HR-MS: Calculated for C14H17INaO2 [M+Na]+: 367.0165, found: 367.0168. 
(Z)-tert-Butyl((3-iodo-3-phenylallyl)oxy)dimethylsilane (5.38) 
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To a solution of (Z)-3-iodo-3-phenylprop-2-en-1-ol (5.36, 1.00 eq., 0.940 mmol, 
244 mg) in dry CH2Cl2 (2 ml) at 0 °C was added triethylamine (2.00 eq., 1.88 mmol, 
264 µl). The color of the solution changes from violet to yellow. After five minutes, 
tert-butylchlorodimethylsilane (1.40 eq., 1.32 mmol, 198 mg) was added. The mixture 
was stirred overnight at room temperature. The reaction was quenched with a sat. aq. 
NH4Cl solution. The formed layers were separated and the aq. layer was extracted three 
times with CH2Cl2. The org. layers were combined, dried over Na2SO4 and 
concentrated. The crude product was purified by column chromatography (SiO2, 
pentane/EtOAc (60:1)) to give the title compound 5.38 (308 mg, 0.823 mmol, 88%) as 
brownish liquid. 
1H-NMR (400 MHz, CDCl3): 7.49 – 7.44 (m, 2 H), 7.34 – 7.24 (m, 4 H), 6.19 (t, 
J = 5.0 Hz, 1 H), 4.39 (d, J = 5.0 Hz, 2 H), 0.93 (s, 9 H), 0.13 (s, 6 H). 
13C-NMR (101 MHz, CDCl3): 142.4, 138.8, 128.6, 128.6, 128.4, 102.1, 69.7, 26.1, 
18.5, -4.9. 
IR (neat): 2954, 2857, 1469, 1365, 1254, 1106, 834, 778, 693. 
EI-MS (70 eV) m/z (%): 318 (17), 317 (100, [M-tBu]+), 215 (75), 189 (38), 185 
(30), 116 (12), 115 (22), 73 (17). 
EA: Calculated for C15H23IOSi: C 48.13% H 6.19%, found: C 48.32% H 6.12%. 
(Z)-(3-(Benzyloxy)-1-iodoprop-1-en-1-yl)benzene (5.39) 
 
A solution of (Z)-3-iodo-3-phenylprop-2-en-1-ol (5.36, 1.00 eq., 0.770 mmol, 
200 mg) in toluene (0.5 ml) was cooled to 0 °C before a cold solution (0 °C) of sodium 
hydroxide (5.00 eq., 3.85 mmol, 154 mg) and tetrabutylammonium hydrogen sulfate 
(0.050 eq., 0.038 mmol, 13 mg) in water (1 ml) was added. After five minutes, benzyl 
bromide (1.50 eq., 1.16 mmol, 138 µl) was added and the reaction was allowed to warm 
to room temperature overnight. The finished reaction mixture was diluted with water 
and extracted three times with TBME. The org. layers were washed with brine, 
combined, dried with Na2SO4 and concentrated. The crude product was purified by 
Kugelrohr distillation (0.35 mbar, 150 to 190 °C) to give the title compound 5.39 
(240 mg, 0.65 mmol, 85%) as brownish oil. 
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1H-NMR (400 MHz, CDCl3): 7.50 – 7.44 (m, 2 H), 7.41 – 7.34 (m, 4 H), 7.34 – 7.27 
(m, 4 H), 6.27 (t, J = 5.4 Hz, 1 H), 4.61 (s, 2 H), 4.29 (d, J = 5.4 Hz, 2 H). 
13C-NMR (101 MHz, CDCl3): 142.4, 138.1, 135.6, 128.8, 128.6, 128.6, 128.4, 
128.0, 128.0, 105.2, 75.7, 73.0. 
GC-MS (70 eV): 350 (0.39, [M]+), 259 (40), 223 (33), 117 (23), 115 (39), 103 (58), 
91 (100). 
IR (neat): 2921, 2852, 1489, 1454, 1354, 1213, 1087, 1028, 751, 694. 
HR-MS: Calculated for C16H15INaO [M+Na]+: 373.0060, found: 373.0061. 
The impurity was identified as the benzylated elimination product 
(3-(benzyloxy)prop-1-yn-1-yl)benzene. 
 
The found 1H-MNR shifts at ((400 MHz, CDCl3): 4.69 (s, 2 H), 4.41 (s, 2 H)) 
correspond to those reported in the literature.25 
(Z)-(((3-Iodo-3-phenylallyl)oxy)methanetriyl)tribenzene (5.40) 
 
A solution of pyridine (1.0 eq., 0.70 mmol, 57 µl) and triphenylmethyl chloride 
(1.00 eq., 0.700 mmol, 195 mg) in CH2Cl2 (1 ml) was cooled to 0 °C. 
(Z)-3-iodo-3-phenylprop-2-en-1-ol (5.36, 1.00 eq., 0.700 mmol, 182 mg) was added and 
the reaction was stirred for 30 minutes at 0 °C and 24 hours at room temperature. Since 
the reaction was not completed, additional pyridine (0.1 eq., 0.07 mmol, 6 µl) and 
triphenylmethyl chloride (0.10 eq., 0.070 mmol, 20 mg) were added and the reaction 
was stirred for another 24 hours. The finished reaction was quenched with a 0.25 M aq. 
HCl solution. The layers were separated and the aq. layer was extracted two times with 
CH2Cl2. The org. layers were subsequently washed with a sat. aq. NaHCO3 solution, 
combined, dried with Na2SO4 and concentrated. The residue was mixed with 
cyclohexane and filtrated over SiO2. The filtrate was concentrated and twice 
recentralized from hot cyclohexane to give the title compound 5.40 (228 mg, 
0.45 mmol, 65%) as white crystals. An X-ray diffraction analysis was performed after 
recrystallization. 
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1H-NMR (500 MHz, CDCl3): 7.51 – 7.48 (m, 6 H), 7.44 – 7.41 (m, 2 H), 7.35 – 7.23 
(m, 12 H), 6.26 (t, J = 5.1 Hz, 1 H), 3.93 (d, J = 5.1 Hz, 2 H). 
13C-NMR (126 MHz, CDCl3): 144.0, 142.4, 136.2, 128.8, 128.6, 128.5, 128.3, 
128.1, 127.3, 103.5, 87.3, 70.5. 
EI-MS (70 eV): 244 (46), 243 (100, [M-Trt]+), 165 (21). 
IR (neat): 3060, 3026, 2930, 2879, 1625, 1597, 1488, 1444, 1371, 1225, 1050, 995, 
899, 846, 745, 691. 
EA: Calculated for C28H23IO: C 66.94% H 4.61%, found: C 66.82% H 4.75%. 
Mp: 101 – 102 °C. 
(Z)-3-Benzyl-6-((tert-butyldimethylsilyl)oxy)-4-phenylhex-4-en-3-ol (5.41) 
 
To a solution of (Z)-tert-butyl((3-iodo-3-phenylallyl)oxy)dimethylsilane (5.38, 
1.1 eq., 0.098 mmol, 37 mg) in dry Et2O (0.5 ml) at -78 °C was added tBuLi (1.6 M 
solution in hexanes, 2.2 eq., 0.196 mmol, 122 µl) over two minutes. After stirring for 
15 minutes at -78 °C, 1-phenyl-2-butanone (1.0 eq., 0.089 mmol, 14 µl) was added neat. 
The reaction was stirred for 1.5 hours at -78 °C and one hour at 0 °C. The reaction was 
quenched with a sat. aq. NH4Cl solution and water. The resulting mixture was extracted 
three times with TBME. The org. layers were combined, dried with Na2SO4 and 
concentrated. The crude product was purified by column chromatography (SiO2, 
pentane/EtOAc (100:1)) to give the title compound 5.41 (6 mg, 0.015 mmol, 17%) as 
clear oil. Side products are the protonated lithium intermediate 
tert-butyl(cinnamyloxy)dimethylsilane26 and the Brook rearrangement product 5.42. 
Rf (SiO2, pentane/EtOAc (10:1)): 0.27. 
1H-NMR (400 MHz, CDCl3): 7.30 – 7.20 (m, 8 H), 7.06 – 7.02 (m, 2 H), 5.58 (t, 
J = 6.1 Hz, 1 H), 4.43 (dd, J = 13.6, 6.3 Hz, 1 H), 4.33 (dd, J = 13.6, 5.8 Hz, 1 H), 3.05 
(d, J = 13.6 Hz, 1 H), 2.87 (d, J = 13.6 Hz, 1 H), 2.48 (s, 1 H), 1.77 (dq, J = 14.6, 7.3 
Hz, 1 H), 1.55 (dq, J = 14.6, 7.3 Hz, 1 H), 0.98 (t, J = 7.4 Hz, 3 H), 0.91 (s, 9 H), 0.08 
(s, 6 H). 
13C-NMR (101 MHz, CDCl3): 146.2, 143.5, 137.2, 133.3, 131.2, 128.8, 128.1, 
127.9, 126.8, 126.6, 78.9, 60.7, 47.5, 33.2, 26.1, 18.5, 8.3, -5.0, -5.0. 
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IR (neat): 3453, 2929, 2856, 1463, 1254, 1073, 835, 703, 633. 
EI-MS (70 eV) m/z (%): 305 (5, [M-Ph]+), 247 (23), 174 (13), 173 (100), 145 (16), 
117 (11), 91 (57), 75 (32), 73 (20), 57 (46). 
HR-MS: Calculated for C25H36NaO2Si [M+Na]+: 419.2377, found: 419.2376. 
Side product 5.42 was identified as the Brook rearrangement product 
(Z)-3-(tert-butyldimethylsilyl)-3-phenylprop-2-en-1-ol. 
 
Rf (SiO2, pentane/EtOAc (10:1)): 0.34. 
1H-NMR (400 MHz, CDCl3): 7.26 (ddd, J = 7.6, 4.5, 1.2 Hz, 2 H), 7.18 (ddd, 
J = 7.3, 3.8, 1.3 Hz, 1 H), 7.05 (dt, J = 3.3, 1.8 Hz, 2 H), 6.30 (t, J = 6.9 Hz, 1 H), 4.34 
(d, J = 6.9 Hz, 2 H), 0.92 (s, 9 H), 0.10 (s, 6 H). 
13C-NMR (101 MHz, CDCl3): 147.1, 146.0, 145.0, 128.0, 127.8, 125.8, 63.0, 27.5, 
18.3, -2.6. 
IR (neat): 3308, 2955, 2857, 1597, 1253, 1013, 820, 774, 701. 
HR-MS: Calculated for C30H48NaO2Si2 [2M+Na]+: 519.3085, found: 519.3083. 
(Z)-3-Benzyl-6-(benzyloxy)-4-phenylhex-4-en-3-ol (5.43) 
 
To a solution of (Z)-(3-(benzyloxy)-1-iodoprop-1-en-1-yl)benzene (5.39, 1.40 eq., 
0.092 mmol, 35 mg) in dry Et2O (1 ml) at -78 °C was added tBuLi (1.6 M solution in 
pentane, 2.8 eq., 0.185 mmol, 116 µl) over two minutes. The mixture turned 
immediately yellow and slightly turbid. After stirring for 20 minutes at -78 °C, a 
solution of 1-phenyl-2-butanone (1.00 eq., 0.0660 mmol, 10.4 µg) in dry Et2O (0.5 ml) 
was added. After stirring for another two hours at -78 °C, the reaction mixture was 
quenched with a half saturated aq. NH4Cl solution and heated to room temperature. The 
resulting mixture was extracted three times with TBME. The org. layers were 
combined, dried with Na2SO4, concentrated and purified by preparative TLC (SiO2, 
pentane/EtOAc (20:1)) to give the title compound 5.43 (10 mg, 0.027 mmol, 41%) as 
colorless honey. 
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1H-NMR (400 MHz, CDCl3): 7.28 – 7.25 (m, 3 H), 7.24 – 7.10 (m, 10 H), 7.01 – 
6.97 (m, 2 H), 5.57 (t, J = 6.1 Hz, 1 H), 4.43 (d, J = 1.4 Hz, 2 H), 4.22 (dd, J = 12.9, 
6.3 Hz, 1 H), 4.13 (dd, J = 12.9, 5.9 Hz, 1 H), 2.95 (d, J = 13.5 Hz, 1 H), 2.77 (d, 
J = 13.6 Hz, 1 H), 2.23 (s, 1 H), 1.68 (dt, J = 14.7, 7.3 Hz, 1 H), 1.46 (dt, J = 14.3, 7.3 
Hz, 1 H), 0.88 (t, J = 7.4 Hz, 3 H). 
13C-NMR (101 MHz, CDCl3): 147.8, 143.3, 138.3, 137.1, 131.2, 130.4, 128.8, 
128.6, 128.2, 128.0, 127.9, 127.8, 126.9, 126.7, 78.9, 72.7, 67.7, 47.5, 33.1, 8.2. 
IR (neat): 3570, 3062, 3029, 2966, 2932, 1494, 1454, 1363, 1074, 737, 701. 
HR-MS: Calculated for C26H28NaO2 [M+Na]+: 395.1982, found: 395.1982. 
((4R,5S)-4-Benzyl-2,2-dimethyl-5-(3-phenylprop-1-en-2-yl)-1,3-dioxolan-4-
yl)methyl pivalate (5.44) 
 
To a solution of (2R,3S)-2,4-dibenzyl-2,3-dihydroxypent-4-en-1-yl pivalate (5.30, 
1.00 eq., 0.445 mmol, 171 mg) in THF (6 ml) was added p-toluenesulfonic acid 
monohydrate (0.1 eq., 0.05 mmol, 8 mg), followed by the addition of 
2-methoxypropene (10.0 eq., 4.46 mmol, 427 µl). The reaction was stirred for five hours 
at room temperature. The reaction mixture was diluted with TBME and a sat. aq. 
NaHCO3 solution. The layers were separated and the aq. layer was extracted twice with 
TBME. The org. layers were washed with brine, combined, dried with Na2SO4 and 
concentrated. The crude product was purified by column chromatography (SiO2, 
pentane/EtOAc (30:1)) to give the title compound 5.44 (202 mg, 0.445 mmol, 
quantitative) as colorless oil. 
Rf (SiO2, pentane/EtOAc (30:1)): 0.44. 
1H-NMR (500 MHz, CDCl3): 7.36 – 7.31 (m, 2 H), 7.27 – 7.17 (m, 8 H), 5.49 (s, 
1 H), 4.97 (s, 1 H), 4.33 (s, 1 H), 3.98 – 3.89 (m, 2 H), 3.63 (d, J = 15.8 Hz, 1 H), 3.44 
(d, J = 15.8 Hz, 1 H), 3.25 (d, J = 14.1 Hz, 1 H), 2.87 (d, J = 14.1 Hz, 1 H), 1.43 (s, 
3 H), 1.27 (s, 9 H), 0.98 (s, 3 H). 
13C-NMR (126 MHz, CDCl3): 178.1, 141.8, 138.6, 135.9, 131.4, 129.2, 128.7, 
128.0, 126.8, 126.6, 114.9, 107.7, 82.5, 80.1, 65.0, 41.0, 40.6, 38.9, 28.5, 27.4, 26.4. 
IR (neat): 2981, 1730, 1379, 1249, 1145, 1068, 995, 914, 856, 740, 700, 654. 
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EI-MS (70 eV) m/z (%): 422 (0.1, [M]+), 273 (26), 188 (82), 171 (23), 132 (33), 91 
(100), 57 (50). 
EA: Calculated for C27H34O4: C 76.75% H 8.11%, found: C 76.37% H 8.07%. 
[α]D (c = 0.28, CHCl3, 84% ee): -17.9°. 
(R)-2-Benzyl-1-((S)-4-benzyl-2,2-dimethyl-1,3-dioxolan-4-yl)allyl pivalate (5.45) 
 
To a solution of (3R,4S)-2,4-dibenzyl-4,5-dihydroxypent-1-en-3-yl pivalate (5.29, 
1.0 eq., 0.068 mmol, 26 mg) in THF, p-toluenesulfonic acid monohydrate (0.1 eq., 
7 µmol, 1 mg) and 2-methoxypropene (10 eq., 0.68 mmol, 65 µl) were added. The 
reaction was stirred for four hours at room temperature. The finished reaction mixture 
was diluted with TBME and a sat. aq. NaHCO3 solution. After stirring for 45 minutes, 
the layers were separated and the aq. layer was extracted twice with TBME. The org. 
layers were washed with brine, combined, dried with Na2SO4 and concentrated. The 
crude product was purified by preparative TLC (SiO2, pentane/EtOAc (20:1)) to give 
the title compound 5.45 (25 mg, 0.060 mmol, 87%) as colorless solid. An X-ray 
diffraction analysis was performed after recrystallization. 
Rf (SiO2, pentane/EtOAc (20:1)): 0.55. 
1H-NMR (500 MHz, CDCl3): 7.34 – 7.27 (m, 4 H), 7.27 – 7.20 (m, 6 H), 5.27 (s, 
1 H), 5.13 – 5.11 (m, 1 H), 4.79 (d, J = 1.2 Hz, 1 H), 3.86 – 3.78 (m, 2 H), 3.72 (d, 
J = 16.6 Hz, 1 H), 3.58 (d, J = 16.6 Hz, 1 H), 3.14 (d, J = 14.2 Hz, 1 H), 2.81 (d, 
J = 14.2 Hz, 1 H), 1.33 (s, 3 H), 1.25 (s, 9 H), 0.86 (s, 3 H). 
13C-NMR (126 MHz, CDCl3): 176.6, 145.6, 139.1, 136.5, 131.7, 129.8, 128.4, 
128.0, 126.7, 126.3, 114.7, 110.6, 84.0, 77.7, 69.3, 41.2, 39.0, 37.7, 27.3, 27.2, 26.1. 
IR (neat): 3029, 2986, 3930, 1736, 1494, 1454, 1373, 1276, 1254, 1136, 1067, 1004, 
908, 842, 755, 701. 
FAB-MS (8 kV Xe) m/z (%): 423 (13, [M+H]+), 321 (15), 263 (19), 191 (69), 133 
(26), 129 (17), 117 (17), 91 (100), 85 (15), 57 (88). 
EA: Calculated for C27H34O4: C 76.75% H 8.11%, found: C 76.05% H 8.19%. 
[α]D (c = 0.51, CHCl3): -20.7°. 
Mp: < 60 °C. 
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((4R,5R)-4-Benzyl-2,2-dimethyl-5-(2-phenylacetyl)-1,3-dioxolan-4-yl)methyl 
pivalate (5.46) 
 
Some crystals of Sudan III were added to a solution of ((4R,5S)-4-benzyl-2,2-
dimethyl-5-(3-phenylprop-1-en-2-yl)-1,3-dioxolan-4-yl)methyl pivalate (5.44, 1.0 eq., 
0.040 mmol, 17 mg) in dry CH2Cl2 (2 ml) and the mixture was cooled to -78 °C. Ozone 
was passed through the solution until the red color disappeared. Subsequently, the 
reaction was flushed with oxygen. After stirring for five minutes, dimethyl sulfide 
(3.0 eq., 0.12 mmol, 9.8 µl) was added at -78 °C. The mixture was stirred for two hours 
at -78 °C and then heated to room temperature. The crude product was purified by 
preparative TLC (SiO2, pentane/EtOAc (10:1)) to give the title compound 5.46 (10 mg, 
0.022 mmol, 56%) as clear honey. 
Rf (SiO2, pentane/EtOAc (10:1)): 0.68. 
1H-NMR (400 MHz, CDCl3): 7.35 – 7.17 (m, 10 H), 4.30 (s, 1 H), 4.13 – 4.05 (m, 
2 H), 4.00 (d, J = 11.5 Hz, 1 H), 3.87 (d, J = 16.7 Hz, 1 H), 3.16 (d, J = 14.2 Hz, 1 H), 
3.00 (d, J = 14.2 Hz, 1 H), 1.53 (s, 3 H), 1.19 (s, 9 H), 0.92 (s, 3 H). 
13C-NMR (101 MHz, CDCl3) δ 205.5, 178.1, 135.5, 133.1, 131.7, 130.1, 128.6, 
128.1, 127.2, 127.0, 109.4, 83.7, 82.6, 65.4, 46.7, 40.1, 38.9, 28.2, 27.3, 26.3. 
IR (neat): 2980, 1730, 1455, 1375, 1281, 1220, 1141, 1087, 1033, 992, 903, 853, 
757, 700. 
HR-MS: Calculated for C26H32NaO5 [M+Na]+: 447.2142, found: 447.2141. 
[α]D (c = 0.37, CHCl3, 84% ee): +3.8°. 
Surprisingly 5.46 showed to be instable and to decompose by standing at room 
temperature for longer periods. The decomposition product was isolated from a batch of 
the (4S,5S)-enantiomer by preparative TLC (SiO2, pentane/EtOAc (20:1)) in 72% yield 
and identified as (S)-(4-benzyl-2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl)methyl pivalate 
(5.47). 
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Rf (SiO2, pentane/EtOAc (20:1)): 0.29. 
1H-NMR (500 MHz, CDCl3): 7.33 – 7.24 (m, 3 H), 7.24 – 7.20 (m, 2 H), 4.37 (d, 
J = 11.9 Hz, 1 H), 4.07 (d, J = 11.9 Hz, 1 H), 3.17 (d, J = 14.0 Hz, 1 H), 2.98 (d, 
J = 14.0 Hz, 1 H), 1.60 (d, J = 0.4 Hz, 3 H), 1.22 (s, 9 H), 0.96 (d, J = 0.4 Hz, 3 H). 
13C-NMR (126 MHz, CDCl3): 177.9, 171.8, 134.2, 130.9, 128.6, 127.7, 110.9, 83.2, 
67.0, 40.7, 38.9, 28.3, 27.8, 27.3. 
IR (neat): 2976, 1791, 1737, 1481, 1456, 1387, 1280, 1234, 1137, 1053, 1001, 926, 
770, 700. 
HR-MS: Calculated for C18H24NaO5 [M+Na]+: 343.1516, found: 343.1517. 
((4S,5R)-4-Benzyl-5-((S)-2-hydroxy-1-phenylbut-3-en-2-yl)-2,2-dimethyl-1,3-
dioxolan-4-yl)methyl pivalate (5.48) 
 
 To a solution of ((4S,5S)-4-benzyl-2,2-dimethyl-5-(2-phenylacetyl)-1,3-dioxolan-4-
yl)methyl pivalate (ent-5.46, 1.0 eq., 0.059 mmol, 25 mg) in dry THF (0.5 ml) at -10 °C 
was added vinylmagnesium bromide (0.7 M solution in THF, 1.8 eq., 0.106 mmol, 
151 µl). After stirring for 30 minutes at -10 °C, the reaction was warmed to 0 °C. As 
TLC showed after three hours only partial conversion, additional vinylmagnesium 
bromide (0.7 M solution in THF, 0.84 eq., 0.050 mmol, 71 µl) was added. After stirring 
for another hour, the reaction was still not finished. As the color started to get darker, it 
was quenched with a sat. aq. NH4Cl solution. The mixture was extracted three times 
with EtOAc. The org. layers were combined, dried with Na2SO4 and concentrated. The 
crude product was purified by preparative TLC (SiO2, pentane/EtOAc (25:1)) to give 
the title compound 5.48 (16 mg, 0.035 mmol, 60%) as a white solid. For X-ray analysis, 
the solid was recrystallized from MeOH. 
Rf (SiO2, pentane/EtOAc (25:1)): 0.48. 
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1H-NMR (400 MHz, CDCl3): 7.33 – 7.24 (m, 3 H), 7.18 (dd, J = 6.5, 3.0 Hz, 2 H), 
7.15 – 7.03 (m, 3 H), 6.91 (dd, J = 7.9, 1.4 Hz, 2 H), 6.51 – 6.36 (m, 1 H), 5.28 (dd, 
J = 17.6, 1.3 Hz, 1 H), 5.16 (dd, J = 11.0, 0.8 Hz, 1 H), 4.10 (d, J = 11.5 Hz, 1 H), 4.02 
(d, J = 11.5 Hz, 1 H), 3.80 (s, 1 H), 3.04 – 2.94 (m, 2 H), 2.80 (d, J = 14.0 Hz, 1 H), 
2.73 (d, J = 13.6 Hz, 1 H), 2.24 (s, 1 H), 1.40 (s, 3 H), 1.25 (s, 9 H), 0.79 (s, 3 H). 
13C-NMR (101 MHz, CDCl3): 177.8, 140.7, 136.1, 135.9, 131.7, 131.2, 128.3, 
127.8, 127.0, 126.2, 113.4, 107.5, 82.9, 79.6, 75.0, 66.4, 47.9, 40.8, 39.0, 28.4, 27.5, 
26.1. 
IR (neat): 3561, 2985, 2931, 1727, 1454, 1374, 1260, 1211, 1152, 1070, 989, 927, 
853, 707. 
HR-MS: Calculated for C28H36NaO5 [M+Na]+: 475.2455, found: 475.2453. 
[α]D (c = 0.13, CHCl3): -32.8°. 
((4S,5R)-4-Benzyl-5-((Z)-5-(benzyloxy)-2-hydroxy-1,3-diphenylpent-3-en-2-yl)-2,2-
dimethyl-1,3-dioxolan-4-yl)methyl pivalate (5.49) 
 
To a solution of (Z)-(3-(benzyloxy)-1-iodoprop-1-en-1-yl)benzene (5.39, 1.1 eq., 
0.073 mmol, 28 mg) in Et2O (0.5 ml) at -78°C was added tBuLi (1.6 M solution in 
pentane, 2.2 eq., 0.15 mmol, 90 µl) in two minutes and the mixture was stirred for 
15 minutes. Subsequently, a solution of ((4S,5S)-4-benzyl-2,2-dimethyl-5-(2-
phenylacetyl)-1,3-dioxolan-4-yl)methyl pivalate (ent-5.46, 1.0 eq., 0.066 mmol, 28 mg) 
in dry Et2O (0.8 ml) was added and the reaction was stirred for 1.5 hours at -78 °C. 
Then, the mixture was heated to room temperature, stirred for another 30 minutes and 
quenched with a half sat. aq. NH4Cl solution. The resulting mixture was extracted three 
times with TBME. The org. layers were washed with brine, combined, dried at Na2SO4 
and concentrated. The crude product was purified by column chromatography (SiO2, 
pentane/EtOAc (1:50 to 1:30)) to give the title compound 5.49 (10 mg, 0.015 mmol, 
23%) as clear oil. 
Rf (SiO2, pentane/EtOAc (10:1)): 0.71. 
O
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1H-NMR (600 MHz, toluene-D8, 343 K): 7.30 (d, J = 6.7 Hz, 2 H), 7.21 (d, J = 7.6 
Hz, 2 H), 7.17 – 7.03 (m, 10 H), 7.02 – 6.91 (m, 6 H), 5.68 (t, J = 6.2 Hz, 1 H), 4.97 (d, 
J = 11.3 Hz, 1 H), 4.45 (d, J = 11.2 Hz, 1 H), 4.29 – 4.20 (m, 2 H), 4.14 (s, 1 H), 4.11 
(dd, J = 13.1, 6.3 Hz, 1 H), 3.71 (dd, J = 13.0, 5.9 Hz, 1 H), 3.39 (d, J = 14.2 Hz, 1 H), 
3.25 (dd, J = 14.2, 2.2 Hz, 2 H), 3.13 (s, 1 H), 2.78 (d, J = 14.1 Hz, 1 H), 1.38 (s, 3 H), 
1.22 (s, 9 H), 0.70 (s, 3 H). 
13C-NMR (151 MHz, toluene-D8, 343 K): 177.5, 146.6, 142.8, 139.1, 137.7, 137.6, 
137.4, 137.2, 132.3, 132.2, 129.7, 128.6, 128.1, 128.1, 128.0, 127.8, 127.3, 127.0, 
126.6, 107.3, 85.4, 83.5, 79.2, 73.1, 68.2, 66.8, 43.9, 40.8, 39.2, 28.4, 27.6, 26.4. 
ESI-MS m/z: 671 ([M+Na]+). 
(2R,3S)-2,4-Dibenzyl-2-hydroxy-3-(methoxymethoxy)pent-4-en-1-yl pivalate (5.50) 
 
A solution of chloromethyl methyl ether (4.0 eq., 1.1 mmol, 84 mg) and sodium 
iodide (4.50 eq., 1.18 mmol, 177 mg) in dioxane (2 ml) was stirred for 20 minutes 
before a solution of freshly distilled diisopropylethylamine (4.50 eq., 1.18 mol, 195 µl) 
and (2R,3S)-2,4-dibenzyl-2,3-dihydroxypent-4-en-1-yl pivalate (5.30, 1.00 eq., 
0.262 mmol, 100 mg) in dioxane (1.5 ml) was added. As after three hours at room 
temperature only little conversion could be observed, the reaction was heated to 60 °C 
for one hour. The reaction did still not proceed as expected and was heated to 100 °C 
for 20 hours. As only little conversion to the double protected product could be 
observed, the reaction mixture was heated to reflux for 24 hours, but no further 
conversion could be observed. Therefore, the reaction was cooled to room temperature 
and water and CH2Cl2 were added. The layers were separated and the aq. layer was 
extracted twice with CH2Cl2. The org. layers were combined, dried with Na2SO4 and 
concentrated. The crude product was purified by column chromatography (SiO2, 
pentane/EtOAc (20:1)) to give the title compound 5.50 (67 mg, 0.157 mmol, 60%) as 
yellowish oil. 
Rf (SiO2, pentane/EtOAc (20:1)): 0.24. 
1H-NMR (500 MHz, CDCl3): 7.33 – 7.15 (m, 10 H), 5.15 (d, J = 0.6 Hz, 1 H), 4.96 
(dd, J = 1.6, 1.6 Hz, 1 H), 4.56 (d, J = 6.6 Hz, 1 H), 4.50 (d, J = 6.6 Hz, 1 H), 4.22 (s, 
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1 H), 3.94 (d, J = 11.4 Hz, 1 H), 3.83 (d, J = 11.4 Hz, 1 H), 3.59 – 3.49 (m, 2 H), 3.39 
(s, 3 H), 3.18 (d, J = 13.8 Hz, 1 H), 2.91 (d, J = 13.8 Hz, 1 H), 2.40 (s, 1 H), 1.20 (s, 
9 H). 
13C-NMR (126 MHz, CDCl3): 178.3, 145.7, 139.4, 136.4, 130.7, 129.7, 128.5, 
128.5, 126.9, 126.3, 117.9, 94.6, 80.1, 75.7, 65.9, 56.6, 40.2, 40.2, 38.9, 27.4. 
IR (neat): 2959, 1730, 1454, 1282, 1151, 1098, 1026, 989, 917, 740, 700. 
HR-MS: Calculated for C26H34KO5 [M+K]+: 465.2038, found: 465.2036. 
[α]D (c = 0.62, CHCl3, 84% ee): +53.6°. 
(2R,3S)-2,4-Dibenzyl-2,3-bis((trimethylsilyl)oxy)pent-4-en-1-yl pivalate (5.52) 
 
To a solution of (2R,3S)-2,4-dibenzyl-2,3-dihydroxypent-4-en-1-yl pivalate (5.30, 
1.0 eq., 0.13 mmol, 50 mg) in CH2Cl2 (2 ml) was added imidazole (15.5 eq., 2.02 mmol, 
133 mg) and the resulting solution was cooled to 0 °C. This was followed by the 
addition of chlorotimethylsilane (10.3 eq., 1.34 mmol, 173 µl) at 0 °C. The reaction was 
allowed to reach room temperature and was stirred for two days. The reaction mixture 
was mixed with some silica before it was concentrated. The formed solid was directly 
used for purification by column chromatography (SiO2, pentane/EtOAc (50:1)) to give 
the title compound 5.52 (67 mg, 0.127 mmol, 98%) as colorless oil. 
Rf (SiO2, pentane/EtOAc (50:1)): 0.33. 
1H-NMR (500 MHz, CDCl3): 7.32 – 7.25 (m, 4 H), 7.24 – 7.19 (m, 6 H), 5.03 (s, 
1 H), 4.72 (d, J = 1.4 Hz, 1 H), 4.23 (s, 1 H), 4.18 (d, J = 11.8 Hz, 1 H), 3.77 (d, 
J = 11.8 Hz, 1 H), 3.54 (s, 2 H), 3.10 (d, J = 13.3 Hz, 1 H), 3.02 (d, J = 13.3 Hz, 1 H), 
1.28 (s, 9 H), 0.08 (s, 9 H), 0.05 (s, 9 H). 
13C-NMR (126 MHz, CDCl3): 178.4, 149.7, 139.9, 137.4, 131.07, 130.1, 128.4, 
128.2, 126.6, 126.1, 115.9, 80.4, 76.2, 67.1, 40.8, 40.0, 39.1, 27.6, 3.0, 0.6. 
IR (neat): 2960, 1731, 1250, 1132, 1099, 1030, 839, 748, 702, 631. 
EI-MS (70 eV) m/z (%): 333 (10), 307 (40), 206 (19), 205 (100), 73 (47), 57 (18). 
EA: Calculated for C30H46O4Si2: C 68.39% H 8.80%, found: C 68.60% H 8.36%. 
[α]D (c = 0.62, CHCl3, 84% ee): -34.3°. 
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A later experiment with lower concentrations and a shorter reaction time gave 
additionally significant amounts of the mono silylated product (2R,3S)-2,4-dibenzyl-2-
hydroxy-3-((trimethylsilyl)oxy)pent-4-en-1-yl pivalate (5.51). 
 
Rf (SiO2, pentane/EtOAc (10:1)): 0.81. 
1H-NMR (500 MHz, CDCl3): 7.32 – 7.26 (m, 4 H), 7.26 – 7.16 (m, 6 H), 5.08 (s, 
1 H), 4.77 (d, J = 1.6 Hz, 1 H), 4.27 (s, 1 H), 3.93 – 3.83 (m, 2 H), 3.62 – 3.50 (m, 2 H), 
3.05 (d, J = 13.8 Hz, 1 H), 2.83 (d, J = 13.8 Hz, 1 H), 2.53 (s, 1 H), 1.21 (s, 9 H), 0.10 
(s, 9 H). 
13C-NMR (126 MHz, CDCl3) δ 178.2, 148.9, 139.6, 136.8, 130.7, 130.0, 128.4, 
128.4, 126.7, 126.2, 115.8, 77.4, 76.0, 65.6, 40.2, 39.7, 38.9, 27.4, 0.3. 
IR (neat): 2960, 1731, 1252, 1156, 1087, 884, 841, 703, 631. 
EI-MS (70 eV) m/z (%): 235 (49), 221 (21), 220 (100), 219 (41), 205 (31), 151 (14), 
133 (14), 129 (13), 91 (29), 85 (53), 75 (12), 73 (53), 57 (82). 
HR-MS: Calculated for C27H39O4Si [M+H]+: 455.2612, found: 455.2610. 
[α]D (c = 0.62, CHCl3, 84% ee): -16.0°. 
(2R,3R)-2-Benzyl-2,3-dihydroxy-4-oxo-5-phenylpentyl pivalate (5.53) 
 
Some crystals of Sudan III were added to a solution of 
(2R,3S)-2,4-dibenzyl-2,3-dihydroxypent-4-en-1-yl pivalate (5.30, 1.0 eq., 0.066 mmol, 
25 mg) in dry CH2Cl2 (5 ml) and the mixture was cooled to -78 °C. Ozone was passed 
through the solution until the red color disappeared. After flushing the reaction mixture 
with oxygen for five minutes, dimethyl sulfide (3.0 eq., 0.20 mmol, 15 µl) was added 
and the solution was stirred for two hours at -78 °C. Then, the mixture was warmed to 
room temperature and concentrated. The crude product was purified by preparative TLC 
(SiO2, pentane/EtOAc (4:1)) to give the title compound 5.53 (17 mg, 0.044 mmol, 67%) 
as white solid. 
Rf (SiO2, pentane/EtOAc (4:1)): 0.60. 
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1H-NMR (400 MHz, CDCl3): 7.36 – 7.18 (m, 10 H), 4.28 – 4.22 (m, 2 H), 4.07 (s, 
2 H), 4.01 (d, J = 11.8 Hz, 1 H), 3.84 (d, J = 5.5 Hz, 1 H), 3.20 (s, 1 H), 2.84 (d, 
J = 13.9 Hz, 1 H), 2.62 (d, J = 13.9 Hz, 1 H), 1.17 (s, 9 H). 
13C-NMR (101 MHz, CDCl3): 210.7, 180.0, 135.0, 133.7, 130.8, 129.9, 128.8, 
128.6, 127.3, 127.2, 76.9, 76.5, 67.9, 48.0, 39.1, 38.8, 27.3. 
IR (neat): 3407, 2979, 2911, 1710, 1293, 1150, 1083, 1037, 700, 665. 
HR-MS: Calculated for C23H28NaO5 [M+Na]+: 407.1829, found: 407.1830. 
[α]D (c = 0.74, CHCl3, 84% ee): -116.9°. 
(2R,3R)-2-Benzyl-4-oxo-5-phenyl-2,3-bis((trimethylsilyl)oxy)pentyl pivalate (5.55) 
 
Some crystals of Sudan III were added to a solution of (2R,3S)-2,4-dibenzyl-2,3-
bis((trimethylsilyl)oxy)pent-4-en-1-yl pivalate (5.52, 1.00 eq., 0.200 mmol, 105 mg) in 
dry CH2Cl2 (10 ml) and the mixture was cooled to -78 °C. Ozone was passed through 
the solution until the red color disappeared. Subsequently, the reaction was flushed with 
oxygen and after stirring for five minutes, dimethyl sulfide (3.0 eq., 0.60mmol, 44 µl) 
was added at -78 °C. The reaction was allowed to reach room temperature within two 
hours before it was concentrated. The crude product was purified by column 
chromatography (SiO2, pentane/EtOAc (50:1)) to give the title compound 5.55 (66 mg, 
0.13 mmol, 62%) as clear oil. 
Rf (SiO2, pentane/EtOAc (30:1)): 0.41. 
1H-NMR (500 MHz, C6D6): 7.36 – 7.33 (m, 2 H), 7.20 – 7.15 (m, 4 H), 7.11 – 7.03 
(m, 4 H), 4.73 (s, 1 H), 4.60 (d, J = 11.8 Hz, 1 H), 4.17 (d, J = 11.8 Hz, 1 H), 4.03 (d, 
J = 15.5 Hz, 1 H), 3.94 (d, J = 15.5 Hz, 1 H), 3.20 (d, J = 13.8 Hz, 1 H), 3.01 (d, 
J = 13.8 Hz, 1 H), 1.24 (s, 9 H), 0.07 (s, 9 H), 0.02 (s, 9 H). 
13C-NMR (126 MHz, C6D6): 207.7, 177.2, 136.5, 134.8, 131.7, 130.3, 128.8, 128.4, 
127.2, 126.9, 80.4, 79.1, 66.3, 49.2, 41.1, 39.0, 27.5, 2.6, 0.2. 
IR (neat): 2960, 1730, 1455, 1251, 1132, 839, 750, 720. 
EI-MS (70 eV) m/z (%): 308 (13), 307 (52), 295 (13), 294 (50), 218 (11), 217 (55), 
206 (20), 205 (100), 147 (11), 91 (28), 73 (65), 57 (32). 
EA: Calculated for C29H44O5Si2: C 65.87% H 8.39%, found: C 66.12% H 8.33%. 
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(R)-2,4-Dibenzyl-2-hydroxy-3-oxopent-4-en-1-yl pivalate (5.56) 
 
To a solution of (2R,3S)-2,4-dibenzyl-2,3-dihydroxypent-4-en-1-yl pivalate (5.30, 
1.00 eq., 0.300 mmol, 115 mg) in CH2Cl2 (5 ml) and DMSO (5 ml) was added 
2-iodoxybenzoic acid (6.00 eq., 1.80 mmol, 504 mg). This mixture was stirred for 
20 hours at room temperature before it was quenched with a sat. aq. NaHCO3 solution. 
After the addition of further water, the layers were separated and the aq. layer was 
extracted three times with CH2Cl2. The org. layers were washed with brine, combined, 
dried with Na2SO4 and concentrated. The crude product was purified by column 
chromatography (SiO2, pentane/EtOAc (1:20)) to give the title compound 5.56 (83 mg, 
0.22 mmol, 73%) as pale yellow honey. 
Rf (SiO2, pentane/EtOAc (10:1)): 0.42. 
1H-NMR (500 MHz, CDCl3): 7.30 – 7.26 (m, 2 H), 7.24 – 7.20 (m, 4 H), 7.14 – 7.09 
(m, 4 H), 6.25 (s, 1 H), 5.73 (t, J = 1.5 Hz, 1 H), 4.52 (d, J = 11.6 Hz, 1 H), 4.30 (d, 
J = 11.5 Hz, 1 H), 3.94 (s, 1 H), 3.51 (s, 2 H), 3.14 – 3.05 (m, 2 H), 1.11 (s, 9 H). 
13C-NMR (126 MHz, CDCl3): 201.8, 178.3, 145.5, 138.3, 134.6, 130.5, 129.5, 
128.7, 128.4, 127.4, 127.3, 126.6, 81.7, 69.8, 43.1, 39.0, 38.9, 27.2. 
IR (neat): 3460, 2976, 2920, 1728, 1685, 1455, 1398, 1364, 1288, 1156, 1050, 1006, 
940, 782, 744, 652. 
HR-MS: Calculated for C24H28KO4 [M+K]+: 419.1619, found: 419.1619. 
[α]D (c = 0.62, CHCl3, 84% ee): -30°. 
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8.6 Towards Maculalactone F, L and M 
cis-Cinnamaldehyde (6.04) 
 
A published procedure27 was modified as follows: In a quartz glass tube, a solution 
of trans-cinnamaldehyde (1.00eq., 11.8 mmol, 1.57 g) in benzene (12 ml) was irradiated 
(λ = 302 nm, 100 W) without stirring until the cis/trans-equilibrium (determine by 
NMR) was reached. The solution was concentrated and the yellowish oil was purified 
by column chromatography (SiO2, pentane/EtOAc (8:1)) to give the title compound 
6.04 (668 mg, 5.1 mmol, 43%) as yellow oil. 
Rf (SiO2, pentane/EtOAc (8:1)): 0.34. 
1H-NMR (400 MHz, CDCl3): 9.88 (d, J = 8.0 Hz, 1 H), 7.00 – 6.84 (m, 5 H), 6.81 
(d, J = 11.6, Hz, 1 H), 5.93 (dd, J = 11.6, 8.0 Hz, 1 H). 
13C-NMR (101 MHz, CDCl3): 191.0, 147.2, 134.6, 130.8, 129.9, 129.4, 128.6. 
The analytical data of product 6.04 correspond to those reported in the literature.27 
3,4,5-Tribenzyl-5-(1-phenylvinyl)furan-2(5H)-one (6.09) 
 
To a suspension of 3-phenyl-3-(2,3,4-tribenzyl-5-oxo-2,5-dihydrofuran-2-
yl)propanal (4.07, 1.0 eq., 0.01 mmol, 5 mg) and NaHCO3 (1.2 eq., 0.01 mmol, 1 mg) in 
THF (0.3 ml) was added palladium acetate (traces) and allyl diethyl phosphate (1.0 eq., 
0.010 mmol, 1.9 µl). The reaction was stirred at 90 °C. After 24 hours, additional allyl 
diethyl phosphate (3.0 eq., 0.030 mmol, 5.7 µl), palladium acetate (traces) and NaHCO3 
(3.6 eq., 0.03 mmol, 3 mg) were added. After another 20 hours at 90 °C, palladium 
acetate (1.3 eq., 0.01 mmol, 3 mg) and NaHCO3 (2.4 eq., 0.02 mmol, 2 mg) were added. 
After another 24 hours at 90 °C, the reaction mixture was filtrated over SiO2. The 
filtrate was mixed with water and the layers were separated. The aq. layer was extracted 
three times with EtOAc. The org. layers were combined, dried with Na2SO4 and 
O
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concentrated. The crude product was isolated by preparative TLC (SiO2, pentane/EtOAc 
(5:1)) to give the title compound 6.09 (3.2 mg, 7.0 µmol, 68%) as yellow oil. 
Rf (SiO2, pentane/EtOAc (5:1)): 0.70. 
1H-NMR (500 MHz, CDCl3) δ 7.30 – 6.99 (m, 16 H), 6.99 – 6.93 (m, 2 H), 6.88 – 
6.84 (m, 2 H), 6.22 (d, J = 7.0 Hz, 2 H), 5.70 (s, 1 H), 5.45 (s, 1 H), 3.70 (d, 
J = 16.6 Hz, 1 H), 3.61 – 3.55 (m, 2 H), 3.29 (d, J = 14.3 Hz, 1 H), 3.14 (d, J = 15.7 Hz, 
1 H), 3.02 (d, J = 15.6 Hz, 1 H). 
IR (neat): 3029, 2919, 2850, 1754, 1495, 1454, 1079, 925, 754, 701. 
HR-MS: Calculated for C33H28NaO2 [M+Na]+: 479.1982, found: 479.1988. 
3-(3,4-Dibenzyl-5-oxo-2,5-dihydrofuran-2-yl)-3-phenylpropanal (6.11) 
 
A solution of 3,4-dibenzylfuran-2(5H)-one (2.06, 1.0 eq., 0.23 mmol, 60 mg), 
trans-cinnamaldehyde (1.2 eq., 0.272 mmol, 34.6 µl) and cinchona alkaloid catalyst 
(2.12, 0.05 eq., 0.01 mmol, 7 mg) in toluene (5.6 ml) was cooled to -10 °C before a 50% 
aq. KOH solution (6.5 eq., 1.48 mmol, 110 µl) was added over five minutes. The 
reaction was vigorously stirred for 1 day at -10 °C before it was filtrated cold over SiO2. 
The filter cake was rinsed with CH2Cl2. The filtrate was concentrated and purified by 
column chromatography (SiO2, pentane/Et2O (2:1)) to give the title compound 6.11 as 
two separated diastereomers (26 mg, 0.058 mmol, 25% and 36 mg, 0.082 mmol, 36%) 
as yellowish oils. A diastereomeric ration of 42:58 could be determined by 1H-NMR of 
the crude mixture. 
First diastereomer: 
Rf (SiO2, pentane/Et2O (5:1)): 0.16. 
1H-NMR (400 MHz, CDCl3): 9.43 (s, 1 H), 7.34 – 7.11 (m, 13 H), 7.03 – 6.97 (m, 
2 H), 4.84 (d, J = 2.3 Hz, 1 H), 3.99 (d, J = 15.7 Hz, 1 H), 3.73 (s, 2 H), 3.68 (ddd, 
J = 7.9, 5.0, 2.9 Hz, 1 H), 3.50 (d, J = 15.7 Hz, 1 H), 2.73 (ddd, J = 18.2, 8.0, 0.9 Hz, 
1 H), 2.49 (dd, J = 18.1, 5.1 Hz, 1 H). 
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13C-NMR (101 MHz, CDCl3): 199.6, 173.5, 161.2, 140.7, 138.2, 135.8, 129.9, 
129.2, 129.0, 129.0, 128.9, 128.6, 128.2, 127.7, 127.5, 126.9, 84.5, 42.9, 40.5, 33.4, 
29.9. 
IR (neat): 3029, 2920, 1750 ,1724, 1494, 1453, 1045, 751, 698. 
HR-MS: Calculated for C27H25O3 [M+H]+: 397.1798, found: 397.1802. 
Second diastereomer: 
Rf (SiO2, pentane/Et2O (5:1)): 0.10. 
1H-NMR (400 MHz, CDCl3): 9.72 (s, 1 H), 7.37 – 7.17 (m, 9 H), 7.17 – 7.02 (m, 
6 H), 6.47 (d, J = 6.8 Hz, 2 H), 5.01 (s, 1 H), 3.82 – 3.70 (m, 2 H), 3.45 (dt, J = 19.0, 
15.7 Hz, 3 H), 3.27 – 3.17 (m, 1 H), 3.09 (d, J = 6.7 Hz, 1 H). 
13C-NMR (101 MHz, CDCl3): 200.0, 173.6, 161.7, 137.3, 136.5, 136.0, 129.3, 
129.1, 128.9, 128.8, 128.6, 128.6, 128.1, 128.0, 127.5, 126.2, 82.9, 47.3, 40.5, 33.4, 
29.2. 
IR (neat): 3029, 2919, 1749, 1721, 1494, 1453, 1053, 731, 702. 
HR-MS: Calculated for C27H25O3 [M+H]+: 397.1798, found: 397.1804. 
3,4,5-Tribenzyl-3-methylfuran-2(3H)-one (6.12)  
 
To a solution of diisopropylamine (1.4 eq., 0.028 mmol, 4.0 µl) in dry THF (0.2 ml) 
at -78 °C was added dropwise BuLi (1.6 M solution in hexane, 1.3 eq., 0.0260 mmol, 
16.3 µl). After stirring for 15 minutes at -78 °C, the mixture was heated to room 
temperature for 15 minutes and cooled again to -78 °C. Subsequently, a solution of 
maculalactone A (1.34, 1.0 eq., 0.02 mmol, 7 mg) in dry THF (0.2 ml) was added over 
ten minutes. The color of the reaction turns to violet. The mixture was stirred for five 
minutes at -78 °C before methyl iodide (1.8 eq., 0.036 mmol, 2.2 µl) was added. The 
reaction was allowed to reach room temperature overnight. The reaction mixture was 
concentrated and dried in high vacuum. The crude product was purified by preparative 
TLC (SiO2, pentane/EtOAc (20:1)) to give the title compound 6.12 (2 mg, 5.4 µmol, 
27%) as yellow oil. 
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Rf (SiO2, pentane/EtOAc (20:1)): 0.31. 
1H-NMR (500 MHz, CDCl3): 7.32 – 7.07 (m, 18 H), 6.62 – 6.58 (m, 2 H), 3.67 (d, 
J = 16.1 Hz, 1 H), 3.48 (d, J = 16.0 Hz, 1 H), 3.44 – 3.35 (m, 2 H), 3.12 (d, J = 13.7 Hz, 
1 H), 2.88 (d, J = 13.7 Hz, 1 H), 1.17 (s, 3 H). 
1H-NMR (400 MHz, C6D6) δ 7.13 – 7.06 (m, 5 H), 7.06 – 6.98 (m, 6 H), 6.92 (d, 
J = 6.7 Hz, 2 H), 6.53 (dd, J = 6.4, 3.1 Hz, 2 H), 3.27 (d, J = 16.1 Hz, 1 H), 3.17 (d, 
J = 15.9 Hz, 1 H), 3.08 (d, J = 16.0 Hz, 1 H), 3.04 – 2.98 (m, 2 H), 2.49 (d, J = 13.6 Hz, 
1 H), 0.95 (s, 3 H). 
13C-NMR (101 MHz, C6D6) δ 180.6, 148.6, 139.1, 136.9, 136.1, 129.8, 128.9, 128.8, 
128.7, 128.6, 127.9, 127.2, 126.8, 126.6, 118.3, 52.8, 43.1, 31.9, 30.3, 23.7. 
IR (neat): 3065, 3029, 2920, 2854, 1789, 1496, 1454, 1096, 1048, 739, 700. 
HR-MS: Calculated for C26H25O2 [M+H]+: 369.1849, found: 369.1847. 
3,7a-Dibenzyl-4,7-diphenyl-7,7a-dihydrobenzofuran-2(6H)-one (4.14) 
 
Method A: This direct method leads to a racemic product. To a solution of 
maculalactone A (1.34, 1.0 eq., 0.080 mmol, 29 mg) in toluene (2 ml) was added 
trans-cinnamaldehyde (3.0 eq., 0.24 mmol, 31 µl) and tetrabutylammonium bromide 
(1.0 eq., 0.080 mmol, 26 mg). To this vigorously stirred mixture was added a 1 M aq. 
NaOH solution (2.5 eq., 0.201 mmol, 201 µl) at 0 °C. The mixture was allowed to reach 
room temperature and was stirred for two days. The finished reaction mixture was 
filtrated over SiO2. The solid was extensively washed with EtOAc. The filtrate was 
concentrated. The crude product was purified by column chromatography (SiO2, 
pentane/EtOAc (7:1)) to give the title compound 4.14 (20 mg, 0.043 mmol, 53%) as 
colorless crystals. An X-ray diffraction analysis was performed. 
Method B: This indirect approach results in an enantiomeric enriched product. To a 
solution of 3-phenyl-3-(2,3,4-tribenzyl-5-oxo-2,5-dihydrofuran-2-yl)propanal (4.07, 
1.0 eq., 0.029 mmol, 14 mg) in toluene (0.5 ml) was added tetrabutylammonium 
bromide (0.3 eq., 9 µmol, 3 mg) before it was cooled to 0 °C. Subsequently, a 1 M aq. 
O
O
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NaOH solution (2.5 eq., 0.0732 mmol, 73.2 µl) was added to the vigorously stirred 
solution. The reaction was let warm to room temperature over a hour. After two days, 
additional tetrabutylammonium bromide (0.7 eq., 0.02 mmol, 7 mg) was added. After 
stirring for another day, the finished reaction was diluted with EtOAc and filtrated over 
SiO2. The filtrate was concentrated and purified by preparative TLC (SiO2, 
pentane/EtOAc (6:1)) to give the title compound 4.14 (8 mg, 0.017 mmol, 58%) as 
colorless solid. 
Rf (SiO2, pentane/EtOAc (5:1)): 0.46. 
1H-NMR (400 MHz, CDCl3): 7.28 – 7.14 (m, 8 H), 7.06 – 6.98 (m, 3 H), 6.97 – 6.88 
(m, 5 H), 6.88 – 6.80 (m, 2 H), 6.33 (dd, J = 4.4, 3.3 Hz, 1 H), 6.06 (d, J = 7.2 Hz, 2 H), 
3.55 (d, J = 6.7 Hz, 1 H), 3.38 (d, J = 14.0 Hz, 1 H), 3.24 (d, J = 14.0 Hz, 1 H), 3.13 
(ddd, J = 21.0, 6.8, 3.1 Hz, 1 H), 2.94 (d, J = 15.0 Hz, 1 H), 2.83 – 2.70 (m, 2 H). 
13C-NMR (101 MHz, CDCl3): 172.9, 154.3, 138.2, 137.7, 137.4, 135.6, 135.0, 
133.5, 130.8, 128.8, 128.7, 128.6, 128.4, 128.2, 128.1, 128.0, 128.0, 127.5, 127.3, 
126.8, 125.6, 86.7, 46.2, 43.6, 32.0, 29.8. 
IR (neat): 3029, 1744, 1494, 1453, 1060, 1033, 752, 697. 
HR-MS: Calculated for C34H29O2 [M+H]+: 469.2162, found: 469.2164. 
Mp: 64 – 65 °C. 
3a,6-Dibenzyl-3,6b-diphenyl-1a,2,3,3a-tetrahydrooxireno[2,3-e]benzofuran-
5(6bH)-one (6.13) 
 
A solution of 3,7a-dibenzyl-4,7-diphenyl-7,7a-dihydrobenzofuran-2(6H)-one (4.14, 
1.0 eq., 0.035 mmol, 16 mg) and Sudan Red III (traces) in CH2Cl2 (1.5 ml) was cooled 
to -78 °C before ozone was bubbled trough the solution. When the color of the reaction 
mixture changed from red to yellow, instead of ozone, pure oxygen was bubbled 
through the solution for 15 minutes. The reaction was quenched with dimethyl sulfide 
(0.1 ml), heated to room temperature and concentrated. The crude mixture was purified 
O
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by preparative TLC (SiO2, pentane/EtOAc (5:1)) to give the title compound 6.13 (9 mg, 
0.019 mmol, 53%) as clear oil. 
Product 6.13 was also isolated as side product in the synthesis of 6.14 and 6.15. 
Rf (SiO2, pentane/EtOAc (5:1)): 0.23. 
1H-NMR (400 MHz, CDCl3): 7.48 (dd, J = 7.8, 1.5 Hz, 2 H), 7.36 – 7.24 (m, 11 H), 
7.19 (t, J = 7.4 Hz, 2 H), 6.94 (t, J = 7.3 Hz, 1 H), 6.85 (t, J = 7.5 Hz, 2 H), 5.83 (d, 
J = 7.2 Hz, 2 H), 3.97 (dd, J = 10.7, 9.3 Hz, 2 H), 3.70 (d, J = 7.4 Hz, 1 H), 3.39 (d, 
J = 13.4 Hz, 1 H), 3.00 (dd, J = 16.4, 7.5 Hz, 1 H), 2.71 (dd, J = 16.4, 4.1 Hz, 1 H), 2.60 
(d, J = 15.7 Hz, 1 H), 2.42 (d, J = 15.7 Hz, 1 H). 
13C-NMR (101 MHz, CDCl3): 171.3, 155.3, 138.5, 137.1, 136.1, 135.2, 133.9, 
131.0, 129.2, 129.2, 128.7, 128.5, 128.2, 127.9, 127.9, 127.6, 127.4, 127.2, 125.5, 88.9, 
63.4, 62.3, 48.8, 43.4, 28.6, 27.8. 
IR (neat): 3032, 2922, 1750, 1495, 1452, 1056, 910, 879, 730, 696. 
HR-MS: Calculated for C34H29O3 [M+H]+: 485.2111, found: 485.2116. 
epi-Maculalactone M (6.14, left) and epi-maculalactone F (6.15, right) 
 
To a suspension of 3,7a-dibenzyl-4,7-diphenyl-7,7a-dihydrobenzofuran-2(6H)-one 
(4.14, 1.0 eq., 0.13 mmol, 62 mg) in CH3CN (0.5 ml) and water (0.7 ml) at room 
temperature were added ruthenium(III) chloride (traces) and sodium periodate (4.1 eq., 
0.540 mmol, 116 mg). The mixture was stirred for three hours at room temperature 
before it was diluted with water and EtOAc. The layers were separated and the aq. layer 
was extracted five times with EtOAc. The org. layers were combined, washed with 
brine, dried with Na2SO4 and concentrated. The products were separated by column 
chromatography (SiO2, pentane/EtOAc (8:1 to 1:1)) to give epi-maculalactone M (6.14, 
21 mg, 0.041 mmol, 32%) as colorless solid, epi-maculalactone F (6.15, 8 mg, 
0.016 mmol, 12%) as solid and product 6.13 (16 mg, 0.033 mmol, 25%) as clear oil. 
epi-Maculalactone M (6.14) 
Rf (SiO2, pentane/EtOAc (1:1)): 0.31. 
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1H-NMR (500 MHz, CDCl3): 7.49 – 7.44 (m, 1 H), 7.38 (d, J = 7.1 Hz, 2 H), 7.28 – 
7.20 (m, 7 H), 7.12 – 7.08 (m, 1 H), 7.03 (t, J = 7.5 Hz, 2 H), 7.00 – 6.90 (m, 5 H), 6.39 
– 6.32 (m, 2 H), 4.00 (dd, J = 11.3, 3.3 Hz, 1 H), 3.29 – 3.21 (m, 2 H), 2.98 (d, 
J = 14.6 Hz, 1 H), 2.86 (d, J = 14.6 Hz, 1 H), 2.55 (dd, J = 16.1, 11.3 Hz, 1 H), 2.34 
(dd, J = 16.1, 3.3 Hz, 1 H). 
13C-NMR (126 MHz, CDCl3): 191.9, 176.1, 171.7, 154.3, 138.0, 138.0, 136.3, 
136.2, 134.6, 134.4, 130.5, 130.2, 129.6, 128.8, 128.7, 128.7, 128.6, 128.3, 128.0, 
127.4, 126.7, 92.9, 48.4, 41.6, 35.6, 31.6. 
IR (neat): 3030, 2924, 2361, 2326, 1760, 1710, 1650, 1597, 1244, 731, 697. 
HR-MS: Calculated for C34H29O5 [M+H]+: 517.2010, found: 517.2017. 
Mp: 74 – 75 °C. 
epi-Maculalactone F (6.15) 
Rf (SiO2, pentane/EtOAc (5:1)): 0.23. 
1H-NMR (500 MHz, CDCl3): 7.43 – 7.37 (m, 3 H), 7.33 – 7.27 (m, 3 H), 7.23 – 7.09 
(m, 10 H), 7.04 – 6.97 (m, 2 H), 6.65 (dd, J = 8.2, 1.0 Hz, 2 H), 4.39 (s, 1 H), 4.09 (d, 
J = 13.6 Hz, 1 H), 3.97 (d, J = 13.6 Hz, 1 H), 3.56 (dd, J = 6.8, 1.7 Hz, 1 H), 3.18 (dd, 
J = 16.5, 6.8 Hz, 1 H), 3.06 (dd, J = 16.5, 1.9 Hz, 1 H), 2.68 – 2.56 (m, 2 H). 
13C-NMR (126 MHz, CDCl3): 209.8, 171.8, 159.5, 139.5, 138.5, 135.9, 134.7, 
132.3, 130.6, 130.0, 129.8, 129.3, 129.1, 128.8, 128.4, 128.2, 127.8, 127.7, 126.9, 
126.3, 86.8, 84.3, 45.4, 45.2, 40.5, 30.2. 
IR (neat): 3474, 3031, 2920, 1753, 1721, 1495, 1453, 1047, 696. 
HR-MS: Calculated for C34H29O4 [M+H]+: 501.2060, found: 501.2064. 
Mp: 83 – 85 °C. 
rac-(E)-3,5-Dibenzyl-4-benzylidene-3-hydroxydihydrofuran-2(3H)-one (6.16) 
 
A solution of maculalactone A (1.34, 1.0 eq., 0.14 mmol, 50 mg) in dry THF (5 ml) 
was cooled to -78 °C before NaHMDS (0.6 M solution in toluene, 2.0 eq., 0.28 mmol, 
470 µl) was added over five minutes. The resulting mixture was stirred for one hour 
O
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before dried triethyl phosphite (distilled from sodium, 1.5 eq., 0.210 mmol, 25.5 µl) was 
added. Then, the gas phase was flushed with oxygen (dried over solid KOH). The 
reaction was stirred for another hour at -78 °C and then heated to 0 °C. After stirring for 
1.5 hours, the reaction was quenched with a 1 M aq. HCl solution. This mixture was 
extracted three times with EtOAc. The org. layers were washed with brine, combined, 
dried with Na2SO4 and concentrated. The crude reaction mixture was purified by 
column chromatography (SiO2, pentane-EtOAc (9:1)) and by preparative TLC (SiO2, 
CH2Cl2-Et2O (9:1)) to give the title compound 6.16 (2.5 mg, 6.7 µmol, 5%) as clear oil. 
Rf (SiO2, CH2Cl2/Et2O (9:1)): 0.75. 
1H-NMR (500 MHz, CDCl3): 7.49 – 7.44 (m, 2 H), 7.40 – 7.35 (m, 1 H), 7.29 – 7.20 
(m, 7 H), 7.18 – 7.15 (m, 2 H), 6.94 – 6.90 (m, 2 H), 6.80 (d, J = 2.6 Hz, 1 H), 5.15 (dt, 
J = 5.6, 3.0 Hz, 1 H), 3.26 (d, J = 12.6 Hz, 1 H), 3.02 (d, J = 12.6 Hz, 1 H), 2.98 (dd, 
J = 14.6, 3.2 Hz, 1 H), 2.68 (dd, J = 14.6, 5.4 Hz, 1 H), 1.62 (s, 1 H). 
13C-NMR (126 MHz, CDCl3): 176.5, 138.8, 135.3, 135.3, 133.4, 130.7, 130.3, 
129.2, 128.8, 128.8, 128.7, 128.6, 128.5, 127.6, 127.4, 81.0, 77.0, 47.1, 37.3. 
IR (neat): 3060, 3030, 2927, 1766, 1496, 1454, 1353, 1150, 1030, 1003, 738, 699. 
HR-MS: Calculated for C25H26NO3 [M+H]+: 388.1907, found: 388.1905. 
rac-epi-Maculalactone L (6.17) 
 
A solution of maculalactone A (1.34, 1.0 eq., 0.085 mmol, 30 mg) in dry THF (2 ml) 
was cooled to -78 °C before NaHMDS (0.6 M solution in toluene, 2.0 eq., 0.17 mmol, 
280 µl) was added over five minutes. The resulting mixture was stirred for one hour 
before triethyl phosphite (distilled from sodium, 1.5 eq., 0.128 mmol, 22.4 µl) was 
added followed by the exchange of the gas phase to oxygen (dried over solid KOH). 
The reaction was stirred for another 4.5 hours at -78 °C before it was quenched with a 
1 M aq. HCl solution at this temperature. The mixture was heated to room temperature 
and extracted twice with EtOAc. The org. layers were washed with a 1 M aq. HCl 
solution, combined, dried with Na2SO4 and concentrated. The crude mixture was 
O
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purified by preparative TLC (SiO2, pentane/EtOAc (4:1)) to give the title compound 
6.17 (1 mg, 2.7 µmol, 3%) as colorless oil and the known compound 2.05 (8 mg, 
0.022 mmol, 25%). 
Rf (SiO2, pentane/EtOAc (4:1)): 0.63. 
1H-NMR (500 MHz, CDCl3): 7.76 – 7.71 (m, 2 H), 7.46 – 7.41 (m, 2 H), 7.40 – 7.35 
(m, 1 H), 7.34 – 7.27 (m, 2 H), 7.21 – 7.18 (m, 2 H), 7.17 – 7.13 (m, 3 H), 6.89 – 6.85 
(m, 2 H), 6.67 (d, J = 1.9 Hz, 1 H), 4.62 (ddd, J = 6.0, 4.1, 2.0 Hz, 1 H), 3.26 (d, 
J = 12.8 Hz, 1 H), 3.21 (dd, J = 14.3, 4.1 Hz, 1 H), 3.05 (d, J = 12.8 Hz, 1 H), 2.98 (dd, 
J = 14.3, 5.8 Hz, 1 H), 1.98 (s, 1 H). 
13C-NMR (101 MHz, CDCl3): 177.4, 136.3, 135.2, 134.6, 133.8, 131.1, 130.6, 
130.2, 130.1, 128.8, 128.7, 128.4, 127.5, 127.4, 82.2, 76.9, 42.3, 40.6. 
IR (neat): 3442, 3062, 3030, 2923, 2853, 1763, 1495, 1454, 1345, 1240, 1148, 1081, 
1040, 752, 699. 
HR-MS: Calculated for C25H26NO3 [M+H]+: 388.1907, found: 388.1905. 
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9.1 Abbreviations, Acronyms and Symbols 
[α]D specific rotation at the sodium D line 
AADC aromatic aminoacid decarboxylase 
Ac acetyl 
acac acetylacetone 
AIBN azobisisobutyronitrile 
aq. aqueous 
BBN 9-borabicyclo[3.3.1]nonane 
Bn benzyl 
Bu butyl 
c concentrated 
cat. catalytic 
COSY correlation spectroscopy 
C4H cinnamate-4-hydroxylase 
DC circular dichroism 
DIPEA diisopropylethylamine 
DIPT diisopropyl tartrate 
DMDO 3,3-dimethyldioxirane 
DMPU 1,3-dimethyltetrahydropyrimidin-2(1H)-one 
d doublet 
DBU 1,8-diazadicyclo[5.4.0]undec-7-ene 
DCC dicyclohexylcarbodiimide 
DET diethyl tartrate 
DIBAL diisopropylaluminium hydride 
DIPA diisopropylamine 
DMAP 4-N,N-dimethylaminopyridine 
DMF N,N-dimethylformamide 
DMP Dess-Martin periodinane 
DMSO dimethyl sulfoxide 
DOPA 3,4-dihydroxyphenylalanine 
dppf 1,1’-bis(diphenylphosphino)ferrocene 
d.r. diastereomeric ratio 
ee enantiomeric excess 
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EI electron impact ionization 
ent enantiomeric 
epi epimeric 
eq. equivalent 
ESI electrospray ionization 
Et ethyl 
EtOAc ethyl acetate 
GC gas chromatography 
h hour(s) 
HMBC heteronuclear multiple-bond correlation spectroscopy 
HMPA hexamethylphosphoramide 
HMQC heteronuclear multiple-quantum correlation spectroscopy 
HPLC high-performance liquid chromatography 
i iso 
IBX 2-iodoxybenzoic acid 
IC50 50% inhibitory concentration 
IR infrared spectroscopy 
J coupling constant 
LC50 50% lethal concentration 
LDA lithium diisopropylamide 
LHMDS lithium bis(trimethylsilyl)amide 
m multiplet 
M mol/l 
MAP mussel adhesive protein 
MCPBA meta-chloroperoxybenzoic acid 
Me methyl 
min minute(s) 
MOM methoxymethyl 
Mp melting point 
Ms mesylate 
MS mass spectrometry / molecular sieves 
NaHMDS sodium bis(trimethylsilyl)amide 
NBS N-bromosuccinimide 
NMO N-methylmorpholine N-oxide 
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NMR nuclear magnetic resonance spectroscopy 
org. organic 
p para 
PAL phenylalanine ammonia lyase 
PCC pyridinium chlorochromate 
PEG polyethylene glycol 
Ph phenyl 
Piv pivaloyl 
PMB p-methoxybenzyl 
ppm parts per million 
Pr propyl 
PTC phase transfer catalyst/catalysis 
PTSA p-toluenesulfonic acid 
PVC polyvinyl chloride 
q quartet 
quant. quantitative 
rac racemic 
Red-Al sodium bis(2-methoxyethoxy)aluminumhydride 
Rf retention factor 
rf reflux 
Rt retention time 
rt room temperature 
s singlet 
SAR structure activity relationsphip 
sat. saturated 
SEM standard error of the mean 
t triplet 
t tert 
TBAB tetrabutylammonium bromide 
TBAF tetrabutylammonium fluoride 
TBAH tetrabutylammonium hydroxide 
TBAI tetrabutylammonium iodide 
TBDMS tert-butyldimethylsilyl 
TBME tert-butyl methyl ether 
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TBT tributyltin compound 
TES trimethylsilyl 
Temp. temperature 
Tf trifluoromethanesulfonate 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TIPS triisopropylsilyl 
TLC thin layer chromatography 
TMS trimethylsilyl 
TOF time of flight 
Trt trityl 
Ts tosyl 
UPLC ultra pressure liquid chromatography 
UV ultraviolet (spectroscopy/light) 
v/v volume per volume  
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9.2 NMR Spectra 
9.2.1 An Improved Synthesis of Maculalactone A 
3,3,4-Tribenzylfuran-2(3H)-one (2.13) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
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3-Benzyl-1-phenylbut-3-en-2-yl 2-benzylacrylate (2.19) 
 
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3 
 
OO
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1-Ethyl 3-(3-oxo-1,4-diphenylbutan-2-yl) 2-benzylmalonate (2.31) as a mixture of 
diastereomers 
 
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3 
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Maculalactone A (1.34) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
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9.2.2 From a Natural Product to a Functional Molecule 
Potassium 3-ethoxy-2-(4-methoxybenzyl)-3-oxopropanoate (3.08) 
 
400 MHz 1H-NMR in D2O 
 
101 MHz 13C-NMR in D2O 
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3-Hydroxy-1-(4-methoxyphenyl)-4-phenylbutan-2-one (3.10) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
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1-Ethyl 3-(3-oxo-1,4-diphenylbutan-2-yl) 2-(4-methoxybenzyl)malonate (3.14) as a 
mixture of diastereomers 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
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1-Ethyl 3-(4-(4-methoxyphenyl)-3-oxo-1-phenylbutan-2-yl) 2-benzylmalonate 
(3.15) as a mixture of diastereomers 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
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1-Ethyl 3-(1-(4-methoxyphenyl)-3-oxo-4-phenylbutan-2-yl) 2-benzylmalonate 
(3.16) as a mixture of diastereomers 
  
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
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4,5-Dibenzyl-3-(4-methoxybenzyl)furan-2(5H)-one (3.17) 
 
500 MHz 1H-NMR in C6D6 
 
126 MHz 13C-NMR in C6D6 
 
O
O
O
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3,5-Dibenzyl-4-(4-methoxybenzyl)furan-2(5H)-one (3.18) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
 
O
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3,4-Dibenzyl-5-(4-methoxybenzyl)furan-2(5H)-one (3.19) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
 
O
O
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4,5-Dibenzyl-3-(4-hydroxybenzyl)furan-2(5H)-one (3.20) 
 
500 MHz 1H-NMR in C6D6 
 
101 MHz 13C-NMR in C6D6 
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4,5-Dibenzyl-3-(4-octylbenzyl)furan-2(5H)-one (3.21) 
 
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3 
 
 
O
O
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4,5-Dibenzyl-3-(4-(2-(2-(2-ethoxyethoxy)ethoxy)ethoxy)benzyl)furan-2(5H)-one 
(3.23)  
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
 
O
O
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4-(4,5-Dimethoxy-2-nitrophenyl)-4-oxobutanoic acid (3.29) 
  
 
400 MHz 1H-NMR in DMSO-d6 
 
101 MHz 13C-NMR in DMSO-d6 
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1-(4,5-Dimethoxy-2-nitrophenyl)-4-hydroxybutan-1-one (3.30)  
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
 
O
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1-(3,4-Dimethoxyphenyl)butane-1,4-diol (3.31) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
 
OH
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4-(3-Chloropropyl)-5-nitrobenzene-1,2-diol (3.35) 
 
400 MHz 1H-NMR in MeOD 
 
101 MHz 13C-NMR in MeOD 
 
ClHO
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4-(3-((Methylsulfonyl)oxy)propyl)-1,2-phenylene dimethanesulfonate (3.36) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
 
OMsMsO
MsO
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3-(4,5-Dihydroxy-2-nitrophenyl)propanoic acid (3.37)  
 
400 MHz 1H-NMR in MeOD 
 
101 MHz 13C-NMR in MeOD 
 
OHHO
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Ethyl 10-(tosyloxy)decanoate (3.42) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
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O-(2-Azidoethyl)-O’-tosylnonadecaethylene glycol (3.45) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
 
O O N3
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Rhodamine B maculalactone A hybrid (3.47) 
 
500 MHz 1H-NMR in MeOD 
 
126 MHz 13C-NMR in MeOD 
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Rhodamine B with linker (3.48) 
 
400 MHz 1H-NMR in MeOD 
 
HPLC (Phenomenex Synergi Hydro-RP, AcN/water + 0.1% HCO2H (2 min 1:19, in 3 
min to 3:7, in 25 min to 4:1), 1 ml/min, 540 nm) 
HO O
N
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9.2.3 Synthetic Studies on Ophiodilactone A and B 
3-Phenyl-3-(2,3,4-tribenzyl-5-oxo-2,5-dihydrofuran-2-yl)propanal (4.07) 
 
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3 
 
O
O O
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3-Phenyl-3-(2,3,4-tribenzyl-5-oxo-2,5-dihydrofuran-2-yl)propanal (6.02) 
 
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3 
 
O
O O
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Triisopropyl((3,4,5-tribenzylfuran-2-yl)oxy)silane (4.11)  
 
500 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
 
O
TIPSO
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rac-Methyl 3-phenyl-3-(2,3,4-tribenzyl-5-oxo-2,5-dihydrofuran-2-yl)propanoate 
(4.13) 
 
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3 
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3,4,5-Tribenzyl-5-(3-hydroxy-1-phenylpropyl)furan-2(5H)-one (4.17)  
 
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3 
 
O
O OH
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3-Phenyl-3-(2,3,4-tribenzyl-5-oxo-2,5-dihydrofuran-2-yl)propanoic acid (4.18) 
 
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3 
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3,4,5-Tribenzyl-5-(3-hydroxy-1-phenylpropyl)-2,5-dihydrofuran-2-ol (4.19) 
 
500 MHz 1H-NMR in C6D6 
 
126 MHz 13C-NMR in C6D6 
 
O
HO OH
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6,7,8-Tribenzyl-5-phenyl-2,9-dioxabicyclo[4.2.1]non-7-ene (4.20)  
 
500 MHz 1H-NMR in C6D6 
 
126 MHz 13C-NMR in C6D6 
 
OO
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3-Phenyl-3-(2,3,4-tribenzyl-2,5-dihydrofuran-2-yl)propan-1-ol (4.24)  
 
500 MHz 1H-NMR in C6D6 
 
126 MHz 13C-NMR in C6D6 
 
O OH
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3-Benzoyl-4,5-dibenzylfuran-2(5H)-one (4.27) 
 
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3 
 
O
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1-Benzyl-4-hydroxy-3-oxo-4,6,7-triphenyl-1,3,4,5,6,7-hexahydroisobenzofuran-5-
carbaldehyde (4.28) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
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3,3a,6a-Tribenzyl-4-hydroxy-6-phenylhexahydro-2H-cyclopenta[b]furan-2-one 
(4.31) 
 
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3 
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3,3a,6a-Tribenzyl-3-hydroxy-6-phenyltetrahydro-2H-cyclopenta[b]furan-2,4(5H)-
dione (4.33) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
 
O
O
O
HO
CHAPTER 9 
262 
 
2,3-Dibenzyl-4-phenylcyclopent-2-enone (4.34)  
 
500 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
 
O
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3-(2,4-Dibenzyl-3-benzylidene-4-hydroxy-5-oxotetrahydrofuran-2-yl)-3-
phenylpropanoic acid (4.35) 
 
400 MHz 1H-NMR in CDCl3 
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9.2.4 Studies on a Linear Approach Towards Ophiodilactone A and B 
(R)-2-Benzyl-1-((S)-2-benzyloxiran-2-yl)prop-2-en-1-ol (5.14) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
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(S)-((R)-2-Benzyloxiran-2-yl)((S)-2-benzyloxiran-2-yl)methanol 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
 
OH
O O
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2,4-Dibenzylpenta-1,4-dien-3-yl formate (5.21) 
  
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3 
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2,4-Dibenzylpenta-1,4-dien-3-one (5.25) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
 
O
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(S)-2-Benzyl-2-((R)-2-benzyl-1-(benzyloxy)allyl)oxirane (5.27) 
 
400 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3 
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((2R,3R)-2-Benzyl-3-(3-phenylprop-1-en-2-yl)oxiran-2-yl)methanol (5.28) 
 
500 MHz 1H-NMR in CDCl3 
 
500 MHz 1H-NMR in C6D6 
 
O
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((2R,3R)-2-Benzyl-3-(3-phenylprop-1-en-2-yl)oxiran-2-yl)methanol (5.28) 
 
101 MHz 13C-NMR in CDCl3 
 
126 MHz 13C-NMR in C6D6 
 
O
HO
 APPENDIX 
271 
 
(3S,4R)-2,4-Dibenzyl-4,5-dihydroxypent-1-en-3-yl pivalate (5.29) 
 
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3 
 
HO OH
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((2R,3S)-2,4-Dibenzyl-2,3-dihydroxypent-4-en-1-yl pivalate (5.30) 
 
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3 
 
PivO OH
OH
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(2R,3S)-2,4-Dibenzyl-2,3-dihydroxypent-4-en-1-yl 4-iodobenzoate (5.34) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
 
O OH
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(Z)-3-Iodo-3-phenylallyl pivalate (5.37) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
 
I
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(Z)-tert-Butyl((3-iodo-3-phenylallyl)oxy)dimethylsilane (5.38) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
 
I
OTBDMS
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(Z)-(3-(Benzyloxy)-1-iodoprop-1-en-1-yl)benzene (5.39) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
 
I
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(Z)-(((3-Iodo-3-phenylallyl)oxy)methanetriyl)tribenzene (5.40)  
 
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3 
 
I
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(Z)-3-Benzyl-6-((tert-butyldimethylsilyl)oxy)-4-phenylhex-4-en-3-ol (5.41) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
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(Z)-3-(tert-Butyldimethylsilyl)-3-phenylprop-2-en-1-ol (5.42) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
 
TBDMS
OH
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(Z)-3-Benzyl-6-(benzyloxy)-4-phenylhex-4-en-3-ol (5.43) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
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((4R,5S)-4-Benzyl-2,2-dimethyl-5-(3-phenylprop-1-en-2-yl)-1,3-dioxolan-
4-yl)methyl pivalate (5.44) 
 
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3 
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(R)-2-Benzyl-1-((S)-4-benzyl-2,2-dimethyl-1,3-dioxolan-4-yl)allyl pivalate (5.45) 
 
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3 
 
OPivOO
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((4R,5R)-4-Benzyl-2,2-dimethyl-5-(2-phenylacetyl)-1,3-dioxolan-4-yl)methyl 
pivalate (5.46) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
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(S)-(4-Benzyl-2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl)methyl pivalate (5.47) 
 
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3 
 
O
OPivO O
 APPENDIX 
285 
 
((4S,5R)-4-Benzyl-5-((S)-2-hydroxy-1-phenylbut-3-en-2-yl)-2,2-dimethyl-1,3-
dioxolan-4-yl)methyl pivalate (5.48) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
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((4S,5R)-4-Benzyl-5-((Z)-5-(benzyloxy)-2-hydroxy-1,3-diphenylpent-3-en-2-yl)-2,2-
dimethyl-1,3-dioxolan-4-yl)methyl pivalate (5.49)  
 
600 MHz 1H-NMR in toluene-d8 at 343 K 
 
151 MHz 13C-NMR in toluene-d8 at 343 K 
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(2R,3S)-2,4-Dibenzyl-2-hydroxy-3-(methoxymethoxy)pent-4-en-1-yl pivalate (5.50) 
 
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3 
 
PivO OH
OMOM
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(2R,3S)-2,4-Dibenzyl-2-hydroxy-3-((trimethylsilyl)oxy)pent-4-en-1-yl pivalate 
(5.51)  
 
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3 
 
PivO OH
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(2R,3S)-2,4-Dibenzyl-2,3-bis((trimethylsilyl)oxy)pent-4-en-1-yl pivalate (5.52) 
 
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3 
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(2R,3R)-2-Benzyl-2,3-dihydroxy-4-oxo-5-phenylpentyl pivalate (5.53) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
 
OPivO OH
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(2R,3R)-2-Benzyl-4-oxo-5-phenyl-2,3-bis((trimethylsilyl)oxy)pentyl pivalate (5.55)  
 
500 MHz 1H-NMR in C6D6 
 
126 MHz 13C-NMR in C6D6 
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(R)-2,4-Dibenzyl-2-hydroxy-3-oxopent-4-en-1-yl pivalate (5.56)  
 
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3 
 
PivO OH
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9.2.5 Towards Maculalactone F, L and M 
3-(3,4-Dibenzyl-5-oxo-2,5-dihydrofuran-2-yl)-3-phenylpropanal (6.11), first 
diastereomer 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
 
O
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3-(3,4-Dibenzyl-5-oxo-2,5-dihydrofuran-2-yl)-3-phenylpropanal (6.11), second 
diastereomer 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
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3,4,5-Tribenzyl-3-methylfuran-2(3H)-one (6.12)  
 
400 MHz 1H-NMR in C6D6 
 
101 MHz 13C-NMR in C6D6 
 
O
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3,7a-Dibenzyl-4,7-diphenyl-7,7a-dihydrobenzofuran-2(6H)-one (4.14) 
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
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3a,6-Dibenzyl-3,6b-diphenyl-1a,2,3,3a-tetrahydrooxireno[2,3-e]benzofuran-
5(6bH)-one (6.13)  
 
400 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
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epi-Maculalactone M (6.14)  
 
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3 
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epi-Maculalactone F (6.15)  
 
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3 
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rac-(E)-3,5-Dibenzyl-4-benzylidene-3-hydroxydihydrofuran-2(3H)-one (6.16) 
 
500 MHz 1H-NMR in CDCl3 
 
126 MHz 13C-NMR in CDCl3 
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rac-epi-Maculalactone L (6.17)  
 
500 MHz 1H-NMR in CDCl3 
 
101 MHz 13C-NMR in CDCl3 
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9.3 Chiral HPLC 
9.3.1 3,4,5-Tribenzyl-5-(3-hydroxy-1-phenylpropyl)furan-2(5H)-one (4.17) 
 
Racemic sample, LOT: Mul136B, (Chiralpak IC column from Daicel, heptane/iPrOH 
(80:20), 0.5 ml/min, 25 °C, 210nm) 
 
Vinylogous Michael addition with PTC 2.12 at 0 to 5 °C, LOT: Mul134B, (Chiralpak 
IC column from Daicel, heptane/iPrOH (80:20), 0.5 ml/min, 25 °C, 210nm) 
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Vinylogous Michael addition with PTC 4.15 at 0 to 5 °C, LOT: Mul135B, (Chiralpak 
IC column from Daicel, heptane/iPrOH (80:20), 0.5 ml/min, 25 °C, 210nm) 
 
Vinylogous Michael addition with PTC 4.16 at 0 to 5 °C, LOT: Mul133B, (Chiralpak 
IC column from Daicel, heptane/iPrOH (80:20), 0.5 ml/min, 25 °C, 210nm) 
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Vinylogous Michael addition with PTC 2.12 at -15 °C, LOT: Sb229.2, (Chiralpak IC 
column from Daicel, heptane/iPrOH (80:20), 0.5 ml/min, 25 °C, 210nm) 
 
Vinylogous Michael addition with PTC 2.12 at -15 °C, scale-up to 0.76 mmol with 
mechanical stirring, LOT: Sb323.2, (Chiralpak IC column from Daicel, heptane/iPrOH 
(80:20), 0.5 ml/min, 25 °C, 208nm) 
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Vinylogous Michael addition with PTC 2.12 at -15 °C, scale-up to 0.76 mmol with 
mechanical stirring, LOT: Sb458.2, (Chiralpak IC column from Daicel, heptane/iPrOH 
(80:20), 0.5 ml/min, 25 °C, 208nm) 
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9.3.2 (R)-2-Benzyl-1-((S)-2-benzyloxiran-2-yl)prop-2-en-1-ol (5.14) 
 
Racemic sample, LOT: Sb19.2, (Chiralpak IC column from Daicel, heptane/iPrOH 
(95:5), 0.5 ml/min, 20 °C, 258nm) 
 
Sharpless with DET, LOT: Sb15.1, (Chiralpak IC column from Daicel, heptane/iPrOH 
(97:3), 0.5 ml/min, 20 °C, 258nm) 
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Sharpless with DIPT, LOT: Sb16.1, (Chiralpak IC column from Daicel, heptane/iPrOH 
(95:5), 0.5 ml/min, 20 °C, 258nm) 
 
Sharpless with DIPT, LOT: Sb125.2, (Chiralpak IC column from Daicel, 
heptane/iPrOH (97:3), 0.5 ml/min, 20 °C, 258nm) 
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9.4 X-Ray Diffraction Analysis 
3,7a-Dibenzyl-4,7-diphenyl-7,7a-dihydrobenzofuran-2(6H)-one (4.14) 
 
formula                          C34H28O2  
formula weight                   468.59  
Z, calculated density            8, 1.258 Mg · m-3  
F(000)                           1984  
description and size of crystal  colourless plate, 0.040 · 0.170 · 0.260 mm3  
absorption coefficient           0.077 mm-1  
min/max transmission             0.99 / 1.00  
temperature                      123K  
radiation(wavelength)            Mo Kα (λ = 0.71073 Å)  
Crystal system, space group      monoclinic, C c  
a                                26.6904(15) Å  
b                                14.6073(8) Å  
c                                13.0650(7) Å  
α                                90°  
β                                103.804(3)°  
γ                                90°  
V                                4946.6(5) Å3  
min/max Θ                        1.600° / 30.133°  
number of collected reflections  30954  
number of independent refections 7274 (merging r = 0.042)  
number of observed reflections   6564 (I>2.0σ(I))  
number of refined parameters     649  
r                                0.0633  
rW                               0.0853  
goodness of fit                  1.0603 
 
O
O
 APPENDIX 
309 
 
3,4,5-Tribenzyl-5-(3-hydroxy-1-phenylpropyl)furan-2(5H)-one (4.17) 
 
formula                          C34H32O3  
formula weight                   488.63 Z,  
calculated density               4, 1.236 Mg · m-3  
F(000)                           1040  
description and size of crystal  colourless plate, 0.040 · 0.170 · 0.210 mm3  
absorption coefficient           0.077 mm-1  
min/max transmission             0.99 / 1.00  
temperature                      123K  
radiation(wavelength)            Mo Kα (λ = 0.71073 Å)  
Crystal system, space group      monoclinic, P 21/c  
a                                14.658(2) Å  
b                                13.7997(18) Å  
c                                13.2307(17) Å  
α                                90°  
β                                101.228(9)°  
γ                                90°  
V                                2625.0(6) Å3  
min/max Θ                        2.046° / 27.497°  
number of collected reflections  32367  
number of independent refections 6010 (merging r = 0.112)  
number of observed reflections   3362 (I>2.0σ(I))  
number of refined parameters     334  
r                                0.0518  
rW                               0.0944  
goodness of fit                  1.1262 
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3-Benzoyl-4,5-dibenzylfuran-2(5H)-one (4.27) 
 
formula                          C25H20O3  
formula weight                   368.43 Z,  
calculated density               4, 1.271 Mg · m-3  
F(000)                           776  
description and size of crystal  colourless plate, 0.040 · 0.130 · 0.210 mm3  
absorption coefficient           0.083 mm-1  
min/max transmission             0.99 / 1.00  
temperature                      123K  
radiation(wavelength)            Mo Kα (λ = 0.71073 Å)  
Crystal system, space group      monoclinic, P 21/c  
a                                11.8690(10) Å  
b                                16.8261(13) Å  
c                                10.4258(9) Å  
α                                90°  
β                                112.399(4)°  
γ                                90°  
V                                1925.0(3) Å3  
min/max Θ                        1.856° / 32.580°  
number of collected reflections  32920  
number of independent refections 6985 (merging r = 0.039)  
number of observed reflections   4482 (I>2.0σ(I))  
number of refined parameters     253  
r                                0.0429  
rW                               0.0829  
goodness of fit                  1.1121  
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1-Benzyl-4-hydroxy-3-oxo-4,6,7-triphenyl-1,3,4,5,6,7-hexahydroisobenzofuran-5-
carbaldehyde (4.28) 
 
formula                          C35H29Cl3O4  
formula weight                   619.97 Z,  
calculated density               2, 1.314 Mg · m-3  
F(000)                           644  
description and size of crystal  colourless block, 0.070 · 0.180 · 0.270 mm3  
absorption coefficient           2.948 mm-1  
min/max transmission             0.59 / 0.81  
temperature                      123K  
radiation(wavelength)            Cu Kα (λ = 1.54180 Å)  
Crystal system, space group      triclinic, P -1  
a                                9.2387(5) Å  
b                                10.1306(6) Å  
c                                17.4005(10) Å  
α                                104.717(2)°  
β                                94.407(2)°  
γ                                92.523(3)°  
V                                1567.08(16) Å3  
min/max Θ                        2.636° / 68.241°  
number of collected reflections  15196  
number of independent refections 5488 (merging r = 0.032)  
number of observed reflections   4843 (I>2.0σ(I))  
number of refined parameters     379  
r                                0.0669  
rW                               0.0790  
goodness of fit                  1.0806  
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(2R,3S)-2,4-Dibenzyl-2,3-dihydroxypent-4-en-1-yl 4-iodobenzoate (5.34) 
 
formula                          C26H25I1O4  
formula weight                   528.39 Z,  
calculated density               2, 1.544 Mg · m-3  
F(000)                           532  
description and size of crystal  colourless needle, 0.030 · 0.040 · 0.310 mm3  
absorption coefficient           1.439 mm-1  
min/max transmission             0.94 / 0.96  
temperature                      123K  
radiation(wavelength)            Mo Kα (λ = 0.71073 Å)  
Crystal system, space group      triclinic, P 1  
a                                5.6359(7) Å  
b                                13.7031(17) Å  
c                                15.0995(17) Å  
α                                82.314(8)°  
β                                79.604(5)°  
γ                                89.600(6)°  
V                                1136.5(2) Å3  
min/max Θ                        1.899° / 27.484°  
number of collected reflections  19016  
number of independent refections 10123 (merging r = 0.036)  
number of observed reflections   7325 (I>2.0σ(I))  
number of refined parameters     560  
r                                0.0441  
rW                               0.0501  
goodness of fit                  1.1145  
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(Z)-(((3-Iodo-3-phenylallyl)oxy)methanetriyl)tribenzene (5.40) 
 
formula                          C28H23I1O1  
formula weight                   502.39 Z,  
calculated density               2, 1.495 Mg · m-3  
F(000)                           504  
description and size of crystal  colourless block, 0.110 · 0.180 · 0.320 mm3  
absorption coefficient           1.452 mm-1  
min/max transmission             0.77 / 0.85  
temperature                      123K  
radiation(wavelength)            Mo Kα (λ = 0.71073 Å)  
Crystal system, space group      triclinic, P -1  
a                                9.7741(3) Å  
b                                11.3226(3) Å  
c                                11.3299(3) Å  
α                                73.3990(10)°  
β                                83.8660(10)°  
γ                                68.1930(10)°  
V                                1115.61(5) Å3  
min/max Θ                        1.876° / 36.318°  
number of collected reflections  38378  
number of independent refections 10736 (merging r = 0.025)  
number of observed reflections   9077 (I>2.0σ(I))  
number of refined parameters     271  
r                                0.0224  
rW                               0.0279  
goodness of fit                  1.0839 
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(R)-2-Benzyl-1-((S)-4-benzyl-2,2-dimethyl-1,3-dioxolan-4-yl)allyl pivalate (5.45) 
 
formula                          C27H34O4  
formula weight                   422.56 Z,  
calculated density               2, 1.170 Mg · m-3  
F(000)                           456  
description and size of crystal  colourless needle, 0.050 · 0.070 · 0.270 mm3  
absorption coefficient           0.611 mm-1  
min/max transmission             0.96 / 0.97  
temperature                      293K  
radiation(wavelength)            Cu Kα (λ = 1.54178 Å)  
Crystal system, space group      triclinic, P -1  
a                                9.2792(4) Å  
b                                10.3290(4) Å  
c                                14.0397(6) Å  
α                                90.580(2)°  
β                                108.348(2)°  
γ                                108.790(2)°  
V                                1199.81(9) Å3  
min/max Θ                        4.557° / 69.427°  
number of collected reflections  14130  
number of independent refections 4331 (merging r = 0.030)  
number of observed reflections   4031 (I>2.0σ(I))  
number of refined parameters     399  
r                                0.0474  
rW                               0.0590  
goodness of fit                  1.1328  
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((4S,5R)-4-Benzyl-5-((S)-2-hydroxy-1-phenylbut-3-en-2-yl)-2,2-dimethyl-1,3-
dioxolan-4-yl)methyl pivalate (5.48) 
 
formula                          C28H36O5  
formula weight                   452.59 Z,  
calculated density               4, 1.208 Mg · m-3  
F(000)                           976  
description and size of crystal  colourless block, 0.050 · 0.130 · 0.190 mm3  
absorption coefficient           0.081 mm-1  
min/max transmission             0.99 / 1.00  
temperature                      123K  
radiation(wavelength)            Mo Kα (λ = 0.71073 Å)  
Crystal system, space group      orthorhombic, P 21 21 21  
a                                7.4755(2) Å  
b                                12.1299(3) Å  
c                                27.4449(6) Å  
α                                90°  
β                                90°  
γ                                90°  
V                                2488.62(11) Å3  
min/max Θ                        1.836° / 31.506°  
number of collected reflections  58760  
number of independent refections 4646 (merging r = 0.047)  
number of observed reflections   3766 (I>2.0σ(I))  
number of refined parameters     298  
r                                0.0341  
rW                               0.0503  
goodness of fit                  1.1242  
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9.5 Various 
9.5.1 Apparatus for Maculalactone A Synthesis 
 
Apparatus for the cyclization of ester 2.31 as described in chapter 2. 
 
Condensor
Dropping funnel
Cotton
4 Å Molecular sieve
Reaction flask
N2
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9.5.2 Absorption and Fluorescence Spectra 
 
Spectra of compound 3.47 with emission at 590 nm under varying extinction and 
extinction at 525 and 570 nm and varying emission. The absolute values vary due to 
differences in the extinction energy. λmax = 568 nm. 
 
Spectra of compound 3.48 with emission at 585 nm under varying extinction and 
extinction at 525 and 568 nm and varying emission. The absolute values vary due to 
differences in the extinction energy: λmax = 563 nm. 
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